Improving the management of asthma and chronic obstructive pulmonary disease by Bereznicki, BJ
  
 
 
 
IMPROVING THE MANAGEMENT OF ASTHMA AND 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
 
 
 
 
 
Bonnie Bereznicki B.Pharm (Hons) 
Submitted in fulfilment of the requirements for the degree of Doctorate of Philosophy 
 
UNIVERSITY OF TASMANIA 
 
September 2011 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 1 
DECLARATION OF ORIGINALITY 
This thesis contains no material that has been accepted for a degree or diploma by the 
University or any tertiary institution, except by way of background information and 
duly acknowledged in the thesis. 
To the best of my knowledge and belief, this thesis contains no material previously 
published or written by any other person except where due acknowledgement is made in 
the text of the thesis, nor does the thesis contain any material that infringes on 
copyright. 
 
Bonnie Bereznicki 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 2 
AUTHORITY OF ACCESS 
This thesis may be made available for loan and limited copying in accordance with the 
Copyright Act 1968. 
 
Bonnie Bereznicki 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 3 
STATEMENT OF ETHICAL CONDUCT 
The research associated with this thesis abides by the international and Australian codes 
on human and animal experimentation, the guidelines by the Australian Government's 
Office of the Gene Technology Regulator and the rulings of the Safety, Ethics and 
Institutional Biosafety Committees of the University. 
 
Bonnie Bereznicki 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 4 
STATEMENT OF CONTRIBUTION 
The first project, ‘sustainability and feasibility of a community pharmacy intervention to 
improve the management of asthma’ was designed and conceptualised by Bonnie 
Bereznicki, Gregory Peterson and Shane Jackson. Bonnie Bereznicki wrote the letters to 
pharmacists, patients and general practitioners. Peter Gee wrote the data-mining 
software. Bonnie Bereznicki and Ian DeBoos wrote the qualitative discussion guide. Ian 
DeBoos and Philippa Hintz performed the participant interviews and qualitative 
analyses.  
The second project, ‘uptake and effectiveness of a community pharmacy intervention to 
improve the management of asthma’ was designed and conceptualised by Bonnie 
Bereznicki, Gregory Peterson and Shane Jackson. Bonnie Bereznicki wrote the letters to 
pharmacists, patients and general practitioners. Peter Gee wrote the data-mining 
software. Bonnie Bereznicki wrote the software instructions. 
The third project, ‘understanding medication persistence in patients with COPD’ was 
designed and conceptualised by Bonnie Bereznicki, Gregory Peterson, Shane Jackson, 
David Marshall, Guy Gavagna and Felicity Hardley. Bonnie Bereznicki wrote the letters 
to pharmacists and patients. Peter Gee wrote the data-mining software. Felicity Hardley 
and Trish Shee wrote the qualitative discussion guide. Felicity Hardley, Trish Shee, and 
Randall James performed the participant interviews and qualitative analyses.  
 
Bonnie Bereznicki 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 5 
ACKNOWLEDGMENTS 
I would like to thank the many people who have provided their support, encouragement 
and guidance throughout my candidature. In particular, Professor Gregory Peterson, Dr 
Shane Jackson and Professor Haydn Walters have provided the necessary leadership 
and stimulation to facilitate the successful completion of this body of work. 
I would also like to acknowledge the contribution of research colleagues that have 
provided their assistance with this work. I would like to thank Peter Gee for his 
dedication to the information technology development required for each project and his 
patience with the required modifications to the software programs as the projects 
progressed. I would also like to thank Kimbra Fitzmaurice for her research management 
skills, and her thoughtful and sensible advice throughout the course of my candidature. 
I would like to acknowledge Ian DeBoos and Philippa Hintz for their assistance with the 
qualitative component of the follow-up asthma study. Thanks also Corinne LeReun for 
her assistance with the statistical interpretation of the quantitative results.  
I would like to offer thanks to Dr Johnson George, Associate Professor Kay Stewart, 
Tabish Zaidi and Jaya Soma from Monash University; and Dr Geoff March, Mike 
Quaass and Nicola Hughes from the University of South Australia, who provided their 
assistance in the planning and implementation stages of the multicentre asthma 
intervention project. Thanks also to respiratory physicians Dr James Markos, Professor 
John Wilson and Associate Professor Hubertus Jersmann for their assistance with the 
pharmacist education sessions. 
I would like to acknowledge Dr Guy Gavagna and David Marshall from Boehringer 
Ingelheim for their assistance in the planning and implementation of the respiratory 
medication persistence study. Thanks also to Dr Felicity Hardley, Trish Shee and 
Randall James from P Group Research for their assistance with the qualitative 
component of this study. 
I would also like to thank Cathy Beswick and Glenn Freeman from the Tasmanian 
Asthma Foundation, and Garry Irving from the Asthma Foundations Australia for their 
continuous support and advice over the course of my candidature. Thanks also to 
members of the Tasmanian Asthma Foundation Medical and Scientific Advisory 
Committee for their enthusiasm and interest towards my work. 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 6 
I would like to acknowledge the support of a number of funding bodies that provided 
support for this body of work. The Asthma Foundations Australia not only funded my 
Honours project, but also financially supported the follow-up asthma study described in 
this thesis, via an Asthma Targeted Intervention Grant. The multicentre asthma 
intervention project was funded by the Australian Government Department of Health 
and Ageing through the Fourth Community Pharmacy Agreement Grants Program 
managed by the Pharmacy Guild of Australia, and the respiratory medication 
persistence study was funded by Boehringer Ingelheim Australia. I am confident that 
these funding bodies have invested in the future of asthma and COPD management in 
Australia. I would also like to thank the participating community pharmacists, general 
practitioners and patients for their cooperation and support throughout each of the 
projects.  
I am grateful for the support of my colleagues at the Tasmanian School of Pharmacy 
and the Unit for Medication Outcomes Research and Education, for their support and 
encouragement. I would also like to acknowledge the School in providing the resources 
and facilities required throughout the course of my candidature. I look forward to 
continuing my research within the School.  
Lastly, I would like to thank my family and friends who have provided me with the 
support necessary to continue this work to completion. I am grateful to my patents for 
their unconditional love and support, and for teaching me that anything is possible. In 
particular I would like to thank my wonderful husband Luke for his understanding, 
patience, advice and unwavering support over the past three years. I would also like to 
thank my gorgeous baby boy Ryan for his beautiful, patient temperament that allowed 
me to write up my thesis from home over the last year. 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 7 
PUBLICATIONS 
All publications listed here resulted from work described in this thesis. 
Peer-reviewed publications 
Bereznicki BJ, Peterson GM, Jackson SL, et al. The sustainability of a community 
pharmacy intervention to improve the quality use of asthma medication. J Clin Pharm 
Ther 2011; 36: 144-151. 
Bereznicki BJ, Peterson GM, Jackson SL, et al. Perceived feasibility of a community 
pharmacy-based asthma intervention: a qualitative follow-up study. J Clin Pharm Ther 
2011; 36: 348-355. 
Bereznicki B, Bereznicki L. Evidence based update: Inhaled anticholinergic 
medications: their role in COPD and adverse cardiovascular events. Australian 
Pharmacist 2010; 29(8): 690-694. 
Bereznicki B, Bereznicki L. Evidence based update: When asthma and COPD overlap 
each other. Australian Pharmacist 2009; 28(9): 782-786. 
Bereznicki B, Peterson G. Aged care: COPD is an important issue in an ageing 
population. Australian Pharmacist 2009; 28(9): 742-746. 
Bereznicki B, Bereznicki L, Peterson G. Evidence based update: Strategies to manage 
COPD. Australian Pharmacist 2008; 27(6): 485-490. 
Bereznicki B, Bereznicki L, Peterson G. Evidence based update: Strategies to manage 
asthma. Australian Pharmacist 2008; 27(5): 414-418. 
Bereznicki BJ, Peterson GM, Jackson SL, et al. Data mining of medication records to 
improve asthma management. Med J Aust. 2008; 189(1): 21-25. 
Bereznicki BJ, Peterson GM, Jackson SL, et al. Pharmacist-initiated general practitioner 
referral of patients with suboptimal asthma management. Pharm World Sci. 2008; 30: 
869-875. 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 8 
Conference abstracts 
Bereznicki B, Peterson G, Jackson S, et al. A community pharmacy intervention 
program to improve the quality use of asthma medication: uptake and effectiveness. 
National Medicines Symposium. Melbourne 2010 [oral presentation]. 
Bereznicki B, Peterson G, Jackson S, et al. Understanding medication persistence in 
patients with COPD. National Medicines Symposium. Melbourne 2010 [oral 
presentation]. 
Bereznicki B, Peterson G, Jackson S, et al. The sustainability of a community pharmacy 
intervention to improve the quality use of asthma medication. National Medicines 
Symposium. Melbourne 2010 [poster]. 
Bereznicki B, Peterson G, Jackson S, et al. Perceived feasibility of a community 
pharmacy-based asthma intervention: a qualitative follow-up study. National Medicines 
Symposium. Melbourne 2010 [poster]. 
Bereznicki B, Peterson G, Jackson S, et al. A community pharmacy intervention 
program to improve the quality use of asthma medication: participant satisfaction. 
National Medicines Symposium. Melbourne 2010 [poster]. 
Bereznicki B, Peterson G, Jackson S, et al. A community pharmacy intervention 
program to improve the quality use of asthma medication. Pharmacy Practice Research 
Summit. Canberra 2010 [oral presentation]. 
Bereznicki B, Peterson G, Jackson S, et al. A community pharmacy intervention 
program to improve the quality use of asthma medication: uptake and effectiveness. 
Pharmacy Practice Research Summit. Canberra 2010 [poster]. 
Bereznicki B, Peterson G, Jackson S, et al. A community pharmacy intervention 
program to improve the quality use of asthma medication: participant satisfaction. 
Pharmacy Practice Research Summit. Canberra 2010 [poster]. 
Bereznicki B, Peterson G, Jackson S, et al. The sustainability of a community pharmacy 
intervention to improve the management of asthma. Australasian Pharmaceutical 
Society Association Conference. Hobart 2009 [oral presentation]. 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 9 
Bereznicki B, Peterson G, Jackson S, et al. Perceived feasibility of a community 
pharmacist-led asthma intervention: a qualitative follow-up study. Australasian 
Pharmaceutical Society Association Conference. Hobart 2009 [poster]. 
Bereznicki B, Jackson S, Peterson G, et al. Drivers and barriers of tiotropium 
persistence in patients with COPD. Thoracic Society of Australia and New Zealand 
Annual Scientific Meeting. Darwin 2009 [poster]. 
Bereznicki B, Jackson S, Peterson G, et al. Understanding medication persistence in 
patients with COPD. Australasian Pharmaceutical Society Association Conference. 
Canberra 2008 [oral presentation]. 
Bereznicki B, Peterson G, Jackson S, et al. The use of pharmacy medication records to 
prompt GP referral of patients with suboptimal asthma management. Australian Asthma 
Conference. Sydney 2008 [oral presentation]. 
Bereznicki B, Peterson G, Jackson S, et al. A community pharmacy-based intervention 
to improve the quality use of asthma medication. National Medicines Symposium. 
Canberra 2008 [oral presentation]. 
 
 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 10 
TABLE OF CONTENTS 
Declaration of originality ..............................................................................................1!
Authority of access........................................................................................................2!
Statement of ethical conduct .........................................................................................3!
Statement of contribution..............................................................................................4!
Acknowledgments.........................................................................................................5!
Publications ...................................................................................................................7!
List of Tables ..............................................................................................................15!
List of Figures .............................................................................................................17!
List of Appendices ......................................................................................................18!
Abbreviations ..............................................................................................................19!
Abstract .......................................................................................................................21!
PART ONE: INTRODUCTION AND OBJECTIVES..............................................24!
PART TWO: IMPROVING THE MANAGEMENT OF ASTHMA.......................26!
Chapter One: Introduction ......................................................................................26!
1.1 Pathophysiology of asthma ...............................................................................26!
1.2 Burden of asthma ..............................................................................................28!
1.3 Asthma control..................................................................................................31!
1.4 Guidelines for the management of asthma........................................................35!
1.5 Self-management plans .....................................................................................40!
1.6 Pharmacological therapy...................................................................................42!
1.6.1 Short-acting beta-2 agonists.......................................................................42!
1.6.2 Inhaled corticosteroids ...............................................................................44!
1.6.3 Long-acting beta-2 agonists .......................................................................47!
1.6.4 Combination therapy..................................................................................50!
1.6.5 Leukotriene receptor antagonists ...............................................................52!
1.6.6 Cromones ...................................................................................................53!
1.6.7 Methylxanthines.........................................................................................54!
1.6.8 Anticholinergics .........................................................................................55!
1.6.9 Anti-IgE treatment .....................................................................................56!
1.6.10 Systemic corticosteroids ..........................................................................57!
1.7 Barriers to optimal asthma management...........................................................59!
1.7.1 Use of inhaled corticosteroids....................................................................59!
1.7.2 Use of Asthma Action Plans ......................................................................63!
1.7.3 Perception of asthma control......................................................................64!
1.7.4 Relationships with healthcare professionals ..............................................67!
1.8 The pharmacist’s role in asthma management..................................................69!
1.9 Data mining dispensing records to perform asthma interventions....................74!
Chapter Two: Sustainability and Feasibility of a Community Pharmacy 
Intervention to Improve the Management of Asthma ...........................................77!
2.1 Aim and objectives............................................................................................77!
2.2 Methods.............................................................................................................77!
2.2.1 Study design and setting ............................................................................77!
2.2.2 Quantitative component .............................................................................78!
2.2.2.1 Recruitment of pharmacies .................................................................78!
2.2.2.2 The data mining software....................................................................78!
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 11 
2.2.2.3 Study population .................................................................................78!
2.2.2.4 Handling of data and statistical analysis .............................................79!
2.2.3 Qualitative component ...............................................................................80!
2.2.3.1 Recruitment of participants .................................................................80!
2.2.3.2 Qualitative interviews .........................................................................81!
2.2.3.3 Handling of data..................................................................................82!
2.2.4 Ethical approval and trial registration........................................................82!
2.3 Results...............................................................................................................83!
2.3.1 Quantitative component .............................................................................83!
2.3.1.1 Study population .................................................................................83!
2.3.1.2 Preventer-to-reliever ratio ...................................................................84!
2.3.1.3 Reliever and preventer usage ..............................................................85!
2.3.1.4 Sensitivity analysis..............................................................................90!
2.3.2 Qualitative component ...............................................................................92!
2.3.2.1 Study population .................................................................................92!
2.3.2.2 General practitioners ...........................................................................92!
2.3.2.3 Community pharmacists .....................................................................95!
2.3.2.4 Patients with asthma............................................................................97!
2.4 Discussion .........................................................................................................99!
2.4.1 Quantitative component .............................................................................99!
2.4.2 Qualitative component .............................................................................102!
2.5 Conclusions.....................................................................................................106!
Chapter Three: Uptake and Effectiveness of a Community Pharmacy 
Intervention to Improve the Management of Asthma .........................................107!
3.1 Aim and objectives..........................................................................................107!
3.2 Methods...........................................................................................................107!
3.2.1 Study design and setting ..........................................................................107!
3.2.2 The data mining software.........................................................................108!
3.2.3 Sample size ..............................................................................................110!
3.2.4 Pharmacy recruitment ..............................................................................111!
3.2.5 Dissemination of project information to GPs ..........................................112!
3.2.6 Random allocation of intervention type...................................................113!
3.2.7 The intervention .......................................................................................114!
3.2.7.1 Installation and running the MedeMine-for-Asthma program..........114!
3.2.7.2 The intervention period.....................................................................116!
3.2.7.3 Support for pharmacists ....................................................................118!
3.2.8 Questionnaire instruments........................................................................118!
3.2.8.1 Asthma Control Test .........................................................................118!
3.2.8.2 Mini Asthma Quality of Life Questionnaire .....................................119!
3.2.8.3 Tool for Adherence Screening Behaviour ........................................119!
3.2.8.4 GP survey..........................................................................................120!
3.2.8.5 Pharmacist satisfaction survey ..........................................................120!
3.2.8.6 Patient satisfaction survey.................................................................120!
3.2.9 Post-intervention follow-up .....................................................................120!
3.2.10 Handling of data and statistical analysis ................................................123!
3.2.11 Ethical approval and trial registration....................................................124!
3.3 Results.............................................................................................................124!
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 12 
3.3.1 Participants...............................................................................................124!
3.3.1.1 Recruitment of pharmacies ...............................................................124!
3.3.1.2 Identification of patients ...................................................................125!
3.3.1.3 Patient exclusions..............................................................................131!
3.3.2 Uptake of the intervention........................................................................131!
3.3.3 Patient and GP survey response rates ......................................................132!
3.3.4 Patient demographics ...............................................................................133!
3.3.5 Outcome measures ...................................................................................134!
3.3.5.1 Dispensing data .................................................................................134!
3.3.5.2 Patient-reported outcomes.................................................................137!
3.3.5.3 GP evaluations ..................................................................................139!
3.3.5.4 Pharmacist satisfaction......................................................................143!
3.3.5.5 Patient satisfaction ............................................................................149!
3.4 Discussion .......................................................................................................152!
3.4.1 Participants...............................................................................................152!
3.4.2 Uptake of the intervention........................................................................153!
3.4.3 Patient and GP survey response rates ......................................................154!
3.4.4 Patient demographics ...............................................................................155!
3.4.5 Outcome measures ...................................................................................156!
3.4.5.1 Dispensing data .................................................................................156!
3.4.5.2 Patient-reported outcomes.................................................................158!
3.4.5.3 GP evaluations ..................................................................................160!
3.4.5.4 Pharmacist satisfaction......................................................................161!
3.4.5.5 Patient satisfaction ............................................................................162!
3.5 Conclusions.....................................................................................................163!
PART THREE: MEDICATION PERSISTENCE IN COPD .................................164!
Chapter Four: Introduction ...................................................................................164!
4.1 Pathophysiology of COPD..........................................................................164!
4.2 Overlap of COPD and asthma.....................................................................168!
4.3 Burden of COPD.........................................................................................172!
4.4 Guidelines for the management of COPD ..................................................174!
4.5 Slowing lung function decline in COPD: smoking cessation .....................177!
4.6 Self-management plans for COPD..............................................................181!
4.7 Pulmonary rehabilitation.............................................................................184!
4.8 Pharmacological therapy.............................................................................186!
4.8.1 Inhaled bronchodilators........................................................................186!
4.8.2 Inhaled corticosteroids .........................................................................190!
4.8.3 Combination therapy............................................................................190!
4.8.4 Methylxanthines...................................................................................192!
4.8.5 Systemic corticosteroids ......................................................................193!
4.8.6 Antibiotics ............................................................................................194!
4.8.7 Oxygen therapy ....................................................................................194!
4.8.8 Mucolytics............................................................................................195!
4.9 Medication adherence and persistence in COPD........................................195!
4.9.1 Definitions of adherence and persistence.............................................195!
4.9.2 Rates of adherence and persistence in COPD......................................197!
4.9.3 Barriers to adherence and persistence in COPD ..................................200!
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 13 
Chapter Five: Understanding Medication Persistence in Patients with COPD 204!
5.1 Aim and objectives..........................................................................................204!
5.2 Methods...........................................................................................................204!
5.2.1 Study design and setting ..........................................................................204!
5.2.2 The data mining software.........................................................................204!
5.2.3 Sample size ..............................................................................................207!
5.2.4 Pharmacy recruitment ..............................................................................208!
5.2.5 Installation and running the MedeMine COPD program.........................208!
5.2.6 Patient questionnaires ..............................................................................210!
5.2.6.1 St. George’s Respiratory Questionnaire............................................210!
5.2.6.2 Brief Illness Perception Questionnaire .............................................211!
5.2.6.3 Beliefs about Medicines Questionnaire ............................................211!
5.2.6.4 Tool for Adherence Screening Behaviour ........................................212!
5.2.6.5 Hospital Anxiety and Depression Scale............................................212!
5.2.7 Patient interviews.....................................................................................213!
5.2.8 Handling of data and statistical analysis ..................................................214!
5.2.9 Ethical approval and trial registration......................................................214!
5.3 Results.............................................................................................................215!
5.3.1 Recruitment of participants ......................................................................215!
5.3.1.1 Pharmacist participation....................................................................215!
5.3.1.2 Identification of patients ...................................................................215!
5.3.1.3 Patient exclusions..............................................................................218!
5.3.1.4 Patient participation ..........................................................................220!
5.3.2 Quantitative analyses ...............................................................................220!
5.3.2.1 Consenting patients’ demographics and dispensing data..................220!
5.3.2.2 Exposure to COPD risk factors .........................................................222!
5.3.2.3 Respiratory-specific health status .....................................................223!
5.3.2.4 Illness perception ..............................................................................224!
5.3.2.5 Beliefs about medicines ....................................................................225!
5.3.2.6 Medication adherence behaviour ......................................................226!
5.3.2.7 Anxiety and depression.....................................................................227!
5.3.2.8 Multivariate analysis .........................................................................228!
5.3.3 Qualitative analyses .................................................................................229!
5.3.3.1 Characteristics of interviewed patients .............................................229!
5.3.3.2 Common themes relating to persistence ...........................................232!
5.3.3.3 Drivers of persistence........................................................................232!
2.3.3.3 Non-persistence.................................................................................235!
5.4 Discussion .......................................................................................................237!
5.4.1 Recruitment of participants ......................................................................237!
5.4.1.1 Pharmacist participation....................................................................237!
5.4.1.2 Identification of patients ...................................................................238!
5.4.1.3 Patient exclusions..............................................................................238!
5.4.1.4 Patient participation ..........................................................................239!
5.4.2 Quantitative analyses ...............................................................................240!
5.4.2.1 Consenting patients’ demographics and dispensing data..................240!
5.4.2.2 Exposure to COPD risk factors .........................................................241!
5.4.2.3 Respiratory-specific health status .....................................................241!
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 14 
5.4.2.4 Illness perception ..............................................................................242!
5.4.2.5 Beliefs about medicines ....................................................................242!
5.4.2.6 Medication adherence behaviour ......................................................243!
5.4.2.7 Anxiety and depression.....................................................................244!
5.4.2.8 Multivariate analysis .........................................................................244!
5.4.3 Qualitative analysis ..................................................................................245!
5.4.3.1 Characteristics of interviewed patients .............................................245!
5.4.3.2 Persistence.........................................................................................245!
5.4.3.3 Non-persistence.................................................................................246!
5.4.4 Study limitations ......................................................................................247!
5.5 Conclusions.....................................................................................................248!
PART FOUR: GENERAL DISCUSSION AND CONCLUSIONS ........................250!
REFERENCES............................................................................................................255!
APPENDICES .............................................................................................................302!
 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 15 
LIST OF TABLES 
Table 1.  Assessment of asthma control ......................................................................32!
Table 2.  Goals of asthma management ......................................................................34!
Table 3.  The Australian Six Step Asthma Management Plan ....................................37!
Table 4.  ICS daily dose equivalents: what is meant by low, medium and high daily 
doses? ...........................................................................................................45!
Table 5.  Rates of severe exacerbations in the COMPASS trial .................................52!
Table 6.  Actions for pharmacists to improve asthma management ...........................71!
Table 7.  Qualitative data analysis – interpretive phenomenology .............................82!
Table 8.  Overall changes in P : R ratio within each group.........................................84!
Table 9.  Wilcoxon post hoc comparisons of P : R ratio within each group...............85!
Table 10.  Overall changes in average daily SABA usage within each group..............86!
Table 11.  Wilcoxon post hoc comparisons of average daily SABA usage within each 
group ............................................................................................................87!
Table 12.  Number of SABA canisters dispensed over the study period ......................87!
Table 13.  Wilcoxon post hoc comparisons of SABA canisters dispensed within each 
group ............................................................................................................88!
Table 14.  Overall changes in average daily ICS usage within each group ..................88!
Table 15.  Wilcoxon post hoc comparisons of average daily ICS usage within each 
group ............................................................................................................89!
Table 16.  Proportion of patients who received at least one supply of ICS in each 
period............................................................................................................90!
Table 17.  Percent changes in median daily ICS and SABA usage over the study period
......................................................................................................................90!
Table 18.  Overall changes in average daily SABA usage amongst long-term 
concessional patients ....................................................................................91!
Table 19.  Wilcoxon post hoc comparisons of SABA usage amongst long-term 
concessional patients ....................................................................................91!
Table 20.  Number of participants interviewed.............................................................92!
Table 21.  General practitioners’ profiles......................................................................93!
Table 22.  Community pharmacists’ profiles ................................................................95!
Table 23.  Patients’ profiles...........................................................................................97!
Table 24.  Pharmacists' willingness to participate ......................................................125!
Table 25.  Stepwise identification of patients .............................................................126!
Table 26.  Patients identified in each pharmacy..........................................................129!
Table 27.  Reasons for patient exclusion.....................................................................131!
Table 28.  Patient demographic variables ...................................................................134!
Table 29.  Pre- and post-intervention dispensing data (treatment-received analysis).135!
Table 30.  Absolute change in daily SABA and ICS usage (treatment-received 
analysis)......................................................................................................136!
Table 31.  Pre- and post-intervention dispensing data (intention-to-treat analysis)....136!
Table 32.  Absolute change in daily SABA and ICS usage (intention-to-treat analysis)
....................................................................................................................137!
Table 33.  Pre- and post-intervention asthma survey results.......................................138!
Table 34.  Post-intervention asthma survey results compared to control....................139!
Table 35.  GPs’ evaluation of the patient ....................................................................140!
Table 36.  Modifications to patient’s asthma therapy .................................................140!
Table 37.  Reasons for GP feeling their patient was not appropriately identified for a 
review.........................................................................................................141!
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 16 
Table 38.  GPs’ perceptions of the intervention..........................................................142!
Table 39.  GPs’ comments regarding the intervention................................................143!
Table 40.  Pharmacists’ perceptions regarding usefulness and appropriateness of the 
intervention ................................................................................................144!
Table 41.  Pharmacists’ reasons for preferring mailed or face-to-face interventions .145!
Table 42.  Pharmacists’ perceptions of the education session, MedeMine-for-Asthma 
and workflow impact..................................................................................146!
Table 43.  Pharmacists’ perceptions regarding general implementation of the 
intervention ................................................................................................147!
Table 44.  Pharmacists’ comments about patient and GP feedback of the intervention
....................................................................................................................148!
Table 45.  Pharmacists’ comments about the project..................................................148!
Table 46.  Patients’ perceptions of the intervention....................................................150!
Table 47.  Patients’ perceptions of asthma care and utilisation of health professionals
....................................................................................................................151!
Table 48.  Patients’ comments regarding the intervention..........................................152!
Table 49.  Spirometric classification of COPD severity .............................................166!
Table 50.  Systemic effects of COPD .........................................................................166!
Table 51.  Risk factors for COPD ...............................................................................167!
Table 52.  Major differences between asthma and COPD management in adults ......171!
Table 53.  Summary of the COPD-X guidelines.........................................................176!
Table 54.  Brief strategies to help a willing patient to quit smoking ..........................180!
Table 55.  Components of comprehensive pulmonary rehabilitation programs .........185!
Table 56.  Methods of measuring adherence...............................................................197!
Table 57.  Pharmacists' willingness to participate ......................................................215!
Table 58.  Patients identified by each pharmacy.........................................................217!
Table 59.  Reasons for patient exclusion by pharmacists ...........................................218!
Table 60.  Patients excluded per pharmacy.................................................................219!
Table 61.  Patient response rates .................................................................................220!
Table 62.  Patient demographics and dispensing data.................................................221!
Table 63.  Comparison of consenting and declining patients’ dispensing data ..........222!
Table 64.  Exposure to COPD risk factors ..................................................................223!
Table 65.  St. George's Respiratory Questionnaire scores ..........................................224!
Table 66.  Illness Perception Questionnaire scores.....................................................225!
Table 67.  Beliefs about Medicines Questionnaires scores.........................................226!
Table 68.  Medication adherence items and scores.....................................................227!
Table 69.  Anxiety and depression items and scores...................................................228!
Table 70.  Multivariate predictors of persistence........................................................229!
Table 71.  Characteristics of interviewed patients ......................................................230!
Table 72.  Characteristics of interviewed patients compared to the rest of the study 
population...................................................................................................231!
Table 73.  Common themes relating to tiotropium persistence...................................232!
 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 17 
LIST OF FIGURES 
Figure 1.  Illustrative representation of the pathophysiological changes in asthma.....27!
Figure 2.  Effect of the interaction of various types of exposures and genetic 
backgrounds on the prevalence of asthma ...................................................28!
Figure 3.  World map of the prevalence of clinical asthma..........................................30!
Figure 4.  The Asthma Score ........................................................................................33!
Figure 5.  Patients achieving a well controlled week in the GOAL study ...................35!
Figure 6.  Asthma Action Plan template.......................................................................41!
Figure 7.  Comparison of the relative effects of increasing doses of fluticasone in 
asthma ..........................................................................................................46!
Figure 8.  Factors influencing patient adherence to medication...................................60!
Figure 9.  Common patient perceptions affecting ICS adherence................................61!
Figure 10.  Patients' perception of asthma control against actual symptom severity 
among regions ..............................................................................................65!
Figure 11.  Self-assessment of asthma control by symptom frequency index among 
participants of an Australian study...............................................................66!
Figure 12.  Patient and healthcare professional behaviour affects asthma control.........67!
Figure 13.  Distribution of asthma and total allocated recurrent health expenditure 
among health sectors, Australia, 2000-01 ....................................................70!
Figure 14.  Timelines for dispensing data analysis ........................................................79!
Figure 15.  Excerpt a GP South (Tasmania) newsletter - February 2009.......................81!
Figure 16.  Number of patients’ dispensing data analysed in each time period .............83!
Figure 17.  Changes in preventer-to-reliever ratios over the study period .....................84!
Figure 18.  List of identified patients in MedeMine-for-Asthma .................................109!
Figure 19.  Viewing patient dispensing history in MedeMine-for-Asthma .................110!
Figure 20.  Excerpt a GP North (Tasmania) newsletter - June 2008............................113!
Figure 21.  Example alert flag in Fred Dispense ..........................................................115!
Figure 22.  MedeMine-for-Asthma screenshot showing exclusion criteria .................116!
Figure 23.  MedeMine-for-Asthma screenshot of ‘extra information’ tab...................118!
Figure 24.  Summary of the project’s methodology.....................................................122!
Figure 25.  Uptake of the intervention by pharmacists.................................................132!
Figure 26.  Mechanisms of underlying airflow limitation in COPD............................165!
Figure 27.  Illustrative representation of the pathophysiological changes in COPD ...165!
Figure 28.  Non-proportional Venn diagram of COPD................................................169!
Figure 29.  Number with emphysema/bronchitis per 1,000 population, Australia ......173!
Figure 30.  Number of articles listed in PubMed under the search terms ‘COPD’ OR 
‘emphysema’ OR ‘chronic bronchitis’ between 1965 and 2005................174!
Figure 31.  Time-course of COPD................................................................................178!
Figure 32.  COPD self-management plan template......................................................182!
Figure 33.  Quantitative definitions of compliance and persistence.............................196!
Figure 34.  Treatment persistence over 18 months for all study drug classes..............199!
Figure 35.  Treatment persistence after three months for naïve and experienced patients
....................................................................................................................199!
Figure 36.  Factors likely to influence patient adherence and persistence in COPD ...201!
Figure 37.  Common causes of poor adherence in COPD patients ..............................202!
Figure 38.  List of identified patients in MedeMine-for-COPD...................................206!
Figure 39.  Viewing patient dispensing history in MedeMine-for-COPD ...................207!
Figure 40.  Excluding patients in MedeMine-for-COPD .............................................209!
Figure 41.  Terms used to describe respiratory condition ............................................232 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 18 
LIST OF APPENDICES 
Sustainability and feasibility of a community pharmacy intervention to improve 
the management of asthma 
Appendix 1. GP invitation letter .................................................................................. 303 
Appendix 2. Project information sheet ........................................................................ 304 
Appendix 3. Participant consent form ......................................................................... 305 
Appendix 4. Pharmacist invitation letter ...................................................................... 306 
Appendix 5. Pharmacist expression of interest form ................................................... 308 
Appendix 6. Pharmacist interview letter ...................................................................... 309 
Appendix 7. Patient recruitment instructions ............................................................... 310 
Appendix 8. Patient invitation letter ............................................................................ 311 
Appendix 9. Discussion guide for qualitative interviews ............................................ 312 
Uptake and effectiveness of a community pharmacy intervention to improve the 
management of asthma 
Appendix 10. Pharmacist invitation letter .................................................................... 317 
Appendix 11. Project synopsis for pharmacists .......................................................... 319 
Appendix 12. Pharmacist expression of interest form ................................................. 322 
Appendix 13. GP project information sheet ................................................................. 323 
Appendix 14. MedeMine-for-Asthma instructions for researchers ............................. 324 
Appendix 15. Pharmacist instructions for mailed intervention .................................... 332 
Appendix 16. Pharmacist instructions for face-to-face intervention ........................... 342 
Appendix 17. Patient intervention letter ...................................................................... 353 
Appendix 18. Patient asthma control survey ............................................................... 354 
Appendix 19. Patient quality of life survey ................................................................. 355 
Appendix 20. Patient medication adherence survey .................................................... 356 
Appendix 21. Patient survey information sheet ........................................................... 357 
Appendix 22. GP letter ................................................................................................. 358 
Appendix 23. GP survey .............................................................................................. 359 
Appendix 24. Pharmacist satisfaction survey .............................................................. 360 
Appendix 25. Patient satisfaction survey ..................................................................... 363 
Appendix 26. Intervention follow-up instructions for researchers .............................. 364 
Appendix 27. Follow-up patient letter ......................................................................... 376 
Understanding Medication persistence in patients with COPD 
Appendix 28. Pharmacist invitation letter .................................................................... 377 
Appendix 29. Project synopsis for pharmacists ............................................................ 379 
Appendix 30. Pharmacist expression of interest form ................................................. 380 
Appendix 31. Patient invitation letter .......................................................................... 381 
Appendix 32. Patient consent form .............................................................................. 382 
Appendix 33. Patient information sheet ....................................................................... 383 
Appendix 34. Patient letter regarding questionnaire .................................................... 385 
Appendix 35. Patient questionnaire ............................................................................. 386 
Appendix 36. Discussion guide for qualitative interviews .......................................... 399 
 
 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 19 
ABBREVIATIONS 
AAP Asthma Action Plan 
BMQ Beliefs About Medicines Questionnaire 
BOLD Burden of Obstructive Lung Disease [study] 
CI Confidence interval 
COMPASS COMPArrison of Symbicort® and Seretide® [study] 
COPD Chronic obstructive pulmonary disease 
DALY Disability adjusted life year 
ED Emergency department 
FDA Food and Drug Administration 
FEV1 Forced expiratory volume in one second 
FVC Forced vital capacity 
GAPP Global Asthma Physician Patient [study] 
GINA Global Initiative for Asthma 
GOAL Gaining Optimal Asthma controL [study] 
GOLD Global Initiative for Chronic Obstructive Lung Disease 
GP General practitioner 
HADS Hospital Anxiety and Depression Scale 
HEPA High-efficiency particulate air 
HFA Hydrofluoroalkane 
HMR Home medication review 
ICAS International Control of Asthma Symptoms [study] 
ICS Inhaled corticosteroid(s) 
ICU Intensive care unit 
Ig Immunoglobulin 
INSPIRE Investigating New Standards for Prophylaxis in Reducing Exacerbations 
[study] 
IPQ Illness Perception Questionnaire 
ISPOR International Society for Pharmacoeconomics and Outcomes Research 
LABA Long-acting beta-2 agonist 
LTRA Leukotriene receptor antagonist 
MiniAQLQ Mini Asthma Quality of Life Questionnaire 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 20 
N/A Not available 
NAC National Asthma Council 
NNH Number needed to harm 
NNT Number needed to treat 
NRT Nicotine replacement therapy 
OR Odds ratio 
OTC Over-the-counter 
PACP Pharmacy Action Care Program 
PaO2 Partial pressure of oxygen in the blood 
PEF Peak expiratory flow 
PhARIA Pharmacy Access / Remoteness Index of Australia 
P : R Preventer-to-reliever 
QOL Quality of life 
RCT Randomised controlled trial 
RM Respiratory medication 
RR Relative risk 
SABA Short-acting beta-2 agonist 
SD Standard deviation 
SGRQ St. George’s Respiratory Questionnaire 
SMART Symbicort® Maintenance And Reliever Therapy 
TABS Tool for Adherence Behaviour Screening 
TORCH TOward a Revolution in COPD Health [study] 
UK United Kingdom 
US United States  
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 21 
ABSTRACT 
Asthma and chronic obstructive pulmonary disease (COPD) are among the top ten most 
common chronic diseases in Australia,1 causing significant social and economic burden 
on the patient, family and healthcare system. More than five million Australians are 
affected by asthma or COPD, and each year these diseases disrupt daily life and 
productivity of many individuals and contribute to thousands of deaths.2 Despite the 
availability of safe and effective respiratory medication, problems such as under-
diagnosis, medication adherence issues and poor understanding of asthma and COPD, 
have led to the conditions being poorly managed in Australia.3,4 The work described in 
this thesis was directed at learning more about how asthma and COPD are managed in 
the community and steps that can be take to improve the management of these 
conditions. 
Community pharmacists assisted in the implementation of all of the projects described 
in this thesis. Community pharmacists are ideally placed in the healthcare system to 
help patients manage chronic diseases in view of their expertise, their regular contact 
with patients and their accessibility. Community pharmacists also have access to 
patients’ dispensing records, meaning they are uniquely placed to monitor medication 
adherence issues. The projects described in this thesis utilised an innovative software 
application (‘MedeMine’) to data mine pharmacy dispensing records and target patients 
with asthma or COPD, as evidenced by the supply of specific medications.  
Part One of this thesis describes two projects targeted at patients with poorly managed 
asthma. The first project was a follow-up study of a previous intervention conducted in 
Tasmanian community pharmacies that saw patients with potentially poorly managed 
asthma referred to their general practitioner (GP) for an asthma management review. 
The intervention resulted in a three-fold improvement in the management of asthma, as 
measured by the ratio of dispensed preventer to reliever medications.5 A follow-up of 
the intervention was conducted to determine whether the improvement in asthma 
management was sustained, and qualitative interviews were conducted with patients, 
community pharmacists and GPs, to determine the perceived feasibility of the 
intervention. The project showed significant, sustained improvements in the ratio of 
dispensed preventer medications to reliever medications for at least 12 months after the 
intervention. The qualitative component of this project indicated that a wider roll-out of 
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the asthma intervention, with an improved process for involving GPs, would be feasible 
and well accepted. Further research should determine the best approach in influencing 
patients’ perceptions of asthma control and whether these perceptions are amenable to a 
more intensive educational intervention. This could result in more efficient asthma 
interventions, translating to improved patient outcomes. 
The second project was designed to test the uptake and effectiveness of two different 
types of community pharmacy-based asthma intervention across three Australian states. 
Community pharmacies throughout South Australia, Tasmania and Victoria 
participated. The project utilised MedeMine to identify patients whose asthma may not 
be well managed, as evidenced by a high provision of reliever medications. The uptake 
and effectiveness of mailed and face-to-face pharmacist interventions were studied. 
Significantly fewer face-to-face interventions were offered to patients compared with 
mailed interventions, and lack of time was the main reason cited for not offering face-
to-face interventions. There were significant improvements in the ratio of dispensed 
preventer medication to reliever medication after each intervention, but these 
improvements were limited by pharmacists’ uptake of the face-to-face intervention. 
Time constraints in busy pharmacies may restrict the uptake and effectiveness of face-
to-face interventions in the ‘real world’ setting, making mailed interventions an 
attractive option. Pharmacists should have both mailed and face-to-face intervention 
options available to ensure maximum uptake and effectiveness of the interventions. 
Part Two of this thesis describes a study that aimed to understand the drivers and 
barriers of persistence with respiratory medication, specifically tiotropium, in patients 
with COPD. MedeMine was installed in pharmacies throughout Tasmania, Australia, 
and patients who were likely to be persistent or non-persistent with tiotropium were 
identified. Patients completed questionnaires and qualitative interviews. Patients’ 
perceptions of the risks and benefits of tiotropium, which appeared to be strongly 
influenced by personal experience and the prescriber’s attitude, were found to be 
determinants of persistence. Identification of these variables can facilitate the 
development of interventions that modify or take account of specific patient adherence 
behaviours and perceptions about the risks and benefits of medication. It is evident that 
increased awareness of the patients’ beliefs about medicines is needed among healthcare 
providers, and patients should be encouraged to express their views about medicine in 
order to optimise and personalise their therapy.  
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This body of work presents a number of solutions to issues surrounding the 
management of asthma and COPD in the community. With the knowledge gained from 
the results of these projects and using aspects of interventions described in this thesis, 
community pharmacists can dramatically improve the management of these conditions. 
Community pharmacists have the necessary skills to communicate with other healthcare 
providers and patients themselves to improve the management of asthma and COPD, 
and software tools such as MedeMine can aid in the efficient targeting of high-risk 
patients. A national roll-out of the asthma intervention, and a specifically designed 
COPD intervention, would result in better health outcomes for patients, and ultimately 
less burden on the health system. 
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PART ONE:                     
INTRODUCTION AND OBJECTIVES 
Asthma and chronic obstructive pulmonary disease (COPD) are among the top ten most 
common chronic diseases in Australia,1 causing significant social and economic burden 
on the patient, family and healthcare system. More than five million Australians are 
affected by asthma or COPD, and each year these diseases disrupt daily life and 
productivity of many individuals and contribute to thousands of deaths.2 Despite the 
availability of safe and effective respiratory medication, problems such as under-
diagnosis, medication adherence issues and poor understanding of asthma and COPD, 
have led to the conditions being poorly managed in Australia.3,4 
Despite its national health priority status, the management of asthma remains a problem 
in Australia. Research has shown that a significant proportion of people with asthma 
still do not have a written AAP, have poorly controlled asthma and over-rely on their 
reliever medication.6 Patients need to be more educated about asthma and the need for 
regular preventive therapy and monitoring, so that their perceptions of asthma control 
are more realistic. Healthcare professionals should also work together to encourage 
patients to be more forthcoming about their asthma symptoms, so that their therapy can 
be tailored and optimised to ensure adequate asthma control.  
There is irrefutable evidence that COPD is a significant public health problem in 
Australia. Unlike asthma, however, it is not a National Health Priority area, despite a 
mortality rate ten times that of asthma and annual costs that exceed $8 billion.7,8 This 
suggests a lack of awareness of the present and future burden from COPD, perceptions 
and societal stigmas around its cause, and insufficient understanding of its public health 
importance.9 In order to reduce the burden of COPD in Australia, it is imperative that 
healthcare professionals develop a collaborative management approach to ensure the 
early and accurate diagnosis of COPD, which can then drive the implementation of 
effective treatments. Patients should also be encouraged to express their views about the 
condition and its treatment in order to optimise and personalise their therapy, ensuring 
adherence and persistence with prescribed medications. 
Pharmacists are ideally placed in the healthcare system to address asthma and COPD 
management issues and they have the necessary skills to communicate with other 
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healthcare providers and patients themselves to improve these conditions. There is 
enormous scope for community pharmacists to become the feedback link between 
patients and GPs, which would answer the societal need for improved management of 
asthma and COPD. Community pharmacists are trained in counselling and educating 
patients about their condition and prescribed medications, and have access to patients’ 
dispending records, meaning they are uniquely placed to monitor medication adherence 
issues. 
Community pharmacists assisted in the implementation of all of the projects described 
in this thesis. While there clearly is the potential for community pharmacists to have an 
impact in improving the management of asthma and COPD, such approaches are most 
likely to be successful if they can be easily integrated into pharmacists’ workflow, and 
the need for further research testing strategies that are pragmatic in busy community 
pharmacies has been identified.10-14 
The work described in this thesis was directed at learning more about how asthma and 
COPD are managed in the community and steps that can be take to improve the 
management of these conditions. The aims of each project descried in this these were to: 
• Determine the sustainability and perceived feasibility of a multidisciplinary 
intervention that utilised community pharmacy dispensing records to identify and 
educate patients with suboptimal asthma management; 
• Utilise community pharmacy dispensing records to test the uptake and 
effectiveness of two different types of community pharmacy-based asthma 
interventions across three Australian states; and 
• Understand the reasons why patients with COPD do and do not persist with 
prescribed medication. 
With the knowledge gained from the results of these projects and using aspects of 
interventions described in this thesis, it is hoped that community pharmacists will gain 
more potential to dramatically improve the management of these conditions. 
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PART TWO: 
IMPROVING THE MANAGEMENT OF ASTHMA 
CHAPTER ONE: INTRODUCTION 
1.1 Pathophysiology of asthma  
Asthma is a disorder defined by its clinical, physiological and pathological 
characteristics. The predominant feature is episodes of shortness of breath and 
wheezing. In fact, the word ‘asthma’ comes from the Greek word !!"#$% (aazein), 
which translates as ‘to breathe with open mouth or to pant.’15 Currently, the Global 
Initiative for Asthma (GINA) definition is: 
“Asthma is a chronic inflammatory disorder of the airways in 
which many cells and cellular elements play a role. The chronic 
inflammation is associated with airway hyper-responsiveness 
that leads to recurrent episodes of wheezing, breathlessness, 
chest tightness and coughing, particularly at night or early in the 
morning. These episodes are usually associated with 
widespread, but variable airflow obstruction within the lung that 
is often reversible either spontaneously or with treatment.”16 
The symptoms of asthma are due to bronchoconstriction, excess mucus production and 
airway inflammation (Figure 1). Episodes of worsening symptoms, or asthma 
exacerbations, are an exaggerated lower airway response to an environmental exposure, 
such as respiratory virus infections, allergens, pollutants, medications or other 
irritants.17 Structural changes reported in the airways of patients with asthma include 
epithelial fragility, goblet cell hyperplasia, enlarged submucosal mucus glands, 
angiogenesis, increased matrix deposition in the airway wall, increased airway smooth 
muscle mass, wall thickening and abnormalities in elastin.18 These alterations are 
thought to be due to genetic influences, early life exposures, duration of disease and 
long-term uncontrolled inflammation.18 
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Figure 1. Illustrative representation of the pathophysiological changes in asthma19 
 
For many patients, asthma begins in infancy, and both genetic and environmental 
factors contribute to its inception and evolution.20 The mechanisms whereby these 
factors influence the development of asthma are complex, and it is likely that key genes 
interact both with environmental factors and with other genes to determine asthma 
susceptibility.21,22 The apparent racial and ethnic differences in the prevalence of asthma 
reflect underlying genetic variances with a significant overlay of socioeconomic and 
environmental factors (Figure 2).23  
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Figure 2. Effect of the interaction of various types of exposures and genetic backgrounds on the 
prevalence of asthma23 
 
In western medicine, use of bronchodilators for the treatment of asthma started at the 
beginning of the twentieth century,24 and it was not until the 1960s that airway 
inflammation was recognised as an underlying feature.25,26 With the recognition that 
immunologically-medicated responses are integrally linked to the development of 
airway inflammation and hence the inception, persistence and severity of disease, 
treatment of asthma is now being directed principally toward these factors.20 This led to 
the rationale of corticosteroids, now the mainstay of asthma therapy.16 There is now 
good evidence that the clinical manifestations of asthma can be controlled with 
appropriate treatment.27 When asthma is controlled, there should be no more than the 
occasional recurrence of symptoms and severe exacerbations should be rare.16 
1.2 Burden of asthma 
Asthma is a significant health issue worldwide and is the focus of various clinical and 
public health interventions. It is one of the most common chronic diseases in the world, 
affecting an estimated 300 million people.28 The prevalence of asthma increases as 
communities adopt western lifestyles and become urbanised, and the prevalence is 
expected to increase to 400 million by 2025.28 Both morbidity and mortality from 
Th e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 355;21 www.nejm.org november 23, 20062232
children to pets early in life, are either ineffective 
or unverified as primary prevention measures. 
Our view, however, is that the rapid progress in 
the identification of protective microbial sub-
stances has great potential for the development 
of prevention strategies to combat the asthma 
epidemic.
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Figure 4. Effect of the Interaction between Various Types of Exposures and Various Genetic Backgrounds in a Range 
of Racial and Ethnic Groups on the Prevalence of Asthma through Pathways Involving Atopy, Airway Inflammation, 
Airway Hyperresponsiveness (AHR), or Other, Unknown Factors.
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asthma are high despite treatment that is effective for the majority of patients. Even in 
developed countries where patients have easy access to treatment, asthma is often 
under-recognised and under-treated, and sometimes fatal.  
The number of disability-adjusted life years (DALYs) lost due to asthma worldwide is 
estimated to be 15 million per year, which is similar to that for diabetes, liver cirrhosis 
and schizophrenia.29 It is estimated that asthma accounts for one in every 250 deaths 
worldwide.28 Many of these deaths are preventable and are due to suboptimal long-term 
medical care and delay in obtaining help during the final attack. 
International population-based studies suggest that Australia has one of the highest 
prevalence rates for asthma in the world,30 affecting an estimated two million people, or 
10-12% of the Australian population (Figure 3).6,8,31 Exacerbations of asthma lead to 
approximately 40,000 hospitalisations and 105,000 emergency department (ED) visits 
annually.6 In 2003, asthma was the eleventh-leading contributor to the overall burden of 
disease in Australia, accounting for 2.4% of the total number of DALYs.32 In the 
2000-01 financial year, health expenditure due to asthma was $693 million, which was 
1.4% of the total health expenditure in that year.33 In 2006, asthma was identified as the 
underlying cause of 402 deaths (139 males and 263 females).8 
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Figure 3. World map of the prevalence of clinical asthma30 
 
Poorly controlled asthma has been shown to have significant detrimental effects on 
quality of life, performance of daily activities,34-37 and has been associated with 
depression.38,39 Patients with uncontrolled asthma have significantly more 
exacerbations, leading to urgent GP visits, ED visits and hospitalisations, and 
consequently higher treatment costs than those with controlled asthma.40-42 
Asthma has a measurable impact on how people assess their overall health status. The 
2004-05 National Health Survey showed that among people with asthma, 42% rated 
their health as ‘excellent’ or ‘very good,’ compared to 58% of people without asthma. 
On the other end of the scale, 28% of people with asthma rated their health as ‘poor’ 
compared to only 14% of people without asthma.31 Most of the impact of asthma is on 
physical functioning and on the ability to perform social roles, such as work or study. 
It is also known that asthma significantly affects quality of life (QOL) and 
psychological health. A South Australian study reported a higher prevalence of 
depression among people with asthma compared with people without asthma.43 
Furthermore, it was found that people with more severe symptoms of asthma (shortness 
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of breath, waking at night with asthma symptoms or morning symptoms) were more 
likely to suffer from major depression than those without severe symptoms. Quality of 
life scores were also lower for the same groups. 
Findings from the 2004-05 Australian National Health Survey showed that the burden 
of asthma in Australia declined and that some improvements in asthma management 
occurred between 2001 and 2004-05.31 However, despite the existence of 
governmental44 and non-governmental44 initiatives aiming to improve asthma care, the 
results also suggested that socioeconomic disparities are widening and there are still a 
number of areas for improvement. Significant clinical problems persist, including 
under-diagnosis,3,45 limited asthma knowledge,3 under-treatment with inhaled 
corticosteroids (ICS),3,31,46 limited possession of written Asthma Action Plans 
(AAPs)3,31,46-49 and poor patient management skills.50 This evidence suggests that there 
needs to be further research into the most effective way to educate people about asthma, 
maintain their knowledge and empower them to take responsibility for managing their 
asthma effectively.3  
1.3 Asthma control 
The assessment of asthma control has become pivotal in the management of asthma. 
However, several surveys in developed nations have shown that the majority of patients 
with asthma do not enjoy adequate asthma control.31,51-56  
Asthma control refers to control of the clinical manifestations of the disease, and is the 
ultimate goal of asthma management.16 There is a clear relationship between asthma 
severity and asthma control. The underlying severity of asthma in a patient may be 
modified by changes in the environment and by the treatment received for asthma. 
Ultimately, the changes in these environmental and treatment factors will impact on the 
patient’s symptoms and their ability to function. Asthma control reflects the combined 
effect of underlying disease severity, environmental exposures and the effectiveness of 
treatment.57  
A number of patient-related variables may influence asthma control. Laforest et al. 
identified several independent patient-related determinants of inadequate asthma 
control, including female gender, active smoking and overweight status.58 Control also 
varied according to the type of asthma supervision. Patients supervised exclusively by 
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specialists (rather than GPs) were more likely to have their asthma properly controlled. 
Patients who were dispensed combined long-acting beta-2 agonist (LABA) and ICS 
therapy were also more likely to have their symptoms properly controlled, particularly 
at higher doses. 
The Australian National Asthma Council (NAC) recommends the day-to-day 
management of asthma, including adjustment of medications, should closely depend on 
ongoing assessment of asthma control.59 Current asthma guidelines suggest a series of 
criteria to assess if asthma is controlled, as displayed in Table 1.  
Table 1. Assessment of asthma control59 
Level of asthma control 
Parameters 
Good Fair Poor 
Daytime symptoms None < 3 days per week ! 3 days per week 
Night-time symptoms Not woken " 1 night per week > 1 night per week 
Physical activity Normal Normal Restricted 
Exacerbations None Mild, infrequent Moderate-severe, frequent 
Missed work/school None None Any 
Reliever use* None < 3 doses per week ! 3 doses per week 
Lung function (PEF and FEV1)† Normal ! 90% personal best < 90% personal best 
*Does not include one dose per day for prevention of exercise-induced symptoms. †PEF = peak 
expiratory flow; FEV1 = forced expiratory volume in one second. 
Asthma control tools are a useful aid in measuring a patient’s asthma status and are 
designed to support patient consultations.59 The Asthma Control Test is a patient-based 
tool developed60 and validated61 for identifying patients with poorly controlled asthma. 
The five-item test is designed to measure the patient’s level of asthma control during the 
preceding four weeks. Items relate to activity limitation, shortness of breath, nighttime 
symptoms, use of short-acting beta-2 agonists (SABAs) and a self-assessment of asthma 
control. The overall score (the ‘Asthma Score’) out of 25 is given by the addition of the 
response to each item, with a score of 20-25 classed as ‘on target’ and a score of 19 or 
less as ‘off target’ (Figure 4). It has been demonstrated that the asthma score has a good 
predictive ability against outcomes related to asthma and also a good ability to detect 
risk factors.62 The responsiveness of the Asthma Control Test to changes in asthma 
control and lung function has also been reported.61 
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Figure 4. The Asthma Score63 
 
GlaxoSmithKline Australia has created a website whereby a patient’s Asthma Score can 
be easily calculated, using validated questions regarding asthma control.63 Healthcare 
professionals can log in to the site and there is a link available to print out a copy of the 
Asthma Control Test for patients to complete, with a referral form to the patient’s GP to 
use if necessary. The Asthma Foundations and the NAC, as well as the Pharmacy Guild 
and Pharmaceutical Society of Australia, support the Asthma Score. The Asthma Score 
is a helpful screening tool to distinguish patients with good symptom control from 
patients with poor symptom control in an objective and feasible way.64 In particular, the 
Asthma Score can help health professionals identify patients with uncontrolled asthma 
and facilitate their ability to follow the patient’s progress with treatment. 
Achievement of asthma control is the aim of asthma management. To achieve this goal 
it is imperative that asthma be treated and monitored appropriately. GINA stated the 
following in regards to the achievement of asthma control: 
“Complete control of asthma is commonly achieved with 
treatment, the aim of which should be to achieve and maintain 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 34 
control for prolonged periods, with due regard to the safety of 
treatment, potential for adverse effects, and the cost of treatment 
required to achieve this goal.”16  
The individual goals of successful asthma management, as outlined in the GINA 
guidelines, are shown in Table 2.16 The development of international16 and national59 
guidelines for the management of asthma attempts to help the achievement of these 
goals become a reality.  
Table 2. Goals of asthma management16 
1. Achieve and maintain control of symptoms 
2. Maintain normal activity levels, including exercise 
3. Maintain pulmonary function as close to normal as possible 
4. Prevent asthma exacerbations 
5. Avoid adverse effects from asthma medications 
6. Prevent asthma mortality 
 
These goals reflect the understanding of asthma as a chronic inflammatory condition 
that requires ongoing monitoring and management. The first goal, “to achieve and 
maintain control of symptoms,” implies that controlling symptoms by suppressing and 
reversing inflammation is more desirable than treating symptoms as they arise.  
The international Gaining Optimal Asthma controL (GOAL) study sought to investigate 
if guideline-defined asthma control was achievable in 3,421 patients with uncontrolled 
asthma.27 This study found that in the majority of patients with uncontrolled asthma 
across a wide range of severities, control of asthma (measured by PEF, rescue 
medication use, symptoms, night-time awakenings, exacerbations and adverse effects of 
medication) could be achieved and maintained (Figure 5). Furthermore, in stepping up 
treatment in attempt to achieve guideline-defined total control, even those patients who 
did not attain the authors’ stringent definition of control showed considerable 
improvements in health status and a reduction in exacerbation rates. 
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Figure 5. Patients achieving a well controlled week in the GOAL study27 
 
Phase I: Dose escalation phase: treatment stepped up until total control achieved, to a maximum of 
500 µg of ICS daily. Phase II: Patients remained on the dose reached in phase I. 
The GOAL study clearly demonstrated that optimal asthma control can be achieved and 
should be the aim of treatment. The approach of aiming for total control and 
maintaining treatment resulted in the virtual elimination of exacerbations and near-
normal QOL in the majority of patients.27 The findings were strengthened by the large 
size of the study, which involved subjects over a wide range of age, geographic 
location, ethnicity and baseline treatment. Subsequently, international16 and national59 
treatment guidelines refer to this study as evidence that the goals of asthma management 
can be achieved and maintained with appropriate preventive therapy.  
1.4 Guidelines for the management of asthma 
While the drug treatments used in the management of asthma have proven efficacy, 
effective management strategies are imperative to ensure their appropriate use and 
reduce morbidly and mortality of the disease. To achieve and maintain asthma control 
for prolonged periods, recommendations for asthma management have been laid out in a 
number of interrelated components. These components include: 
• Development of a patient/healthcare professional partnership; 
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• Identifying and reducing exposure to risk factors, monitoring control through 
assessment of symptoms and medication use; and  
• Establishing individual plans for disease management and for managing 
exacerbations.16,65 
Several barriers have been shown to reduce the availability, affordability, dissemination 
and efficacy of optimal asthma therapies. As well as the patient barriers identified (such 
as poor education, culture differences and low income), the lack of symptom-based 
guidelines and low public health priority have been recognised as barriers to reducing 
the burden of asthma.28,29 In 1989, the GINA program was initiated in an effort to raise 
awareness among public health and government officials, healthcare professionals and 
the general public that morbidity due to asthma was on the increase.28 GINA works with 
health professionals around the world in an attempt to reduce asthma prevalence, 
morbidity and mortality through resources such as evidence-based guidelines for asthma 
management. The management of asthma has improved considerably over the past 
decade; the World Health Organisation states “asthma management plans have reduced 
mortality and severity in countries where they have been applied.”29 
In Australia, the NAC was launched in 1989, with the major objective of improving 
asthma management in Australia through an educational strategy and the 
implementation of an Australian Asthma Management Plan.66 The NAC was an 
initiative of the stakeholders in asthma care (Thoracic Society of Australia and New 
Zealand, Royal Australian College of General Practitioners, Pharmaceutical Society of 
Australia and the Asthma Foundations Australia) with support from the pharmaceutical 
industry to promote common approaches to asthma management.66 The Australian 
Asthma Management Plan provided guidance and recommendations for health 
professionals in the management of asthma according to a Six Step Plan (Table 3).  
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Table 3. The Australian Six Step Asthma Management Plan59 
1. Assess asthma severity 
Assess overall severity when the patient is stable, not during an acute attack 
2. Achieve best lung function 
Treat with intensive asthma therapy until ‘best’ lung function is achieved 
Back-titrate to lowest dose that maintains good symptom control and best lung function 
3. Maintain best lung function: identify and avoid trigger factors 
Identify and avoid trigger factors and inappropriate medication 
4. Maintain best lung function: optimise medication program 
Treat with the least number of medications and use the minimum doses necessary 
Ensure the patient understands the difference between ‘preventer,’ ‘reliever,’ and ‘symptom controller’ 
medications 
Take active steps to reduce the risk of adverse effects from medication 
5. Develop an action plan 
Discuss and write down an individualised care plan for the management of exacerbations 
Detail the increase in medication doses and include when and how to gain rapid access to medical care 
6. Educate and review regularly 
Ensure patients and their families understand the disease, the rationale for their treatment and how to 
implement their action plan 
Review inhaler technique at each consultation 
Review adherence at each consultation 
 
After the implementation of these consensus-based guidelines, there was evidence to 
suggest that the NAC may have contributed to increased awareness and improved 
management of asthma in Australia.67 However, during the late 1990s it became clear 
that a higher level of activity was needed to maintain the progress of the NAC, as 
asthma management was still suboptimal.49,50,68 
In recognition of the significant burden that asthma places on the Australian community 
in terms of health, social, economic and emotional costs, Australian Health Ministers 
announced asthma as a National Health Priority Area in 1999.69 Subsequently, the 
Commonwealth Government announced the $48.4 million National GP Asthma 
Initiative in the 2001 National Health Budget to improve health outcomes of people 
with moderate-to-severe asthma. The GP Asthma Initiative promotes the use of the 
Asthma Cycle of Care (formerly the Asthma 3+ Visit Plan), which utilises a structured 
approach to asthma care, as the best practice model of managing asthma, recognising 
that effective long-term management of asthma requires ongoing care and regular 
review. The Asthma Cycle of Care has largely replaced the Six Step Asthma 
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Management Plan in general practice. Currently, the two most important resources for 
asthma management in Australia are the Asthma Cycle of Care and the Asthma 
Management Handbook.70 
The Asthma Cycle of Care encourages partnerships in proactive asthma care between 
the patient and their health professionals, and involves at least two asthma-related 
consultations within 12 months for a patient with moderate-to-severe asthma. The visits 
include an assessment of asthma severity and level of asthma control, a review of the 
patient’s use of asthma-related medication and devices, and asthma self-management 
education. An integral part of the Asthma Cycle of Care is the development of a written 
Asthma Action Plan (AAP), which helps the patient or carer recognise worsening 
asthma and adjust asthma therapy accordingly, in an attempt to prevent severe 
exacerbations.  
At a minimum, the Asthma Cycle of Care must include: 
• At least two asthma related consultations within 12 months for a patient with 
moderate-to-severe asthma; 
• At least one of these consultations (the review consultation) to have been planned 
at a previous consultation; 
• Documentation of diagnosis and assessment of asthma severity and level of 
asthma control; 
• Review of the patient’s use of, and access to, asthma related medication and 
devices; 
• A written asthma action plan (or documented alternative if the patient is unable 
to use a written action plan); 
• Provision of asthma self-management education; and  
• Review of the written or documented asthma action plan.70,71 
Ongoing patient education is vital to creating a partnership between patients and 
healthcare professionals, which can then contribute to successful asthma care.65 
However, it has been shown that the acquisition of knowledge by patients does not 
necessarily translate into effective self-management behaviour.72,73 It is therefore 
imperative that the patient not only understands their condition, including the purpose of 
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medication and inhalation technique, but also the importance and value of self-
monitoring and self-management of their asthma. Overall, four main components of 
asthma education programs have been identified:  
• Information about asthma;  
• Self-monitoring;  
• Regular medical review; and  
• A written action plan.74 
The NAC also publishes the Asthma Management Handbook, which is revised every 3-
4 years. It comprises guidelines for delivery of best-practice asthma care in general 
practice plus practical strategies for implementation.70 
The Asthma Management Handbook aims to help clinicians and other health 
professionals make changes in their practice based on sound evidence, and where 
evidence is lacking, the consensus opinion of Australian experts has been incorporated. 
The Handbook acknowledges the difficulties of providing organised care in the primary 
care setting and tries to provide practical strategies that will assist with diagnosis, 
ongoing management and patient education. While primarily aimed at GPs, the 
Handbook is also intended as a resource and teaching tool for community pharmacists, 
nurses, asthma educators, ambulance officers, consumer representatives and healthcare 
students, emphasising a team approach to asthma care. The latest (2006) edition 
contains: 
• Updated diagnostic, management and prescribing guidelines; 
• Expanded material on asthma and allergy, exercise-induced asthma, occupational 
asthma, asthma in pregnancy and in older people and co-morbidities; 
• More detail on diet and complementary medicine; 
• New chapters on smoking cessation and asthma prevention; and 
• Practical advice on providing structured asthma care in the primary care setting.59 
The Asthma Management Handbook and the Asthma Cycle of Care remain the 
backbone of asthma care in Australian general practice. However, a number of 
Australian studies have reported that, unfortunately, asthma management still falls well 
short of the NAC guidelines. Research has shown that a significant proportion of people 
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with asthma still do not have a written AAP,3,31,46-48 have poorly controlled asthma, and 
do not regard asthma as a chronic disease, but rather an intermittent problem requiring 
emergency management.75-77 It is unclear whether incomplete implementation of the 
NAC guidelines is the result of time shortage or lack of interest on the part of the GP or 
the patient. There is evidence to suggest that even extensive educational strategies have 
limited impact on clinical care and outcomes.78 There are clearly barriers to the 
implementation of certain components of the guidelines, particularly in light of the 
evidence for low rates of AAP possession and use of ICS, which need to be overcome.  
1.5 Self-management plans 
An integral part of the Asthma Cycle of Care is the development of a written AAP, 
which helps the patient or carer recognise worsening asthma. AAPs have become a core 
component of asthma management in Australia in accordance with best practice 
guidelines. The idea of a written action plan is that the patient is given a set of rules by 
which to alter therapy, dependent on either PEF monitoring or symptom levels. The 
implication is that an appropriate, early response to deterioration will prevent dangerous 
exacerbations and will generally improve health-related QOL. AAPs contain four 
essential components:  
• Instructions on when to increase treatment; 
• How to increase treatment; 
• The duration of the treatment increase; and  
• When to cease self-management and seek medical help.79  
An individualised AAP should be tailored to the patient’s underlying asthma severity 
and treatment. An example of an AAP template developed by the NAC, the Australian 
Department of Health and Ageing, and the Asthma Foundations Australia as part of the 
Asthma Cycle of Care,80 is shown in Figure 6. 
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Figure 6. Asthma Action Plan template80 
 
A key part of AAP use is helping people with asthma to observe themselves and their 
own actions, and learn from these to support self-care behaviours and integrate these 
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into their daily routines.79 Increasing patient participation in their own care has been 
shown to be associated with improved asthma management, independent of asthma 
symptoms.81 Gibson et al. found that patients with asthma have a strong desire for 
knowledge of their condition, but do not prefer to make decisions alone during an 
exacerbation. The preferred option is for joint decision making between the patient and 
GP.82 On the other hand, Adams et al. reported that patients preferred GPs to assume the 
major role in most decision-making about their management. However, they wished to 
retain control in choosing when to seek care and wanted shared decisions regarding 
initiating changes in medications during a moderate exacerbation.83 In fact, it has been 
shown that lower preferences for autonomy in decision making with regard to initiating 
treatment changes during an asthma exacerbation are associated with an increased risk 
of admission to hospital with asthma.84  
It is essential that the provision of a written AAP be coupled with self-management 
education and regular GP reviews. Together, these are high-profile parts of Steps 5 and 
6 of the Australian Asthma Management Plan: ‘develop an action plan’ and ‘educate 
and review regularly.’ A systematic review of 36 RCTs provided evidence that the use 
of a written AAP in conjunction with training in self-management and regular medical 
review improves health outcomes in patients with asthma.74 Self-management education 
reduced hospitalisations (relative risk [RR] 0.64, 95% confidence interval [CI] 0.50-
0.82), ED visits (RR 0.82, 95% CI 0.73-0.94), unscheduled visits to the doctor (RR 
0.68, 95% CI 0.56-0.81), days off work or school (RR 0.79, 95% CI 0.67-0.93), 
nocturnal asthma (RR 0.67, 95% CI 0.56-0.79) and QOL (standard mean difference 
0.29, 95% CI 0.11-0.47). Furthermore, evidence from a case-control study of people 
who had died from asthma showed that the presence of a written AAP was associated 
with a 70% reduction in the risk of death.85 
1.6 Pharmacological therapy 
1.6.1 Short-acting beta-2 agonists 
Short-acting beta-2 agonists (SABAs) such as salbutamol and terbutaline are the 
mainstay drugs for acute relief of asthma symptoms, and the prevention of exercise-
induced bronchoconstriction.59 Asthma management guidelines recommend that an 
inhaled SABA be prescribed as standard reliever therapy and should be carried by all 
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patients with symptomatic asthma (except those using Symbicort® Maintenance And 
Reliever Therapy).16,59 
The beta agonists, one of the oldest classes of drugs used in medicine, were used in the 
treatment of asthma long before their mechanism was understood.86 Non-selective 
adrenoceptor agonists have been used to relieve bronchoconstriction for at least 5,000 
years, but were only introduced into western medicine in the 1920s.87 More selective 
beta-2 agonists, such as fenoterol, salbutamol and terbutaline, were developed in the 
1960s.24 
The link between the use of SABA and the rising asthma death rate has been the subject 
of ongoing debate.88 A number of studies have implicated regular and perhaps excessive 
use of SABA in asthma deaths and near-death emergencies89-95 and worse clinical 
outcomes.96-98 While the epidemic deaths from asthma have only occurred with 
isoprenaline and fenoterol, both of which have subsequently been withdrawn from the 
market,86 salbutamol has never been associated with an increased risk of asthma deaths, 
despite the very high sales in many countries.99 The concerns about adverse outcomes 
with frequent and regular SABA use are likely to have mainly been related to 
suboptimal use of ICS in patients whose asthma was inadequately controlled and 
treated.85 
The development of tolerance to bronchodilator activity may be a concern with patients’ 
prolonged use of SABAs.100 Some studies have shown a reduction in bronchodilator 
response with prolonged treatment with SABAs,101-103 while others have shown that 
patients with asthma are resistant to the development of SABA tolerance.104-106 Multiple 
mechanisms may modulate clinical responses to SABAs, such as genetic variation, 
receptor function, coexisting bronchial inflammation and interactions with other 
drugs.107 Genetic polymorphisms affecting amino-acids at positions 16 and 27 within 
the beta-2 receptor gene have been implicated in the asthma phenotypes and influence 
on the variability observed in response to use of bronchodilator agents used in the 
treatment of asthma.108,109 
A systematic review of 44 RCTs gave reassuring evidence against the concerns over 
regular use of SABAs.110 All trials consisted of an experimental group (who were given 
a SABA regularly, together with a SABA for rescue use) and a control group (who were 
given a matching placebo for regular use with an SABA for rescue use). While the 
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regular treatment groups required less rescue medication and had fewer days with 
asthma symptoms, no significant differences were found in airway calibre 
measurements or exacerbation rates. Nevertheless, SABAs are recommended in all 
stages of asthma on an as-needed basis only, as they do not treat the underlying 
inflammation. Increasing use of SABAs is a warning of deterioration of asthma control 
and indicates the need to reassess management.16 
1.6.2 Inhaled corticosteroids 
Current international16 and Australian59 guidelines recommend that all patients with 
persistent asthma of all levels of severity use ICS as preventive therapy. ICS are 
currently the most effective anti-inflammatory medications for the treatment of 
persistent asthma. Their clinical benefits include decreased asthma symptoms,111-114 
improved lung function,111-114 fewer exacerbations,115 fewer hospitalisations116-120 and 
fewer asthma-related deaths.121-124 However, they do not cure asthma, and when they 
are discontinued deterioration of clinical control follows within weeks to months in a 
proportion of patients.125-127 
It is well established that in adults, persistent asthma requires regular long-term 
preventive medication to maintain good control.128 Evidence-based guidelines over the 
past decade, including the NAC’s Six Step Asthma Management Plan, have emphasised 
the importance of the regular use of anti-inflammatory drugs (preferably ICS) as first-
line therapy for anything more severe than occasional mild asthma and a shift of 
approach away from reliance on relievers. Asthma guidelines recommend that 
maintenance ICS be prescribed at the lowest effective dose according to the severity of 
the condition.16,59 The NAC recommends that treatment with ICS should be considered 
for patients with any of the following: 
• Exacerbations of asthma in the last two years; 
• Use of reliever medication three times a week or more; 
• Asthma symptoms three times a week or more; 
• Waking at least one night per week due to asthma symptoms; and/or 
• Impaired lung function.59 
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There have been a number of studies in the international literature indicating that a high 
usage of reliever medication, relative to preventer medication, is associated with poorer 
clinical outcomes of asthma, including increased ED visits and hospital 
admissions.117,129-132 Eisner et al. found that dispensing of medium to high level ICS 
therapy was associated with a reduced risk of intensive care unit (ICU) admission, 
whereas high level inhaled beta-2 agonist dispensing was associated with an increased 
risk of both ICU admission and endotracheal intubation for asthma. Importantly, 
stratified analysis indicated that this excess risk was observed only among patients not 
receiving ICS therapy.131 Salamzadeh et al. reported similar findings: patients who had 
a lower ratio of regularly prescribed preventers to relievers were prescribed more oral 
prednisolone rescue courses for acute exacerbations. The authors mentioned that GPs 
and/or patients tended to control the asthma worsening episodes by prescribing/taking 
more relievers rather than preventive anti-inflammatory inhalers which are 
recommended as the mainstay of treatment.129  
It has been reported that for patients with asthma who require ICS, starting at a 
moderate dose (Table 4) is equivalent to starting with a high dose and stepping down, 
and that initial medium ICS doses appear to be more effective than an initial low ICS 
dose.133 It is essential that the ICS treatment is individualised, as too high a dose may 
result in adverse effects and too low a dose may result in under treatment and poor 
asthma control. 
Table 4. ICS daily dose equivalents: what is meant by low, medium and high daily doses?59 
Dose level Ciclesonide Beclomethasone-HFA* Fluticasone Budesonide 
Low 80-160 µg 100-200 µg 100-200 µg 200-400 µg 
Medium 160-320 µg 200-400 µg 200-400 µg 400-800 µg 
High Over 320 µg Over 400 µg Over 400 µg Over 800 µg 
*HFA = Hydrofluoroalkane 
While the available ICS differ in their potencies, (beclomethasone-HFA equivalence: 
beclomethasone-HFA 100 #g = fluticasone 100 #g = budesonide 200 #g = ciclesonide 
80 #g134-136) available evidence suggests that they have similar clinical effects at 
equivalent doses.137-140 ICS demonstrate a relatively flat dose-response relationship for 
the majority of important clinical efficacy measures, however, patients with more severe 
symptoms and poorer asthma control may benefit from higher doses.141-143 In mild-to-
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moderate asthma, marked clinical improvements have been seen in most studies in the 
low-to-moderate dose range.141-143 Doses in excess of that range increase the risk of 
systemic adverse effects.144 
More pronounced than the dose-related clinical effects of ICS, are the dose-related 
adverse effects. For most patients, the main effect of increasing ICS dose in asthma is to 
increase adverse effects, with little additional benefit to the patient (Figure 7). 
Figure 7. Comparison of the relative effects of increasing doses of fluticasone in asthma145 
 
Results for fluticasone are displayed in terms of benefit (number needed to treat; NNT) and harm (number 
need to harm; NNH) on a logarithmic scale, with the relevant portion of the 95% CI (shaded area). 
*Significant heterogeneity present (P < 0.05). 
There is an increased risk of systemic adverse effects with long-term treatment with 
high dose ICS. An important adverse effect is dose-related suppression of the 
hypothalamic-pituitary-adrenal axis. A systematic review of 27 RCTs found that 
marked adrenal suppression occurs with high doses of ICS above 750 #g per day 
(fluticasone-equivalent).146 Other dose-related adverse effects, such as osteoporosis, 
glaucoma, cataracts and skin thinning are largely restricted to adult patients treated 
long-term with high dose ICS. 
Of particular concern to parents is growth suppression from ICS, and a number of 
studies have been conducted to determine the effect of ICS on height. In the Prevention 
of Early Asthma in Kids trial the difference in growth rate was significant between the 
fluticasone and control groups in the first year of the study (6.6 ± 1.0 cm per year in the 
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fluticasone group versus 7.3 ± 1.0 cm per year in the placebo group, P < 0.01), but not 
during the second year of treatment.147 In the third year observation period, the children 
who had been regularly treated with ICS grew more quickly than the children in the 
control group (7.0 ± 0.8 cm per year versus 6.4 ± 0.9 cm per year, P < 0.01). In the 
Childhood Asthma Management Program study, children using inhaled budesonide 
were 1.1 cm shorter than the controls at the end of the four-year treatment phase.148 
However, a 14-year prospective study of children treated with budesonide found that 
while growth decreased significantly after commencing budesonide, from a mean of 
6.1 cm per year (95% CI 5.7-6.5) to 5.1 cm per year in the first year (95% CI 4.7-5.5, 
P < 0.001) and 5.2 cm per year in the second year (95% CI 5.1-5.9, P < 0.05), 
subsequent growth was no different to controls.149 Furthermore, there was no relation 
between the initial reduction in growth rate after commencing ICS therapy and the 
difference between predicted and attained adult height, suggesting that the initial growth 
suppression was transient and had little long-term consequence. Evaluation of growth in 
children with asthma is complicated, because the severity of asthma has been 
demonstrated to have a significant negative correlation with height, regardless of ICS 
therapy.150 Although the apparent safety of low dose ICS in children with respect to 
growth suppression seems evident, it remains important to monitor growth in all 
children who take ICS long-term, at any dose.59 
Because of the potential of ICS for causing dose-related adverse effects, asthma 
management guidelines recommend a reduction in their dose once asthma control is 
established.16,59 In particular, the NAC recommends that the step-down of ICS should be 
considered after effective asthma control has been in place for 6- 12 weeks, decreasing 
the dose by approximately 25 to 50% each time.59 There is evidence that a reduction in 
ICS dose can be achieved by adopting a sensible step-down approach, without 
compromising asthma control.151 
1.6.3 Long-acting beta-2 agonists 
Long-acting beta-2 agonists (LABAs), or ‘symptom controllers,’ provide prolonged 
bronchodilation, reduction in day- and night-time symptoms, improved quality of sleep 
and reduced requirement for SABAs.152 However, while salmeterol is a partial agonist 
at the beta-2 receptor, achieving maximum effect after about 60 minutes,153 eformoterol 
is almost a full agonist, achieving a more rapid onset of action with substantial effect at 
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five minutes similar to salbutamol.154 In contrast to SABAs, LABAs were designed 
specifically for regular use, as their duration of action is at least 12 hours. LABAs were 
introduced as prospective ‘symptom controllers,’ to prevent symptoms, whether 
spontaneous or due to some environmental or activity-related airway hyper-
responsiveness.155 The results of 31 RCTs have demonstrated that regular use of 
LABAs gives significantly better asthma control, as measured by lung function and 
frequency of symptoms, than regular use of SABAs.156 While a decrease in lung 
function has been demonstrated with SABAs,101,102 no tendency to develop tolerance 
has been demonstrated with salmeterol157,158 or eformoterol.159-161 
A systematic review of 67 RCTs (42,333 patients) demonstrated significant advantages 
of LABA treatment compared to placebo, regardless of whether patients were taking 
ICS or not.162 Patients treated with LABAs demonstrated significantly improved lung 
function, as demonstrated by improved morning PEF, evening PEF and FEV1, 
significantly fewer symptoms, less use of rescue medication and higher quality of life 
scores.  
When LABAs were first developed and marketed, concerns about the link between 
regular use of SABA and asthma deaths were the subject of ongoing debate. It was 
initially suggested that LABAs could be free of the fatal adverse drug reactions 
associated with their short-acting counterparts.163 Since then, two large RCTs have been 
performed to test the hypothesis that the use of LABAs in patients with asthma is 
associated with a increased risk of death.164,165 
The Serevent® Nationwide Surveillance Study was a 16-week RCT whereby 25,180 
patients with asthma were randomly allocated to salmeterol 50 #g twice daily or 
salbutamol 200 #g four times daily.164 The only significant difference between the 
groups was the number of medical withdrawals due to asthma, which were fewer with 
salmeterol than with salbutamol (2.91% versus 3.79%, &2 = 13.6, P < 0.001). Death due 
to any cause occurred in 0.32% of the patients in the salmeterol group and in 0.24% of 
the patients in the salbutamol group (RR 1.35, &2 = 1.3, P = 0.25). The corresponding 
figures for death due to asthma or airway disease were 0.07% and 0.02% (RR 3.00, 
P = 0.11). The main conclusion of this trial was that more deaths occurred with 
salmeterol but, compared with salbutamol, this difference was not statistically different. 
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The Salmeterol Multicenter Asthma Research Trial was a 28-week safety study that 
compared salmeterol 42 #g twice daily to placebo in the treatment of patients with 
asthma.165 Following an interim analysis of 26,355 patients, the study was terminated 
due to an excess of respiratory-related deaths in the salmeterol group. Respiratory-
related deaths occurred in 0.18% of the patients in the salmeterol group and in 0.08% of 
the patients in the placebo group (RR 2.16, 95% CI 1.06-4.41, P < 0.05). The 
corresponding figures for asthma-related deaths were 0.10% and 0.02% (RR 4.37, 
95% CI 1.25-15.34, P < 0.05), and for combined asthma-related deaths or life-
threatening experiences were 0.28% and 0.17% (RR 1.71, 95% CI 1.01-2.89, P < 0.05). 
Post-hoc exploratory subgroups suggested that African-Americans and those not on ICS 
at baseline were at particular risk of respiratory- or asthma-related deaths or life-
threatening experiences. 
In a recent systematic review, the data from the two large studies164,165 were combined; 
in patients who were not taking ICS, compared to regular salbutamol or placebo, there 
was a significant increase in risk of asthma-related death with regular salmeterol (odds 
ratio [OR] 9.52, 95% CI 1.24-73.09).166 Because the confidence interval was wide, it 
could not be concluded that the ICS abolish the risks or regular salmeterol. In addition, 
the review of 26 RCTs comparing salmeterol to placebo found that all cause mortality 
was higher with regular salmeterol than placebo, but the increase was not significant 
(OR 1.33, 95% CI 0.85-2.10). However, non-fatal serious adverse events were 
significantly increased when regular salmeterol was compared to placebo (OR 1.14, 
95% CI 1.01-1.28). Similarly, a systematic review of 22 RCTs comparing eformoterol 
to placebo found that all cause mortality was higher with regular eformoterol than 
placebo, but the increase was not significant (OR 1.52, 95% CI 0.24-9.71). Again, non-
fatal serious adverse events were significantly increased when regular eformoterol was 
compared to placebo (OR 1.57, 95% CI 1.05-2.37).167 
While acknowledging the value of LABAs in asthma treatment, asthma management 
guidelines insist that these drugs should only be used alongside ICS either as separate 
inhalers or, preferably as combination products in the same inhaler. LABA 
monotherapy is not recommended.16,59  
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1.6.4 Combination therapy 
The addition of LABA to ICS should be considered when asthma symptoms or 
suboptimal lung function persist on a medium dose of ICS, or when it is desirable to 
reduce the current dose of ICS while maintaining optimal asthma control.59 
A systematic review of 10 RCTs demonstrated that the addition of a LABA to ICS 
therapy improves asthma symptoms, reduces exacerbations and permits a reduction in 
ICS maintenance dose.168 Specifically, studies that compared reduced dose ICS/LABA 
combination to a fixed moderate to high dose ICS reported significant improvements in 
lung function and percent rescue free days with the ICS/LABA combination therapy. 
LABA permitted a reduction of 37% in patients on minimum maintenance ICS and up 
to 60% in patients on maintenance ICS without deterioration in asthma control. 
However, the review also found no significant difference in the number of severe 
exacerbations requiring oral corticosteroids when comparing the ICS/LABA 
combination to ICS alone. Another systematic review of 30 RCTs, published in the 
same year, compared ICS/LABA combination to a higher dose of ICS. This review 
reported similar findings, with significant improvements in lung function, symptom-free 
days and use of rescue SABA with combination therapy, but no significant difference in 
the rate of patients with exacerbations requiring systemic corticosteroids.169 However, a 
third systematic review of 49 RCTs compared LABA to placebo in addition to ICS and 
reported a reduced risk of exacerbations with ICS/LABA combination therapy.170 The 
addition of a daily LABA reduced the risk of exacerbations requiring systemic 
corticosteroids by 19% (RR 0.81, 95% CI 0.73-0.90). The number needed to treat for 
one extra patient to be free from exacerbation for one year was 18 (95% CI 13-33). 
Furthermore, it has been demonstrated that adding a LABA to an ICS is significantly 
more effective in increasing time with well controlled asthma when compared to 
increasing the ICS dose fourfold.171 
In addition to their bronchodilator action, there is also evidence that LABAs have an 
anti-inflammatory and anti-remodelling effect on the airway in patients already taking 
ICS.172,173 Treatment of human lung fibroblasts and vascular smooth muscle cells with 
beta-2 agonists has been shown to cause enhanced movement of the glucocorticoid-
glucocorticoid receptor complex from the cytoplasm into the nucleus, where it 
modulates gene transcription and exerts its anti-inflammatory action.174 
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There is insufficient evidence at present to recommend use of combination ICS/LABA 
therapy rather than ICS alone as first-line treatment.175 The NAC recommends a LABA 
should be the first choice for add-on therapy in patients whom adequate asthma control 
is not achieved despite low dose ICS treatment, after ruling out poor adherence and poor 
inhalation technique as causes.59 In an attempt to improve adherence, devices are 
available combining ICS and LABA therapy in a single inhaler.  
Currently, two ICS/LABA combinations are available in single inhalers. Seretide® 
contains fluticasone and salmeterol, and Symbicort® contains budesonide and 
eformoterol. Due to the increasing use of these combinations, a systematic review was 
recently performed on five RCTs (5,537 patients) to compare the relative effects of 
fluticasone/salmeterol and budesonide/eformoterol.176 Lung function outcomes, 
symptoms, use of rescue medication, exacerbations requiring systemic corticosteroids, 
ED visits, hospital admissions and adverse events were not significantly different 
between treatments. 
In light of the growing evidence that many patients neglect their preventer medication 
and over-rely on reliever medication, a new asthma management strategy has been 
evaluated in a series of clinical trials.177-180 The strategy utilises a single inhaler 
containing an ICS (budesonide) and a LABA with immediate onset of action 
(eformoterol) for both maintenance therapy and symptom relief. For patients with 
persistent asthma symptoms despite the regular use of ICS, studies have found that 
fewer severe exacerbations occurred with the maintenance and reliever regimen when 
compared to the conventional combination regimen of regular ICS plus a SABA when 
required. Table 5 summarises the results of COMPASS, the only published double-blind 
trial where the maintenance and reliever regimen was compared to a higher-dose 
conventional regimen.177 
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Table 5. Rates of severe exacerbations in the COMPASS trial177 
Treatment group Severe exacerbations per 100 patients per six months 
Average daily ICS dose 
(budesonide equivalent) 
Budesonide with eformoterol 
(maintenance and reliever regimen) 
(n = 1107) 
   12* 604 µg 
Budesonide with eformoterol plus 
terbutaline as needed (conventional 
regimen) (n = 1105) 
16 800 µg 
Fluticasone with salmeterol plus 
terbutaline as needed (conventional 
regimen) (n = 1123) 
19 800 µg 
*The number of severe exacerbations was significantly less than with the budesonide with eformoterol 
conventional regimen (P < 0.01) and also significantly less than with the fluticasone with salmeterol 
conventional regimen (P < 0.001). 
In August 2007, the Pharmaceutical Benefits Scheme listing of budesonide with 
eformoterol 100/6 µg and 200/6 µg (Symbicort®) was extended to allow Australians 
who experience frequent asthma symptoms while receiving combination ICS/LABA 
therapy or ICS alone to use the alternative budesonide with eformoterol maintenance 
and reliever regimen.181 The NAC has endorsed this new regimen (commonly called 
Symbicort® Maintenance And Reliever Therapy; SMART), with a SMART-specific 
written AAP now available.80 
1.6.5 Leukotriene receptor antagonists 
According to current national59 and international16 guidelines, ICS are the preferred 
anti-inflammatory medications for the treatment of persistent asthma. However, 
leukotriene receptor antagonists (LTRAs; montelukast and zafirlukast) may be an 
alternative treatment for mild persistent asthma. Placebo-controlled trials have 
demonstrated that LTRAs improve lung function, reduce symptoms and asthma 
exacerbations in adults182-184 and children.185-187 
A systematic review of 27 RCTs found that LTRAs are less effective than ICS in adults 
with asthma. Patients treated with LTRAs were 65% more likely to suffer an 
exacerbation requiring systemic corticosteroids (RR 1.65, 95% CI 1.36-2.00).188 In 
patients already on ICS, LTRAs cannot be substituted without risking the loss of asthma 
control.189-191 While the addition of a LTRA to ICS therapy appears to be comparable to 
increasing the dose of ICS,192 a systematic review of 15 RCTs found that LABAs are 
more effective than LTRAs as add-on therapy.193 The risk of exacerbations requiring 
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systemic corticosteroids was 17% lower with ICS plus a LABA when compared to ICS 
plus a LTRA (RR 0.83, 95% CI 0.71-0.97). 
Clinical guidelines for adult patients, in accordance with safety and efficacy data, 
recommend that LTRAs be reserved as add-on therapy to ICS when LABAs are not 
tolerated, or when adequate control of asthma is not achieved with first line therapy.16,59  
1.6.6 Cromones 
Cromones (cromoglygate and nedocromil) are anti-inflammatory agents that may be 
used as an alternative to ICS for the long-term treatment of asthma. Cromones have the 
advantage of having a well-established safety profile, with no significant adverse 
effects.194  
Although their efficacy is well-established in adults,195 systematic reviews have casted 
doubt on the efficacy of cromones in children.196,197 The cromones appear to work best 
for patients who have mild asthma, although they are not effective for all such patients, 
and it is difficult to predict which patients will respond.198 Therapeutic efficacy is 
usually obvious within one to two weeks but a four-week trial is recommended before 
considering other treatments.59 
A systematic review of 17 RCTs involving 1,279 children and eight RCTs involving 
321 adults found that ICS were superior to cromoglygate on measures of lung function 
and asthma control for both adults and children with chronic asthma.199 Among children 
aged 2 to 18 years, ICS were associated with a higher final mean FEV1 (weighted mean 
difference 70 mL, 95% CI 20-110) and higher mean PEF (weighted mean difference 
17.3 L/minute, 95% CI 11.3-23.3). In addition, ICS were associated with fewer 
exacerbations (weighted mean difference -1.18 exacerbations per year, 95% CI -2.5 to 
-0.21), lower asthma symptom scores, and less rescue bronchodilator use than 
cromoglygate. Among adults, ICS were similarly associated with a higher final mean 
FEV1 (weighted mean difference 210 mL, 95% CI 130-280) and higher mean PEF 
(weighted mean difference 28.2 L/minute, 95% CI 18.7-37.6). ICS were also associated 
with fewer exacerbations (weighted mean difference -3.30 exacerbations per year, 
95% CI -5.62 to -0.98), lower asthma symptom scores among cross-over trials but not 
parallel trials, and less rescue bronchodilator use than cromoglygate. When added to 
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ICS therapy, cromoglygate has shown little or no benefit,200-203 suggesting it is not 
effective as steroid-sparing therapy. 
International guidelines state that the role of cromones in long-term treatment of asthma 
in adults and children is limited.16 Because their action is short, inhaled cromones must 
be used four times daily, an inconvenient regimen for long-term treatment. While there 
is a role for cromoglygate and nedocromil in the prevention of exercise-induced 
asthma,59 they are less effective than SABAs.204 
1.6.7 Methylxanthines 
Asthma management guidelines recommend that theophylline can be used as add-on 
therapy to patients not controlled by low doses of ICS, but recommend LABAs as being 
more effective with fewer adverse effects.16,59 Theophylline may be indicated as 
maintenance treatment in patients with severe asthma who require multiple drugs to 
achieve symptom control.59,205  
There is evidence that theophylline has anti-inflammatory and immunomodulatory 
actions at lower plasma concentrations (5-10 mg/L).206-210 However, these inflammatory 
actions do not render theophylline an alternative anti-inflammatory agent to ICS in 
asthma management, as several studies have shown that ICS have a more preferable 
risk/benefit profile than theophylline in the treatment in asthma.211-215 
Theophylline may be useful as add-on therapy to ICS in some patients. In patients with 
severe asthma, its benefits have been demonstrated by significant improvement in lung 
function and asthma symptoms after the addition of theophylline to high doses of 
ICS,216 and by the worsening of lung function and asthma symptoms when theophylline 
is withdrawn, even when high doses of ICS or oral corticosteroids are continued.207,217-
221 Studies have also reported a steroid-sparing effect of theophylline.222 However, the 
role of theophylline in the treatment of asthma has declined, and has now been largely 
superseded by LABAs.59 
A systematic review of 12 RCTs (1,344 patients) found that LABAs, particularly 
salmeterol, are significantly more effective than theophylline, regardless of concomitant 
ICS use.223 While there was no significant difference between salmeterol and 
theophylline in FEV1 predicted, salmeterol treatment led to significantly better morning 
PEF (mean difference 16.71 L/minute, 95% CI 8.91-24.51) and evening PEF (mean 
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difference 15.58 L/minute, 95% CI 8.33-22.83). Salmeterol also reduced the use of 
SABA, while eformoterol, used in two studies, was reported to be as effective as 
theophylline. Salmeterol was significantly less likely to produce central nervous system 
adverse events (RR 0.50, 95% CI 0.29-0.86) and gastrointestinal adverse events (RR 
0.30, 95% CI 0.17-0.55) when compared to theophylline. 
The soluble ethylene diamine salt of theophylline, aminophylline, was originally 
developed for intravenous administration and shown to be very effective in acute severe 
asthma, particularly in patients who had not responded well to adrenaline.224 However, 
in the management of acute asthma exacerbations, intravenous aminophylline has been 
superseded by the use of high doses of SABAs, as they are more effective and safer. 
Aminophylline does not appear to confer any additional benefit when added to SABAs 
and is now usually reserved for the rare patients with severe exacerbations who do not 
respond adequately to SABA therapy.225 
The benefits of theophylline are limited by its toxicity. It has a narrow therapeutic index 
requiring dose titration and regular monitoring of serum concentrations to avoid adverse 
effects. Early pharmacokinetic studies demonstrated that the bronchodilator effect of 
theophylline was related to plasma concentration of 5-20 mg/L, but above 20 mg/L, 
adverse effects were very common.226,227 This led to recommendations for a therapeutic 
range of 10-20 mg/L. Theophylline is extensively metabolised in the liver by 
CYP1A2,228 thus drugs that inhibit this enzyme may increase plasma theophylline 
concentrations to levels that produce adverse effects.229 The most common adverse 
effects are headache, nausea and vomiting, abdominal discomfort and restlessness. 
There may also be increased gastric acid secretion, abdominal discomfort, 
gastoesophageal reflux and diuresis. At high concentrations, convulsions, cardiac 
arrhythmias and death may occur.230 
1.6.8 Anticholinergics 
Ipratropium and tiotropium are inhaled anticholinergic bronchodilators with a slower 
onset of action (30-60 minutes) than SABAs. Ipratropium has a duration of action of 
approximately four hours, whereas tiotropium’s duration of action is close to 24 hours. 
The addition of ipratropium to a SABA has shown benefit in the initial management of 
moderate-to-severe asthma exacerbations.231 A systematic review of 32 RCTs (3,611 
patients) found significant reductions in hospital admissions in both children (RR 0.73, 
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95% CI 0.63-0.85) and adults (RR 0.68, 95% CI 0.53-0.86) who received inhaled 
anticholinergics combined with a SABA, compared to those receiving SABA alone in 
the emergency setting.232 Combined treatment also produced a significant increase on 
spirometric tests at 60-120 minutes after the last treatment in children and adults. 
The role of inhaled anticholinergics in the day-to-day management of asthma is limited. 
Systematic review evidence suggests that although ipratropium is better than placebo in 
adults with chronic asthma, the size of the effect is small.233 When used in combinations 
with a SABA, ipratropium does not appear to add much benefit. Available data has not 
shown any clear advantages of ipratropium over placebo in children with chronic 
asthma.234,235 While clear benefits of inhaled anticholinergics in the long-term 
management of asthma are yet to be established they are recognised as alternative 
bronchodilators for patients who experience such adverse effects as tachycardia, 
arrhythmia and tremor from beta-2 agonists.16 
1.6.9 Anti-IgE treatment 
Omalizumab is a recombinant monoclonal anti-immunoglobulin (Ig) E antibody 
approved for the treatment of patients with severe allergic asthma, who are already 
being treatment with ICS and who have raised serum IgE levels.16,59,236 Elevated serum 
levels of IgE in response to common aeroallergens are a key component in the 
pathogenesis of atopic asthma.237,238 Omalizumab prevents free serum IgE from 
attaching to mast cells and other effector cells and prevents IgE mediated inflammatory 
changes.239,240 Studies in patients with atopic asthma showed that anti-IgE antibodies 
decrease serum IgE levels in a dose-dependent manner and allergen-induced 
bronchoconstriction during both the early and late-phase responses to inhaled 
allergen.241,242 
A systematic review of 14 RCTs (3,143 patients) demonstrated the efficacy of 
omalizumab in patients with mild-to-severe allergic asthma with high serum levels of 
IgE.243 Omalizumab was effective in reducing asthma exacerbations as an adjunctive 
therapy to ICS (OR 0.52, 95% CI 0.41-0.65), and during ICS tapering phases of clinical 
trials (OR 0.47, 95% CI 0.37-0.60). Treatment with omalizumab also significantly 
improved symptoms, quality of life and asthma control scores, and significantly reduced 
the requirement for rescue medication. In addition, omalizumab led to a significant 
reduction in ICS consumption compared with placebo (-119 #g per day, 95% CI 
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-154 to -183), and a significant increase in the number of patients who were able to 
reduce their dose of ICS by over 50% (OR 2.50, 95% CI 2.02-3.10) or completely 
withdraw their ICS (OR 2.50, 95% CI 2.00-3.13). However, the authors concluded that 
the clinical value of the reduction in ICS consumption has to be considered in the light 
of the high cost of omalizumab. 
Approximately 5-10% of patients with asthma have severe disease that often fails to 
respond to conventional therapy, and these patients account for more than 50% of the 
total healthcare costs associated with asthma.28 Several studies have demonstrated the 
cost-effectiveness of omalizumab for the treatment of severe allergic asthma, in patients 
who are not controlled with maximal conventional therapy.244-247 In patients who 
respond to therapy, the cost-effectiveness of omalizumab compares well to other 
biologic treatments for chronic illnesses.248 In Australia, omalizumab is not on the 
federally funded Pharmaceutical Benefits Scheme, and is estimated to cost each patient 
about $23,500 a year for three injections per month.249 Reimbursement of 
pharmaceuticals in Australia is based on cost-effectiveness, and the usual process 
involves evaluation of clinical trial data for grouped subjects, with approval to use the 
drug based on eligibility criteria. While the cost-effectiveness for patients with severe 
allergic asthma in Australia has not yet been evaluated, small Australian studies have 
demonstrated that patients with difficult/therapy-resistant asthma respond well to 
omalizumab.250-252 The studies raised a number of issues relating to the best method of 
using this treatment in such patients. In particular, the need to identify individual 
responders to omalizumab using single-patient controlled trials, rather than widespread 
use in patients with difficult asthma, was acknowledged. It is hoped that this approach 
represents an opportunity to balance rational prescribing with appropriate access to 
omalizumab in certain patients.250 
1.6.10 Systemic corticosteroids 
Systemic corticosteroids are useful for treating the airway oedema and increased 
bronchial secretions associated with the inflammation in acute asthma exacerbations.253 
The early use of systemic corticosteroids delivered by either oral or intravenous routes 
during moderate-to-severe exacerbations is a principal treatment choice in asthma 
management guidelines.16,59 A systematic review of 12 RCTs (863 patients) determined 
that the early use (within one hour of arrival) of systemic corticosteroids for acute 
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asthma in the ED significantly reduced admission rates compared with placebo (OR 
0.50, 95% CI 0.31-0.81), with the number needed to treat to prevent one admission 
being 8 (95% CI 5-21).254 This benefit was more pronounced in those not already 
receiving systemic corticosteroids (OR 0.37, 95% CI 0.19-0.70) and those experiencing 
a more severe exacerbation (OR 0.35, 95% CI 0.21-0.59). Adverse effects were not 
significantly different between corticosteroids and placebo, suggesting that ED 
treatment with systemic corticosteroids is safe. A separate analysis of six RCTs (374 
patients) found that a short course (3-10 days) of systemic corticosteroids after ED 
discharge significantly reduced chances of a relapse (RR 0.38, 95% CI 0.20-0.74) 
without major adverse effects. The benefit lasted about three weeks.255 Further 
systematic review evidence on dosing schedules suggest that high-dose corticosteroids, 
at least in hospitalised patients, are no more effective than moderate and low doses.256 
There is no evidence to suggest the advantage offered by systemic corticosteroids in 
moderate-to-severe asthma is related to the route of administration.253 Until further 
evidence is available, it is reasonable to select oral corticosteroids as the first-line choice 
while reserving intravenous corticosteroids for patients who are too dyspnoeic to 
swallow, are incubated or unable to tolerate oral medications.  
In patients whose asthma exacerbation has not resolved despite an increase in ICS or 
combination therapy, a short course of oral corticosteroids of 40-50 mg given daily for 
7-10 days, depending on the severity of the exacerbation, is recommended.16,59 When 
symptoms have subsided and lung function has approached the patient’s best value, the 
oral corticosteroids can be stopped without tapering, provided that treatment with ICS 
continues.257 However, there is no evidence to suggest that prolonging the course 
beyond 10 days is indicated.257 
Long-term oral corticosteroid therapy may be required for severely uncontrolled 
asthma, but its use is limited by the risk of significant adverse effects including 
osteoporosis, diabetes, hypothalamic-pituitary-adrenal axis suppression, obesity, 
cataracts, glaucoma and skin thinning.16 Systematic review evidence suggests that, in 
the management of adults with chronic asthma, a daily dose of prednisolone 7.5 mg/day 
appears to be equivalent to a moderate to high dose of ICS (300-2000 #g/day).258 
Alternate-day doses of oral corticosteroids and doses less than 5 mg/day appeared to be 
less effective than low to moderate dose ICS. If oral corticosteroids have to be 
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administered on a long-term basis, the lowest effective dose should be prescribed, and 
attention must be paid to measures that minimise the systemic adverse effects.16 
1.7 Barriers to optimal asthma management 
1.7.1 Use of inhaled corticosteroids 
Despite the overwhelming evidence that regular use of ICS improves health outcomes in 
patients with asthma, a National Health Survey highlighted evidence that the use of ICS, 
the cornerstone of drug therapy for asthma, is not well targeted. Many people who 
would benefit from ICS therapy were not doing so, with only 14% of people with 
current asthma reporting that they used their ICS every day or night in the previous two 
weeks. Furthermore, among people who were using SABAs every day (implying the 
presence of persistent asthma that is poorly controlled), only 37% also used ICS on 
three or more days per week and 60% did not use ICS at all.31  
In asthma, as with other chronic conditions, poor adherence to treatment and medical 
advice is common.259,260 Barriers to ICS use must be overcome before widespread 
benefits of ICS therapy are seen. Patients’ perception of their condition and their need 
for treatment limit the adherence to ICS therapy, and therefore the reported 
effectiveness of ICS. Patient adherence to medication is influenced by a number of 
factors relating to how the individual judges the necessity of their treatment relative to 
their concerns (Figure 8).261 It has been reported that non-adherence to ICS therapy is 
strongly correlated with treatment beliefs, in particular, doubts about the necessity for 
medication to maintain health and concerns about the potential adverse effects.262 
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Figure 8. Factors influencing patient adherence to medication261 
 
It has been found that a large proportion of patients with asthma do not understand the 
role of their medications and have many misconceptions and fears in regard to ICS, 
reducing their willingness to use them.263,264 However, a review of articles regarding the 
safety of ICS concluded the following: 
“ICS have minimal side effects in most patients when taken at 
recommended doses. The benefits of ICS therapy clearly 
outweigh the risks of uncontrolled asthma, and ICS should be 
prescribed routinely as first-line therapy for children and adults 
with persistent disease.”265 
In addition to fear of corticosteroid-related adverse effects, it has been reported that 
factors such as the cost of medication, lack of symptoms, lack of immediate effect, and 
concern over long-term use of medicines and loss of effectiveness over time, might be 
important in contributing to the under-use of ICS.51,262,266-269 Figure 9 displays the 
degree to which variations in reported adherence to ICS could be explained by patients’ 
perceptions of asthma medication. 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 61 
Figure 9. Common patient perceptions affecting ICS adherence262 
 
Baiardini et al. showed how different factors may modulate adherence to asthma 
treatment.267 Relationships between treatment adherence and depression, anxiety and 
coping strategies were identified. The presence of anxiety was positively correlated with 
fear of medication adverse effects and difficulty in accepting the illness, and negatively 
correlated with acceptance of illness limitations. The presence of depression was 
negatively correlated with acceptance of illness limitations, knowledge of illness and the 
ability to identify worsening signs.267 The authors concluded that general difficulties, 
fears, perspectives and resources, if neglected, might result in barriers that diminish 
asthma control. The findings suggest that identifying motivations behind non-adherence 
may result in more effective patient-focused care and improved asthma outcomes. 
The Australian Centre for Asthma Monitoring examined patterns of asthma medication 
use in Australia, and reported that people living in remote areas use asthma medications 
less often than people living in cities, which may reflect differences in the accessibility 
of healthcare services. Furthermore, people with concession cards, who are able to 
purchase medications at a much cheaper price than general patients, use ICS and 
LABAs more often than general patients, which raises the possibility that the price 
charged to general patients represents a barrier to the use of preventive medications for 
asthma.270 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 62 
An Australian qualitative study exploring the burden of asthma on the lives of people 
presenting to hospital EDs found that the cost of asthma medication was an issue for 
nearly two-thirds of patients.271 Some participants performed their own ‘cost-benefit’ 
analysis, weighing up expense, perceived adverse effects and potential benefits of their 
medications. As a consequence, a significant proportion chose to alter medication doses, 
in an attempt to prolong medication use, or to not take prescribed medications. The 
authors concluded that to achieve a therapeutic partnership, doctors need to be aware of 
the substantial social, personal and financial burden of asthma for their patients, and 
should recognise that patients’ perceptions of treatment cost may compromise treatment 
adherence. 
Patients require constant reinforcement when provided with information as they tend to 
forget or are unable to recall pertinent facts, which may then impact on their adherence 
to medication and overall satisfaction.272 It has been demonstrated that instruction and 
demonstration can have a large impact on the percentage of patients who use an inhaler 
correctly.273 Failure to instruct patients on how to use inhalers and to reinforce these 
instructions will decrease adherence, whatever the drug or inhalation device. Poor 
inhalation technique ultimately represents a form of unintentional non-adherence and 
can be easily overcome by close monitoring and continuing education by the healthcare 
professional. 
Inadequate use of ICS could be due to under-prescribing and/or poor adherence with 
therapy. It has been suggested that the major reason that GPs fail to prescribe ICS is 
disagreement with recommendations, particularly regarding where the balance lies 
between their benefits and the risk of complications and adverse effects.274 The 
implementation of best practice guidelines for asthma management requires not only 
insights into the perspectives of those living with asthma, but also an understanding of 
what GPs’ priorities are for achieving optimal outcomes in people with asthma, and the 
barriers they face in delivering this care. Goeman et al. conducted a qualitative study 
asking GPs what their main concerns were for achieving best outcomes in people with 
asthma.275 The GPs in the study identified both structural and knowledge barriers. These 
included the time required and the cost of providing asthma management and patient 
education, as well as accessing relevant continuing medical education. Tumiel-Berhalter 
et al. showed that knowledge of GPs and their attitudes towards asthma management 
guidelines were associated with regular use of anti-inflammatory asthma medication.276 
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These findings reinforce the view that GP-perceived usefulness is critical to 
implementing asthma guidelines and ensuring adequate prescribing of ICS. 
1.7.2 Use of Asthma Action Plans 
National guidelines for the management of asthma consistently recommend that all 
patients with asthma should have an individualised written AAP.59 Most Australians 
with asthma, however, do not have AAPs.3,31,46-49 Findings from the 2004-05 National 
Health Survey showed that while there has been an improvement on the rate of 
possession of an AAP since 2001, less than one-quarter (23%) of people with asthma 
possessed a written AAP in 2004-05, and approximately 5% of people with asthma had 
never heard of an AAP.31  
While there is strong evidence for the effectiveness of written AAPs, especially in 
combination with education and regular review, for this evidence to translate into 
practice both the GP and the patient need to be willing to participate. It has been shown 
that the most common reason for not possessing an AAP was simply that the patient had 
not been given one by his or her doctor.277 A study which sought to identify factors 
associated with uptake of the Asthma 3+ Visit Plan (which incorporates development of 
an AAP) found that GP workload, paperwork and perceived administrative burden were 
major factors to implementing the plan.278  
A qualitative study of views of health professionals and patients on guided self-
management plans for asthma found that health professionals worried about ‘blind 
obedience’ with self-management plans. Concern was expressed that patients would 
rely on a written plan and not return for regular review, or that the plans ‘encouraged 
dependency.’ All GPs tended to agree that the plans were difficult to implement in 
everyday practice given the constraints of time and tended to militate against a 
meaningful doctor-patient relationship.75 
A confounding factor of AAP possession is whether patients actually use their plans. 
Douglass et al. found that not all patients with an AAP used it, and that scores for 
asthma knowledge did not differ between those who had an AAP and those who were 
not confident to use it.277 This finding demonstrates that there are indeed other patient 
barriers to the use of an AAP. Interestingly, Jones et al. reported the following:  
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“Many patients with mild-to-moderate asthma do not regard it as 
a chronic disease that needs regular monitoring and therapeutic 
adjustments. Indeed, they prefer to manage it as an intermittent 
acute disorder, and they are uncomfortable with a guided self-
management plan that reinforces asthma as a chronic, ongoing 
disease needing monitoring and managing.”75 
Patients’ preference to treat their asthma as an acute disorder is a common finding,75-77 
and represents a clear barrier to patient-implementation of AAPs. The NAC therefore 
promotes the concept of patient-centred healthcare,279 a system designed to respect the 
patient’s preferences, values and needs.280 The concept aims to facilitate a shift from a 
medical model to a patient-centred healthcare model through enhancing patients’ and 
carers’ roles. Patient-centred healthcare recognises that human behaviour influences 
outcomes, and that chronic conditions with complex management require more complex 
means of interaction with the patient to ensure adherence to agreed treatment plans and 
improved QOL and clinical outcomes.280 It has been reported that most patients with 
AAPs modify them according to their perceptions of asthma severity and likely disease 
outcome.277 Therefore, to facilitate the implementation of a prescribed action plan, 
healthcare providers need to acknowledge and include the patient’s personal experience 
of their disease. It is hoped that this shift towards a more patient-centred approach to 
asthma management will improve the prevalence of AAP possession and 
implementation by increasing patient participation, as this has been shown to be 
associated with improved asthma management.81 
1.7.3 Perception of asthma control 
A well-documented patient barrier to optimal asthma management and control is an 
underestimation of disease severity on the part of the patient.46,51,52,55,281,282 Patients may 
unnecessarily accept symptoms, assuming that frequent symptoms, exacerbations and 
lifestyle limitations are an inevitable consequence of having asthma.51 In the Asthma 
Insights and Reality in Europe study, only 5% of adults met all the criteria for asthma 
control as defined in the GINA guidelines, but 66% of adults considered that they had 
no asthma symptoms or had only mild asthma.52 Globally, surveys have indicated that 
32-49% of patients experiencing severe symptoms and 39-70% of patients with 
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moderate symptoms believe that their asthma is well controlled or completely 
controlled,55 as shown in Figure 10. 
Figure 10. Patients' perception of asthma control against actual symptom severity among regions55 
 
A nation-wide study aiming to assess the burden of asthma and describe asthma 
management in Australia reported low rates of effective asthma therapy use, including 
in those with features of poor asthma control.46 Furthermore, there was discordance 
between the classification of asthma control, on the basis of reported symptom 
frequency and asthma management guidelines, and patients’ own evaluation of how 
well their asthma had been controlled. Many patients who reported frequent symptoms 
regarded their asthma as ‘well controlled.’ In fact, nearly half the patients with daily 
asthma symptoms responded in this way and only a small minority reported that their 
asthma was poorly controlled (Figure 11). 
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Figure 11. Self-assessment of asthma control by symptom frequency index among participants of an 
Australian study46 
 
 
Interestingly, poor perceptions of asthma control can be a problem in GPs as well as 
their patients. A recent practice audit of Canadian GPs attempted to address the gap 
between asthma control achieved and asthma control achievable.283 Of the 10,428 
patients assessed by 354 GPs, 59% were uncontrolled, 19% well controlled and 23% 
totally controlled. GPs overestimated control, regarding only 42% uncontrolled. 
Additionally, GPs were found to be discordant with guideline classification of asthma 
control in 31% of uncontrolled patients, 13% of well-controlled patients and 2% of 
totally controlled patients. Most commonly, GPs were discordant with guideline criteria 
when patients showed a lack of control in only one parameter, most often the overuse of 
reliever medication. 
The 2005 International Control of Asthma Symptoms (ICAS) survey of patients and 
GPs found that despite the majority of patients being seen by GPs having mild-to-
moderate asthma, most patients reported an absence of asthma control and many 
reported significant lifestyle restrictions.284 The findings corresponded with high levels 
of concerns amongst GPs that patients accept their symptoms as normal, and frustration 
that their patients were not more forthcoming about their symptoms. These findings 
suggest that too many patients have symptoms that they accept as being a normal 
consequence of their condition and many rely heavily on their rescue medication. 
* 
“Poorly controlled” 
“Somewhat controlled” 
“Well controlled” 
Participants were asked 
“Overall, how well would 
you say your asthma has 
been controlled in the 
last four weeks?” 
 
 
* 
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Indeed, patients’ underestimation of asthma severity has been shown to result in 
inappropriate medication use.285 
The results of the ICAS survey emphasised that action is required to encourage patients 
to view their asthma more seriously and to be more proactive in reporting symptoms to 
their GP. These actions, coupled with greater prompting of patients by GPs and other 
health professionals about their asthma, should help to optimise asthma management. 
These findings are consistent with other research suggesting that patients prefer to 
manage their asthma as an acute intermittent disorder rather than a chronic ongoing 
disease that needs monitoring and managing.75-77 
1.7.4 Relationships with healthcare professionals 
There are many possible reasons for suboptimal asthma control. However, regardless of 
the underlying causes, the level of control achieved reflects the behaviour of both 
healthcare professionals and patients (Figure 12). Differences in the perspectives of 
patients and healthcare professionals could affect their behaviours, and consequently, 
the achievement of asthma control. It may be possible for healthcare professionals to 
improve asthma control by achieving a greater understanding of the patient’s 
perspective.286 An Australian study found that GPs often have relatively poor insights 
into self-management practices, even in high-risk patients.287 The authors concluded 
that this should be considered when planning future campaigns to improve asthma 
management and further reduce mortality. 
Figure 12. Patient and healthcare professional behaviour affects asthma control286 
 
Patterns of provision of healthcare, including non-specialist care, have been described in 
various populations as important factors affecting the use of asthma medication. Adams 
Effective treatments and 
management plans 
Optimal outcomes 
Behaviour 
Healthcare professional 
Prescribing treatment 
Recommending management plan 
Patient 
Adherence with treatments and recommendations 
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et al. sought to examine the influence of patterns of care delivery and prescriber 
behavioural factors on the use of anti-inflammatory medication by patients with asthma. 
Being under the care of respiratory specialists, having regularly scheduled GP visits for 
asthma, possession of a written AAP and possession of private health insurance were all 
found to be significant indicators for ICS use for asthma.288  
Effective communication between GPs and patients is integral for asthma management 
to be successful. An Australian qualitative study of patient language about worsening 
asthma found that there were important differences in the language patients and GPs 
used to describe worsening asthma.289 ‘Attack’ was the most commonly used word in 
asthma, and while it is simple and evocative it is limited in its utility, as patients used it 
for a wide spectrum of episodes. Furthermore, it was found that social context strongly 
influenced patients’ choice of language; patients commonly downplayed the severity of 
episodes to avoid causing alarm or attracting criticism. Such behaviour may be 
hazardous, as it could cause delays in obtaining medical assistance. The findings clearly 
highlighted gaps in language about asthma. Without readily understood and 
unambiguous words for the use in educational material and AAPs, communication 
breakdown may occur, impeding appropriate and timely management of worsening 
asthma. The authors concluded that healthcare providers should be encouraged to 
establish a relationship with patients in which patient language is understood and 
reflected back by the provider, to ensure effective communication about worsening 
asthma.289  
Moffat et al. reported that poor healthcare professional-patient communication seems to 
largely explain the poor uptake of best practice guidelines in general practice and 
primary care.282 In particular, healthcare professionals reported lacking the necessary 
communication skills for dealing with patient asthma control issues, particularly where 
these were non-medical (for example, identification of patients’ health beliefs and 
confidence in managing their own asthma and relevant non-medical lifestyle factors 
impacting on control). There is clearly a need to identify key communication skills for 
effective healthcare professional-patient partnerships in asthma management. 
Aside from effective communication with patients, a good doctor-patient relationship is 
essential for achieving asthma control. Achieving a ‘therapeutic partnership’ has a 
major influence on optimal health outcomes and patient satisfaction.290,291 It has been 
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demonstrated that patients who rate their GP more highly in terms of ability to explain 
asthma management, willingness to spend time with the patient and encouragement to 
participate in treatment decisions, report ICS use significantly more often than patients 
with less favourable ratings of their GP’s behaviour.288 It is frequently assumed that 
patients presenting to hospital EDs with asthma do not have good GP-patient 
relationships, or may not even have a GP for asthma care.292 Douglass et al. performed a 
qualitative study examining the nature of patients’ relationship with their GPs in those 
presenting to hospital EDs for asthma care.293 While nearly all the patients enrolled in 
the study had a GP whom they saw for their asthma, the findings identified that 
perceptions of GPs’ competence, ability to listen and time constraints were important 
influences on GP-patient relationships. Participants expressed feelings of being rushed 
or wishing that the GP had time to sit and listen, and they expected the GP to be 
respectful of their own knowledge and experience of disease. The findings led the 
authors to urge GPs to ascertain patients’ expectations of consultations and to respect a 
patient’s interpretations of their symptoms and disease experiences in order to achieve a 
therapeutic partnership.293 
The Global Asthma Physician Patient (GAPP) survey was designed to uncover asthma 
attitudes and treatment practices among separate groups of GPs and patients, with the 
goal of identifying barriers to optimal management.294 Findings of the GAPP survey 
revealed that there was a direct relationship between the quality of GP-patient 
communication, the level of adverse effects from medication and the extent of patient 
adherence. Furthermore, patient education on their disease and treatment was identified 
as a major barrier to optimal asthma management. Patient responses revealed a low 
level of asthma education, and this had a negative impact on treatment outcomes. 
However, patient education is unlikely to improve outcomes unless it allows patients to 
improve their self-management skills, as it has been demonstrated that programs that 
offer knowledge without self-management skills do not reduce hospitalisation rates or 
urgent GP visits.72,73  
1.8 The pharmacist’s role in asthma management 
Community pharmacists are in a unique position to help patients manage chronic 
diseases in view of their expertise, their regular contact with patients and their 
accessibility. Pharmacists frequently see patients with asthma in the community, many 
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of whom may have suboptimal asthma control. Community pharmacies therefore 
represent an excellent site to screen for patients who may be at risk from their asthma 
and to address critical issues in asthma management in the community. 
The Australian Centre for Asthma Monitoring reported that over half of all asthma 
expenditure is attributable to pharmaceuticals (Figure 13).33 Indeed, every year 
Australian pharmacists fill more than seven million prescriptions for asthma 
medications, which remain the principal treatment for the disease.295 
Figure 13. Distribution of asthma and total allocated recurrent health expenditure among health 
sectors, Australia, 2000-0133 
 
When dispensing prescriptions for asthma medication, pharmacists can play a pivotal 
role in educating patients about their therapy and condition (Table 6). This may be 
particularly important for encouraging adherence to ICS therapy, even when no 
symptoms are present. 
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Table 6. Actions for pharmacists to improve asthma management296,297 
1. Educate patients about asthma medications 
2. Instruct patients about the proper technique for inhaling medications 
3. Regularly review the patient’s dispensing history to assess mediation adherence 
4. Encourage patients regularly purchasing non-prescription asthma relievers to see their GPs 
5. Help patients use peak flow meters appropriately 
6. Educate patients with persistent asthma on the importance of regular ICS therapy, taking time to 
reassure them that the benefits of ICS therapy outweigh the risks of uncontrolled asthma 
7. Ensure that patients know how to recognise worsening asthma and what to do in such a scenario. 
8. Encourage patients to ask their GP about developing an AAP if they do not have one already 
9. Help patients understand their asthma management plans 
10. Ask patients to complete an asthma control test while they are waiting for their prescription, discuss 
their results and refer if necessary 
 
As members of the healthcare team, pharmacists can help improve the pharmacological 
management of asthma by teaching patients about their medications, how to use them 
and the importance of using them as prescribed. Alerting GPs to suspected problems, 
such as under-using ICS therapy or over-using relievers, will provide an opportunity for 
the GP to consider changes in a patient’s management plan when appropriate.296,298  
A review of international literature from 1997 to April 2008 revealed a substantial 
increase in outcome-based asthma management programs that include the services of a 
pharmacist.299 The considerable increase in the number of research reports supporting 
pharmaceutical care in patients with asthma is consistent with the expanding role of 
pharmacists in this field in all parts of the world. Over the last decade, pharmacists have 
been active in asthma education in the community via various approaches. Examples of 
some activities include small group education to asthma patients in various settings, 
education to nurses about asthma, promotion of asthma awareness though fund-raising 
and participation in local and national organisations.  
Studies conducted in Australia indicate that pharmacists are well placed to deliver 
interventions to improve asthma control and health outcomes, and patients report high 
levels of satisfaction with such services.5,300-304 The largest Australian pharmacy-based 
asthma intervention study assessed the impact of a pharmacy asthma care program 
(PACP; an ongoing cycle of assessment, goal setting, monitoring and review).301 Fifty 
pharmacies participated in the study, half of which implemented the PACP, while the 
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other half provided usual care to control patients. The intervention resulted in improved 
asthma control, improved adherence to preventer medication, decreased mean daily 
dose of reliever medication, a shift in medication profile from reliever only to a 
combination of preventer, reliever ± LABA, as well as improved scores on risk of non-
adherence, QOL and perceived control of asthma questionnaires. The authors concluded 
that while the study showed that community pharmacists can add value to the care of 
asthma in terms of clinical and humanistic outcomes, further research is required to 
determine which components of the service are critical to improve asthma control and to 
determine the intensity of the service required to sustain the improvement.301 
Despite the efforts of the NAC in propagating their best practice guidelines, they are 
still not widespread in practice. One of the barriers reported by pharmacists in 
intervening successfully is their lack of sufficient knowledge.305,306 In a survey 
conducted with a sample of 1,610 Australian pharmacists by the Victorian College of 
Pharmacy and the NAC, practicing pharmacists’ knowledge about asthma was not 
adequate.307 Well-designed educational strategies are required to encourage health 
professionals to understand and adopt best practice guidelines into everyday practice.  
An Australian study was designed to bridge the gap between the ideal and reality of 
what is achieved in community pharmacies and addressed the training needs of 
community pharmacists with an educational program.308 In the intervention area, 15 
pharmacies were trained with the educational intervention, and they provided 
specialised asthma care to 52 patients over six months, while in the control area, 12 
pharmacists provided usual care to 50 patients. The intervention pharmacists were 
highly satisfied with the education received and rated most aspects highly. 
Improvements in patient clinical, humanistic and economic outcomes in the intervention 
group were obtained. 
A Canadian pilot study evaluated the impact of an asthma continuing education program 
on community pharmacists’ knowledge and interventions, as well as the appropriate use 
of asthma medications among patients.309 Whilst pharmacists’ knowledge improved 
after the continuing education program, the number of interventions reported during the 
six-month period following the program was low and did not differ significantly 
compared to the control group of pharmacists. Furthermore, the appropriateness of 
asthma medication use among patients did not improve once the continuing education 
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program had been completed. The authors suggested that other identified barriers may 
have explained why pharmacists did not intervene more frequently. Possible 
impediments to a pharmacist’s intervention to improve asthma management have been 
identified, and include difficulties in contacting GPs, attitudes of GPs towards 
pharmacists, lack of time, insufficient technical support, absence of a confidential 
consulting area and lack of patients’ cooperation.310 
An Australian study in rural New South Wales was designed to address the issue of 
asthma awareness in a rural community and the involvement of the community 
pharmacist in proactive health promotion. The study reported that pharmacists 
demonstrated an overwhelming enthusiasm for their role in health promotion.311 
Training enabled them to overcome their personal barriers, lack of confidence and 
resistance to a new concept. It was also reported that most of the pharmacists involved 
in the study continued with asthma services and have since been providing 
comprehensive disease state management in their community. 
With patients frequently visiting pharmacies for prescription refills, community 
pharmacists are in an ideal position to identify medication-related problems that may 
impede optimal asthma management. A specialist asthma service offered by community 
pharmacists was evaluated in New Zealand over a two-year period.312 For the 100 
patients enrolled in the trial, an average of 4.3 medication-related problems were 
identified per patient, with two-thirds of these compliance-related. The most common 
interventions were revision of patients' AAPs, referral and medication counselling. The 
benefits of this service included reduced reliever use and improved symptom control in 
around two-thirds of patients. 
A rigorous evaluation of community pharmacist involvement in asthma management 
was conducted in the United States (US), which compared patients receiving 
pharmaceutical care (including education and peak flow monitoring) to a control group 
that received peak flow monitoring alone and another control group that received usual 
care.10 Although improvement in PEF was better in the intervention than in the usual 
care group, it was no better than in the peak flow control group. Furthermore, there were 
no differences among the groups in pre- and post- intervention improvement in QOL or 
medication adherence. It was concluded that providing a peak flow meter to patients 
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with asthma improved respiratory function, but that pharmaceutical care provided no 
incremental benefit.  
An important lesson from this study was that the relatively intensive program had a poor 
uptake and implementation by pharmacists, and this was the most likely explanation for 
the somewhat disappointing findings.10 Despite the intensive efforts by the investigators 
in designing a pragmatic program and reinforcing its use, it was not used consistently. 
The pharmacists only viewed the data in the study computer half the time patients filled 
prescriptions, and they documented interventions only 50% of the time that those 
records were viewed. Thus, the intended intervention was not implemented often, 
presumably because of time constraints.  
While there clearly is the potential for community pharmacists to have an impact in 
improving the management of asthma, such approaches are most likely to be successful 
if they do not require significant time and training on the part of the pharmacist. The 
authors of the US study concluded that additional research evaluating interventions to 
improve asthma management should be conducted in ‘real-world’ community 
pharmacies using strategies that are pragmatic in busy pharmacies.10  
1.9 Data mining dispensing records to perform asthma interventions 
In the pilot research leading up to the work described in this thesis, researchers at the 
Tasmanian School of Pharmacy developed a ‘data mining’ software application 
(‘MedeMine’) that seamlessly extracts data from the market-leading pharmacy 
dispensing software system in Australia (Fred Dispense; Fred Health).5 About 50% of 
community pharmacies in Australia use this dispensing system. The software 
application was designed to assist community pharmacists to use their medication 
records to identify people who may have poorly controlled asthma. It was intended to 
trial a computer-assisted intervention requiring minimal time and training on the part of 
the pharmacist, yet answering the societal need for improved asthma management. In 
October 2006, forty-two pharmacies throughout Tasmania participated in a pilot study, 
and used the software application to data mine dispensing records and generate a list of 
patients who had received three or more canisters of SABA in the preceding six months. 
Identified patients were randomised to an intervention or control group. Intervention 
patients were contacted by the community pharmacy via mail, and sent an intervention 
pack consisting of a personalised letter suggesting a visit to their GP for a review of 
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their asthma management, educational material from the Asthma Foundations Australia 
(‘Asthma: the basic facts’313), questionnaires assessing asthma knowledge, asthma 
control and asthma-related QOL, and a letter and questionnaire to hand to their GP. 
Control patients received no active intervention during the data collection phase other 
than the pharmacist’s usual care. All patients were given asthma-related questionnaires 
six months later (April 2007). Due to ethical considerations, control patients were sent 
an intervention pack at this stage, similar to that sent to intervention patients six months 
earlier. Thirty-five pharmacies completed the project, providing 702 intervention and 
849 control patients. The primary outcome measure was the ratio of dispensed 
preventers (ICS) to dispensed relievers (SABAs), and secondary outcome measures 
were other patterns in dispensed asthma medication (e.g. LABAs) and asthma 
questionnaire scores.  
The intervention resulted in: 
• A three-fold increase in the preventer-to-reliever (P : R) ratio (P < 0.0001);5 
• A shift in medication profile from reliever only to a combination of ICS ± 
reliever ± LABA (P < 0.01);5 and 
• Significant improvements in self-reported asthma control (P < 0.001) and 
asthma-related QOL (P < 0.05).304  
Satisfaction with the intervention was encouraging among all participants, with the 
majority of GPs, pharmacists and patients agreeing that this type of program would 
improve asthma care in the community if implemented on a larger scale. The 
intervention seemed to be pragmatic in its implementation with more than 90% of 
pharmacists agreed that the MedeMine program was easy to use and that the project 
required a minimal amount of their time. 
A number of pharmacists who participated in the pilot study indicated that they would 
prefer to hand out the intervention material to patients face-to-face, rather than mail the 
packs out. This highlighted the need for finding a balance between interventions that are 
pragmatic for busy community pharmacies, which require minimal disruption to the 
pharmacist’s workflow, whilst encouraging and supporting the involvement of the 
pharmacist in the delivery of the intervention.  
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It was concluded that the intervention should be followed-up to determine whether the 
improvements in asthma management are sustainable, and varying levels of pharmacist 
interventions should be trialled on a larger scale. The asthma research described in this 
thesis expands on the aforementioned pilot study. In order for this type of study to be 
implementable on a national scale, the sustainability, feasibility and likely uptake by 
pharmacists, GPs and patients needed to be determined. 
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CHAPTER TWO: 
SUSTAINABILITY AND FEASIBILITY OF A COMMUNITY PHARMACY 
INTERVENTION TO IMPROVE THE MANAGEMENT OF ASTHMA 
2.1 Aim and objectives 
This study aimed to determine the sustainability and perceived feasibility of a 
multidisciplinary intervention that utilised community pharmacy dispensing records to 
identify and educate patients with suboptimal asthma management. Specifically, the 
objectives were to: 
• Determine the long-term effect of the intervention on the ratio of dispensed 
asthma preventer medications to dispensed asthma reliever medications; 
• Determine the optimum frequency of the intervention to gain sustained 
improvements; 
• Determine patient, community pharmacist and GP perceptions regarding the 
intervention; 
• Determine the barriers and enablers to the national implementation of a best-
practise intervention; and 
• Determine what practice changes are required to successfully implement the 
intervention on a national scale. 
2.2 Methods 
2.2.1 Study design and setting 
This project was a follow-up to a pilot study that was conducted in 2006-07. Briefly, the 
pilot study involved the utilisation of a software application that data mined community 
pharmacy dispending records to identify patients who had received three or more 
canisters of SABAs in the six-month pre-intervention period. A multidisciplinary 
educational intervention was implemented, that referred such patients to their GP for a 
review. De-identified and uniquely coded dispensing data was collected at the end of a 
six-month post-intervention period to determine the impact of the intervention on the 
ratio of dispensed ICS to dispensed SABAs.5 
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The present study involved both quantitative and qualitative approaches. Firstly, a 
follow-up of the intervention was conducted to determine whether the improvement in 
asthma management was sustained. Secondly, qualitative interviews were conducted 
with patients, community pharmacists and GPs, to determine the perceived feasibility of 
the community pharmacy intervention. The study was conducted in Tasmania, 
Australia. 
2.2.2 Quantitative component 
2.2.2.1 Recruitment of pharmacies  
Community pharmacists who participated in the previous asthma intervention were 
informed about the follow-up study by telephone. Each pharmacy was offered a $50 
honorarium for participating in the follow-up project. With the pharmacists’ consent, 
each pharmacy was visited and the modified version of the data mining software was 
installed on the main dispensing computer. 
2.2.2.2 The data mining software 
The information technology development under this study involved modifying the 
existing data mining software application so that it could re-identify patients who were 
targeted for an intervention in 2006-07. This would allow for the follow-up dispensing 
data for all patients to be compared to their pre- and post- intervention data collected 
originally. Each patient was uniquely coded to enable this. Upon installing the updated 
software on a pharmacy’s dispensing computer, the dispensing data was de-identified, 
compressed and encrypted using a blowfish algorithm.314 The information was then 
transferred via the Internet using a secure 1024 bit transfer protocol to a secure server at 
the University of Tasmania. Back-ups of the encrypted, de-identified data were also 
copied to a portable USB device. 
2.2.2.3 Study population 
The original intervention was a controlled study design. The data mining software 
identified patients who had received three or more canisters of asthma reliever 
medication in the six-month pre-intervention period, and randomised patients to an 
intervention or control group. For ethical reasons, control patients received an 
intervention at the end of the six-month post-intervention period, if they had again 
received three or more relievers in this time period. Therefore, the follow-up data 
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analysis described here was not controlled, and consequently the original intervention 
and control groups were referred to as Group 1 and Group 2, respectively. For the 
purposes of this study, the time periods are shown in Figure 14. 
Figure 14. Timelines for dispensing data analysis 
 
2.2.2.4 Handling of data and statistical analysis 
The asthma medications included in the analyses were inhaled SABAs (relievers) and 
ICS (preventers). Prior to performing statistical analyses, the dispensed quantities of 
asthma medications were converted to a standard equivalent dose: 
• Salbutamol equivalence: salbutamol 100 #g = terbutaline 250 #g;315 and 
• Beclomethasone-HFA equivalence: beclomethasone-HFA 100 #g = fluticasone 
100 #g = budesonide 200 #g = ciclesonide 80 #g.134-136  
The key variable examined statistically was the preventer-to-reliever (P : R) ratio in 
each of the study periods. The P : R ratio was calculated for each patient as the average 
beclomethasone-equivalent usage per day divided by the average salbutamol-equivalent 
usage per day. In accordance with other studies that have used the ratio,129,316-319 
LABAs were not included as preventers in this ratio because they are not appropriate as 
single-preventer medication therapy.320,321 However, their efficacy should have been 
reflected indirectly by lowering the number of relievers required and thus increasing the 
P : R ratio. The ICS and SABA usages were then analysed separately to determine 
where any changes in the P : R ratio originated. 
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As SABAs are available without a prescription, and over-the-counter (OTC) supplies 
are not always recorded, a sensitivity analysis on SABA usage was performed. This 
analysis was performed on all long-term concessional patients, with the assumption that 
this cohort of patients received minimal supplies of non-prescription SABAs, owing to 
their reimbursement on the Pharmaceutical Benefits Scheme. Comparing the recorded 
non-prescription supplies of SABAs in the long-term concessional and non-
concessional patients validated this assumption. Long-term concession patients were 
defined as those who received prescriptions at the concession rate throughout the entire 
study period.  
All variables were collated and entered into a statistical software package, Statview 5.01 
(Abacus Concepts Inc, Berkeley, California, US). Data were analysed statistically using 
the Friedman’s test for overall within-group changes, and the Wilcoxon signed rank test 
with Bonferroni correction for post hoc assessments of significance between time 
periods. The Bonferroni adjusted critical value controlled for multiple comparison 
testing, and was obtained by dividing the original threshold P value (0.05) by the total 
number of comparisons made (six).322,323 Categorical demographic variables were 
compared using the Chi Square test. A significance level of P < 0.05 was used for the 
Friedman’s test, and P < 0.008 was used for post hoc tests.322,323   
2.2.3 Qualitative component 
2.2.3.1 Recruitment of participants 
In order to inform local GPs about the project, a project summary was sent to the 
southern, northern, and north-western Divisions of General Practice in Tasmania to be 
included in local newsletters (Figure 15). GPs who participated in the previous 
intervention were sent an invitation letter (Appendix 1), project information sheet 
(Appendix 2) and participant consent form (Appendix 3). Community pharmacists who 
participated in the previous intervention were sent a letter inviting them to participate in 
a qualitative interview, and requesting their involvement in the recruitment of patients 
(Appendix 4). Pharmacists were required to fax an expression of interest form to the 
researchers, indicating whether they felt the study would be worthwhile and they had 
time to participate (Appendix 5). Pharmacists who agreed to participate in a qualitative 
interview were sent a pharmacist interview letter (Appendix 6), project information 
sheet (Appendix 2) and participant consent form (Appendix 3), and those who agreed to 
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assist in the recruitment of patients were sent patient recruitment instructions with the 
identification numbers of the former participants from their pharmacy (Appendix 7) and 
patient recruitment packs containing patient invitation letters (Appendix 8), project 
information sheets (Appendix 2) and participant consent forms (Appendix 3), as well as 
the required number of postage paid envelopes. Participating GPs, pharmacists and 
patients were offered $200, $100 and $50 honoraria, respectively.  
Figure 15. Excerpt a GP South (Tasmania) newsletter - February 2009 
 
2.2.3.2 Qualitative interviews 
All participants underwent a 30-40 minute semi-structured in-depth interview. The 
participants themselves chose the location for the interview, for example their home or 
workplace. The intervention process was discussed, and participants were asked to 
describe their views and experiences of the intervention, and any issues they felt may 
require attention if the intervention was to be implemented on a national scale. The 
face-to-face discussion guide, as displayed in Appendix 9, incorporated all of the 
qualitative objectives under each of the following discussion points: 
• How asthma is/should be managed; 
• Perceived roles of GPs and community pharmacists in the management of 
asthma; 
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• Feelings and perceptions regarding the community pharmacy asthma 
intervention;  
• Drivers and barriers to the national implementation of a best-practice pharmacy-
led asthma intervention; and 
• Practice changes required to successfully implement an asthma intervention. 
Different interview guides were used for patients, GPs and community pharmacists, 
thereby varying the content and technical complexity from the perspective of the 
interviewee. There was an emphasis on open questioning and exploring interesting 
aspects in relation to specific topics. Two researchers, trained and experienced in the 
interview process, independently conducted the interviews. Best practice stipulated that 
the interviewers were independent of the previous intervention and unknown to the 
participants. Care was taken to ensure that the interview procedure was consistent 
throughout the study period.  
2.2.3.3 Handling of data 
Detailed notes were taken during and after each interview, including verbatim quotes. 
Both interviewers who were not involved in the previous intervention participated in the 
analysis, to minimise any investigator bias.324 The interview notes were carefully read 
through several times and analysed independently by the interviewers using interpretive 
phenomenology. The qualitative analysis encompassed the three general phases of 
familiarisation, data reduction and interpretation (Table 7).  
Table 7. Qualitative data analysis – interpretive phenomenology 
Familiarisation The researchers read the notes, to familiarise themselves with the data and to identify the various themes that had emerged. 
Data reduction Interview responses were analysed, identifying similarities and differences by topic and segment. All data were then summarized into key points. 
Interpretation 
All relevant quotes were selected for their illustrative value. Consensus was reached by 
discussion between the researchers. The themes were not defined in advance, and all 
authors agreed on the major findings that arose from the analysis. 
 
2.2.4 Ethical approval and trial registration 
The quantitative component of this project was approved by the Tasmanian Health and 
Medical Human Research Ethics Committee (ethics reference number H9039), and the 
qualitative component was approved by the Tasmanian Social Sciences Human 
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Research Ethics Committee (ethics reference number H10378). The study was 
registered with the Australian New Zealand Clinical Trial Registry (registration number 
ACTRN12609000196246). 
2.3 Results 
2.3.1 Quantitative component 
2.3.1.1 Study population 
Of the 35 pharmacies that completed the original intervention, 28 (80.0%) were able to 
provide follow-up dispensing data. Of the seven pharmacies that were not able to 
provide follow-up dispensing data, three were no longer using the Fred dispensing 
system, and therefore had incompatible software, and four were unable to provide data 
due to unforeseen software issues. Figure 16 shows detailed information on the 
availability of patients’ data in each of the time periods. 
Figure 16. Number of patients’ dispensing data analysed in each time period* 
 
*Pharmacy data unavailable implies the patient data was unavailable due to software incompatibility or 
unforeseen software issues; Patient data unavailable implies the pharmacy data was available, but the 
patient’s last prescription ever supplied by the pharmacy was dispensed prior to the data collection period; 
Not eligible for intervention implies the patients’ data was not analysed for sustainability because they did 
1,551 patients met inclusion criteria at baseline 
Group1  
May 06 - Oct 06 (n = 702) 
Nov 06 - Apr 07 (n = 759) 
 
Nov 06 - Apr 07 (n = 667) 
 
Patient data unavailable (n = 90)  
Group 2 
May 06 - Oct 06 (n = 849) 
Patient data unavailable (n = 35) 
Pharmacy data unavailable (n = 136) 
Patient data unavailable (n = 50) 
 
May 07 - Oct 07 (n = 481) 
 
May 07 - Oct 07 (n = 319) 
 
Nov 07 - Apr 08 (n = 421) 
 
Nov 07 - Apr 08 (n = 297) 
 
Patient data unavailable (n = 60) 
 
Pharmacy data unavailable (n = 140) 
Patient data unavailable (n = 53) 
Not eligible for intervention (n = 247) 
 
Patient data unavailable (n = 22) 
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not receive three or more reliever canisters in the preceding six-month period and thus did not receive an 
intervention. 
2.3.1.2 Preventer-to-reliever ratio 
In Group 1, the median P : R ratio increased from 0.1 in the six-month period before the 
intervention, to 0.3 thereafter. In Group 2, the median P : R ratio remained at 0.1 in the 
first two six-month periods before the intervention, and increased to 0.2 thereafter 
(Figure 17).  
Figure 17. Changes in preventer-to-reliever ratios over the study period 
 
As displayed in Table 8, Friedman’s test showed significant changes of the P : R ratio 
over time, within each group (Group 1, &2 = 12.9, df = 3, P < 0.01; Group 2, &2 =  18.4, 
df = 3, P < 0.001).  
Table 8. Overall changes in P : R ratio within each group* 
Patients 6-12 months 
pre-
intervention 
0-6 months 
pre-
intervention 
0-6 months 
post-
intervention 
6-12 months 
post-
intervention 
12-18 months 
post-
intervention 
P 
Group 1 N/A 0.1 (0.0 - 0.5) 0.3 (0.0 - 0.8) 0.3 (0.0 - 0.7) 0.3 (0.0 - 0.8) < 0.01 
Group 2 0.1 (0.0 - 0.5) 0.1 (0.0 - 0.5) 0.2 (0.0 - 0.8)  0.2 (0.0 - 0.6)  N/A < 0.001 
*Figures represent median (interquartile range).  
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Table 9 displays the results of the Wilcoxon post hoc comparisons of the P : R ratio 
between time periods, for each group. In Group 1, post hoc comparisons showed 
significant increases in the P : R ratio between the 0-6 months pre-intervention period 
and (i) the 0-6 months post intervention period, (ii) the 6-12 months post-intervention 
period, and (iii) the 12-18 months post-intervention period.  
In Group 2, post hoc comparisons showed significant increases in the P : R ratio 
between the 0-6 months pre-intervention period and (i) the 0-6 months post-intervention 
period, and (ii) the 6-12 months post-intervention period. 
Table 9. Wilcoxon post hoc comparisons of P : R ratio within each group* 
Time periods compared Z P 
Group 1   
0-6 months pre-intervention to 0-6 months post-intervention 5.7 < 0.0001 
0-6 months pre-intervention to 6-12 months post-intervention 4.8 < 0.0001 
0-6 months pre-intervention to 12-18 months post-intervention 3.7 < 0.001 
0-6 months post-intervention to 6-12 months post-intervention 0.6 0.5 
0-6 months post-intervention to 12-18 months post-intervention 0.2 0.8 
6-12 months post-intervention to 12-18 months post-intervention 0.2 0.9 
Group 2   
6-12 months pre-intervention to 0-6 months pre-intervention 0.7 0.5 
6-12 months pre-intervention to 0-6 months post-intervention 2.6 < 0.01 
6-12 months pre-intervention to 6-12 months post-intervention 1.6 0.1 
0-6 months pre-intervention to 0-6 months post-intervention 4.4 < 0.0001 
0-6 months pre-intervention to 6-12 months post-intervention 3.7 < 0.001 
0-6 months post-intervention to 6-12 months post-intervention 0.9 0.4 
*Using a significance level with Bonferroni correction for multiple comparisons, P < 0.008.  
2.3.1.3 Reliever and preventer usage 
Friedman’s test showed significant changes in the average daily SABA usage over time, 
within each group (Group 1, &2 = 282.5, df = 3, P < 0.0001; Group 2, &2 = 178.4, df = 3, 
P < 0.0001; Table 10). 
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Table 10. Overall changes in average daily SABA usage within each group* 
Patients 6-12 months 
pre-
intervention 
0-6 months 
pre-
intervention 
0-6 months 
post-
intervention 
6-12 months 
post-
intervention 
12-18 months 
post-
intervention 
P 
Group 1 N/A 
655.7 
(437.2 - 874.3) 
425.5 
(209.4 - 796.0) 
437.2 
(218.6 - 874.3) 
218.6 
(82.0 - 655.7) 
< 0.0001 
Group 2 
655.7 
(437.2 - 874.3) 
437.2 
(207.3 - 851.1) 
655.7 
(437.2 - 1092.9) 
437.2 
(218.6 - 874.3) 
N/A < 0.0001 
*Figures represent median usage in #g (interquartile range). 
Table 11 displays the results of the Wilcoxon post hoc comparisons of the daily SABA 
usage between time periods, for each group. In Group 1, post hoc comparisons showed 
significant decreases in the average daily SABA usage between the 0-6 months pre-
intervention period and (i) the 0-6 months post-intervention period, (ii) the 6-12 months 
post-intervention period, and (iii) the 12-18 months post-intervention period. There 
were also significant decreases in the average daily SABA usage between the 0-6 
months post-intervention and 12-18 months post-intervention periods, and between the 
6-12 months post-intervention and 12-18 month post-intervention periods.  
In Group 2, post hoc comparisons showed significant decreases in the average daily 
SABA usage between the 6-12 months pre-intervention and (i) the 0-6 months pre-
intervention periods, and (ii) the 6-12 months post-intervention periods. There were also 
significant decreases in average daily SABA usage and between the 0-6 months post-
intervention and 6-12 months post-intervention periods. 
In Group 2, there were significant increases in the average daily SABA usage between 
the 6-12 months pre-intervention and 0-6 months post-intervention periods. There were 
also significant increases in the average daily SABA usage between the 0-6 months pre-
intervention and (i) the 0-6 months post-intervention period, and (ii) the 6-12 months 
post-intervention periods.  
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Table 11. Wilcoxon post hoc comparisons of average daily SABA usage within each group* 
Time periods compared Z P 
Group 1   
0-6 months pre-intervention to 0-6 months post-intervention 14.0 < 0.0001 
0-6 months pre-intervention to 6-12 months post-intervention 10.8 < 0.0001 
0-6 months pre-intervention to 12-18 months post-intervention 14.1 < 0.0001 
0-6 months post-intervention to 6-12 months post-intervention 0.9 0.4 
0-6 months post-intervention to 12-18 months post-intervention 6.8 < 0.0001 
6-12 months post-intervention to 12-18 months post-intervention 7.8 < 0.0001 
Group 2   
6-12 months pre-intervention to 0-6 months pre-intervention 11.2 < 0.0001 
6-12 months pre-intervention to 0-6 months post-intervention 4.4 < 0.0001 
6-12 months pre-intervention to 6-12 months post-intervention 10.4 < 0.0001 
0-6 months pre-intervention to 0-6 months post-intervention 6.0 < 0.0001 
0-6 months pre-intervention to 6-12 months post-intervention 11.6 < 0.0001 
0-6 months post-intervention to 6-12 months post-intervention 7.4 < 0.0001 
*Using a significance level with Bonferroni correction for multiple comparisons, P < 0.008. 
Table 12 displays number of SABA canisters dispensed within each group. The 
Friedman’s test showed significant changes in the number of SABA canisters dispensed 
over time, within each group (Group 1, &2 = 298.0, df = 3, P < 0.0001; Group 2, 
&2 = 187.2, df = 3, P < 0.0001). 
Table 12. Number of SABA canisters dispensed over the study period* 
Patients 6-12 months 
pre-
intervention 
0-6 months 
pre-
intervention 
0-6 months 
post-
intervention 
6-12 months 
post-
intervention 
12-18 months 
post-
intervention 
P 
Group 1 N/A 6 (4 - 8) 4 (2 - 7) 4 (2 - 8) 2 (1 - 6) < 0.0001 
Group 2 6 (2 - 8) 4 (2 - 8) 6 (4 - 10) 4 (2 - 8) N/A < 0.0001 
*Figures represent median number of relievers  (interquartile range). 
Table 13 displays the results of the Wilcoxon post hoc comparisons of the number of 
SABA dispensed between time periods, for each group. The comparisons showed the 
same significant differences between time periods as the average daily SABA usage. 
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Table 13. Wilcoxon post hoc comparisons of SABA canisters dispensed within each group* 
Time periods compared Z P 
Group 1   
0-6 months pre-intervention to 0-6 months post-intervention 13.3 < 0.0001 
0-6 months pre-intervention to 6-12 months post-intervention 10.7 < 0.0001 
0-6 months pre-intervention to 12-18 months post-intervention 14.1 < 0.0001 
0-6 months post-intervention to 6-12 months post-intervention 1.0 0.3 
0-6 months post-intervention to 12-18 months post-intervention 6.8 < 0.0001 
6-12 months post-intervention to 12-18 months post-intervention 7.8 < 0.0001 
Group 2   
6-12 months pre-intervention to 0-6 months pre-intervention 10.7 < 0.0001 
6-12 months pre-intervention to 0-6 months post-intervention 4.3 < 0.0001 
6-12 months pre-intervention to 6-12 months post-intervention 10.3 < 0.0001 
0-6 months pre-intervention to 0-6 months post-intervention 6.0 < 0.0001 
0-6 months pre-intervention to 6-12 months post-intervention 11.4 < 0.0001 
0-6 months post-intervention to 6-12 months post-intervention 7.4 < 0.0001 
*Using a significance level with Bonferroni correction for multiple comparisons, P < 0.008. 
Friedman’s test showed significant changes in the average daily ICS usage over time, 
within each group (Group 1, &2 = 39.1, df = 3, P < 0.0001; Group 2, &2 = 54.9, df = 3, 
P < 0.0001; Table 14). 
Table 14. Overall changes in average daily ICS usage within each group* 
Patients 6-12 months 
pre-
intervention 
0-6 months 
pre-
intervention 
0-6 months 
post-
intervention 
6-12 months 
post-
intervention 
12-18 months 
post-
intervention 
P 
Group 1 N/A 
109.3 
(0.0 - 327.9) 
66.3 
(0.0 - 315.8) 
109.3 
(0.0 - 327.9) 
65.6 
(0.0 - 303.3) 
< 0.0001 
Group 2 
65.6 
(0.0 - 327.9) 
0.0 
(0.0 - 271.0) 
163.9 
(0.0 - 409.8) 
82.0 
(0.0 - 327.9) 
N/A < 0.0001 
*Figures represent median usage in #g (interquartile range). 
Table 15 displays the results of the Wilcoxon post hoc comparisons of the daily ICS 
usage between time periods, for each group. In Group 1, post hoc comparisons showed 
significant decreases in the average daily ICS usage between the 0-6 months pre-
intervention and 12-18 months post-intervention periods, between the 0-6 months post-
intervention and 12-18 months post-intervention periods, and between the 6-12 months 
post-intervention and 12-18 months post-intervention periods. 
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In Group 2, post hoc comparisons showed significant decreases in the average daily ICS 
usage between the 6-12 months pre-intervention and 0-6 months pre-intervention 
periods, and between the 0-6 months post-intervention and 6-12 months post-
intervention periods. 
In Group 2, there were also significant increases in the average daily ICS usage between 
the 6-12 months pre-intervention and 6-12 months post-intervention periods, and 
between the 0-6 months pre-intervention and 6-12 months post-intervention periods. 
Table 15. Wilcoxon post hoc comparisons of average daily ICS usage within each group* 
Time periods compared Z P 
Group 1   
0-6 months pre-intervention to 0-6 months post-intervention 3.1 < 0.01 
0-6 months pre-intervention to 6-12 months post-intervention 1.7 0.1 
0-6 months pre-intervention to 12-18 months post-intervention 4.7 < 0.0001 
0-6 months post-intervention to 6-12 months post-intervention 0.7 0.5 
0-6 months post-intervention to 12-18 months post-intervention 3.8 < 0.001 
6-12 months post-intervention to 12-18 months post-intervention 5.5 < 0.0001 
Group 2   
6-12 months pre-intervention to 0-6 months pre-intervention 4.5 < 0.0001 
6-12 months pre-intervention to 0-6 months post-intervention 0.2 0.8 
6-12 months pre-intervention to 6-12 months post-intervention 1.6 0.1 
0-6 months pre-intervention to 0-6 months post-intervention 1.6 0.1 
0-6 months pre-intervention to 6-12 months post-intervention 4.8 < 0.0001 
0-6 months post-intervention to 6-12 months post-intervention 6.4 < 0.0001 
*Using a significance level with Bonferroni correction for multiple comparisons, P < 0.008. 
Table 16 displays the proportion of patients who received at least one supply of ICS in 
each six-month period. Within each group, the proportion of patients using ICS changed 
significantly from one period to the next. Approximately half of the patients were not 
using any ICS throughout most of the study period.  
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Table 16. Proportion of patients who received at least one supply of ICS in each period 
Patients 6-12 months 
pre-
intervention 
0-6 months 
pre-
intervention 
0-6 months 
post-
intervention 
6-12 months 
post-
intervention 
12-18 
months post-
intervention 
Group 1      
ICS ± LABA ± SABA N/A 
387/702  
(55.1%) 
347/667  
(52.0%) 
261/481 
(54.3%) 
220/421 
(52.3%) 
No ICS N/A 
315/702 
(44.9%) 
320/667 
(48.0%) 
220/481 
(45.7%) 
201/421 
(47.7%) 
P value  < 0.0001 < 0.0001 < 0.0001  
Group 2      
ICS ± LABA ± SABA 
443/849  
(52.2%) 
361/759  
(47.6%) 
192/319  
(60.2%) 
167/297  
(56.2%) 
N/A 
No ICS 
406/849 
(47.8%) 
398/759 
(52.4%) 
127/319 
(39.8%) 
130/297 
(43.8%) 
N/A 
P value  < 0.0001 < 0.0001 < 0.0001   
 
Table 17 clarifies the changes in ICS and SABA usage, by displaying the percent 
changes in median ICS and SABA average daily usage over the study period. The table 
displays a greater decrease in SABA usage, compared to ICS over the study period in 
both groups.  
Table 17. Percent changes in median daily ICS and SABA usage over the study period 
Time after initial data collection ICS SABA 
Group 1   
6 months –39.3% –35.1% 
12 months 0.0% –33.3% 
18 months –40.0% –66.6% 
Group 2   
6 months –100.0% –33.3 
12 months 149.8% 0.0% 
18 months 25.0% –33.3% 
Average percent change over the study period –0.75% –33.6% 
 
2.3.1.4 Sensitivity analysis 
A significantly reduced proportion of long-term concessional patients collected one or 
more recorded supply of non-prescription SABA, as compared to the non-concessional 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 91 
patients (31/519 [6.0%] versus 159/1032 [15.4%] respectively, &2 = 28.6, P < 0.0001). 
Friedman’s test showed significant decreases in the average daily SABA usage over 
time, within each group (Group 1, &2 = 282.5, df = 3, P < 0.0001; Group 2, &2 = 178.4, 
df = 3, P < 0.0001; Table 18). 
Table 18. Overall changes in average daily SABA usage amongst long-term concessional patients* 
Patients 6-12 months 
pre-
intervention 
0-6 months 
pre-
intervention 
0-6 months 
post-
intervention 
6-12 months 
post-
intervention 
12-18 months 
post-
intervention 
P 
Group 1 N/A 
655.7 
(437.2 - 874.3) 
439.6 
(216.2 - 829.0) 
437.2 
(218.6 - 874.3) 
273.2 
(0.0 - 655.7) 
< 0.0001 
Group 2 
874.3 
(437.2 - 1120.2) 
800.0 
(594.8 - 1098.9) 
655.7 
(437.2 - 1092.9) 
437.2 
(218.6 - 874.3) 
N/A < 0.0001 
*Figures represent median (interquartile range). 
Table 19 displays the results of the Wilcoxon post hoc comparisons of the daily SABA 
usage between time periods, for long-term concessional patients in each group. The post 
hoc analyses confirmed the significant decrease in SABA usage after each intervention.  
Table 19. Wilcoxon post hoc comparisons of SABA usage amongst long-term concessional patients* 
Time periods compared Z P 
Group 1   
0-6 months pre-intervention to 0-6 months post-intervention 9.7 < 0.0001 
0-6 months pre-intervention to 6-12 months post-intervention 7.4 < 0.0001 
0-6 months pre-intervention to 12-18 months post-intervention 12.3 < 0.0001 
0-6 months post-intervention to 6-12 months post-intervention 1.9 < 0.1 
0-6 months post-intervention to 12-18 months post-intervention 5.4 < 0.0001 
6-12 months post-intervention to 12-18 months post-intervention 7.5 < 0.0001 
Group 2   
6-12 months pre-intervention to 0-6 months pre-intervention 0.2 0.9 
6-12 months pre-intervention to 0-6 months post-intervention 3.2 < 0.01 
6-12 months pre-intervention to 6-12 months post-intervention 9.2 < 0.0001 
0-6 months pre-intervention to 0-6 months post-intervention 4.0 < 0.0001 
0-6 months pre-intervention to 6-12 months post-intervention 10.0 < 0.0001 
0-6 months post-intervention to 6-12 months post-intervention 6.6 < 0.0001 
*Using a significance level with Bonferroni correction for multiple comparisons, P < 0.008. 
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2.3.2 Qualitative component 
2.3.2.1 Study population 
Of the 26 GPs, 24 pharmacists, and 81 patients who were invited to participate, six 
(23.1%), 10 (41.7%), and 10 (12.3%) were enrolled in the study, respectively. One 
female and five male GPs were interviewed. They were aged between 44 and 56 years, 
had an average of 26 years experience in general practice, and worked 25-50 hours per 
week. Three female and seven male community pharmacists were interviewed. They 
were aged between 31 and 55 years, had an average of 18 years experience in 
community pharmacy, and worked 30-60 hours per week. Seven female and three male 
patients, aged between 51 and 96 years, were interviewed. Typically, they visited their 
GP specifically for an asthma consultation once or twice a year, or more often if they 
had other co-morbidities. However, several reported actively avoiding asthma-related 
medical consultations by telephoning their GP to obtain repeat prescriptions. Only one 
patient had seen a respiratory specialist in the previous 12 months, and most had never 
seen a specialist. One had been hospitalised for asthma on five occasions. Table 20 
displays the sample of GPs, community pharmacist and patients who participated in an 
interview. 
Table 20. Number of participants interviewed 
Location Respondent type 
North-western Tasmania Southern Tasmania  
Total 
General practitioners 4 2 6 
Pharmacists 6 4 10 
Patients with asthma 4 6 10 
Total 14 12 26 
 
2.3.2.2 General practitioners 
Table 21 displays the relevant demographical profiles of each GP interviewed. 
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Table 21. General practitioners’ profiles   
Gender  Age Years in general 
practice 
Hours 
practice 
per week 
Number 
patients in 
total practice 
Estimated percentage of 
patients with asthma in 
practice 
Male 45 20 50 Unknown $10% 
Male 49 25 45 15,000 $10% 
Male 55 30 50 20,000 $5% 
Male 53 28 45 11,000 $5% 
Female 56 31 25 Unknown 5-10% 
Male 44 20 40+ Unknown 8% 
 
Most GPs believed that community pharmacists were well placed to refer patients to 
GPs when they had underestimated the severity of their asthma and were over-relying 
on reliever medications. The intervention was perceived as an extension of pharmacists’ 
responsibilities: 
“It was an excellent process as I can prescribe six months of 
Ventolin® and six months of Seretide® and they may stop the 
Seretide® and just use the Ventolin® and I don’t have any way to 
check up on this [but pharmacists do].” (Male, 49) 
“Pharmacists are good monitors of over users of prescriptions.” 
(Male, 53) 
“They [pharmacists] can identify if there is too much Ventolin® 
being used.” (Male, 55) 
“Pharmacists can be an early warning system.” (Male, 44) 
The positive views of the intervention were dependent on good GP⁄pharmacist 
relationships: 
“Pharmacists are a good point of advice especially if there is too 
much Ventolin® used, and I don’t mean a fly-by-nighter. It is 
more when you have a pharmacist where you have a good 
relationship.” (Male, 49) 
There was also some apprehension towards the intervention process. Any negative 
views of the intervention seemed to be related to a lack of understanding or a reluctance 
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to accept pharmacist input, especially if they perceived this as an encroachment on their 
own area of responsibility: 
“As long as they [pharmacists] don’t overstep their mark.” 
(Male, 49) 
Some GPs questioned the credibility of pharmacists, and raised a potential conflict of 
interest in promoting good asthma management in a retail environment: 
“...Because they [pharmacists] sell stuff... that’s their business... 
there’s always going to be a conflict of interest.” (Male GP, 53) 
General practitioners would welcome advice from pharmacists at the time of 
interventions, so they could make notes to raise the issue with patients at subsequent 
visits. An area where GPs believed the intervention could have been improved was the 
lack of direct communication provided to them about their patients. They felt that they 
should have been informed that their patients were given intervention packs: 
“If they [pharmacists] suggest something to my patients then I 
expect to be told... The patient could get confused if the GP is 
not aware of what has been said to them by the pharmacist.” 
(Male, 55) 
There were suggestions made to inform GPs at the time of the intervention: 
“If there was patient consent the pharmacist and doctor could 
discuss it, or even better the pharmacy software could send a 
message electronically... like a pathology report.” (Male, 45) 
General practitioners expressed that patients were rarely forthcoming about problems 
with their asthma, even after being referred for an asthma management review by their 
pharmacists. One aspect commented on, was that the intervention relied on patients to 
initiate contact with their GP, and further when they did go to the GP, to inform the GP 
what they had been given and told: 
“Often patients come and don’t say anything. It would be 
helpful if they would say that my pharmacist said I had to come 
and see you.” (Male, 45) 
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A related issue was that it was hard to reach chronically non-adherent asthma patients. 
Even if presented with an intervention pack, it was thought to be unlikely that such 
patients would take any action. They believed that this issue might have decreased the 
efficiency of the intervention process: 
“It’s always going to be tough to get to the noncompliant.” 
(Male, 55) 
2.3.2.3 Community pharmacists  
Table 22 displays the relevant demographical profiles of each community pharmacist 
interviewed. 
Table 22. Community pharmacists’ profiles 
Gender Age Owner or 
manager 
Years in 
community 
pharmacy 
Hours practice 
per week 
Accredited to do 
HMR* 
Male 40 Owner 18 60 No 
Male 37 Owner 14 50 No 
Male 31 Owner 9 48 No 
Male 32 Manager 9 43 No 
Female 34 Owner 11 38 Yes 
Female 41 Owner 18 25 Yes 
Male 50 Owner 28 60 Yes 
Male 44 Owner 20 50 No 
Male 50 Owner 27 30-35 No 
Female 55 Owner 30 30 No 
*Home Medication Review 
Pharmacists felt that patients can be apathetic about asthma, fail to seek medical advice 
and can self-medicate with their own or other people’s reliever medication. The 
perception seemed to be that the use of asthma relievers has been ‘normalised in the 
community’: 
“They [patients] can use a puffer every few days and when you 
talk to them they think they are well off.” (Male, 37) 
“Most [patients] have a fix it now mentality rather than use a 
preventer.” (Female, 34) 
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Pharmacists assessed the asthma intervention positively. They spoke of being more 
engaged in asthma-related discussions with patients following the intervention and 
believed that a larger roll-out of the asthma intervention would be a positive move 
towards recognition of their role in patient care: 
“It jogged the memory about what we should be doing with 
asthma... we can be a lot more proactive.” (Female, 41) 
“We had some good results... one particularly resistant patient 
went to the GP and now takes a preventer.” (Male, 44) 
“I’d hope that all pharmacists would want to be involved... It’s 
what we’re trained for...” (Female, 34) 
The use of dispensing data to identify patients who may have suboptimal management 
of their asthma was seen to be a positive, as there was a lot of information retained by 
pharmacists, which could be used to benefit patients: 
“We have a lot of information in our computers which we don’t 
use.” (Male, 40) 
The data mining software program was positively assessed as easy to use and the 
intervention was implemented very easily, with minimal disruptions to workflow: 
“The time taken was minimal and it was not imposing.” 
(Male, 32) 
“The system was easy to use - we figured out how to use it.” 
(Male, 31) 
“It did not take any time at all. It was a breeze compared to 
[another research project] where everything had to be done on 
paper... It [this project] was all electronic so it was easy.” 
(Male, 40) 
There were some suggestions made for an improvement in the intervention process, 
including more direct involvement of the GP. Like GPs, pharmacists suggested that it 
would be better if GPs were informed at the same time as patients perhaps with a 
courtesy letter or electronic notification: 
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“It would have been good to talk to the doctor, but I don’t know 
about privacy.” (Male, 37) 
“It’s in the pharmacist’s best interest for the GP to be informed.” 
(Male, 31) 
2.3.2.4 Patients with asthma 
Table 23 displays the relevant demographical profiles of each patient interviewed. 
Table 23. Patients’ profiles 
Gender  Age Visits to GP for asthma in last 12 months 
Visit to respiratory 
specialist in last 12 months 
Ever hospitalised 
for asthma 
Male 67 2-3 No No 
Female 62 1-2 No No 
Female 96 12-20 No No 
Male 55 1-2 No No 
Female 56 1-2 No No 
Female 84 12 Yes No 
Female 55 1 No Yes 
Female 51 0 No No 
Male 70 1-2 No No 
Female 64 3-4 No No 
 
Patients spoke of their pharmacist as a good person and reported a strong personal 
relationship. Frequently, it was this relationship that was important to patients’ 
acceptance of any increased pharmacy activity: 
“He [the pharmacist] always asks about me and how I am going, 
and he has given me some helpful advice on my asthma.” 
(Male, 67) 
“Pharmacists are good as [you can ask a question and] they 
don’t make you feel like a goose.” (Female, 62) 
“I see him [the pharmacist] more than the doctor. He tells me 
what to do, what the medications are all for, he’s really helpful.” 
(Male, 70) 
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However, it was evident that patients’ expectations of pharmacists’ activity were 
relatively low, and they more commonly asked their doctor for advice on their asthma: 
“If I needed some advice I’d go to the doctors.” (Female, 64) 
“She is the doctor so she should be the one telling me [about 
asthma management].” (Male 67) 
Most patients perceived their asthma as currently well managed and controlled. 
However, these perceptions were in direct contrast to both the evidence they provided of 
the amount of reliever medication required daily and the symptoms they described: 
“I am always short of breath... some people have bad asthma, 
but that is not me...” (Female, 84) 
“I measure my asthma by my shortness of breath which is 
always present.” (Male, 67) 
“I have the Flixotide® in the morning and at night and have one 
or two puffs of Ventolin® every four hours.” (Female, 55) 
Patients, especially those who had good relationships with their local pharmacist, were 
very accepting of the asthma intervention and the subsequent mailed out information, 
and they were pleased someone was keeping track of their health: 
“Anything they can do to improve how asthma is treated is OK 
by me.” (Female, 55) 
“It’s good that someone’s looking into it [asthma].” 
(Female, 51) 
Most patients interviewed did not take any action as a result of the intervention to either 
visit their doctor to discuss their asthma or to change their asthma therapy. Most had the 
opinion that their asthma was well controlled and did not see the need to visit their GP: 
“I didn’t see my doctor as I felt alright, and I didn’t mention 
anything to him.” (Male, 67) 
“If I was feeling poorly then I would have done something.” 
(Female, 84) 
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“I didn’t follow up because nothing could be changed 
anyway...” (Female, 55) 
Some perceived their GPs as busy people, so they did not want to bother their GP with 
something that was not really an issue in their minds: 
“I wonder if it is worthwhile [contacting her GP] as I don’t want 
to be a nuisance.” (Female, 84) 
“I know they [GPs] are busy, and I don’t want to take up too 
much of their time. I would have to have a hand cut off to worry 
them.” (Female, 62) 
Thus, patients were reluctant to adopt suggestions from pharmacists to make GP 
appointments for asthma reviews, or when they did make an appointment, they may not 
have raised any issues with their asthma.  
2.4 Discussion 
2.4.1 Quantitative component 
This project demonstrated a sustained improvement in the P : R ratio for at least 12 
months after the intervention. It has been shown that the P : R ratio can be applied as a 
surrogate measure to assess the quality of prescribing for asthma, and is an important 
factor related to asthma morbidity.129,318 An increased P : R ratio has been associated 
with improved asthma symptoms,318 reduced need for rescue courses of oral 
prednisolone,129 and reduced emergency department visits,316 hospital admissions319 and 
urgent GP visits.317 
There has been other studies examining asthma management which have used the 
number of canisters130,131 or defined daily doses129,319 as a measure of ICS use. The 
limitation of using the number of canisters is that it does not account for the number of 
doses per canister or differing drug potencies, whereas a limitation of using defined 
daily doses is the poor representation of the widely accepted dose equivalence. A 
particular strength of this study is the fact that the potencies and doses per canister were 
taken into account, allowing a more accurate representation of ICS and SABA use, and 
therefore ensuring an accurate P : R ratio. 
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It has previously been demonstrated that dispensing of medium-to-high level ICS 
therapy is associated with a reduced risk of ICU admission, whereas high level inhaled 
SABA dispensing is associated with an increased risk of both ICU admission and 
endotracheal intubation for asthma.131 Importantly, stratified analysis indicated that this 
excess risk is observed only among patients not receiving ICS therapy.131 Therefore, the 
increased P : R ratio reported by this project should be interpreted with caution. Despite 
the fact that the P : R ratio was the primary outcome measure used in this project, 
further analyses were necessary in order to determine whether the increase in the P : R 
ratio resulted from an increased preventer usage or a decreased reliever usage, before 
any conclusions could be drawn. 
Further analysis found that the increased P : R ratio was largely due to a reduction in the 
average daily use of reliever medication. A number of international studies have 
demonstrated improved asthma outcomes with decreased reliance on reliever 
medications.325-327 
The average salbutamol-equivalent daily usages of SABA ranged from 218.6 #g to 
655.7 #g, which is equivalent to 2-6 puffs per day, over the study period. Unfortunately, 
this range of daily SABA consumption is well above what is recommended by the NAC 
and Asthma Foundations Australia, who state that usage of reliever medication on three 
or more occasions per week is indicative of suboptimal asthma control.59,328 According 
to Australian asthma management guidelines, and assuming all dispensed medication 
had been consumed, patients using this quantity of reliever medication should be 
classed as having poor asthma control, and should be receiving regular ICS therapy.59 
The assumption that dispensing correlates with medication use was a limitation of this 
study, as discussed later. 
While it was encouraging to see a sustained improvement in the P : R ratio and decrease 
in reliever usage, it was somewhat disappointing that the usage of ICS did not increase 
over the study period. The median beclomethasone-HFA equivalent daily usage of ICS 
over the study period fell within or below the ‘low dose’ range according to the NAC.59 
Assuming all dispensed medication had been consumed, the average daily usage of 
SABA reported over the study period indicated that the majority of patients analysed 
would be classified as having poor asthma control, and should therefore be maintained 
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on moderate-to-high dosages of ICS, as well as a LABA.59 Unfortunately, 
approximately half of the patients were not using any ICS over the study period. 
Inadequate use of ICS could be due to under-prescribing and/or poor adherence with 
therapy. It has been found that a large proportion of patients with asthma do not 
understand the role of their medications and have many misconceptions and fears in 
regard to ICS, reducing their willingness to use them.263 In addition, it has been widely 
demonstrated that patients prefer to manage their asthma as an acute intermittent 
disorder rather than a chronic ongoing disease that needs monitoring and managing.75-77 
Patients’ perceptions of their condition and their need for treatment limit the adherence 
to ICS therapy, and therefore the reported effectiveness of ICS. Barriers to ICS use must 
be overcome before widespread benefits of ICS therapy are seen.  
The results showed decreases in reliever usage after the intervention in Group 1, but 
increases in reliever usage after the intervention amongst patients in Group 2. 
Furthermore, the preventer usage decreased immediately after the intervention in 
Group 1, but increased immediately after the intervention in Group 2. While these 
patterns in reliever and preventer usage resulted in increases in the P : R ratios in both 
groups, it is important to note the effect of seasonal variation on the results. Group 1 
received the intervention in late October 2006, whereas Group 2 received the 
intervention in late April 2007. Therefore, warmer summer months were represented in 
Group 1’s 0-6 month post-intervention dispensing data, and colder winter months were 
represented in Group 2’s 0-6 month post-intervention data. Winter months often result 
in poor asthma control,329,330 which may explain the differences in preventer usage from 
one six-month period to the next. 
There are potential limitations to the quantitative component of this study. It was 
assumed that the dispensed quantity of reliever medication equated with actual 
medication consumption, but factors such as storing relievers in different sites, sharing 
medication with family members and misplacing medication could complicate the 
picture. It is also possible that non-prescription supply of relievers, which is not always 
recorded in the dispensing software, resulted in underestimation of reliever medication 
usage. Underestimation may also have arisen from the assumption that asthma 
medications were not being dispensed at other pharmacies. However, the same level of 
underestimation would have applied to both groups and in all study periods. 
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Furthermore, the research team attempted to account for this underestimation in the 
patient identification algorithm used by the data mining software, by being considerably 
generous in the quantity of relievers that indicated suboptimal management.  
Not all of the patients originally included in the study were eligible for inclusion in the 
follow-up study. Ineligible patients either did not receive the intervention, or did not 
have available data at the time of follow-up. It could not be assumed that the 
unavailability of patent data implied that the patient was no longer using asthma 
medication. Thus, it was deemed more accurate to exclude these patients, avoiding 
skewing of the data. However, when interpreting the results presented here it should be 
borne in mind that the outcomes only apply to half of the patients in the original sample. 
Furthermore, all data were collected in one single state (Tasmania), therefore caution 
must be exercised in extrapolating the findings to the rest of the Australian population 
as there may be local effects not present in other Australian states or territories. 
2.4.2 Qualitative component 
This study provided valuable information regarding the perceptions of GPs, community 
pharmacists and patients towards a community pharmacy-based asthma intervention. 
The acceptance and support of these key stakeholders is vital to ensure adequate uptake 
and effectiveness of future interventions. Although there have been a number of 
community pharmacy-based asthma interventions published which report improved 
patient outcomes,301,303,331,332 this seems to be the first data reported on the views of 
GPs, pharmacists, and patients of such an intervention. 
There was a general acceptance of the intervention process by participants. Both GPs 
and patients expected pharmacists to intervene when patients’ therapies could be 
suboptimal or detrimental to their health. Indeed, the patients were very accepting of the 
intervention as it provided both positive attention and reassurance that their medications 
were being actively monitored. 
The acceptance by GPs of pharmacy interventions seemed dependent on the existing 
relationships with pharmacists. If the relationship was professionally cordial and 
respectful then any information provided to GPs was generally well received. GPs were 
sometimes reluctant to accept pharmacist input resulting from interventions if they 
perceived this as an encroachment on their own area of responsibility. This finding is in 
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line with previous studies, which have shown that GPs tend to express concerns about 
pharmacists assuming roles they considered to be general practice activities.333-335 It has 
previously been reported that GPs may sometimes be offended by the introduction of a 
pharmacist-led health service, feeling that it implied shortcomings in their existing level 
of care.336 This means that pharmacists need to ensure that perceived boundaries in 
patient care are approached with caution in order to reduce the risk of misinterpretation 
about the intent of these types of interventions. Another concern was the credibility of 
pharmacists, and the potential conflict of interest of promoting health in a retail 
environment. Previous studies have demonstrated that many GPs see community 
pharmacists as business-people, shopkeepers or specialist retailers, and believe that this 
represents a conflict of interest in healthcare.333,337,338 Interestingly, a previous study of 
patients’ perceptions suggested that this conflict may, in practice, not be overly 
significant; many of the participants were able to recall experiences of their own where 
a pharmacist had clearly put patients before profit, not just in respect of their health, but 
also in terms of convenience and financial gain for the patient.339 
GPs would welcome advice from pharmacists at the time of interventions, so they could 
make notes to raise the issue with patients at subsequent visits. With this change to the 
procedure, it is likely that the number of asthma reviews would increase, as the onus on 
the patient to initiate action would be reduced. The researchers discouraged this initial 
pharmacist/GP contact in the original intervention due to concerns about privacy and 
patient consent. If direct notification of GPs is to be used at the time of asthma 
interventions then there will be a need to advise GPs easily and efficiently, and patient 
consent in this process needs to be taken into account. This could involve some form of 
electronic notification, as GPs, in most cases, would not want to receive a phone call 
from pharmacists given the perceived non-urgency of the review. Thus, a business 
practice change may be required to accommodate electronic communication with GPs 
by pharmacists. 
Pharmacists believed that a national roll-out of the asthma intervention would be a 
positive move towards improved asthma management in the community. It was 
encouraging to learn that community pharmacists implemented the intervention very 
easily, with minimal disruptions to workflow. Time has clearly been identified in 
previous studies as a major factor that significantly prevents community pharmacists 
from undertaking any additional extended role in healthcare.11-14,340,341 The workload in 
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community practice is such that research is perceived as having a low priority because it 
would have to be taken on as an additional role.13 Academic researchers should be 
sensitive to time constraints and responsibilities of community-based investigators when 
they develop study procedures. If community pharmacists are to become involved in 
pharmacy practice research, it is necessary to develop a strategy that recognises the 
workload issues in community pharmacy practice. 
Patients’ general satisfaction with pharmacy services was high, but their perceived 
benefit of the intervention was lower. This is in line with previous results from 
satisfaction studies, confirming satisfaction ratings with pharmacy services are generally 
high, although patients’ expectations of pharmacists’ capabilities are low.338,342-345 It is 
apparent that patients expect their pharmacist to process prescriptions rapidly and 
provide basic medication information, and that pharmacists are effective in meeting 
these expectations. However, most consumers apparently do not expect to consult with 
their pharmacist or receive pharmaceutical care services.343 These comments convey the 
important message that much work still needs to be done to educate the public about the 
training and roles of the pharmacist.343 Unfortunately, the public’s poor knowledge and 
low expectations can justify a reduced desire for an extended role of the pharmacist in 
the community.342 
Patients were reluctant to adopt suggestions from pharmacists to make GP appointments 
for asthma reviews, or when they did make an appointment, they may not have raised 
any issues with their asthma. While there is an appreciation of pharmacists’ interest in 
patient health, this did not necessarily translate into compliance with the suggestions 
made at the time of the intervention. The reason for this related primarily to patients’ 
optimistic views of their asthma control. All patients seemed to accept they would have 
asthma symptoms throughout their life, and they did not expect that an improvement in 
their asthma management was possible. This is in keeping with the substantial evidence 
that patients with asthma tend to under-estimate their asthma severity,46,51,52,55,281,282 and 
it represents a major barrier to the uptake of asthma interventions. It was interesting that 
despite these perceptions and reluctance to comply with the suggestions made at the 
time of the intervention, patients were pleased that ‘something was being done’ to help 
patients with asthma. This suggests that patients may be failing to recognise their own 
role in managing their asthma, and more education may be required to encourage 
patients to take a more proactive approach with their asthma management. Furthermore, 
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patients need to be made aware that putting up with their symptoms may actually be 
detrimental to their health,18 and that complete control of asthma is achievable in the 
majority of patients.27 
It is possible that patients’ under-estimation of their symptom severity may have 
influenced the reported success of the intervention, as patients who considered their 
asthma as well controlled were unlikely to have sought further medical advice. Most 
interviewed patients assumed their asthma was well controlled because any symptoms 
were alleviated with relievers, and they did not want to ‘bother’ their busy GPs. This 
means that few GP appointments were made and even fewer asthma discussions ensued, 
thus reducing the beneficial outcomes of the program. Despite this low number, the 
quantitative data indicated a three-fold increase in the preventer-to-reliever ratio after 
the intervention.5 Clearly those patients who did attend the GP for medication review 
had a positive outcome in terms of improved preventer usage and a decreased reliance 
on reliever medication. It also suggests that the educational material provided by the 
pharmacist may have had some impact on asthma management. The positive outcome 
when patients were reviewed by the GP underscores the importance of the review 
process. Nevertheless, the main limitation to the uptake and effectiveness of asthma 
interventions may be patients’ views and acceptance of their asthma symptoms. More 
research may be required to further explore patients’ beliefs and perceptions about 
asthma in order to determine the best way to target health behaviours amenable to an 
intervention. 
There are limitations to the qualitative component of this study. Whereas a large number 
of GPs, pharmacists and patients with asthma were approached, many failed to respond 
to the request for their involvement or stated that they were unable to participate. The 
absence of these opinions may have resulted in biases within the data. It should also be 
noted that the respondent sample is inherently biased for two reasons. Firstly, these 
participants had already demonstrated willingness to participate in such research. 
Secondly, the interviews were administered after participants learned of the positive 
results of the intervention. Furthermore, the study was conducted by selecting a sample 
of respondents from northern and southern Tasmania. Thus, the findings may not be 
representative of the total Australian experience of the management of patients with 
asthma. As in all qualitative studies, the generalisability of the results is conceptual 
rather than statistical.346 However, qualitative studies are applicable for exploratory 
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work even though they are unable to test hypotheses and are not automatically 
generalisable. To explore the extent and prevalence of views expressed a quantitative 
approach is needed. However, the findings may be generalised as the attitudes expressed 
here have been reported elsewhere for patients, GPs and pharmacists.11-14,333-345 
Nevertheless, the results provide valuable information regarding the perceived 
feasibility of a community pharmacy-based asthma intervention. It allowed for 
exploration of participants’ views and experiences of the intervention, and the findings 
provide impetus for future research in this area. 
2.5 Conclusions  
This study reinforces the concept that community pharmacists are ideally placed to 
screen for patients who may have suboptimal asthma control, with the potential to 
address critical issues in asthma management in the community. The intervention 
described required minimal time and training on the part of the pharmacist,5 yet resulted 
in significant, sustained improvements in the ratio of dispensed preventer medications to 
reliever medications.  
The qualitative component of this project indicated that there is room for improvement 
in the efficiency of the asthma intervention so that more patients identified with 
potentially sub-optimally managed asthma could be reviewed by GPs. The result of 
more efficient asthma interventions would flow through to an even greater success rate 
in terms of preventer usage. 
In conclusion, a national roll-out of the asthma intervention, with an improved process 
for targeting patients and involving GPs, should be feasible and well accepted. To gain 
sustained improvements in asthma management, the intervention should be repeated at 
least once every 12 months. The intervention has the potential to show widespread 
improvements in asthma management, resulting in better asthma control and improved 
health outcomes for Australia.  
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CHAPTER THREE: 
UPTAKE AND EFFECTIVENESS OF A COMMUNITY PHARMACY 
INTERVENTION TO IMPROVE THE MANAGEMENT OF ASTHMA  
3.1 Aim and objectives 
This study aimed to utilise community pharmacy dispensing records to test the uptake 
and effectiveness of two different types of community pharmacy-based asthma 
interventions across three Australian states. Specifically, the objectives were to: 
• Determine how the uptake by pharmacists influences the effectiveness of mailed 
and face-to-face asthma interventions; 
• Significantly improve the preventer-to-reliever asthma medication ratio in the 
intervention cohort compared to control; 
• Significantly improve the patient-reported asthma control, asthma-related quality 
of life and medication adherence in the intervention cohort compared to control; 
and 
• Determine the perceptions of pharmacists, GPs and patients towards the 
intervention program. 
3.2 Methods 
3.2.1 Study design and setting 
This study was a community pharmacy-based intervention, designed to improve the 
management of asthma. The study involved the modification of a software application 
so that pharmacists could use it to identify patients whose asthma may not be well 
managed, as evidenced by a high provision of reliever medications. This was a 
multicentre study, involving three Australian universities in Tasmania, Victoria and 
South Australia. Researchers at the University of Tasmania managed the study and 
oversaw the intervention in Tasmanian pharmacies, while researchers at Monash 
University and the University of South Australia oversaw the intervention in Victorian 
and South Australian pharmacies, respectively. 
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3.2.2 The data mining software 
In 2006, researchers at the Tasmanian School of Pharmacy developed a data mining 
software application (‘MedeMine’) that seamlessly extracts data from the market-
leading pharmacy dispensing software system in Australia (Fred Dispense; Fred 
Health). About 50% of community pharmacies in Australia use this dispensing system.  
The information technology development under this study involved modifying the 
existing software application to identify patients with poorly managed asthma, as 
evidenced by the quantity of inhaled reliever medication dispensed in the preceding 12 
months. Using a pre-specified algorithm, the program identified patients who had 
received six or more relievers (inhaled SABAs) in the preceding 12 months. This 
indicated that they may have been using, on average, three or more doses per day of 
reliever medication, which exceeds the level recommended in current guidelines for 
optimal asthma control.59 To ensure that patients who were likely to be consistent 
(rather than seasonal) high users of reliever medication were identified, eligible patients 
needed to have received at least three SABA canisters in each of the two preceding six-
month periods. 
Patients receiving regular preventer medications (ICS) were also identified if they 
fulfilled the aforementioned criteria, as they may have been receiving a dose of ICS that 
was too low or may have been using their ICS incorrectly. In either case, they may have 
needed a review of their asthma therapy. 
Specific exclusions were written into the program algorithm to ensure that the patients 
selected for our study were likely to be people with poorly managed asthma who were 
under the care of a GP. The program excluded patients receiving: 
• Inhaled anticholinergics (tiotropium or ipratropium) or oral methylxanthines 
(theophylline or choline theophyllinate), indicating the likely presence of chronic 
obstructive pulmonary disease (COPD); or 
• Leukotriene-receptor antagonists (montelukast or zafirlukast), indicating that the 
patient may either be under 18 years of age, or an adult with the probable 
presence of severe asthma, meaning the patient was likely to be under the care of 
a respiratory specialist. 
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The data mining program automatically ranked the list of identified patients in order of 
greatest to least number of reliever canisters dispensed in the preceding 12 months. The 
patient receiving the greatest number of relievers was randomly assigned to the 
intervention or control group, with subsequent patients being alternately assigned to the 
control or intervention group. For each patient assigned to the control group, two 
patients were assigned to the intervention group. This ensured an approximately even 
distribution of patients across the mailed intervention group, the face-to-face-
intervention group and the control group. 
The initial exclusion and group allocation process was concealed from the pharmacist 
and occurred automatically upon running the application (‘MedeMine-for-Asthma’), 
with only the resulting list of intervention patients available for viewing. To ensure an 
even geographical spread of intervention and control patients, the allocation process was 
repeated in each pharmacy.  
Figure 18 displays a screen shot of an example list of patients identified using 
MedeMine-for-Asthma. Personalised letters, coded surveys and address labels could 
also be printed from this screen. 
Figure 18. List of identified patients in MedeMine-for-Asthma 
 
A patient’s dispensing information could be viewed in detail by highlighting the 
patient’s name and clicking on ‘select patient.’ Dispensing information on the 
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MedeMine-for-Asthma screen, as shown in Figure 19, was engineered to look the same 
as that seen in the Fred dispensing system so that pharmacists would have an instant 
familiarity with the layout and presentation of the information. The patient screen used 
four tabs (‘asthma-related dispensings,’ ‘collated history,’ ‘all dispensing history’ and 
‘extra information’). The first three tabs displayed the patient’s history in different 
ways; the ‘asthma-related dispensings’ tab showed details of all respiratory medication, 
the ‘collated history’ counted the number of supplies of each medication dispensed, and 
‘all dispensing history’ displayed a sequential history for the patient. How much 
information was displayed was determined by selecting ‘months history to display’ (1, 
3, 6, 9, 12 or all). The ‘extra information’ tab gave the pharmacist the facility to enter 
free text relating to the patient. Patients could be excluded from the study by selecting a 
reason from the drop-down ‘reason for exclusion’ menu on the top right-hand side of 
the screen. 
Figure 19. Viewing patient dispensing history in MedeMine-for-Asthma 
 
3.2.3 Sample size 
Based on sample size calculations using the normal approximation to the binomial 
distribution and incorporating a continuity correction, a total of 788 patients was 
estimated as being statistically adequate at a power of 80% and P = 0.05. This was 
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based on the assumption that the intervention would result in an average 0.2 difference 
in the preventer-to-reliever ratios, as demonstrated in a previous pharmacy-based 
asthma intervention.5  
3.2.4 Pharmacy recruitment 
A convenience sample of community pharmacies throughout Tasmania, Victoria and 
South Australia were informed about the study via telephone, and sent a letter 
(Appendix 10) and project synopsis (Appendix 11) informing them about the study and 
inviting them to participate if they were a current user of the Fred dispensing system. 
The intention was to recruit at least 60 pharmacies. In Tasmania, many pharmacies that 
were known to use the Fred dispensing system were not invited to participate. This was 
due to their prior participation in the pilot study,5,304 and the possibility that the 
inclusion of these pharmacies may have skewed the pre-intervention data. In Victoria 
and South Australia, there was no prior knowledge of which pharmacies did and did not 
use the Fred dispensing system. Thus, pharmacies were contacted until recruitment 
targets were reached. 
Pharmacists were required to fax an expression of interest form to the researchers, 
indicating whether they felt the study would be worthwhile and they had time to 
participate (Appendix 12). Follow-up phone calls were made to pharmacists who did 
not send back the expression of interest form.  
Information and education sessions were held in each state for pharmacists involved in 
the study. For those pharmacists unable to attend an information session, a personalised 
one-on-one visit was arranged closer to the time of the project implementation. The 
information sessions were two hours in length and covered an overview of asthma 
management in Australia, an outline of the study’s aim and methods, and a 
demonstration of the MedeMine-for-Asthma software. In addition, a respiratory 
specialist physician from each region attended the information sessions and discussed 
the incidence and morbidities of asthma and current management guidelines.  
Each pharmacy was remunerated for their time attending the information sessions and 
for their involvement in the study. A nominal payment of $200 per pharmacy, plus 
reimbursement for the postage costs incurred throughout the course of the study, was 
made in two instalments, after the intervention period and at the study’s completion. 
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The MedeMine-for-Asthma program calculated the amount that could be invoiced based 
on the number of patient letters that had been mailed.  
3.2.5 Dissemination of project information to GPs 
To provide advanced warning to local GPs in each region, information was sent to the 
relevant Divisions of General Practice in each state, to be published in a monthly 
newsletter (Figure 20). In addition, pharmacists were provided with a GP information 
sheet (Appendix 13) to send to local GPs. 
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Figure 20. Excerpt a GP North (Tasmania) newsletter - June 2008 
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3.2.6 Random allocation of intervention type 
Each participating pharmacy was randomly assigned to deliver only one type of 
intervention; mailed or face-to-face. In each state, a complete list of participating 
pharmacies was created, and pharmacies were sorted according to their distance from 
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the state’s capital city. The first pharmacy on each list was randomly allocated to 
perform mailed or face-to-face interventions, with subsequent pharmacies being 
alternately assigned to perform face-to-face or mailed interventions. This type of 
randomisation process ensured an even geographical spread of pharmacists performing 
each type of intervention. Furthermore, allocating pharmacies to perform one type of 
intervention ensured that the pharmacists’ preference for one intervention type over 
another did not influence the uptake. 
Pharmacists randomised to perform mailed interventions were to use the MedeMine-for-
Asthma program to print personalised letters and coded surveys for eligible intervention 
patients and their GPs, and mail the intervention packs to patients. Pharmacists 
randomised to perform face-to-face interventions were to use the MedeMine-for-
Asthma program to print personalised letters and coded surveys for eligible intervention 
patients and their GPs, and hand the intervention packs to patients, with counselling, as 
they presented to the pharmacy during the intervention period.  
3.2.7 The intervention 
3.2.7.1 Installation and running the MedeMine-for-Asthma program 
Researchers in Victoria and South Australia were provided with instructions for 
installing the MedeMine-for-Asthma program on the main dispensing computer in each 
pharmacy (Appendix 14). Once the software had been installed, pharmacists were 
advised of the type of intervention they had been allocated to perform, and given 
instructions on how to use the MedeMine-for-Asthma program to perform the 
intervention (Appendices 15 and 16). 
Upon the installation of the program in each pharmacy, the researcher was required to 
enter a password depending on the type of intervention the pharmacy had been 
randomised to perform. The MedeMine-for-Asthma program was engineered to perform 
specific applications for each type of intervention. For example, the program would 
allow all patient letters and surveys to printed at once for the mailed intervention, and 
then calculate the number printed to determine the amount of money that the pharmacist 
could claim for postage costs at the end of the intervention period. Patient letters and 
surveys could only be printed individually for the face-to-face intervention, and   
postage costs were not added onto the amount of money that the pharmacist could claim 
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at the end of the intervention period. Having to print letters and surveys individually 
discouraged pharmacists from printing them all at once and handing them out as the 
patients presented to the pharmacy. The reasoning for this was that once the letters and 
surveys had been printed for each patient, the program registered the patient as having 
received the intervention. Pharmacists were therefore encouraged to print each set of 
letters and surveys immediately prior to handing to each patient. 
As a reminder for pharmacists performing the face-to-face intervention to print and 
hand out intervention packs to patients as they presented to the pharmacy, the 
MedeMine-for-Asthma program placed an alert flag in the intervention patients’ 
dispensing information that would appear on the screen when the pharmacist dispensed 
any medication for that patient (Figure 21). This alert flag would only appear if the 
password entered after the program was installed indicated that the pharmacy would be 
performing the face-to-face intervention. Furthermore, the flag was automatically 
removed from a patient’s dispensing information if the pharmacist excluded a patient, or 
if the letters and surveys for a patient had already been printed. 
Figure 21. Example alert flag in Fred Dispense 
 
Before mailing or handing out any intervention packs, the pharmacists were encouraged 
to examine the dispensing information for the intervention patients and use their 
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professional judgement, based on their knowledge of each patient, to decide whether the 
patient was eligible to receive an intervention. The pharmacists were encouraged to 
include all patients unless they met the pre-defined exclusion criteria, which were listed 
in a drop-down menu, as shown in Figure 22. Pharmacists who were excluding patients 
from receiving an intervention were to choose a reason from the list above the black line 
(primary exclusion reasons), and those who were excluding patients from further 
participation after they had received an intervention were to chose a reason from the list 
below the black line (secondary exclusion reasons). In addition, if the pharmacist 
needed to exclude a patient for any other reason, they could select ‘other...’ and type the 
reason. 
Figure 22. MedeMine-for-Asthma screenshot showing exclusion criteria 
 
Pharmacists were blinded to the control patients’ identities until the end of the 12-month 
post-intervention period. In this way, it was intended that control patients would receive 
no active intervention other than the pharmacist’s usual care. 
3.2.7.2 The intervention period 
The intervention period began in June 2008 and ran for six weeks. Pharmacists 
performing the mailed intervention were encouraged to mail out all the intervention 
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packs, and pharmacists performing the face-to-face intervention were encouraged to 
hand out as many intervention packs as possible, during this time.  
The MedeMine-for-Asthma program generated a personalised letter to send to each 
intervention patient. The contents of the letter indicated that, based on the record of 
medication that had been dispensed recently, the pharmacist was concerned that the 
patient’s asthma may not be ideally controlled and that it would be advisable for the 
patient to visit his or her GP for an asthma management review.  
Intervention patients were sent an asthma intervention pack containing the following 
information:  
• A MedeMine-for-Asthma-generated personalised letter (Appendix 17);  
• Supporting educational material provided by the Asthma Foundations Australia 
(‘Asthma: the basic facts’);313 
• MedeMine-for-Asthma-generated and uniquely coded asthma control 
(Appendix 18), quality of life (Appendix 19), and adherence behaviour 
(Appendix 20) questionnaires, to be self-completed;  
• A standard (non-personalised) letter about the surveys (Appendix 21);  
• A MedeMine-for-Asthma-generated letter (and medication history) to give to 
their GP (Appendix 22);  
• A standard  (non-personalised) letter about the study to give to their GP 
(Appendix 13); and  
• A MedeMine-for-Asthma-generated a uniquely coded satisfaction/perception 
questionnaire to give to their GP (Appendix 23).  
Pharmacists were encouraged to document any feedback received from patients or GPs, 
or relevant details of the face-to-face intervention in the ‘extra information’ tab, as 
displayed in Figure 23. Each time the MedeMine-for-Asthma program was accessed, 
the de-identified and encrypted dispensing information, as well as additional 
information entered into the program, was automatically sent via the Internet to a secure 
server at the University of Tasmania. 
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Figure 23. MedeMine-for-Asthma screenshot of ‘extra information’ tab 
 
3.2.7.3 Support for pharmacists 
Pharmacists were encouraged to contact their local researcher if they had any queries or 
concerns relating to the study. In addition, a researcher telephoned all pharmacists every 
two weeks throughout the intervention period, to ask how the study was progressing and 
offer advice and support if needed. 
3.2.8 Questionnaire instruments 
3.2.8.1 Asthma Control Test 
The Asthma Control Test (ACT)60 is a validated 5-item test designed to measure the 
patient’s level of asthma control during the preceding four weeks (only two weeks was 
used in this study, in an attempt to be consistent with the Mini Asthma Quality of Life 
Questionnaire). Items relate to use of reliever medication, shortness of breath, night-
time symptoms, activity limitation and self-assessed asthma control. Each item contains 
a 5-point scale where 5 = completely controlled and 1 = not at all controlled, and the 
overall score out of 25 is given by the addition of the response to each item. Patients 
were also asked to indicate their gender, age group (< 18, 18-29, 30-39, 40-49, 50-59 or 
! 60 years) and whether or not they possessed a written AAP. These parameters were 
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added on to the end of the shortest questionnaire (the Asthma Control Test) for 
convenience. 
3.2.8.2 Mini Asthma Quality of Life Questionnaire 
The Mini Asthma Quality of Life Questionnaire (MiniAQLQ) is a validated 15-item 
questionnaire designed to measure the patient’s perspective of the impact of asthma on 
their QOL during the preceding two weeks.347 The MiniAQLQ contains items relating 
to symptom severity (shortness of breath, difficulty in sleeping and chest tightness, 
coughing and wheezing), the effect on emotional function (frustration, concern and 
fear), the effect of environmental stimuli (dust and cigarette smoke) and limitation of 
activities (strenuous, moderate, social and work-related activities). Each item contains a 
7-point-scale where 7 = no impairment and 1 = maximum impairment, and the overall 
score was given by the average value for the response to the items. Each domain of the 
questionnaire allows for calculation of separate scores for symptoms, emotions, 
environment and activities, as well as the overall QOL score.  
3.2.8.3 Tool for Adherence Screening Behaviour 
The Tool for Adherence Behaviour Screening (TABS) is a validated scale that screens 
both intentional and unintentional non-adherence to pharmacological and non-
pharmacological disease management.348 The TABS measures adherent and non-
adherent behaviour on five-point Likert-type scales, with higher scores indicating higher 
degrees of adherent and non-adherent behaviour. Adherence items relate to having a 
strict routine for using medications, keeping medications close to where they are 
needed, having enough medication so that they don’t run out and pushing oneself to 
following the doctor’s instructions. Non-adherence items relate to getting confused 
about one’s medications, making changes to the recommended management to suit 
one’s lifestyle, varying the recommended management based on how one is feeling and 
putting up with medical problems before taking any action. The items used in the TABS 
were developed based on common adherence issues experienced by a sample of 
chronically ill patients and cover domains, judged by experts, to be important in 
adherence screening.348 
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3.2.8.4 GP survey 
There were two parts to the GP survey. The first part contained three questions, and was 
patient-specific, focusing on (i) any modifications made in regards the patient’s asthma 
therapy, (ii) whether the GP felt that the patient was appropriately identified as needing 
a review of their asthma therapy and (iii) whether the GP agreed that the patient would 
benefit from the intervention. The second part of the questionnaire assessed the GP’s 
opinions on the usefulness of the project and of projects such as this one. Specifically, it 
assessed whether the GP agreed that (i) pharmacists are well placed to identify patients 
who may need review of their asthma therapy, (ii) there is an evident need for improved 
asthma management in the community and (iii) this type of program delivered by 
community pharmacists would be likely to improve asthma care in the community if 
implemented on a larger scale. 
3.2.8.5 Pharmacist satisfaction survey 
Pharmacists were asked to complete a satisfaction survey (Appendix 24) at the end of 
the six-week intervention period. The survey questions assessed the pharmacists’ beliefs 
about the evident need for, the appropriateness of and the effectiveness of the 
intervention, as well issues relating to implementation of the intervention in usual 
practice. 
3.2.8.6 Patient satisfaction survey 
All included intervention patients were sent a satisfaction survey (Appendix 25) at the 
end of the post-intervention period. The questions assessed the perceived usefulness and 
appropriateness of the intervention, as well as the satisfaction with the level of asthma 
care usually received by doctors and community pharmacists. 
3.2.9 Post-intervention follow-up 
Twelve months after the intervention, the researchers in Victoria and South Australia 
were provided with instructions for the post-intervention site visits (Appendix 26). The 
control patients’ identities were revealed, and pharmacists examined their dispensing 
information to determine whether they were eligible to be included in the study (that is, 
they did not meet any of the exclusion criteria). For ethical reasons, all included control 
patients who had received six or more relievers in the post-intervention period were sent 
an intervention pack, the same as that sent to intervention patients 12 months earlier. 
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Control patients who received less than six relievers in the post-intervention period were 
not sent an intervention pack, but their dispensing data were still included in the 
analyses, because they were otherwise eligible to remain in the study. 
Intervention patients received a follow-up letter (Appendix 27), and were again 
provided with the three questionnaires on asthma control, asthma-related QOL and 
medication adherence behaviour knowledge, as well as a satisfaction questionnaire. 
Figure 24 displays a summary of the project’s methodology. 
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Figure 24. Summary of the project’s methodology 
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3.2.10 Handling of data and statistical analysis 
All surveys and dispensing data were de-identified. Patient and GP surveys were coded 
with unique identification numbers that could be linked to patients’ dispensing data, but 
could not be re-identified by the researchers.  
The asthma medications included in the analyses were inhaled SABAs (relievers) and 
ICS (preventers). Prior to performing statistical analyses, the dispensed quantities of 
asthma medications were converted to a standard equivalent dose: 
•  Salbutamol equivalence: salbutamol 100 #g = terbutaline 250 #g;315 and 
• Beclomethasone-HFA equivalence: beclomethasone-HFA 100 #g = fluticasone 
100 #g = budesonide 200 #g = ciclesonide 80 #g.134-136  
Because eformoterol can now be prescribed as a reliever, as part of the Symbicort® 
Maintenance And Reliever Therapy regimen, it was counted as a reliever (with 3 #g of 
eformoterol equivalent to 100 #g of salbutamol)349 if the dispensing instructions 
indicated it was being used in this manner.  
The preventer-to-reliever (P : R) ratio was calculated for each patient as the average 
beclomethasone-equivalent usage per day divided by the average salbutamol-equivalent 
usage per day. The primary outcome measure was the P : R ratio of dispensed asthma 
medication, and secondary outcome measures were other patterns in dispensed asthma 
medication, asthma questionnaire scores and participant satisfaction. 
All variables were collated and entered into a statistical software package, Statview 5.01 
(Abacus Concepts Inc, Berkeley, California, USA). Parametric data are presented as 
means ± standard deviations, and nonparametric data are presented as medians 
(interquartile ranges). Within-group comparisons of dispensing data were conducted 
using the Wilcoxon signed-rank test, and between-group comparisons were conducted 
using the Kruskal-Wallis test. Post hoc testing was performed using the Mann Whitney 
test with Bonferroni correction. The Bonferroni adjusted critical value controlled for 
multiple comparison testing, and was obtained by dividing the original threshold P 
value (0.05) by the total number of comparisons made (three).322,323  
The dispensing data was analysed using the treatment-received method, whereby only 
patients who received the intervention were compared to controls. To account for 
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uptake of the intervention by pharmacists, the dispensing data was also analysed using 
the intention-to-treat method, whereby all eligible patients were analysed for changes in 
dispensing data. 
Within group comparisons of asthma questionnaire scores were conducted using the 
paired Student’s t-test, and each intervention group was compared to the control group 
using the unpaired Student’s t-test. Proportional data were analysed using the %2 test. A 
significance level of P < 0.05 was used for all statistical procedures, with the exception 
of the post hoc Mann Whitney test, in which a Bonferroni adjusted significance level of 
P < 0.0167 was used.322,323  
3.2.11 Ethical approval and trial registration 
This project received ethical approval from the Tasmanian Health and Medical Human 
Research Ethics Committee (ethics reference number H9823), Monash University’s 
Human Research Ethics Committee (ethics reference number 2008000274) and the 
University of South Australia’s Human Research Ethics Committee (ethics reference 
number P056/08). The study was registered with the Australian New Zealand Clinical 
Trial Registry (registration number ACTRN12608000119392). 
3.3 Results 
3.3.1 Participants 
3.3.1.1 Recruitment of pharmacies 
A total of 459 pharmacies were invited to participate in the study by telephone and mail. 
Table 24 displays the responses of pharmacists to the expression of interest form and 
follow-up telephone calls. 
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Table 24. Pharmacists' willingness to participate  
Pharmacies contacted Response 
All states 
(n = 459) 
Tasmania  
(n = 69) 
Victoria      
(n = 163) 
South 
Australia      
(n = 227) 
Use the Fred dispensing system and willing to 
participate 71 (15.5%) 9 (13.0%) 37 (22.7%) 25 (11.0%) 
Do not use the Fred dispensing system 231 (50.3%) 53 (76.8%) 35 (21.5%) 143 (63.0%) 
Use the Fred dispensing system, but do not 
feel able to participate 157 (34.2%) 7 (10.1%) 91 (55.8%) 59 (26.0%) 
 
Of the 71 pharmacies that agreed to participate, 36 (50.7%) were randomised to perform 
the mailed intervention, and 35 (49.3%) were randomised to perform the face-to-face 
intervention.  
3.3.1.2 Identification of patients 
The stepwise identification of patients is shown in Table 25. Total patient numbers were 
available for 62 (87.3%) of the 71 pharmacies. Each pharmacy database contained an 
average of 6,461 patients. Of these patients, an average of 548 (8.5%) were identified as 
having received one or more reliever canister in the past 12 months, excluding those 
who had received methylxanthines, inhaled anticholinergics or leukotriene receptor 
antagonists). Of these patients, an average of 23 (4.2%) were identified as having 
received six or more reliever canisters in the past 12 months, with three or more in both 
of the two previous six-month periods. 
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Table 25. Stepwise identification of patients 
Pharmacy 
ID State 
Total patients in 
pharmacy database 
Patients dispensed '1 
reliever in past 12 months*† 
Patients dispensed '6 
relievers in past 12 months† 
1 Tas 16,717 1,527 (9.1%) 47 (3.1%) 
2 Tas 1,225 134 (10.9%) 12 (9.0%) 
3 Tas 3,482 359 (10.3%) 21 (5.8%) 
4 Tas 12,723 895 (7.0%) 25 (2.8%) 
5 Tas 5,278 323 (6.1%) 9 (2.8%) 
6 Tas 4,163 339 (8.1%) 20 (5.9%) 
7 Tas 4,913 588 (12.0%) 37 (6.3%) 
8 Tas 14,126 1,346 (9.5%) 21 (1.6%) 
9 Tas 13,534 1,332 (9.8%) 59 (4.4%) 
10 Vic 2,608 198 (7.6%) 9 (4.5%) 
11 Vic N/A N/A 10 
12 Vic 7,977 558 (7.0%) 47 (8.4%) 
13 Vic 7,144 872 (12.2%) 64 (7.3%) 
14 Vic 1,574 202 (12.8%) 13 (6.4%) 
15 Vic 3,271 227 (6.9%) 26 (11.5%) 
16 Vic 2,579 205 (7.9%) 7 (3.4%) 
17 Vic 4,445 404 (9.1%) 14 (3.5%) 
18 Vic 6,689 757 (11.3%) 37 (4.9%) 
19 Vic 3,822 233 (6.1%) 6 (2.6%) 
20 Vic 16,391 1,741 (10.6%) 45 (2.6%) 
21 Vic 8,662 750 (8.7%) 18 (2.4%) 
22 Vic 2,516 190 (7.6%) 4 (2.1%) 
23 Vic 2,781 206 (7.4%) 15 (7.3%) 
24 Vic 5,463 357 (6.5%) 8 (2.2%) 
25 Vic 14,453 959 (6.6%) 8 (0.8%) 
26 Vic 3,305 198 (6.0%) 4 (2.0%) 
27 Vic 1,402 108 (7.7%) 9 (8.3%) 
28 Vic 4,680 257 (5.5%) 9 (3.5%) 
29 Vic 3,299 378 (11.5%) 16 (4.2%) 
30 Vic 3,094 255 (8.2%) 10 (3.9%) 
31 Vic 13,682 1,034 (7.6%) 27 (2.6%) 
32 Vic 16,200 1,076 (6.6%) 42 (3.9%) 
33 Vic N/A N/A 26  
34 Vic N/A N/A 17 
35 Vic 3,765 274 (7.3%) 11 (4.0%) 
36 Vic 4,533 383 (8.4%) 17 (4.4%) 
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37 Vic 9,285 571 (6.1%) 9 (1.6%) 
38 Vic 4,583 511 (11.1%) 36 (7.0%) 
39 Vic 4,204 338 (8.0%) 13 (3.8%) 
40 Vic 17,130 1228 (7.2%) 39 (3.2%) 
41 Vic N/A N/A 12 
42 Vic N/A N/A 22 
43 Vic 5,961 482 (8.1%) 36 (7.5%) 
44 Vic 3,777 203 (5.4%) 5 (2.5%) 
45 Vic 3,379 294 (8.7%) 10 (3.4%) 
46 Vic 8,815 472 (5.4%) 16 (3.4%) 
47 SA 2,564 245 (9.6%) 16 (6.5%) 
48 SA N/A N/A 5  
49 SA 1,385 186 (13.4%) 18 (9.7%) 
50 SA N/A N/A 45 
51 SA 1,259 119 (9.5%) 3 (2.5%) 
52 SA 4,157 365 (8.8%) 26 (7.1%) 
53 SA 11,353 1111 (9.8%) 59 (5.3%) 
54 SA 6,443 663 (10.3%) 36 (5.4%) 
55 SA 8,886 844 (9.5%) 32 (3.8%) 
56 SA 4,207 339 (8.1%) 13 (3.8%) 
57 SA 16,216 1,548 (9.5%) 55 (3.6%) 
58 SA 5,958 692 (11.6%) 45 (6.5%) 
59 SA 6,541 485 (7.4%) 17 (3.5%) 
60 SA 5,481 466 (8.5%) 12 (2.6%) 
61 SA 2,922 308 (10.5%) 21 (6.8%) 
62 SA 3,112 271 (8.7%) 9 (3.3%) 
63 SA 10,261 988 (9.6%) 28 (2.8%) 
64 SA N/A N/A 12 
65 SA 13,080 995 (7.6%) 17 (1.7%) 
66 SA 5,905 534 (9.0%) 14 (2.6%) 
67 SA 1,948 207 (10.6%) 8 (3.9%) 
68 SA N/A N/A 5 
69 SA 2,788 201 (7.2%) 3 (1.5%) 
70 SA 1,951 159 (8.1%) 4 (2.5%) 
71 SA 6,553 481 (7.3%) 12 (2.5%) 
*Excluding patients who had received any methylxanthines, inhaled anticholinergics or leukotriene 
receptor antagonists. †Figures represent number of patients (percent of number in column to the left).  
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The MedeMine-for-Asthma program identified a total of 1,483 patients (510 [34.4%] 
mailed intervention patients, 480 [32.4%] face-to-face intervention patients and 493 
[33.2%] control patients) from 71 pharmacies. Table 26 displays the number of patients 
identified in each pharmacy. 
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Table 26. Patients identified in each pharmacy 
Pharmacy ID State Intervention type Patients identified*    
(n = 1483) 
Intervention†    
(n = 990) 
Control†    
(n = 493) 
1 Tas Face-to-face 47 (3.2%) 31 (66.0%) 16 (34.0%) 
2 Tas Mailed 12 (0.8%) 8 (66.7%) 4 (33.3%) 
3 Tas Face-to-face 21 (1.4%) 14 (66.7%) 7 (33.3%) 
4 Tas Face-to-face 25 (1.7%) 17 (68.0%) 8 (32.0%) 
5 Tas Mailed 9 (0.6%) 6 (66.7%) 3 (33.3%) 
6 Tas Mailed 20 (1.3%) 14 (70.0%) 6 (30.0%) 
7 Tas Mailed 37 (2.5%) 25 (67.6%) 12 (32.4%) 
8 Tas Face-to-face 21 (1.4%) 14 (66.7%) 7 (33.3%) 
9 Tas Mailed 59 (4.0%) 40 (67.8%) 19 (32.2%) 
10 Vic Face-to-face 9 (0.6%) 6 (66.7%) 3 (33.3%) 
11 Vic Mailed 10 (0.7%) 7 (70.0%) 3 (30.0%) 
12 Vic Mailed 47 (3.2%) 31 (66.0%) 16 (34.0%) 
13 Vic Face-to-face 64 (4.3%) 42 (65.6%) 22 (34.4%) 
14 Vic Face-to-face 13 (0.9%) 9 (69.2%) 4 (30.8%) 
15 Vic Mailed 26 (1.8%) 17 (65.4%) 9 (34.6%) 
16 Vic Face-to-face 7 (0.5%) 5 (71.4%) 2 (28.6%) 
17 Vic Face-to-face 14 (0.9%) 9 (64.3%) 5 (35.7%) 
18 Vic Mailed 37 (2.5%) 25 (67.6%) 12 (32.4%) 
19 Vic Face-to-face 6 (0.4%) 4 (66.7%) 2 (33.3%) 
20 Vic Mailed 45 (3.0%) 30 (66.7%) 15 (33.3%) 
21 Vic Face-to-face 18 (1.2%) 12 (67.7%) 6 (33.3%) 
22 Vic Mailed 4 (0.3%) 3 (75.0%) 1 (25.0%) 
23 Vic Mailed 15 (1.0%) 10 (66.7%) 5 (33.3%) 
24 Vic Mailed 8 (0.5%) 5 (62.5%) 3 (37.5%) 
25 Vic Mailed 8 (0.5%) 5 (62.5%) 3 (37.5%) 
26 Vic Face-to-face 4 (0.3%) 3 (75.0%) 1 (25.0%) 
27 Vic Face-to-face 9 (0.6%) 6 (66.7%) 3 (33.3%) 
28 Vic Face-to-face 9 (0.6%) 6 (66.7%) 3 (33.3%) 
29 Vic Face-to-face 16 (1.1%) 10 (62.5%) 6 (37.5%) 
30 Vic Mailed 10 (0.7%) 7 (70.0%) 3 (30.0%) 
31 Vic Mailed 27 (1.8%) 18 (66.7%) 9 (33.3%) 
32 Vic Face-to-face 42 (2.8%) 28 (66.7%) 14 (33.3%) 
33 Vic Face-to-face 26 (1.8%) 17 (65.4%) 9 (34.6%) 
34 Vic Mailed 17 (1.1%) 11 (64.7%) 6 (35.3%) 
35 Vic Face-to-face 11 (0.7%) 7 (63.6%) 4 (36.4%) 
36 Vic Mailed 17 (1.1%) 12 (70.6%) 5 (29.4%) 
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37 Vic Mailed 9 (0.6%) 6 (66.7%) 3 (33.3%) 
38 Vic Face-to-face 36 (2.4%) 24 (66.7%) 12 (33.3%) 
39 Vic Face-to-face 13 (0.9%) 9 (69.2%) 4 (30.8%) 
40 Vic Mailed 39 (2.6%) 26 (66.7%) 13 (33.3%) 
41 Vic Mailed 12 (0.8%) 8 (66.7%) 4 (33.3%) 
42 Vic Mailed 22 (1.5%) 15 (68.2%) 7 (31.8%) 
43 Vic Mailed 36 (2.4%) 24 (66.7%) 12 (33.3%) 
44 Vic Mailed 5 (0.3%) 4 (80.0%) 1 (20.0%) 
45 Vic Face-to-face 10 (0.7%) 7 (70.0%) 3 (30.0%) 
46 Vic Face-to-face 16 (1.1%) 10 (62.5%) 6 (37.5%) 
47 SA Face-to-face 16 (1.1%) 11 (68.8%) 5 (31.3%) 
48 SA Mailed 5 (0.3%) 4 (80.0%) 1 (20.0%) 
49 SA Mailed 18 (1.2%) 12 (67.7%) 6 (33.3%) 
50 SA Face-to-face 45 (3.0%) 30 (66.7%) 15 (33.3%) 
51 SA Mailed 3 (0.2%) 2 (66.7%) 1 (33.3%) 
52 SA Mailed 26 (1.8%) 17 (65.4%) 9 (34.6%) 
53 SA Mailed 59 (4.0%) 39 (66.1%) 20 (33.9%) 
54 SA Face-to-face 36 (2.4%) 24 (66.7%) 12 (33.3%) 
55 SA Mailed 32 (2.2%) 21 (65.6%) 11 (34.4%) 
56 SA Face-to-face 13 (0.9%) 8 (61.5%) 5 (38.5%) 
57 SA Face-to-face 55 (3.7%) 37 (67.3%) 18 (32.7%) 
58 SA Mailed 45 (3.0%) 30 (66.7%) 15 (33.3%) 
59 SA Face-to-face 17 (1.1%) 11 (64.7%) 6 (35.3%) 
60 SA Face-to-face 12 (0.8%) 8 (66.7%) 4 (33.3%) 
61 SA Face-to-face 21 (1.4%) 14 (66.7%) 7 (33.3%) 
62 SA Mailed 9 (0.6%) 6 (66.7%) 3 (33.3%) 
63 SA Face-to-face 28 (1.9%) 18 (64.3%) 10 (35.7%) 
64 SA Mailed 12 (0.8%) 8 (66.7%) 4 (336.3%) 
65 SA Face-to-face 17 (1.1%) 11 (64.7%) 6 (35.3%) 
66 SA Face-to-face 14 (0.9%) 10 (71.4%) 4 (28.6%) 
67 SA Face-to-face 8 (0.5%) 5 (62.5%) 3 (37.5%) 
68 SA Mailed 5 (0.3%) 4 (80.0%) 1 (20.0%) 
69 SA Mailed 3 (0.2%) 2 (66.7%) 1 (33.3%) 
70 SA Face-to-face 4 (0.3%) 3 (75.0%) 1 (25.0%) 
71 SA Mailed 12 (0.8%) 8 (66.7%) 4 (33.3%) 
*Figures represent number (%) of total patients identified. †Figures represent number (%) of total patients 
identified in each pharmacy. 
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3.3.1.3 Patient exclusions 
Of the 510 mailed intervention patients identified, 47 (9.2%) were excluded from the 
study, leaving 463 (90.8%) patients eligible to receive an intervention. Of the 480 face-
to-face intervention patients identified, 38 (7.9%) were excluded from the study, leaving 
442 (92.1%) patients eligible to receive an intervention. Of the 493 control patients 
identified, 59 (12.0%) were excluded from the study, leaving 434 (88.0%) control 
patients. Table 27 displays the reasons for patient exclusion by pharmacists. 
Table 27. Reasons for patient exclusion 
Reason for exclusion All patients 
(n = 144) 
Mailed 
intervention 
(n = 47) 
Face-to-face 
intervention           
(n = 38) 
Control    
(n = 59) 
Under 18 years old* 30 (20.8%) 16 (34.0%) 7 (18.4%) 7 (11.9%) 
Patient has COPD* 27 (18.8%) 2 (4.3%) 2 (5.3%) 23 (39.0%) 
Too confused* 26 (18.1%) 6 (12.8%) 6 (15.8%) 14 (23.7%) 
Nursing home resident* 17 (11.8%) 5 (10.6%) 8 (21.1%) 4 (6.8%) 
May cause undue distress* 14 (9.7%) 6 (12.8%) 3 (7.9%) 5 (8.5%) 
No longer a regular patient 12 (8.3%) 9 (19.1%) 1 (2.6%) 2 (3.4%) 
Doctor’s bag / first aid kit 9 (6.3%) 1 (2.1%) 6 (15.8%) 2 (3.4%) 
Other medical condition 5 (3.5%) 1 (2.1%) 3 (7.9%) 1 (1.7%) 
Deceased* 3 (2.1%) 1 (2.1%) 1 (2.6%) 1 (1.7%) 
Under specialist care 1 (0.7%) 0 (0.0%) 1 (2.6%) 0 (0.0%) 
*Pre-defined exclusion criteria. 
3.3.2 Uptake of the intervention 
Of the 463 patients who were eligible for a mailed intervention, 414 (89.4%) were sent 
an intervention pack by their pharmacist. Of the 442 patients who were eligible for a  
face-to-face intervention, 235 (53.2%) were offered an intervention pack by their 
pharmacist. Of the 207 patients who were not offered a face-to-face intervention, 118 
(57.0%) patients had at least one prescription dispensed during the intervention period, 
whereas 89 (43.0%) did not present to the pharmacy during the intervention period. 
Therefore, a total of 353 face-to-face intervention patients presented to the pharmacy 
during the intervention period, of which 235 (66.6%) were offered an intervention, and 
118 (33.4%) were not. 
Taking opportunity to intervene into account, significantly fewer face-to-face 
intervention patients were offered an intervention, compared with mailed intervention 
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patients (66.6% versus 89.4%, respectively; %2 = 64.2, P < 0.0001). Figure 25 displays 
the uptake of the mailed and face-to-face interventions by pharmacists. 
Figure 25. Uptake of the intervention by pharmacists 
 
3.3.3 Patient and GP survey response rates 
Of the 409 patients who received a mailed intervention, 34 (8.3%) returned the baseline 
surveys and 60 (14.7%) returned the post-intervention surveys. Of the 34 patients who 
responded to the baseline surveys, 11 (32.4%) responded again to the post-intervention 
surveys. Of the 409 patients who received a mailed intervention (which included a 
survey to hand to their GP), a total of 14 (3.4%) GPs completed and returned a GP 
evaluation survey. Out of 34 completed baseline patient surveys, 11 (32.4%) could be 
linked to their corresponding GP surveys. There were three GP surveys returned which 
did not have a corresponding patient survey. 
990 intervention patients 
identified by MedeMine-
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480 (48.5%) face-to-face 
intervention patients 
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Of the 230 patients who received a face-to-face intervention, 40 (17.4%) returned the 
baseline surveys and 48 (20.9%) returned the post-intervention surveys. Of the 40 
patients who responded to the baseline surveys, 18 (45.0%) responded again to the post-
intervention surveys. Of the 230 patients who received a face-to-face intervention, a 
total of 20 (8.7%) GPs completed and returned a GP evaluation survey. Out of 40 
completed baseline patient surveys, 19 (47.5%) could be linked to their corresponding 
GP surveys. There was one GP survey returned which did not have a corresponding 
patient survey. 
Of the 434 control patients, 334 (77.0%) had received six or more relievers in the post-
intervention period, and were sent a mailed intervention at the end of the study period. 
Of the 334 control patients who received an intervention, 18 (5.4%) returned the 
questionnaires. Of the 334 control patients who received an intervention, a total of 14 
(4.2%) GPs completed and returned a GP evaluation questionnaire. Out of 18 completed 
patient questionnaires, 10 (55.6%) could be linked to their corresponding GP 
questionnaires. There were four GP questionnaires returned which did not have a 
corresponding patient questionnaire. 
Overall, the average patient questionnaire return rate was 13.3%, and the average GP 
questionnaire return rate was 5.4%. 
3.3.4 Patient demographics 
The mailed intervention, face-to-face intervention and control patients were well 
matched with respect to demographic measures. No significant differences were 
observed between the three groups in terms of age or gender, as displayed in Table 28.  
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Table 28. Patient demographic variables 
Parameter All patients 
(n = 171) 
Mailed 
intervention 
(n = 83) 
Face-to-face 
intervention 
(n = 70) 
Control    
(n = 18) 
P 
Age (years)     
<18 3 (1.8%) 1 (1.2%) 2 (2.9%) 0 (0.0%) 
18-29 8 (4.7%) 5 (6.0%) 2 (2.9%) 1 (5.6%) 
30-39 5 (2.9%) 3 (3.6%) 2 (2.9%) 0 (0.0%) 
40-49 21 (7.0%) 10 (12.0%) 10 (14.3%) 1 (5.6%) 
50-59 27 (12.3%) 13 (15.7%) 13 (18.6%) 1 (5.6%) 
!60 107 (62.6%) 51 (61.4%) 41 (58.6%) 15 (83.3%) 
Gender     
0.79 
Male 80 (46.8%) 37 (44.6%) 32 (45.7%) 11 (61.1%) 
Female 91 (53.2%) 46 (55.4%) 38 (54.3%) 7 (38.9%) 
0.43 
 
3.3.5 Outcome measures  
3.3.5.1 Dispensing data  
Using the treatment-received method of analysis, there were significant improvements 
in the P : R ratio in both intervention groups and the control group, after the intervention 
(Table 29). The magnitude of improvement in the face-to-face intervention group was 
greater than that in the mailed intervention group, which was greater than that in the 
control group (Z = -5.38, -5.16 and -4.56 respectively). The improvement in the P : R 
ratios were mainly due to significant decreases in the daily SABA usage within each 
group. There were no significant changes in the daily ICS usage in the mailed or face-
to-face intervention group. However, there were significant increases in the daily ICS 
usage in the control group. 
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Table 29. Pre- and post-intervention dispensing data (treatment-received analysis) 
Asthma medication Pre-intervention Post intervention P Z 
P : R ratio     
Mailed intervention 0.15 (0.00 - 0.42) 0.19 (0.00 - 0.55) < 0.0001 -5.16 
Face-to-face intervention 0.15 (0.00 - 0.46) 0.21 (0.00 - 0.75) < 0.0001 -5.38 
Control 0.14 (0.00 - 0.42) 0.16 (0.00 - 0.50) < 0.0001 -4.56 
Kruskal-Wallis P 0.68 0.46   
Daily SABA usage (µg)     
Mailed intervention 655.7 (546.5 - 983.6) 563.4 (328.8 - 966.8) < 0.0001 -6.92 
Face-to-face intervention 765.0 (546.5 - 1092.9) 657.5 (329.9 - 1043.0) < 0.0001 -6.26 
Control 655.7 (546.5 - 983.6) 634.9 (339.0 - 987.3) < 0.0001 -5.74 
Kruskal-Wallis P 0.03 0.07   
Daily ICS usage (µg)     
Mailed intervention 123.0 (0.0 - 327.9) 103.0 (0.0 - 354.0) 0.48 -0.70 
Face-to-face intervention 118.5 (0.0 - 375.7) 164.4 (0.0 - 422.0) 0.14 -1.48 
Control 95.9 (0.0 - 327.9) 102.3 (0.0 - 359.6) 0.03 -2.17 
Kruskal-Wallis P 0.44 0.62   
 
The absolute changes in daily SABA and ICS usage after the intervention (using the 
treatment-received method of analysis) are displayed in Table 30. There was a 
difference of borderline significance in the absolute change in SABA usage between the 
three groups (df  = 2, H = 5.29, P = 0.07). Post hoc Mann-Whitney tests showed that 
there was (i) a non-significant trend (borderline significance) for the change in SABA 
usage in the mailed intervention patients to be greater than control (Z = -1.79, P = 0.07), 
(ii) a non-significant trend for the change in SABA usage in the face-to-face 
intervention patients to be greater than control (Z = -2.19, P = 0.03 [Bonferroni adjusted 
significance level of P < 0.0167]), and (iii) no significant difference in the absolute 
change in SABA usage between the mailed and face-to-face interventions. There was no 
significant difference in the absolute change in ICS usage between the three groups. 
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Table 30. Absolute change in daily SABA and ICS usage (treatment-received analysis) 
Patient group Change in daily SABA usage Change in daily ICS usage 
Mailed intervention -159.5 (-393.0 - 92.0) 0.0 (-64.6 - 69.8) 
Face-to-face intervention -170.0 (-421.00 - 22.8) 0.0 (-53.3 - 84.3) 
Control -99.0 (-3223.5 - 106.0) 0.0 (-49.1 - 83.7) 
Kruskal-Wallis P 0.07 0.57 
 
Using the intention-to-treat method of analysis, there were significant improvements in 
the P : R ratio in both intervention groups and the control group, after the intervention 
(Table 31). The magnitude of improvement in the mailed intervention group was greater 
than that in the control group, which was greater than that in the face-to-face 
intervention group (Z = -5.41, -4.56 and -2.77, respectively). The improvement in the 
P : R ratios were mainly due to significant decreases in the daily SABA usage within 
each group. There was no significant change in the daily ICS usage in the mailed 
intervention group. However, there was a non-significant trend for the daily ICS usage 
to increase after the face-to-face intervention, and a significant increase in the daily ICS 
usage in the control group. 
Table 31. Pre- and post-intervention dispensing data (intention-to-treat analysis) 
Asthma medication Pre-intervention Post intervention P Z 
P : R ratio     
Mailed intervention 0.15 (0.00 - 0.44) 0.20 (0.00 - 0.58) < 0.0001 -5.41 
Face-to-face intervention 0.12 (0.00 - 0.42) 0.16 (0.00 - 0.69) 0.006 -2.77 
Control 0.14 (0.00 - 0.42) 0.16 (0.00 - 0.50) < 0.0001 -4.56 
Kruskal-Wallis P 0.54 0.68   
Daily SABA usage (µg)     
Mailed intervention 655.7 (546.5 - 983.6) 549.5 (219.2 -788.7) < 0.0001 -7.49 
Face-to-face intervention 655.7 (546.5 - 1005.5) 593.8 (328.8 - 967.3) < 0.0001 -8.04 
Control 655.7 (546.5 - 983.6) 634.9 (339.0 - 987.3) < 0.0001 -5.74 
Kruskal-Wallis P 0.62 0.25   
Daily ICS usage (µg)     
Mailed intervention 109.3 (0.0 - 327.9) 102.7 (0.0 - 353.7) 0.47 -0.73 
Face-to-face intervention 82.0 (0.0 - 327.9) 110.4 (0.0 - 394.7) 0.08 -1.73 
Control 95.9 (0.0 - 327.9) 102.3 (0.0 - 359.6) 0.03 -2.17 
Kruskal-Wallis P 0.48 0.95   
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The absolute changes in daily SABA and ICS usage after the intervention (using the 
intention-to-treat method of analysis) are displayed in Table 32. There was a difference 
of borderline significance in the absolute change in SABA usage between the three 
groups (df = 2, H = 4.84, P = 0.09). Post hoc Mann-Whitney tests showed that there was 
(i) a non-significant trend (borderline significance) for the change in SABA usage in the 
mailed intervention patients to be greater than control (Z = -1.90, P = 0.06), (ii) a non-
significant trend (borderline significance) for the change in SABA usage in the face-to-
face intervention patients to be greater than control (Z = -1.93, P = 0.05), and (iii) no 
significant difference in the absolute change in SABA usage between the mailed and 
face-to-face interventions. There was no significant difference in the absolute change in 
ICS usage between the three groups. 
Table 32. Absolute change in daily SABA and ICS usage (intention-to-treat analysis) 
Patient group Change in daily SABA usage Change in daily ICS usage 
Mailed intervention -162.0 (-387.5 - 91.5) 0.00 (-64.1 - 68.0) 
Face-to-face intervention -145.0 (-421.0 - 46.3) 0.00 (-52.9 - 83.4) 
Control -99.0 (-323.5 - 106.0) 0.00 (-53.9 - 82.2) 
Kruskal-Wallis P 0.09 0.66 
 
3.3.5.2 Patient-reported outcomes 
There were no significant improvements in patient-reported asthma control, quality of 
life or medication adherence behaviour after the intervention (Table 33). However, there 
was a non-significant trend for improved asthma control after the face-to-face 
intervention (t = -1.8, P = 0.09). There was also a significant increase in the proportion 
of patients who possessed written AAPs after the face-to-face intervention (%2 = 4.0, 
P < 0.05), but not after the mailed intervention. 
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Table 33. Pre- and post-intervention asthma survey results 
Patient-reported outcome  Pre-intervention Post intervention P 
Asthma control    
Mailed intervention 18.3 ± 4.3 17.9 ± 4.1 0.20 
Face-to-face intervention 16.5 ± 4.8 17.2 ± 4.7 0.09 
Quality of life - symptoms    
Mailed intervention 4.9 ± 1. 3 4.9 ± 1.1 0.51 
Face-to-face intervention 4.6 ± 1.4 4.7 ± 1.4 0.70 
Quality of life - emotions    
Mailed intervention 4.8 ± 1.9 4.9 ± 1.7 0.71 
Face-to-face intervention 4.3 ± 1.9 4.4 ± 1.8 0.74 
Quality of life - environment    
Mailed intervention 4.9 ± 1.6 4.9 ± 1.6 0.41 
Face-to-face intervention 4.4 ± 1.8 4.6 ± 1.8 0.21 
Quality of life - activity limitation    
Mailed intervention 5.6 ± 1.3 5.3 ± 1.4 0.63 
Face-to-face intervention 4.8 ± 1.6 5.0 ± 1.6 0.93 
Quality of life - overall    
Mailed intervention 5.1 ± 1.2 5.0 ± 1.2 0.42 
Face-to-face intervention 4.5 ± 1.4 4.7 ± 1.5 0.74 
Adherent behaviour    
Mailed intervention 16.3 ± 4.4 16.3 ± 4.4 0.87 
Face-to-face intervention 15.5 ± 4.1 17.0 ± 3.7 0.48 
Non-adherent behaviour    
Mailed intervention 8.4 ± 2.9 9.6 ± 3.5 0.42 
Face-to-face intervention 9.7 ± 2.8 8.2 ± 3.2 0.64 
Possession of a written AAP    
Mailed intervention 15/34 (41.1%) 20/60 (33.3%) 0.89 
Face-to-face intervention 8/40 (20.0%) 16/48 (33.3%) < 0.05 
 
There were no significant differences in the post-intervention asthma questionnaire 
scores or AAP possession between the intervention groups and the control group 
(Table 34). However, there was a non-significant trend for an increased adherence score 
and a decreased non-adherence score in the face-to-face intervention group, compared 
to control.  
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Table 34. Post-intervention asthma survey results compared to control 
Patient-reported outcome  Intervention Control P 
Asthma control    
Mailed intervention 17.9 ± 4.1 16.3 ± 4.8 0.18 
Face-to-face intervention 17.2 ± 4.7 16.3 ± 4.8 0.53 
Quality of life - symptoms    
Mailed intervention 4.9 ± 1.1 4.5 ± 1.5 0.16 
Face-to-face intervention 4.7 ± 1.4 4.5 ± 1.5 0.65 
Quality of life - emotions    
Mailed intervention 4.9 ± 1.7 4.38 ± 1.7 0.28 
Face-to-face intervention 4.4 ± 1.8 4.38 ± 1.7 0.97 
Quality of life - environment    
Mailed intervention 4.9 ± 1.6 4.8 ± 1.6 0.86 
Face-to-face intervention 4.6 ± 1.8 4.8 ± 1.6 0.61 
Quality of life - activity limitation    
Mailed intervention 5.3 ± 1.4 4.8 ± 1.8 0.19 
Face-to-face intervention 5.0 ± 1.6 4.8 ± 1.8 0.67 
Quality of life - overall    
Mailed intervention 5.0 ± 1.2 4.6 ± 1.5 0.24 
Face-to-face intervention 4.7 ± 1.5 4.6 ± 1.5 0.88 
Adherent behaviour    
Mailed intervention 16.3 ± 4.4 15.4 ± 3.3 0.44 
Face-to-face intervention 17.0 ± 3.7 15.4 ± 3.3 0.10 
Non-adherent behaviour    
Mailed intervention 9.6 ± 3.5 8.0 ± 2.6 0.07 
Face-to-face intervention 8.2 ± 3.2 8.0 ± 2.6 0.86 
Possession of a written AAP    
Mailed intervention 20/60 (33.3%) 6/18 (33.3%) > 0.99 
Face-to-face intervention 16/48 (33.3%) 6/18 (33.3%) > 0.99 
 
3.3.5.3 GP evaluations 
Of the 48 GPs who responded to the questionnaire, 29 (60.4%) indicated that they 
modified, or intended to modify the patient’s therapy as a result of this project, and 39 
(81.3%) felt that this project appropriately identified their patient as needing a review of 
their asthma therapy (Table 35).  
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Table 35. GPs’ evaluation of the patient* 
Statement Yes No 
I modified (or intend to modify) this patient’s therapy as a result of this project 
Mailed intervention (n = 15) 7 (46.7%) 7 (46.7%) 
Face-to-face intervention (n = 19) 13 (68.4%) 5 (26.3%) 
Control (n = 14) 9 (64.3%) 5 (35.7%) 
Overall (n = 48) 29 (60.4%) 17 (35.4%) 
I feel that this project appropriately identified my patient as needing a review of their asthma therapy 
Mailed intervention (n = 15) 11 (73.3%) 3 (20.0%) 
Face-to-face intervention (n = 19) 16 (84.2%) 2 (10.5%) 
Control (n = 14) 12 (85.7%) 2 (14.3%) 
Overall (n = 48) 39 (81.3%) 7 (14.6%) 
*Figures represent number (percent) of responses. Percentages may not add up to 100 due to blank 
responses. 
Table 36 summarises the modifications to patients’ asthma therapy as stated by the GPs. 
Table 36. Modifications to patient’s asthma therapy* 
Summarised response Overall 
(n = 28) 
Mailed 
intervention 
(n = 7) 
Face-to-face 
intervention 
(n = 13) 
Control 
(n = 9) 
Added/increased ICS 11 (39.3%) 6 (85.7%) 3 (23.1%) 2 (22.0%) 
Education regarding regular use of 
preventer and use of reliever only 
when required 
8 (28.6%) 0 (0.0%) 5 (38.5%) 4 (44.4%) 
Added LABA 2 (7.1%) 0 (0.0%) 0 (0.0%) 2 (22.2%) 
Smoking cessation advice 1 (3.6%) 0 (0.0%) 1 (7.7%) 0 (0.0%) 
Asthma management plan reviewed 1 (3.6%) 0 (0.0%) 1 (7.7%) 0 (0.0%) 
Added long-acting anticholinergic  1 (3.6%) 0 (0.0%) 0 (0.0%) 1 (11.1%) 
No elaboration 4 (14.3%) 1 (14.3%) 3 (23.1%) 0 (0.0%) 
*Figures represent number (percent) of responses. Percentages may not add up to 100 due to blank 
responses. 
Of the 7 GPs who did not feel that their patient was appropriately identified as needing a 
review, 5 (71.4%) provided reasons for this (Table 37).  
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Table 37. Reasons for GP feeling their patient was not appropriately identified for a review 
“[Medication] list [provided by the pharmacy] is not up to date. Patient is on a preventer.” 
“Patient was advised on last visit by myself that she needed review.” 
“Bad lungs deteriorating; has lung damage; try to collaborate in the next 2-6 months of which course I 
should take.” 
“Having very regular checks with respiratory nurse and spirometry. Current medication all necessary and 
used in preventer capacity.” 
“Wife uses patient's reliever at times so dispensing information in this case did not reflect use.” 
 
Table 38 displays GPs’ perceptions of the intervention. Most GPs agreed or strongly 
agreed that their patient would benefit from the intervention (32/48, 66.6%). The 
majority also agreed or strongly agreed that pharmacists are well placed to identify 
patients who may need a review of their asthma therapy (36/48, 75.0%), that there was 
an evident need for improved asthma control in the community (37/48, 77.1%) and that 
this type of program delivered by community pharmacists would improve asthma care 
in the community if implemented on a larger scale (33/48, 68.8%). 
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Table 38. GPs’ perceptions of the intervention* 
Statement Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
I believe that my patient will benefit from this project 
Mailed intervention (n = 15) 3 (20.0%) 6 (40.0%) 4 (26.7%) 0 (0.0%) 1 (6.7%) 
Face-to-face intervention (n = 19) 4 (21.1%) 10 (52.6%) 4 (21.1%) 0 (0.0%) 0 (0.0%) 
Control (n = 14) 2 (14.3%) 7 (50.0%) 4 (28.6%) 0 (0.0%) 1 (7.1%) 
Overall (n = 48) 9 (18.8%) 23 (47.9%) 12 (25.0%) 0 (0.0%) 2 (4.2%) 
I believe that pharmacists, utilising dispensing records, are well placed to identify patients who may need 
a review of their asthma by their doctor 
Mailed intervention (n = 15) 7 (46.7%) 2 (13.3%) 5 (33.3%) 0 (0.0%) 0 (0.0%) 
Face-to-face intervention (n = 19) 9 (47.4%) 9 (47.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Control (n = 14) 2 (14.3%) 7 (50.0%) 1 (7.1%) 3 (21.4%) 1 (7.1%) 
Overall (n = 48) 13 (27.1%) 23 (47.9%) 6 (12.5%) 3 (6.3%) 1 (2.1%) 
I believe that there is an evident need for improved asthma control in the community 
Mailed intervention (n = 15) 5 (33.3%) 8 (53.3%) 0 (0.0%) 1 (6.7%) 0 (0.0%) 
Face-to-face intervention (n = 19) 7 (36.8%) 9 (47.4%) 2 (10.5%) 0 (0.0%) 0 (0.0%) 
Control (n = 14) 1 (7.1%) 7 (50.0%) 4 (28.6%) 2 (14.3%) 0 (0.0%) 
Overall (n = 48) 13 (27.1%) 24 (50.0%) 6 (12.5%) 3 (6.3%) 0 (0.0%) 
I believe that this type of program delivered by community pharmacists would be likely to improve 
asthma control in the community if implemented on a larger scale 
Mailed intervention (n = 15) 2 (13.3%) 7 (46.7%) 3 (20.0%) 2 (13.3%) 0 (0.0%) 
Face-to-face intervention (n = 19) 6 (31.6%) 9 (47.4%) 3 (15.8%) 0 (0.0%) 0 (0.0%) 
Control (n = 14) 2 (14.3%) 7 (50.0%) 3 (21.4%) 2 (14.3%) 0 (0.0%) 
Overall (n = 48) 10 (20.8%) 23 (47.9%) 9 (18.8%) 4 (8.3%) 0 (0.0%) 
*Figures represent number (percent) of responses. Percentages may not add up to 100 due to blank 
responses. 
A number of GPs provided comments about the intervention, pharmacists’ involvement 
and asthma in general (Table 39).  
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Table 39. GPs’ comments regarding the intervention 
“Good program.” 
“Identification & dispensing & consumption.” 
“[The intervention] needs to be well targeted. Otherwise, [it’s] not an efficient use of resources. I'd 
therefore have some concerns.” 
“It [the intervention] is a great idea [as] it will sort of what percentage of Australia that do have asthma 
and what percentage that is and what we can do to help medical and physical.” 
“Asthma control requires asthma clinics at GP level with regular patient reviews.” 
“Good idea.” 
“It [the intervention] has advantages as well as disadvantages.” 
“People are also panicking over asthma. Parents of children who do not have it [asthma] rush kids to 
doctors whenever they cough.” 
“[This project involved] education of the general population rather than spoon-feeding people who do not 
or will not comply with treatment. That approach wastes resources on patients who will continue non-
compliance.” 
“Here I am again filling in yet another survey along with pharmacy generated question sheets on diabetes, 
hypertension etc. etc. Overall, together with sheets ++ [sic] from other authorities they are a profound 
"time waster." As with most GPs I don't even get time for a lunch break.” 
“Too much interference by pharmacists into many areas of medicine. Stick to selling teddy bears and 
orthotics.” 
“Often repeats are made for scripts for Webster packs etc. that are not yet due.” 
 
3.3.5.4 Pharmacist satisfaction  
Of the 71 pharmacists who participated in the project, 46 (64.8%) completed and 
returned a satisfaction survey. Table 40 displays pharmacists’ perceptions regarding the 
usefulness and appropriateness of the intervention. The majority of pharmacists agreed 
or strongly agreed that (i) there is an evident need for improved asthma control in the 
community (45/46, 97.8%), (ii) the project appropriately identified patients with poorly 
controlled asthma (37/46, 80.4%) and (iii) the patients identified to be in the 
intervention group would generally benefit from the project (42/46, 91.3%). The 
majority of pharmacists were not sure whether mailing information and surveys to 
patients only is an appropriate way to help them improve their asthma management and 
control (19/46, 41.3%), while the majority agreed or strongly agreed that handing out 
information and surveys to patients (face-to-face) only is an appropriate way to help 
them improve their asthma management and control (34/46, 73.9%). 
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Table 40. Pharmacists’ perceptions regarding usefulness and appropriateness of the intervention* 
Response (n = 46) Statement 
Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
I believe that there is an evident need for 
improved asthma control in the community 
24 
(52.2%) 
21 
(45.7%) 
0  
(0.0%) 
1   
(2.2%) 
0     
(0.0%) 
I believe that this project appropriately 
identified patients with poorly controlled asthma 
13 
(28.3%) 
24 
(52.2%) 
7 
(15.2%) 
2   
(4.3%) 
0     
(0.0%) 
I believe that the patients identified to be in the 
intervention group will generally benefit from 
this project 
9  
(19.6%) 
33 
(71.7%) 
4  
(8.7%) 
0     
(0.0%) 
0     
(0.0%) 
I believe that mailing information and surveys to 
patients only is an appropriate way to help them 
improve their asthma management and control 
0     
(0.0%) 
11 
(23.9%) 
19 
(41.3%) 
13 
(28.3%) 
1     
(2.2%) 
I believe that handing out information and 
surveys to patients (face-to-face) only is an 
appropriate way to help them improve their 
asthma management and control 
3    
(6.5%) 
31 
(67.4%) 
9 
(19.6%) 
2   
(4.3%) 
0     
(0.0%) 
*Figures represent number (percent) of responses. Percentages may not add up to 100 due to blank 
responses. 
The majority of pharmacists indicated that they would prefer to perform a face-to-face 
intervention in usual practice (41/46 [89.1%] preferred face-to-face, 8/46 [8.7%] 
preferred mailed). Table 41 displays the reasons given for preferring face-to-face or 
mailed interventions. 
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Table 41. Pharmacists’ reasons for preferring mailed or face-to-face interventions 
Reasons for preferring a face-to-face intervention 
“Face-to-face intervention [is] probably more effective as some patients won't read information you give 
them.” 
“[Provides an opportunity to] get to know the patient.” 
“Many of the patients identified are elderly and [receiving the] mail out [intervention pack] was a bit 
confusing [and] overwhelming for some of them. Face-to-face gives you a better chance to explain to the 
customer what it's all about.” 
“I think that face-to-face intervention will always be more likely to be accepted by the patient than a mail 
out approach.” 
“Mailings may make people feel as though their records are being used incorrectly.” 
“Better compliance if it’s [the intervention] face-to-face.” 
“Occasional language difficulties mean can only discuss issues face-to-face.” 
“I think face-to-face interaction from a pharmacist has more impact.” 
“Face-to-face gives you a chance to elaborate to the patient.” 
“This [face-to-face intervention] allows the pharmacist to assess the patient's technique, as this is one of 
the main determining factors of asthma control 
“Face-to-face intervention enables the pharmacist to clarify any issues and concerns regarding asthma 
management.” 
“Patients are much more receptive to surveys and counselling/educating when the pharmacist spends time 
with them and explains the process rather than just mailing something out.” 
“Face-to-face would be the ideal method because the pharmacist is able to speak with the patient directly 
and voice any other information or concerns. However, patients may not come in for an extended period 
of time, which may delay the intervention.” 
“Obviously face-to-face discussion is more likely to be taken seriously by a patient than a mail out. Also 
more personal and shows professional care for patient.” 
“I believe face-to-face to be a better method but I don't think that is appropriate as a single strategy. 
Mailings as a supplement would be good (occasionally).” 
“[I’d prefer to perform the intervention] face-to-face but often they [patients] will not wait (too rushed 
etc.)” 
“Face-to-face contact would give me the opportunity to discuss the intervention with each patient, in a 
way that would ensure as much as possible that they had a good understanding of the benefits of such an 
undertaking and the usefulness of taking part.” 
“I am in a unique position, being a one-man pharmacy and so have personal contact with all my patients. 
A great trust has developed over the years and face-to-face is the only way to go. A mail out is too 
impersonal in my situation.” 
“One-on-one is better.” 
Reasons for preferring mailed intervention: 
“Face-to-face [intervention] may feel defensive.” 
“Due to a lack of time in day-to-day pharmacy practice mailing the information allows patients to digest 
the information at their own pace without any pressure. This also allows the patient to go over the 
information and come back to the pharmacy if they have any questions.” 
No preference: 
“Both options are useful tools. Some patients prefer face-to-face intervention [and] some prefer written 
information.” 
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Table 42 displays pharmacists’ perceptions of the education session, MedeMine-for-
Asthma and workflow impact. The majority of pharmacists agreed or strongly agreed 
that (i) the education session increased their confidence in dealing with asthma 
management issues (34/46, 73.9%), (ii) the education session increased their confidence 
in using the MedeMine-for-Asthma program (36/36, 78.3%) and (iii) the MedeMine-
for-Asthma program was simple to use (38/46, 82.6%). Most pharmacists agreed or 
strongly agreed that participation in the project required a minimal amount of their time 
(42/46, 91.3%). The majority of pharmacists disagreed or strongly disagreed that using 
the MedeMine-for-Asthma program and implementing the intervention negatively 
impacted their usual workflow (28/46, 60.9%), while most agreed or strongly agreed 
that the potential benefits to patients with asthma outweighed the impact on their 
workflow (42/46, 91.3%). 
Table 42. Pharmacists’ perceptions of the education session, MedeMine-for-Asthma and workflow 
impact* 
Response (n = 46) Statement 
Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
The education session for pharmacists increased 
my confidence in dealing with asthma 
management issues 
12 
(26.1%) 
22 
(47.8%) 
10 
(21.7%) 
2   
(4.3%) 
0     
(0.0%) 
The education session for pharmacists increased 
my confidence in using the MedeMine-for-
Asthma program 
10 
(21.7%) 
26 
(56.5%) 
20 
(43.5%) 
0     
(0.0%) 
0     
(0.0%) 
I found the MedeMine-for-Asthma program 
simple to use 
9  
(19.6%) 
29 
(63.0%) 
8 
(17.4%) 
0     
(0.0%) 
0     
(0.0%) 
Participation in this project required a minimal 
amount of my time 
7  
(15.2%) 
35 
(76.1%) 
4  
(8.7%) 
0   
(0.0%) 
0     
(0.0%) 
Using the MedeMine-for-Asthma program and 
implementing the intervention negatively 
impacted my usual workflow 
0    
(0.0%) 
5 
(10.9%) 
13 
(28.3%) 
20 
(43.5%) 
8   
(17.4%) 
I believe that the potential benefits to patients 
with asthma outweighed the impact on my 
workflow 
12 
(26.1%) 
30 
(65.2%) 
3  
(6.5%) 
1   
(2.2%) 
0     
(0.0%) 
*Figures represent number (percent) of responses. Percentages may not add up to 100 due to blank 
responses. 
Table 43 displays pharmacists’ perceptions regarding general implementation of the 
intervention. The majority of pharmacists agreed or strongly agreed that (i) they would 
feel more confident about managing patients with asthma if MedeMine-for-Asthma was 
routinely available to use (33/46, 71.7%), (ii) pharmacists, utilising dispensing records, 
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are well placed to identify patients who may need review of their asthma by their doctor 
(45/46, 97.8%) and (iii) this type of program delivered by community pharmacists will 
improve asthma control in the community if implemented on a larger scale (46/46, 
100.0%). 
Table 43. Pharmacists’ perceptions regarding general implementation of the intervention*  
Response (n = 46) Statement 
Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
I would feel more confident about managing 
patients with asthma if MedeMine-for-Asthma 
was routinely available to use 
5  
(10.9%) 
28 
(60.9%) 
11 
(23.9%) 
2   
(4.3%) 
0     
(0.0%) 
I believe that pharmacists, utilising dispensing 
records, are well placed to identify patients who 
may need review of their asthma by their doctor 
12 
(26.1%) 
33 
(71.7%) 
1  
(2.2%) 
0     
(0.0%) 
0     
(0.0%) 
I believe that this type of program delivered by 
community pharmacists will improve asthma 
control in the community if implemented on a 
larger scale 
10 
(21.7%) 
35 
(76.1%) 
0     
(0.0%) 
0     
(0.0%) 
0     
(0.0%) 
Would you be willing to participate in other 
similar projects utilising dispensing records to 
improve the management of chronic diseases? 
Yes:                  
41 (89.1%) 
No:                      
0 (0.0%) 
Unsure:               
4 (8.7%) 
*Figures represent number (percent) of responses. Percentages may not add up to 100 due to blank 
responses. 
Twelve pharmacists (26.1%) indicated that they received some form of feedback from 
patients or GPs regarding the project. Table 44 displays the comments made by 
pharmacists regarding any feedback given. 
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Table 44. Pharmacists’ comments about patient and GP feedback of the intervention 
“Dr [sic] found this a useful tool to speak to patient about their usage, technique about their asthma 
inhalers.” 
“Enthusiastic response from local GP for project but disappointing minimal response (as yet?) from 
patients concerned. Needs my (positive) input regarding response and value of intervention? (as discussed 
when presenting the surveys originally) Oh well?!” 
“Only ONE patient who believed that their asthma was well controlled even though they used the reliever 
every day.” 
“Unsure about completing survey as managed by a specialist rather than their GP. Apathy about 
completing survey.” 
“Positive.” 
“Some patients gave positive comments. Others were indifferent and not interested. No GP feedback as 
yet.” 
“Drs in area should also receive a package or meeting if on a large scale.” 
“Only one patient.” 
“I thought there would be more feedback although we only had small sample. Several commented they 
had received mail out info [sic].” 
 
A number of pharmacists also provided comments about the intervention (Table 45). 
Table 45. Pharmacists’ comments about the project 
“Idea is good but I think a face-to-face intervention would have gone better with my customers.” 
“The use of OTC Ventolin® should be legislated to be recorded (i.e. the old S3 recordable) so these 
patients can also be identified.” 
“Criteria are limiting option as can think of several patients who could improve their asthma management 
in co-operation with myself and local GP, if they were not excluded by criteria e.g. under 18s and NH 
[nursing home] residents. ‘Some’ of those selected are ‘lost cases’ i.e. lifestyle and attitudes unlikely to 
improve their response or inclination (e.g. chronic smoker with emphysema who won't use ICS + LABA 
therapy).” 
“This project enables the pharmacist to take more control on management of asthmatics.” 
“Would be great if the MedeMine program routinely flagged patients for us to ‘chat with,’ rather than 
having to remember to try and review their history when dispensing - if on many medications the time to 
review the history for 3-6 months can be extensive.” 
“Elderly and non-English speaking patients form a significant proportion of our patient demographic and 
hence some of our patients identified by this asthma program were ruled out as the material posted would 
be too difficult to understand - therefore printing the material in another language, e.g. Greek/Italian may 
be beneficial.” 
“I've come to believe that just mailing out the ‘intervention pack’ may limit the usefulness of this project 
as in my experience face to face counselling only seems to reinforce written material as I think would be 
the case here. I'd be interested to know which intervention approach (mailed out or face-to-face) was 
more successful.” 
“I feel some of my patients should have been included in this project and somehow didn't fit the criteria.” 
“[There is a] need [for] this research project intervention - to continue, to be self-managed by the 
pharmacy, [and] to continue reporting on.” 
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3.3.5.5 Patient satisfaction  
Table 46 displays patients’ perceptions of the intervention. The majority of patients 
agreed or strongly agreed that they were appropriately identified by their pharmacist as 
needing a review of my asthma by their doctor (49/108, 45.4%). Most patients also 
agreed or strongly agreed that (i) use of their asthma reliever reduced over the last year 
(47/108, 43.5%), (ii) they found the information on asthma management that was sent 
out with the surveys useful (69/108, 63.9%) and (iii) their asthma control had improved 
as a result of the project (46/108, 42.6%). The majority of patients agreed or strongly 
agreed that pharmacists are well placed to identify patients who may need a review of 
their asthma by their doctors (82/108, 75.9%) and that that this type of program 
delivered by community pharmacists will improve asthma care in the community if 
implemented on a larger scale (88/108, 81.5%). 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 150 
Table 46. Patients’ perceptions of the intervention* 
Statement Strongly 
agree 
Agree Unsure Disagree Strongly 
disagree 
I feel that I was appropriately identified by my pharmacist as needing a review of my asthma by my 
doctor 
Mailed intervention (n = 60) 8 (13.3%) 20 (33.3%) 15 (25.0%) 7 (11.7%) 2 (3.3%) 
Face-to-face intervention (n = 48) 6 (12.5%) 15 (31.3%) 16 (33.3%) 4 (8.3%) 2 (4.2%) 
Overall (n = 108) 14 (13.0%) 35 (32.4%) 31 (28.7%) 11 (10.2%) 4 (3.7%) 
Use of my asthma reliever medication (Ventolin, Airomir, Asmol, Bricanyl) has reduced over the last year 
Mailed intervention (n = 60) 6 (10.0%) 17 (28.3%) 9 (15.0%) 16 (26.7%) 5 (8.3%) 
Face-to-face intervention (n = 48) 5 (10.4%) 19 (39.6%) 4 (8.3%) 13 (27.1%) 3 (6.3%) 
Overall (n = 108) 11 (10.2%) 36 (33.3%) 13 (12.0%) 29 (26.9%) 8 (7.4%) 
I found the information on asthma management that was sent out with the surveys 12 months ago useful 
Mailed intervention (n = 60) 7 (11.7%) 30 (50.0%) 14 (23.3%) 2 (3.3%) 0 (0.0%) 
Face-to-face intervention (n = 48) 2 (4.2%) 30 (62.5%) 6 (12.5%) 2 (4.2%) 0 (0.0%) 
Overall (n = 108) 9 (8.3%) 60 (55.6%) 20 (18.5%) 3 (2.8%) 0 (0.0%) 
I believe that my asthma control has improved as a result of this project 
Mailed intervention (n = 60) 5 (8.3%) 22 (36.7%) 21 (35.0%) 4 (6.7%) 1 (1.7%) 
Face-to-face intervention (n = 48) 2 (4.2%) 17 (35.4%) 15 (31.3%) 6 (12.5%) 1 (2.1%) 
Overall (n = 108) 7 (6.5%) 39 (36.1%) 36 (33.3%) 10 (9.3%) 2 (1.9%) 
I believe that pharmacists are well placed to identify patients who may need a review of their asthma by 
their doctors 
Mailed intervention (n = 60) 10 (16.7%) 33 (55.0%) 9 (15.0%) 2 (3.3%) 0 (0.0%) 
Face-to-face intervention (n = 48) 6 (12.5%) 33 (68.8%) 6 (12.5%) 1 (2.1%) 0 (0.0%) 
Overall (n = 108) 16 (14.8%) 66 (61.1%) 15 (13.9%) 3 (2.8%) 0 (0.0%) 
I believe that this type of program delivered by community pharmacists will improve asthma care in the 
community if implemented in a larger program 
Mailed intervention (n = 60) 14 (23.3%) 36 (60.0%) 6 (10.0%) 0 (0.0%) 0 (0.0%) 
Face-to-face intervention (n = 48) 12 (25.0%) 26 (54.2%) 7 (14.6%) 0 (0.0%) 0 (0.0%) 
Overall (n = 108) 26 (24.1%) 62 (57.4%) 13 (12.0%) 0 (0.0%) 0 (0.0%) 
*Figures represent number (percent) of responses. Percentages may not add up to 100 due to blank 
responses. 
Table 47 displays patients’ perceptions of asthma care and utilisation of health 
professionals. The majority of patients agreed or strongly agreed that they are satisfied 
with the level of asthma care that they usually receive from their doctor (101/108, 
93.5%) and from their pharmacist (91/108, 84.3%). While most patients agreed or 
strongly agreed that they regularly discuss their asthma control and/or management with 
their doctor (83/108, 76.9%), fewer did so with their pharmacist (42/108, 38.9%). 
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Table 47. Patients’ perceptions of asthma care and utilisation of health professionals* 
Statement Strongly 
agree 
Agree Unsure Disagree Strongly 
disagree 
I am satisfied with the level of asthma care that I usually receive from my doctor 
Mailed intervention (n = 60) 20 (33.3%) 35 (58.3%) 1 (1.7%) 0 (0.0%) 0 (0.0%) 
Face-to-face intervention (n = 48) 16 (33.3%) 30 (62.5%) 1 (2.1%) 0 (0.0%) 0 (0.0%) 
Overall (n = 108) 36 (33.3%) 65 (60.2%) 2 (1.9%) 0 (0.0%) 0 (0.0%) 
I am satisfied with the level of asthma care that I usually receive from my pharmacist 
Mailed intervention (n = 60) 13 (21.7%) 36 (60.0%) 4 (6.7%) 0 (0.0%) 0 (0.0%) 
Face-to-face intervention (n = 48) 12 (25.0%) 30 (62.5%) 3 (6.3%) 1 (2.1%) 0 (0.0%) 
Overall (n = 108) 25 (23.1%) 66 (61.1%) 7 (6.5%) 1 (0.9%) 0 (0.0%) 
I regularly discuss my asthma control and/or management with my doctor 
Mailed intervention (n = 60) 16 (26.7%) 31 (51.7%) 1 (1.7%) 4 (6.7%) 0 (0.0%) 
Face-to-face intervention (n = 48) 13 (27.1%) 23 (47.9%) 5 (10.4%) 3 (6.3%) 0 (0.0%) 
Overall (n = 108) 29 (26.9%) 54 (50.0%) 6 (5.6%) 7 (6.5%) 0 (0.0%) 
I regularly discuss my asthma control and/or management with my pharmacist 
Mailed intervention (n = 60) 6 (10.0%) 17 (28.3%) 9 (15.0%) 13 (21.7%) 5 (8.3%) 
Face-to-face intervention (n = 48) 1 (2.1%) 18 (37.5%) 9 (18.8%) 12 (25.0%) 3 (6.3%) 
Overall (n = 108) 7 (6.5%) 35 (32.4%) 18 (16.7%) 25 (23.1%) 8 (7.4%) 
*Figures represent number (percent) of responses. Percentages may not add up to 100 due to blank 
responses 
A number of patients provided comments about the intervention, pharmacists’ 
involvement in management and their asthma in general (Table 48).  
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Table 48. Patients’ comments regarding the intervention 
“I often find doctors and pharmacists have different views on the use of asthma meds [sic].” 
“This is a good project. I feel that asthma is like a 'silent killer' in our society. You really don't tell people 
you have asthma - than you have an attack with them, and I ALWAYS feel embarrassed - because they 
get so worried - being ignorant - that you will die in front of them.” 
“How much money are you spending of my taxes?” 
“A very good idea - I did a survey test with a department of the Alfred Hospital about 2 years ago. I have 
other medical problems beside asthma, which makes it a problem to be specific sometimes, i.e. blood 
pressure, arthritis.” 
“My doctor selects my medication and dosage, etc. [and] the pharmacist supplies it.” 
“I find my pharmacist most helpful in many ways.” 
“[I’m] quite happy with the way I use my medication.” 
“If chemists were to have on display ‘Asthma Action Kits’ with solid information, fact sheets, asthma 
plan sheets and doctor/chemist follow-up plan sheets for free, I feel it would be a good incentive for 
people with asthma like myself to take one and take a pro-active approach at doing something to 
encourage asthma management. Thankyou.” 
“My pharmacist is on top of my asthma control...” 
“My [pharmacy name] pharmacist, [pharmacist’s name] is a gem, he liaised with my doctor [doctor’s 
name], and I could not ask for any more from my pharmacist.” 
“My chemist is [pharmacist’s name] and is always willing to help.” 
“I find this [project] a great idea.” 
“My asthma is well controlled by my preventative meds [sic]. However, any additional information is 
always a bonus. It is possible to live with asthma IF managed. Keep up the good work.” 
“I use Ventolin® 4 times a day and that seems to control my asthma.” 
 
3.4 Discussion 
3.4.1 Participants 
Approximately 50% of Australian pharmacies use the Fred dispensing system. 
However, of the pharmacies invited to participate, the proportions who were not users 
of the Fred dispensing system did not seem to reflect this. In Tasmania, approximately 
three-quarters of the pharmacies contacted were not using Fred. It should be noted that 
many pharmacies that were known to use the Fred dispensing system were not invited to 
participate. This was due to their prior participation in the pilot study,5,304 and the 
possibility that the inclusion of these pharmacies may have skewed the pre-intervention 
data. In Victoria and South Australia, there was no prior knowledge of which 
pharmacies did and did not use the Fred dispensing system. Thus, pharmacies were 
contacted until recruitment targets were reached. In Victoria, less than one-quarter of 
the pharmacies contacted did not use Fred, while in South Australia, nearly two-thirds 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 153 
indicated that they did not use Fred. The proportion of pharmacies that used the Fred 
dispensing system therefore seemed to differ between the states. Approximately one-
third of the pharmacists who were contacted used the Fred dispensing system but were 
not willing to participate. Unfortunately, data exploring the reasons behind their 
unwillingness to participate was not collected. Follow-up of these pharmacists to 
determine their perceived barriers to participating in the study may be beneficial to 
future research.  
3.4.2 Uptake of the intervention 
Despite efforts to design a pragmatic program and reinforce its use, not all pharmacies 
followed the study protocol when it came to disseminating the intervention packs. In 
those pharmacies randomised to perform the face-to-face intervention, approximately 
20% of patients did not receive a prescription during the six-week intervention period, 
thus the pharmacist would not have had the opportunity to offer these patients an 
intervention. However, even when the opportunity to intervene was taken into account, 
significantly fewer face-to-face intervention patients were offered an intervention, 
compared with mailed intervention patients. Several factors may have contributed to 
pharmacists’ willingness to participate and comply with the study methods and 
protocols. Attendance at the pharmacist education session, time constraints and 
individual beliefs and perceptions of what constitutes poor asthma control may have 
influenced the dissemination of intervention packs. It is likely that one of the factors 
limiting the uptake of the face-to-face intervention was time constraints. Pharmacists 
who performed the mailed intervention were free to print and compile the intervention 
packs during quieter times of the day, whereas those who performed the face-to-face 
intervention were prompted to print and compile the packs as each patient presented to 
the pharmacy for prescriptions. Although this should have only taken a few minutes, 
approximately one-third of the electronic prompts were not acted on. This would 
undoubtedly limit the effectiveness of face-to-face interventions on an intent-to-treat 
basis. 
While there clearly is the potential for community pharmacists to have an impact in 
improving the management of asthma, such approaches are most likely to be successful 
if they do not require significant time and additional training on the part of the 
pharmacist. The need for further research using strategies that are pragmatic in busy 
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community pharmacies has previously been identified.10 Disease state management 
programs may have better uptake and outcomes if they were to utilise information 
technology, such as MedeMine-for-Asthma, to assist in identification of patients who 
might be eligible and most likely to benefit from these programs. MedeMine-for-
Asthma could assist in the tailoring of information to patients enrolled in disease state 
management programs and maximise the efficient use of the pharmacist’s time. 
3.4.3 Patient and GP survey response rates 
The average patient response rate of the mailed questionnaires was approximately 13%. 
This response rate was relatively low, considering that the average patient response rate 
to postal questionnaires (without reminders or incentives) reported in medical journals 
is approximately 20-50%.350,351  
The personalised letter that was provided with the questionnaires encouraged patients to 
make an appointment with their GP at their earliest possible convenience. Perceived 
need for a medical consultation, as well as the cost of a consultation and potential cost 
of increasing asthma therapy (e.g. the addition if ICS therapy) may have been patient-
related barriers to visiting their GP. It is conceivable that some patients did not bother to 
return the questionnaires if they did not follow the advice of seeking a review of their 
asthma by their GP. Furthermore, patients’ perception of their disease severity (e.g. 
overestimation of asthma control) and hence their need for an intervention may have 
limited the motivation to participate. 
The average GP response rate of the mailed questionnaires was approximately 5%. The 
presence of a paired GP questionnaire could not be used as a surrogate measure for 
whether receiving an intervention letter prompted a visit to the GP. Two unknown 
factors needed to be taken into consideration when analysing GP questionnaires: 
• Patient willingness to visit their GP and give them the questionnaire, and 
• GP willingness to complete the questionnaire. 
It could not be assumed that the presence or absence of a corresponding GP 
questionnaire denoted whether or not the patient visited their GP after receiving a letter 
from their pharmacy. There were five possible scenarios that may have influenced the 
presence or absence of a corresponding GP questionnaire: 
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• The patient visited their GP, gave them the questionnaire and it was completed 
and returned; 
• The patient visited their GP, gave them the questionnaire and it was completed 
but not returned; 
• The patient visited their GP, gave them the questionnaire and it was not 
completed nor returned; 
• The patient visited their GP, but did not give them the questionnaire; or 
• The patient did not visit their GP. 
Lack of time and/or interest on the GPs’ part may have influenced their participation. It 
has previously been reported that the perceived additional workload and paperwork are 
barriers to implementing interventions designed to improve asthma care.275,278,352 
Nevertheless, the GP questionnaires provided a useful insight into the management of a 
number of patients’ asthma therapy, as well as an encouraging opinion of the value of 
this project. 
3.4.4 Patient demographics 
The mailed intervention, face-to-face intervention and control patients were well 
matched with respect to demographic measures at baseline. More than half of the 
patients who responded to the questionnaires were aged 60 years or older. It is possible 
that this reflected either a higher prevalence of asthma or a greater participation rate in 
this age group, or both. However, a National Health Survey reported that patients aged 
55 years or older actually have a lower prevalence of asthma, with patients aged 
between 15 and 35 years having the highest prevalence.31 Conversely, it has been 
reported that older patients have higher participation rates in asthma interventions than 
younger patients.353,354 
Similarly, females accounted for more than half of the patients who responded to the 
questionnaires. It is likely that this reflected a higher prevalence of asthma among 
females,31 and a higher participation rate,355 both of which have been reported 
previously. 
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3.4.5 Outcome measures 
3.4.5.1 Dispensing data 
The intervention resulted in significant improvements in the P : R ratio in both 
intervention groups and the control group. Using the treatment received method of 
analysis, the magnitude of improvement in the face-to-face intervention group was 
greater than that in the mailed intervention group, which was greater than that in the 
control group. The improved effectiveness of the face-to-face intervention may have 
been due to two key factors: (i) the personalised delivery by a pharmacist, and (ii) the 
patients’ perception of their asthma severity and control at the time of the intervention. 
The face-to-face intervention would undoubtedly be expected to have a greater impact 
on a patient-by-patient basis, due to the personalised method of delivery by their 
community pharmacist, someone they presumably know and trust. The pharmacist had 
the option of delivering tailored advice to each patient, and the patient had the 
opportunity to raise any queries or concerns they may have had. Furthermore, the 
intervention was delivered at a time the patient had presenting to the pharmacy for the 
collection of their medications (including, quite possibly, their asthma medication), so it 
is likely that their overall health and asthma was at the front of their minds at the time. 
Moreover, if the patient had presented to the pharmacy specifically to collect a reliever 
inhaler, their perception of their asthma severity may have been worse than if they had 
received the intervention pack in the mail on any other day. A worse perception of one’s 
asthma severity may have increased the acceptance of the intervention by such patients, 
and improved adherence to the recommendations made. 
Unfortunately, the seemingly improved effectiveness of the face-to-face intervention 
compared to the mailed intervention was offset by its decreased delivery by 
pharmacists. Taking the decreased delivery of the face-to-face intervention into account, 
the overall magnitude of improvement in the mailed intervention group was greater than 
that in the face-to-face intervention group. It seems that time constraints in busy 
pharmacies may restrict the uptake and effectiveness of face-to-face interventions in the 
‘real world’ setting. Hence, perhaps both intervention options should be made available, 
for the pharmacist to deliver at their own discretion. 
It should be noted that the P : R ratio and reliever usage also significantly improved in 
the control group (albeit, to a lesser degree than in the intervention groups). Changes in 
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the control group may have also reflected a change in pharmacists’ behaviour towards 
all patients with asthma presenting to the pharmacy, due to a heightened awareness of 
asthma management issues arising from participation in the project (including 
attendance at the education sessions). This effect, known as the Hawthorne Effect, 
stipulates that the mere awareness of being under observation can alter the way in which 
a person behaves. If there is a demonstrable benefit from participating in clinical 
research, for whatever reason, then this has implications for good clinical practice and 
for improving care. The Hawthorne Effect is a component of the non-specific effects of 
trial participation, but is not controlled for by usual controlled trial designs.356 
Another important point to note is that most of the significant differences arose from 
within-group comparisons rather than between-group comparisons. It was unfortunate 
that there were not enough differences between the groups after the intervention to 
detect any statistical significance. However, post hoc between-group analysis of the 
reduction in reliever usage demonstrated trends of borderline significance for both 
intervention groups to have a great reduction in reliever usage after the intervention than 
the control. 
Despite the fact that the P : R ratio was the primary outcome measure used in this 
project, further analyses were necessary in order to determine whether the increase in 
the P : R ratio resulted from an increased preventer usage or a decreased reliever usage, 
before any conclusions could be drawn. Further analysis found that the increased P : R 
ratio was largely due to a reduction in the average daily use of reliever medication (of 
borderline statistical significance). A number of international studies have demonstrated 
improved asthma outcomes with decreased reliance on reliever medications.129,316-319 
Additionally, a number of studies have implicated regular and perhaps excessive use of 
SABA in asthma deaths and near-death emergencies89-95 and worse clinical outcomes.96-
98 The concerns about adverse outcomes with frequent and regular SABA use are likely 
to have mainly been related to suboptimal use of ICS in patients whose asthma was 
inadequately controlled and treated.85 
The average salbutamol-equivalent daily usage of SABA before the intervention was 
655.7 #g, which equates to 6-7 puffs per day. This range of daily SABA consumption 
was well above what is recommended by the National Asthma Council and Asthma 
Foundations Australia, who state that usage of reliever medication on three or more 
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occasions per week is indicative of suboptimal asthma control.59,328 According to 
Australian asthma management guidelines, and assuming all dispensed medication had 
been consumed, patients using this quantity of reliever medication should be classed as 
having poor asthma control, and should have been receiving regular ICS therapy.59 
Therefore, the algorithm used by the MedeMine-for-Asthma program seemed to 
appropriately identify patients who were likely to have poor asthma control. The 
identical medians in daily pre-intervention SABA usage between the three groups in the 
intention-to-treat analyses demonstrated the effectiveness of the randomisation process 
included in the program’s identification algorithm. By ranking all identified patients by 
their SABA usage and then randomly assigning them to the intervention or control 
group, the program ensured that the groups were well-matched at baseline. 
It was assumed that the dispensed quantity of reliever medication equated with actual 
medication consumption, but factors such as storing relievers in different sites and 
misplacing medication could complicate the picture. These factors may have resulted in 
reduced measurement precision of medication usage, but are unlikely to have introduced 
systematic bias, as they existed both before and after the intervention and in both 
intervention and control groups. It is also possible that non-prescription supply of 
relievers, which is not always recorded in the dispensing software, resulted in 
underestimation of reliever medication usage. Underestimation may also have arisen 
from the assumption that asthma medications were not being dispensed at other 
pharmacies. However, the same level of underestimation would have applied to both 
groups and in both the pre- and post-intervention periods. 
While it was encouraging to see a sustained improvement in the P : R ratio and decrease 
in reliever usage, it was somewhat disappointing that the usage of ICS did not 
significantly increase as a result of the intervention. Reasons for no change in preventer 
use could be because people used them better and/or people started using the preventer 
that had been dispensed previously, which would not be picked up in increased 
dispensings. There may be barriers to ICS use, which need to be addressed in future 
intervention programs. 
3.4.5.2 Patient-reported outcomes 
It was somewhat disappointing that there were no significant improvements in patient-
reported asthma control, quality of life or medication adherence behaviour after the 
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intervention. We have previously demonstrated that a mailed intervention significantly 
improved patient-reported asthma control and quality of life six months after the 
intervention.304 Therefore, one of the reasons for no improvement in this study may 
have been due to the delayed follow-up (12 months) after the intervention. Perhaps the 
improvements in patent-reported outcomes previously demonstrated would not be 
sustainable over a 12-month period. It should be mentioned that the reason for using a 
12-month follow-up in this study was to ensure that seasonal variations in dispensing 
pattern and asthma control did not influence the results. Another reason for the lack of 
significant improvement in most patient-reported outcomes may have been due to the 
low return rate of the patient questionnaires. Therefore, small sample sizes may have 
prevented any significant differences from being detected.  
There was, however, a non-significant trend for improved asthma control after the face-
to-face intervention, but not after the mailed intervention. This adds weight to the 
treatment-received analysis of dispensing data, which suggested that the face-to-face 
intervention was more effective than the mailed intervention among those patients who 
actually received the intervention. Due to the low questionnaire response rate, it was not 
known what total proportion of patients sought a review of their asthma therapy as a 
result of receiving an intervention pack. The improvements in asthma control therefore 
may have been GP-initiated, via prescribing additional preventer therapy, or patient-
related, via an increased awareness of their condition after being alerted to their high 
reliever usage. 
There was also a significant increase in the proportion of patients who possessed written 
AAPs after the face-to-face intervention, but not after the mailed intervention. Providing 
an individualised written AAP is a high-profile part of Steps 5 and 6 of the Australian 
Asthma Management Plan: “develop an action plan” and “educate and review 
regularly.”357 The use of a written AAP in conjunction with training in self-management 
and regular medical review has been shown to reduce asthma-related unscheduled visits 
to the doctor, days off work or school and risk of death, as well as improved asthma 
symptoms and quality of life.74,85  
It has previously been reported that it was not possible to achieve AAP ownership in 
100% of people with asthma, despite referrals for this purpose,300 and it has been 
suggested that a better collaborative inter-professional network needs to be established 
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so that all healthcare professionals support AAP ownership.301 Perhaps in future, asthma 
interventions could focus more on the development of a written AAP, and 
reinforcement of the plan by community pharmacists, to tie in more closely with the 
current objectives of the Asthma Foundations, although the patient- and GP-related 
barriers to the implementation of AAPs, as discussed earlier in this thesis, would need 
to be addressed. 
3.4.5.3 GP evaluations 
There were two sets of GP surveys; those from the intervention patients sent out at the 
time of the intervention, and those from the control patients, sent out 12 months after 
the original intervention. The ‘intervention’ GP surveys supported intervention 
outcomes, whereas the ‘control’ GP surveys simply provided further insight into GPs’ 
perception of asthma control and asthma therapy. 
While the low return rate to the GP survey limits the generalisation of these results, the 
GP responses provided a useful insight into the management of a number of patients’ 
asthma therapy, as well as an encouraging opinion of the value of this project. More 
than half of GPs who returned questionnaires indicated that they modified or intended to 
modify their patient’s asthma therapy. The modifications, as stated by the GP, were 
predominately the addition of ICS therapy. It has already been shown in a number of 
studies that regular use of ICS can reduce asthma symptoms,171,358 prevent 
exacerbations and hospitalisations,171,359 and reduce asthma mortality.121 Other 
modifications to patients’ therapy included simple education regarding the regular use 
of ICS and over-reliance on relievers, changes to existing ICS therapy, the addition of a 
LABA or anticholinergic therapy, review of asthma management plan and smoking 
cessation advice.  
More than 80% of GPs agreed that their patient was appropriately identified for a 
review of their asthma therapy and nearly two-thirds agreed or strongly agreed that their 
patient would benefit from this project. This was particularly encouraging, as it added 
strength to the algorithm used by the MedeMine-for-Asthma program in appropriately 
identifying patients who are in need for improved asthma management. 
The second part of the GP questionnaire assessed the GPs’ opinions on the usefulness of 
this project and of projects such as this one. Specifically, it assessed whether the GP 
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agreed that (i) pharmacists are well placed to identify patients who may need review of 
their asthma therapy, (ii) there is an evident need for improved asthma management in 
the community, and (iii) this type of program delivered by community pharmacists 
would be likely to improve asthma care in the community if implemented on a larger 
scale. Importantly, the majority of GPs agreed with these statements. Indeed, it has been 
reported that one of the priorities GPs nominate for achieving best outcomes for asthma 
care is facilitating regular patient review.275 Unfortunately, there still seems to be some 
negative attitudes towards pharmacists and their role in healthcare. This was classically 
illustrated by a quote made by one GP:  
“Too much interference by pharmacists into many areas of 
medicine. Stick to selling teddy bears and orthotics.” 
One key way to overcome this type of attitude is for pharmacists to continue to perform 
interventions, with effective collaborations with GPs, with the ultimate aim of 
improving patient care. More interventions such as this one can demonstrate that 
pharmacists can effectively use skills and resources to improve health outcomes. 
It has been well documented that a potential patient barrier to optimal asthma 
management and control is the patients’ underestimation of their disease severity.51,52,281 
The 2005 International Control of Asthma Symptoms (ICAS) survey of patients and 
GPs found high levels of concerns amongst GPs that patients accept their symptoms as 
normal, and frustration that their patients were not more forthcoming about their 
symptoms.284 It seemed that too many patients have symptoms that they accept as being 
part of their condition and many rely heavily on their rescue medication. This 
intervention included a personalised letter to patients who were ‘high-users’ of reliever 
medications, suggesting that this may indicate that their asthma was not under control. 
By bringing their attention to the fact that their asthma could be better controlled and 
suggesting that they see their GP for a review of their asthma, the project attempted to 
bridge the gap between patients and GPs to improve asthma management. 
3.4.5.4 Pharmacist satisfaction  
The pharmacist satisfaction questionnaire was a useful insight into the perception of the 
project’s methods, usefulness and relevance. More than 80% of pharmacists agreed that 
the project appropriately identified patients with poorly controlled asthma, and more 
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than 90% agreed that the patients identified to be in the intervention group would 
benefit from the project. Again, this added strength to the algorithm used by the 
MedeMine-for-Asthma program in appropriately identifying patients who were in need 
of education for improved asthma management. Interestingly, the majority of 
pharmacists were not sure whether mailing information and surveys to patients only is 
an appropriate way to help them improve their asthma management and control, while 
more than 70% agreed that handing out information and surveys to patients (face-to-
face) only is an appropriate way to help them improve their asthma management and 
control. When asked which type of intervention they would prefer to perform in usual 
practice, nearly 90% indicated that they would prefer to perform the face-to-face 
intervention. This was despite the fact that significantly fewer face-to-face intervention 
patients were offered an intervention, compared with mailed intervention patients. This 
suggests that the pharmacists’ personal beliefs about the nature of the intervention did 
not affect the uptake. Other factors such as time constraints may have limited the uptake 
of the face-to-face intervention. Indeed, one pharmacist also made the comment that 
patients are often too rushed to receive an intervention in the pharmacy. Comments 
made by pharmacists regarding their preference for intervention type suggested that the 
main reasons for preferring to perform the face-to-face intervention were the 
personalisation and delivery of professional care and increased acceptance by patients.  
3.4.5.5 Patient satisfaction 
The patient satisfaction survey provided a useful insight into perceptions of asthma 
medication, the need for an intervention to improve asthma management, and the 
perceptions towards and utilisation of healthcare professionals. It was very encouraging 
that most patients agreed that they were appropriately identified by their pharmacist as 
needing a review of their asthma by their doctor, and that their asthma control had 
improved as a result if the intervention. Most patients also seemed to recognise the 
potential role that pharmacists can play in improving asthma management, with three-
quarters of patients agreeing that pharmacists are well placed to identify patients who 
may need a review of their asthma by their doctors, and more than 80% agreeing that 
this type of program delivered by community pharmacists would improve asthma care 
in the community if implemented on a larger scale. 
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More than 80% of patients indicated that they were satisfied with the level of asthma 
care that they usually receive from their doctor and from their pharmacist. It was 
surprising and somewhat disappointing that while three-quarters of patients agreed that 
they regularly discuss their asthma control and/or management with their doctor, only 
one-third did so with their pharmacist. Nevertheless, many positive comments were 
made about pharmacists, and the fact they are very willing to help patients with their 
asthma. 
3.5 Conclusions 
Community pharmacy dispensing records can be effectively utilised, with appropriately 
designed data mining software, to identify patients with suboptimal asthma 
management, who can then be referred to their GP for review. The face-to-face 
intervention improved asthma management to a greater degree than the mailed 
intervention, but only among those who received the intervention. Time constraints in 
busy pharmacies may limit the uptake and effectiveness of face-to-face interventions in 
the ‘real world’ setting. Pharmacists should have both mailed and face-to-face 
intervention options available to ensure maximum uptake and effectiveness of the 
interventions. 
Using the MedeMine-for-Asthma program, approximately 1500 patients were identified 
from 71 pharmacies as having suboptimal asthma management. If the program were to 
be made compatible with all dispensing systems, and the intervention was implemented 
on a national scale, more than 100,000 patients could be readily identified from 
approximately 5,000 pharmacies. The MedeMine-for-Asthma program was shown to be 
pragmatic in its use, and with minor modifications, it could potentially be utilised to 
perform interventions to improve the management of other chronic conditions.  
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PART THREE:          
MEDICATION PERSISTENCE IN COPD 
CHAPTER FOUR: INTRODUCTION 
4.1 Pathophysiology of COPD 
Chronic obstructive pulmonary disease (COPD) is a disease state characterised by a 
progressive limitation of airflow in the lungs which, unlike asthma, is not fully 
reversible by medication.360 the characteristic symptoms of COPD are chronic and 
progressive dyspnoea, cough and sputum production. The Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) definition for COPD is: 
“COPD is a preventable and treatable disease with some 
significant extrapulmonary effects that may contribute to the 
severity in individual patients. Its pulmonary component is 
characterised by airflow limitation that is not fully reversible. 
The airflow limitation is usually progressive and associated with 
an abnormal inflammatory response of the lung to noxious 
particles or gases.”360 
It is important to note that the terms ‘chronic bronchitis’ and ‘emphysema’ are no longer 
included in the formal definition of COPD, although they are still used clinically.360 
Emphysema is a pathologic term used to describe destruction of the alveolar-capillary 
membrane, and chronic bronchitis is a clinical term used to describe the presence of 
cough or sputum production for at least a three-month duration during two consecutive 
years.361 
The chronic airflow limitation characteristic of COPD is caused by a mixture of small 
airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), 
the relative contributions of which varies between patients (Figure 26).360  
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 165 
Figure 26. Mechanisms of underlying airflow limitation in COPD360 !
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Prolonged exposure to toxic gases or particles causes chronic inflammation, which 
results in structural changes and narrowing of the small airways (Figure 27).362 
Destruction of the lung parenchyma, also by inflammatory processes, leads to the loss 
of alveolar attachments to the small airways and decreased lung elastic recoil.363-365 
These changes result in a prolonged time constant for lung emptying and decreases 
expiratory airflow.366 
Figure 27. Illustrative representation of the pathophysiological changes in COPD367 
 
Airflow limitation, measured by reduced FEV1, progresses slowly over several decades, 
so that most patients with symptomatic COPD are in late middle age or are elderly.368 
Spirometry is essential for diagnosis and provides a useful description of the severity 
and pathological changes in COPD (Table 49).360 
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Table 49. Spirometric classification of COPD severity369 
COPD classification Post-bronchodilator FEV1 
Stage I: mild FEV1/FVC* ratio < 0.70, FEV1 ! 80% predicted 
Stage II: moderate FEV1/FVC ratio < 0.70, 50% " FEV1 < 80% predicted 
Stage III: severe FEV1/FVC ratio < 0.70, 30% "FEV1 < 50% predicted 
Stage IV: very severe 
FEV1/FVC ratio < 0.70, FEV1 < 30% predicted or  
< 50% predicted plus chronic respiratory failure† 
*FVC = Forced vital capacity. †Respiratory failure: arterial partial pressure of oxygen < 60 mm Hg with 
or without arterial partial pressure of CO2 > 50 mm Hg while breathing air at sea level. 
The natural course of COPD is complicated by the development of extra-pulmonary 
effects, including systemic inflammation, weight loss, skeletal muscle dysfunction, 
cardiovascular disease, anxiety, depression and osteoporosis (Table 50).370 The high 
burden of COPD resulting from respiratory symptoms is further contributed to by these 
systemic effects, leading to a pronounced deterioration of health status, a diminished 
QOL and increased mortality.371 While the relationships between the pulmonary and 
extra-pulmonary effects of COPD are not fully understood, local and systemic 
inflammation, oxidative stress and disturbances in neuro-hormonal states are some of 
the likely mechanisms.372 The involvement of common susceptible genes or risk factors 
is also possible. 
Table 50. Systemic effects of COPD370 
Type of effects Examples of effects 
Oxidative stress373,374 
Activated inflammatory cells375,376 Systemic inflammation 
Increased plasma levels of cytokines and acute phase 
proteins377,378 
Increased resting energy expenditure379 
Abnormal body composition380 Nutritional abnormalities and weight loss 
Abnormal amino acid metabolism381 
Loss of muscle mass 
Abnormal muscle structure/function382,383 Skeletal muscle dysfunction 
Exercise limitation384 
Cardiovascular effects (e.g. ischemic heart disease)385 
Nervous system effects (e.g. anxiety and depression)386 Other potential systemic effects 
Osteoskeletal effects (e.g. osteoporosis)387 
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COPD is a heterogeneous disease process that varies greatly from person to person with 
respect to lung pathology, natural history of disease and systemic effects and co-
morbidities.388,389 The risk for COPD is related to an interaction between genetic factors 
and many different environmental exposures.390 It appears that an enhanced or abnormal 
inflammatory response to inhaled particles or gases, beyond the normal protective 
inflammatory response in the lungs, is a characteristic feature of COPD and has the 
potential to produce lung injury.391 Cigarette smoking is by far the most commonly 
encountered risk factor for COPD.390 The population-attributable risk of smoking 
(current smoking and ex-smoking) for COPD is reportedly up to 78%.392 This 
population-attributable risk identifies that at least 22% of COPD still needs to be 
explained by other genetic and environmental risk factors. However, due to complex 
relationships between the known risk factors for COPD, individuals with similar 
smoking and exposure histories can vary a great deal in their predisposition to the 
disease, severity of their disease and response to intervention. Most of the evidence 
concerning risk factors for COPD (Table 51) comes from cross-sectional 
epidemiological studies that identify associations rather than cause-and-effect 
relationships. 
Table 51. Risk factors for COPD 
Type of risk factor Examples 
Tobacco smoke393-395 
Occupational dusts (organic and inorganic)396 
Indoor air pollution from heating and cooking with biomass397,398 
Exposure to particles 
Outdoor air pollution398,399 
Genetic  Hereditary deficiency of the serine protease inhibitor alpha-1 antitrypsin400-403 
Low birth weight404,405 
Lung growth and development 
Reduced maximal attained lung function406 
Infections Exposure to respiratory infections in childhood405,407 
Ageing Age over 40 years393,394 
Prevalence of COPD higher in males393,408 
Gender 
Females may be more susceptible to the effects of tobacco smoke409-411 
Socioeconomic status Low socioeconomic status and/or factors relating to low socioeconomic status (e.g. poor nutrition and high exposure to particles)412,413 
Asthma 
There is a large overlap between people who have a clinical diagnosis 
of COPD and asthma, and people with asthma can lose lung function 
more rapidly than people without asthma414-416 
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4.2 Overlap of COPD and asthma 
Asthma and COPD have important similarities and differences. Both are chronic 
inflammatory diseases that involve the small airways and cause airflow limitation, both 
result from gene-environment interactions and both are usually characterised by mucous 
and bronchoconstriction. Differentiation between asthma and COPD is important 
because the prognosis, treatment goals and several aspects of the guideline-
recommended management strategies differ for these diseases.16,360 Once COPD is 
established, the only interventions that influence life expectancy are smoking cessation 
and oxygen therapy.360 By contrast, most patients with asthma have a normal life 
expectancy if they maintain regular preventive anti-inflammatory medication.16 
Although overlaps exist in the disease characteristics of asthma and COPD, careful 
history, physical examination and lung function testing often reveal information that 
facilitates distinction between these diseases, allowing better tailoring of therapy. A 
misdiagnosis of COPD or asthma may lead to inadequate management of patients and to 
escalating healthcare costs. An early and accurate diagnosis can help ensure optimal and 
cost-effective management of patient care. 
Until recently, the presence or absence of reversibility of airflow obstruction was 
thought to be the major distinction between asthma and COPD, with reversibility being 
the hallmark of asthma and mainly irreversibility being the hallmark of COPD.417 In 
reality asthma and COPD are not single entities; each has a spectrum of reversibility and 
there is ‘overlap,’ most likely associated with the varying extent and the ‘mix’ of both 
structural and inflammatory changes, and the predominant anatomic site within the lung 
at which these occur.418 Individual patients commonly share the traits of different 
obstructive lung diseases.419,420 A graphical representation of this relationship was first 
presented as the non-proportional Venn diagram of chronic airflow obstruction 
(Figure 28). 
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Figure 28. Non-proportional Venn diagram of COPD421 
 
The subsets comprising COPD are shaded. Subset areas are not proportional to the actual relative subset 
sizes. Asthma is by definition associated with reversible airflow obstruction although, in variant asthma, 
special manoeuvres may be necessary to make the obstruction evident. Patients with asthma whose 
airflow obstruction is completely reversible (subset 9) are not considered to have COPD. Because in 
many cases it is virtually impossible to differentiate patients with asthma whose airflow obstruction does 
not remit completely from persons with chronic bronchitis and emphysema who have partially reversible 
airflow obstruction with airway hyperreactivity, patients with unremitting asthma are classified as having 
COPD (subsets 6, 7 and 8). Chronic bronchitis and emphysema with airflow obstruction usually occur 
together (subset 5), and some patients may have asthma associated with these two disorders (subset 8). 
Individuals with asthma who have been exposed to chronic irritation, as from cigarette smoke, may 
develop chronic productive cough, which is a feature of chronic bronchitis (subset 6). Persons with 
chronic bronchitis and/or emphysema without airflow obstruction (subsets 1, 2 and 11) are not classified 
as having COPD. Patients with airway obstruction due to diseases with known aetiology or specific 
pathology such as cystic fibrosis or obliterative bronchiolitis (subset 10) are not included in this 
definition. 
It is well established that airway remodelling can occur in long-standing, poorly treated 
asthma and results in partially reversible airflow obstruction.422,423 Therefore, in many 
patients with long-standing asthma there is a component of irreversible airflow 
obstruction with reduced lung function and incomplete response to a short-acting 
bronchodilator or to an oral or inhaled corticosteroid. This makes the diagnosis of 
obstructive lung disease somewhat challenging in older adults. However, despite similar 
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airflow obstruction, elderly patients with asthma have distinct characteristics compared 
to patients with COPD.424 Long-term asthma has also been associated with an 
accelerated decline of FEV1.414 If patients with asthma sometimes show COPD-related 
phenotypes such as irreversible airflow obstruction and lung function decline, patients 
with COPD may exhibit airflow functional signs that are characteristic of asthma. 
Indeed, partial response to a bronchodilator is a common feature in patients with COPD, 
with almost 50% of patients showing significant improvement in FEV1 after a 
bronchodilator.425,426 Interestingly, among patients with COPD, reversibility after 
bronchodilators appears to be associated with other asthma-related phenotypes, such as 
bronchial hyper-responsiveness.427 
Just how commonly does asthma and COPD co-exist? A number of studies have 
attempted to answer this question by analysing health surveys, Medicaid data, general 
practice databases or by classifying patients according to respiratory characteristics 
derived from international consensus guidelines. Amongst patients with obstructive 
lung disease, the reported overlap of asthma and COPD ranges from 17-55% of 
patients.419,428,429 Variations in the rates of overlap seem to stem from different methods 
of classification and differing study populations. Furthermore, diagnostic confusion 
between asthma and COPD appears commonly in the primary care setting.430 The 
proportion of patients with mixed disease seems to increase with age,419 and the burden 
of the concomitant diseases is reportedly much higher than the combined burden of both 
individually.429  
Asthma and COPD tend to be treated with the same medications, with variations on 
emphasis (Table 52). Asthma is optimally treated with regular anti-inflammatory 
medications (preferably ICS), and short-acting bronchodilators are used when needed.16 
COPD is usually treated with long-acting bronchodilators, which provide symptomatic 
benefits, and ICS to reduce the frequency of exacerbations.360 Whilst chronic 
inflammation underlies both asthma and COPD, the nature of the inflammation differs, 
as does the response to anti-inflammatory medications.431,432 
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Table 52. Major differences between asthma and COPD management in adults59 
Asthma   COPD 
Regular ICS treatment is recommended for patients 
of all ages with persistent asthma. 
ICS are generally reserved for patients with severe 
disease and frequent exacerbations, or those who 
have shown improvement with ICS therapy 
Inhaled anticholinergic agents (e.g. tiotropium, 
ipratropium) are not commonly used. 
Inhaled anticholinergic agents improves dyspnoea, 
exacerbation rates, exercise capacity and health 
status 
Antibiotics are rarely indicated to manage 
exacerbations 
The use of antibiotics is often appropriate in the 
management of exacerbations 
 
Differences in these diseases can be found in the goals of treatment. In asthma, 
treatment should be aimed at primarily achieving normal or near-normal lung function 
and preventing symptoms, which allows patients to live a relatively normal life.16 In 
COPD, the goal of therapy is to reduce the progressive nature of the disease with a 
focus on reducing symptoms and exacerbations while improving physical functioning 
and quality of life.360 Basically, the pharmacological treatment of asthma is driven by 
the need to suppress the chronic inflammation, whereas in COPD, pharmacological 
treatment is driven by the need to reduce symptoms.417 
While consensus-based management guidelines for asthma and COPD acknowledge 
that the two diseases may co-exist, succinct treatment recommendations for mixed cases 
are lacking. Management should therefore be tailored to the individual’s symptoms, 
physical functioning and frequency of exacerbations. Future research is required to 
determine whether patients with coexisting signs of asthma and COPD may benefit 
from management strategies that are based on multiple functional, morphologic and 
immunologic assessments rather than a categorisation into rigid diagnostic labels of 
either asthma or COPD.433 
Tailoring treatment to individual patients and assessing its benefits carefully should 
maximise quality of life, reduce adverse effects of medication, optimise physical 
function and better prepare patients for exacerbations.434 Adapting management 
strategies to meet the individual patient’s needs should be the overriding consideration 
in achieving better outcomes for patients with obstructive airways disease. 
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4.3 Burden of COPD 
COPD is an important cause of morbidity, mortality and healthcare costs worldwide. 
Estimates from the World Health Organisation’s Global Burden of Disease and Risk 
Factors project estimated that COPD was the fifth leading cause of death worldwide in 
2001435 and will be the third leading cause by 2020.436 The World Health Organisation 
estimates that more than 2.5 million people die of COPD each year, which is about the 
same mortality rate as HIV/AIDS. Many sources of variation can affect estimates of 
COPD prevalence, including sampling methods, response rates and quality of 
spirometry.360 Despite these complexities, data is emerging that enable some 
conclusions to be drawn regarding COPD prevalence. The Burden of Obstructive Lung 
Disease (BOLD) initiative developed standardised materials for estimating COPD 
prevalence using post-bronchodilator spirometry testing plus questionnaires about 
respiratory symptoms, health status and exposure to COPD risk factors.437 It was 
estimated the worldwide prevalence of stage II or higher COPD for people aged 40 
years or older to be 10.1% overall, 11.8% for men and 8.5% for women.393,394 
Furthermore, there is evidence that the prevalence of COPD (stage I) is appreciably 
higher in smokers and ex-smokers than in non-smokers, in those over 40 years than 
those under 40, and in men than in women.438 
COPD is currently the tenth leading cause of disease burden in the world, causing 
approximately 2% of the entire global burden of disease.439 It is expected that COPD 
will move up to the fifth leading cause of disease burden by 2020,440 unless action is 
take to control leading risk factors for the disease.  
COPD is also a significant health problem in Australia. Estimates from the 2004-05 
National Health Survey indicated that about 2.9% of the Australian population had 
emphysema or bronchitis, with the prevalence rising to 7.8% by the age of 75 years and 
over (Figure 29).8 
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Figure 29. Number with emphysema/bronchitis per 1,000 population, Australia 2004-058 
 
Figure 29 displays a higher than expected prevalence in people ages less than 40 years, 
possibly due to the reliance on self-report of the broadly defined conditions of chronic 
bronchitis and emphysema. More recent estimates from the Australian part of the 
BOLD population-based prevalence study suggest a prevalence of 9.3% in those aged 
40 years or older.437 
Among Australians aged 55 years and over, COPD is a far more common cause of 
deaths and hospitalisations than asthma. The Australian Centre for Asthma Monitoring 
reported that COPD accounts for ten times more deaths and six times more 
hospitalisations than asthma.441 With 4,761 deaths attributed to it in 2006,8 COPD is a 
major cause of death in Australia, ranking fifth among the common causes of death in 
the country.2 Furthermore, COPD is associated with a level of disability in about 34% 
of sufferers, rising to 68% in those aged 65 years and over,2 and it is the third leading 
cause of burden of disease in Australia.442 
Because of the high prevalence of the disease and the potential for severe disability, 
COPD represents a substantial economic and social burden. In 2008, the financial cost 
of COPD was $8.8 billion.7 Of this, $6.8 billion (76.6%) was productivity lost due to 
lower employment, absenteeism and premature deaths of Australians with COPD. 
In the past, imprecise and variable definitions of COPD, as well as under-recognition 
and under-diagnosis, have made it difficult to quantify the prevalence, morbidity and 
mortality of the condition. Despite the escalating problem, COPD has been an orphan 
disease over the past two decades, worldwide and in Australia.443 This has been 
attributed to a lack of knowledge about the disease, a negative attitude towards the 
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disease (because of its mainly self-inflicted nature), a perceived lack of effective drug 
treatments and limited success with prevention. Fortunately, research into COPD and its 
management has increased substantially since the 1990s (Figure 30), and with this has 
come an increased awareness of the condition. The global burden of COPD has finally 
been recognised, with the development of evidence-based management guidelines over 
the last decade.360,443 However, the challenge remains to improve the recognition and 
management of COPD. 
Figure 30. Number of articles listed in PubMed under the search terms ‘COPD’ OR ‘emphysema’ 
OR ‘chronic bronchitis’ between 1965 and 2005444 
Ferguson carried out an in-depth comparison of the ATS,
ERS, and BTS guidelines in 2000.30 He noted that while
the ATS document was the most comprehensive and thor-
oughly referenced of the three (the others consisting more
of overviews), all relied primarily on consensus opinion
and empirical recommendations, and none was explicitly
evidence-based. The target audience for the ERS guideline
was respiratory specialists, whereas the ATS and BTS
guidelines were intended for use by generalists and spe-
cialists in other disciplines. Overall, Ferguson found a high
degree of agreement between the 3 CPGs with respect to
both subjects covered and areas emphasized. However, as
he pointed out, there were important differences in spiro-
metric criteria for mild, moderate, and severe obstruction
(Table 1). A patient with a forced expiratory volume in the
first second (FEV1) of 45% of the predicted value would
be classified as having severe disease by ERS criteria, but
moderate disease by ATS and BTS criteria. Similarly, with
an FEV1 of 55% of predicted, the same patient would have
moderate disease according to the BTS and the ERS but
only mild disease according to the ATS.
Although the ATS,15 BTS,21 and ERS16 guidelines agreed
in general with respect to pharmacologic therapy for pa-
tients with clinically stable COPD, there were differences
among them that implied differences in management. All
recommended inhaled short-acting bronchodilators as pri-
mary therapy for airflow obstruction. However, the BTS21
and ERS16 documents provided no recommendation for
the choice between ! agonists and anticholinergics (while
noting the greater potential for adverse effects with the
former), whereas the ATS guideline15 recommended! ago-
nists for as-needed use and anticholinergics for scheduled
administration. Long-acting inhaled bronchodilators were
described by the ATS and ERS as potentially useful for
nighttime awakening and early-morning symptoms, while
the BTS cited a need for further studies before any rec-
ommendation could be made. The ATS was more support-
ive of theophylline as a second-line therapeutic agent than
were either the BTS or the ERS. All 3 guidelines recom-
mended long-term oral corticosteroid administration only
for patients shown to respond favorably to these agents.
With respect to inhaled corticosteroids, the BTS and ERS
guidelines recommended them if patients were proven “re-
sponders,” whereas the ATS made no recommendation,
pending further study results.
A thoughtful analysis of COPD CPGs released during
the 1990s was published by Lacasse and colleagues.31 In
their evaluation of 15 guidelines,13–25,28,29 they found sev-
eral areas of potentially important disagreement. These
areas included the preferential use of ! agonists versus
anticholinergics for first-line bronchodilator therapy, the
indications for mucolytic agents, the role of inhaled cor-
ticosteroids, the use of oxygen therapy for patients with
transient desaturation during sleep or exercise, and recom-
mendations for lung-volume-reduction surgery. In agree-
ment with earlier data on CPGs in general,32 Lacasse et al
found that currently available guidelines for COPD were
not evidence-based and probably reflected “the biases of
selective experience rather than scientific knowledge.”31
Lacasse and associates also found shortcomings in the
clarity and readability of the guidelines. They pointed out
that, while the ideal method for guideline development
was uncertain, most would probably agree that explicitly
stating each recommendation and identifying the level of
evidence upon which it is based, using a standardized
scheme, should be included. These authors also called for
provision for regular updates to the guidelines, for specific
attention to how the guidelines are to be implemented, and
for investigation into the impacts of this implementation
on clinical practice and patient outcomes.
In 1998, the National Heart, Lung, and Blood Institute
and the World Health Organization convened a workshop
to address the inconsistencies and shortcomings of previ-
ous COPD guidelines, as well as to develop strategies for
wider guideline dissemination and implementation. Work-
Fig. 1. Total number of articles listed in PubMed under the search
terms “COPD OR emphysema OR chronic bronchitis” for each
5-year period between 1965 and 2005 (through November 21,
2005). The white bars represent articles in English, and the hatched
bars represent all cited articles.
Table 1. Comparison of Spirometric Criteria for Disease Severity in
3 Prominent COPD Guidelines From the Mid-1990s, Using
FEV1 as a Percentage of the Predicted Value
Severity
FEV1 Percent of Predicted
ATS BTS ERS
Mild " 50 " 60 " 70
Moderate 35–49 40–59 50–69
Severe ! 35 ! 40 ! 50
COPD " chronic obstructive pulmonary disease
FEV1 " forced expiratory volume in the first second
ATS " American Thoracic Society COPD guideline15
BTS " British Thoracic Society COPD guideline21
ERS " European Thoracic Society COPD guideline16
REVIEW AND COMPARISON OF COPD PRACTICE GUIDELINES
RESPIRATORY CARE • MARCH 2006 VOL 51 NO 3 279
 
4.4 Guidelines for the management of COPD 
In 1998, in an effort to bring more attention to COPD, its management and its 
prevention, the US National Heart, Lung and Blood Institute and the World Health 
Organisation formed the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD).360 The GOLD Expert Panel consisted of health professionals from around the 
world with expertise in respiratory medicine, epidemiology, socioeconomics, public 
health and health education.445 The model for this initiative was the Global Initiative for 
Asthma, an international strategy for developing comprehensive evidence-based 
guidelines on asthma control and management using a committee of experts.16 The 
central objectives of GOLD are to: 
• Increase awareness of COPD amongst governments, public health officials, 
healthcare workers and the general public; 
All cited articles 
Articles in English 
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• Improve prevention and management of the disease; 
• Decrease COPD morbidity and mortality; and  
• Encourage new research into the disease.360 
In 2001, GOLD published a consensus report outlaying recommendations for the 
diagnosis, management and prevention of COPD. Importantly, the report includes 
grades for the weight of scientific evidence supporting each recommendation. The 
GOLD strategy presents a COPD management plan divided into four components:  
• Assessment and monitoring of disease;  
• Reduction of risk factors;  
• Management of stable COPD; and  
• Management of exacerbations.  
Information and recommendations presented in the GOLD report are based on “the best-
validated current concepts of COPD pathogenesis and the available evidence on the 
most appropriate management and prevention strategies.”360 The report is updated 
annually to reflect changing evidence in best practice. 
In recognition of the significant burden that COPD places on the Australian community, 
the Australian Lung Foundation and Thoracic Society of Australia and New Zealand 
developed clinical practice guidelines to improve the diagnosis and management of 
COPD, called COPD-X (Table 53).446 The guidelines, based upon the GOLD strategy 
for COPD diagnosis, management and prevention, aim to affect changes in clinical 
practice based on sound evidence and shift the emphasis from a predominant reliance on 
pharmacological treatment of COPD to a range of interventions which include patient 
education, self-management of exacerbations and pulmonary rehabilitation.446  
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Table 53. Summary of the COPD-X guidelines443 
C: Confirm diagnosis and assess severity Evidence* 
Smoking is the most important risk factor for COPD Level I 
Consider COPD in patients with other smoking-related diseases Level I 
Consider COPD in all smokers and ex-smokers older than 35 years Level II 
The diagnosis of COPD rests on the demonstration of airflow limitation which is 
not fully reversible Level II 
O: Optimise function Evidence*  
Inhaled bronchodilators provide symptom relief in patients with COPD and may 
increase exercise capacity Level I 
Long-acting bronchodilators provide sustained relief of symptoms in moderate-to-
severe COPD Level I 
Long-term use of oral corticosteroids is not recommended Level I 
Inhaled corticosteroids should be considered in patients with a documented 
response or those who have severe COPD with frequent exacerbations Level II 
Pulmonary rehabilitation reduces dyspnoea, anxiety and depression, improves 
exercise capacity and quality of life and may reduce hospitalisation Level I 
P: Prevent deterioration Evidence*  
Smoking cessation reduces the rate of decline of lung function Level I 
General practitioners and pharmacists can help smokers quit Level I 
Treatment of nicotine dependence is effective and should be offered to smokers Level I 
Pharmacotherapies double the success of quit attempts; behavioural techniques 
further increase the quit rate by up to 50% Level I 
Influenza vaccination reduces the risk of exacerbations, hospitalisation and death Level I 
Inhaled corticosteroids are indicated for patients with a documented response or 
who have severe COPD with frequent exacerbations Level II 
Mucolytics may reduce the frequency and duration of exacerbations Level I 
D: Develop a support network and self-management plan Evidence* 
Pulmonary rehabilitation increases patient/carer knowledge base, reduces carer 
strain and develops positive attitudes towards self-management and exercise Level I 
COPD imposes handicaps which affect both patients and carers Level II 
Multidisciplinary care plans and individual self-management plans may help to 
prevent or manage crises Level II 
X: Manage eXacerbations Evidence* 
Inhaled bronchodilators are effective treatments for acute exacerbations Level I 
Oral corticosteroids reduce the severity of and shorten recovery from acute 
exacerbations Level I 
Exacerbations with clinical signs of infection (increased volume and change in 
colour of sputum and/or fever, leukocytosis) benefit from antibiotic therapy Level II 
Multidisciplinary care may assist home management Level II 
*Level I evidence = systematic review of RCTs, level II evidence = one or more RCTs. 
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Despite widely distributed evidence-based management guidelines, knowledge of and 
adherence to the guidelines amongst doctors remains suboptimal.4,447-451 Multiple 
studies demonstrate that doctors are often slow to adopt best clinical practices into their 
daily patterns of care,78 and patients do not have the resources to recognise the gaps 
between available care and the care they receive.452 Existing COPD guidelines have 
depended largely on diffusion and dissemination of their recommendations.453 However, 
only the GOLD guidelines designed an implementation strategy concurrently with the 
guidelines.454 
Disseminating guidelines requires an appreciation of the issues that prevent translation 
of guideline definitions of best practice into improved patient care.454 Few data exist 
regarding attitudes towards existing COPD guidelines amongst doctors. In the 
Netherlands, Jans et al. began a guideline implementation project that first assessed 
barriers to acceptance of COPD and asthma guideline recommendations among 
GPs.455,456 They then designed an implementation strategy to overcome these barriers 
and promote guideline adherence in a randomised, controlled trial. One year after the 
project started, they found greater adherence to guideline recommendations and 
improved patient outcomes, as measured by lung function and symptom scores.  
Although some COPD is managed satisfactorily in the community, there is still room 
for substantial improvement.4 Clearly, there needs to be further research into effective 
ways of educating patients, doctors and the general community about COPD. 
4.5 Slowing lung function decline in COPD: smoking cessation 
Smoking cessation is the single most effective, and cost-effective, intervention in most 
people to reduce the risk of developing COPD and stop its progression.360 While there is 
evidence from epidemiological studies that non-smokers can develop chronic airflow 
obstruction,457,458 tobacco smoke remains the most important cause of COPD 
worldwide, with up to 50% of smokers being noted to develop the condition.390 FEV1 
declines at about 60 mL per year in susceptible smokers, compared to the decline with 
normal aging of about 30 mL per year in non-smokers.459 The accelerated decline in 
lung function is related to current and past exposure to cigarette smoke. For example, 
evidence has shown that current smokers have a steeper decline in lung function than 
ex-smokers, while ex-smokers have a steeper decline than people who have never 
smoked.460 If a susceptible smoker stops smoking, he/she will not recover lost lung 
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function, but the subsequent rate of decline in lung function is likely to revert to normal 
(Figure 31).461  
Figure 31. Time-course of COPD461 
 
*The figure shows the rate of loss of FEV1 for a hypothetical, susceptible smoker, and the potential effect 
of stopping smoking early or late in the course of COPD. Other susceptible smokers will have different 
rates of loss, thus reaching ‘disability’ at different ages. The normal FEV1 ranges from below 80% to 
above 120%, so this will affect the starting point for the patient’s data. 
Smoking cessation is the only evidence-based treatment that has been proven to slow 
down the development of COPD by preventing further deterioration of lung function. 
The most rigorous evaluation of smoking cessation and the rate of decline in lung 
function was the US Lung Health Study. In a prospective RCT, 5,887 smokers with 
mild-to-moderate airway obstruction were randomised to one of two smoking cessation 
groups (smoking cessation ± ipratropium therapy) or to a control group. Participants in 
the two smoking intervention groups showed significantly smaller declines in FEV1 
than those in the control group.462 Participants who stopped smoking experienced an 
improvement in FEV1 in the year after quitting (an average of 47 mL or 2%). The 
subsequent rate of decline in FEV1 among sustained quitters was half the rate among 
continuing smokers, 31 mL versus 62 mL, comparable to that of never-smokers.463 
Interestingly, further follow-ups showed that participants who made several attempts to 
quit smoking, even with subsequent relapses, had less loss of lung function at 
comparable cumulative doses of cigarettes than those who continued to smoke.464 
However, reductions of up to 50% in smoking amount had no observable effect on the 
decline in FEV1.465 
* 
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There is also evidence that the slowed decline in FEV1 is sustained years after quitting. 
An 11-year follow-up of the Lung Health Study demonstrated that differences in lung 
function between treatment groups persisted; sustained quitters had an FEV1 rate of 
decline of 26.7 mL per year, intermittent quitters lost 47.5 ml year, and those who 
continued to smoke throughout the 11 years declined by 60.0 mL per year.466  
A 14.5-year follow-up on mortality among participants from the Lung Health Study 
showed that death rates were significantly higher in the usual care group than in the 
intervention groups (10.38 per 1000 person-years versus 8.83 per 1,000 person-years; 
P < 0.05). When survival was analysed according to smoking habit, mortality was 6.04 
per 1,000 person-years in sustained quitters, 7.77 per 1,000 person-years in intermittent 
quitters and 11.09 per 1,000 person-years in continuing smokers. Death rates were 
significantly related to smoking habit from coronary heart disease (P < 0.05), 
cardiovascular disease (P < 0.001), lung cancer (P < 0.01) and other causes 
(P < 0.05).467 
In addition to preventing accelerated decline in lung function, smoking cessation has 
been shown to significantly improve respiratory symptoms468 and airway hyper-
responsiveness469 in patients with COPD. The role of smoking cessation on underlying 
inflammatory processes in the lungs is less clear. Data from well-designed studies 
regarding the effects on inflammation and remodelling are lacking, and the few 
available studies show contradictory results.470 It has been shown that bronchial 
epithelial remodelling was reduced by smoking cessation;471 however, acute 
inflammatory processes are ongoing,471-473 which may simply reflect a repair process 
but not ongoing damage to the lung tissue.470 
The GOLD guidelines recommend that all smokers, including those who may be at risk 
for COPD as well as those who already have the disease, should be offered the most 
intensive smoking cessation intervention feasible.360 Currently, accepted best practice is 
summarised by a five-step plan for intervention, published by the US Public Health 
Service (Table 54).474 The plan provides a strategic framework helpful to healthcare 
professionals interested in helping their patients to stop smoking. Cessation of smoking 
is a process rather than a single event, and smokers move between various stages of 
being not ready, unsure, ready, quitting and relapsing before achieving long-term 
success. The aim of initial intervention is to advance one stage in the cessation cycle.443 
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For a patient ready to quit, appropriate treatment should be initiated, with the 
formulation of a quit plan. For a patient not ready to make a quit attempt, a brief 
intervention designed to promote the motivation to quit should be provided.475 
Table 54. Brief strategies to help a willing patient to quit smoking474 
1. ASK - systematically identify smokers at every visit 
Implement an office-wide system that ensures that, for every patient at every visit, smoking status is 
queried and documented. 
2. ADVISE - strongly urge all smokers to quit 
In a clear, strong and personalised manner, urge every smoker to quit. 
3. ASSESS - determine willingness to make a quit attempt 
Ask every smoker if he or she is willing to make a quit attempt at this time (e.g. within the next 30 
days). 
4. ASSIST - aid the patient in quitting 
Help the patient with a quit plan; provide practical counselling; provide intra-treatment social support; 
recommend the use of approved pharmacotherapy unless contraindicated; provide supplementary 
materials. 
5. ARRANGE - schedule follow-up contact 
Schedule follow-up contact; whether in person or via telephone. 
 
There is good evidence that health professionals can substantially increase quitting and 
readiness to quit in the population. Even a brief (three-minute) period of counselling to 
urge a smoker to quit results in smoking cessation rates of 5-10%.476 Furthermore, 
collaborative efforts among health professionals are more effective than interventions 
by only one type of health professional; a survey of 1,723 smokers found that being 
asked about smoking by two or more types of professionals substantially increased the 
odds of recent quitting (OR 2.37; 95% CI 1.15-4.88).477 
Pharmacotherapy is an important cornerstone in the treatment of nicotine dependence. 
Various forms of nicotine replacement therapy (NRT) (chewing gum, transdermal 
patches, inhalers, sublingual tablets and lozenges) are effective and well tolerated. 
Various forms of NRT increase the rate of quitting by 50-70%.478 Antidepressants, such 
as bupropion and nortriptylline, and nicotine receptor partial agonists, such as 
varenicline, are also very effective, but a not as well tolerated than NRT.479,480 It is 
imperative that smoking cessation interventions involve combinations of psychological 
and social support mechanisms, in addition to pharmacotherapy. A systematic review of 
RCTs on smoking cessation interventions conducted on patients with COPD, concluded 
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that combination treatment (psychosocial plus pharmacological intervention) is superior 
to no treatment or psychosocial intervention alone.481 
4.6 Self-management plans for COPD 
Self-management interventions improve various outcomes for many chronic 
conditions.482 Providing an individualised written self-management plan is a high-
profile part of the fourth step of the COPD-X Plan: “develop a support network and 
self-management plan.”443 Research in self-management plans for COPD is relatively 
new, and variable results have been reported in the literature. The concept of self-
management plans for patients with COPD is derived from their success in asthma 
management indicating doses and medications to take for maintenance therapy and for 
exacerbations. Instructions for crises are often included (Figure 32). 
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Figure 32. COPD self-management plan template483 
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Much of the evidence on self-management programs for COPD comes from a Canadian 
multifaceted self-management program, ‘Living Well with COPD,’ which was one of 
the first studies to produce conclusive results.484 The multicentre RCT involved 191 
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patients from seven hospitals, and provided evidence that a multi-component, skill-
oriented disease-specific self-management program can improve both short- and long-
term health outcomes of COPD. The trial evaluated an intervention consisting of a 
comprehensive patient education program administered through weekly visits by trained 
health professionals over a two-month period with monthly telephone follow-up. After 
12 months, hospital admissions for exacerbations of COPD were reduced by 39.8% in 
the intervention group compared to the usual care group (P < 0.05), and admissions for 
other health problems were reduced by 57.1% (P < 0.05). ED visits were reduced by 
41.0% (P < 0.05) and unscheduled physician visits by 58.9% (P < 0.01). A two-year 
follow-up of the intervention demonstrated a reduction in all-cause hospitalisations of 
26.9% and in ED visits of 21.1% in the intervention group as compared to the usual care 
group.485 In addition, the program demonstrated obvious economic benefits due to 
decreased healthcare utilisation costs.486 The ‘Living Well with COPD’ program has 
been approved by the ministry of Québec and has since been implemented in all the 
regions of the province.487 Most of the health professionals in Québec use this evidence-
based program to educate their COPD patients. 
 However, a similar RCT of a self-management intervention involving a skill-oriented 
patient education program and near-home fitness program failed to show any positive 
effects.488 No differences in quality of life, symptoms or walking distance were reported 
between the intervention (n = 127) or control (n = 121) patients. A systematic review on 
self-management education for patients with COPD could not draw any conclusions 
about its effectiveness because of the large variation of outcome measures used in a 
limited number of included studies, and noted that there is an evident need for more 
large RCTs with a long-term follow-up, before more conclusions can be drawn.489 
A systematic review showed that action plans used in COPD have positive effects on 
self-management knowledge, and help patients recognise and react appropriately to an 
exacerbation by promptly self-initiating antibiotics and oral corticosteroids.490 However, 
there was no evidence that these changes to patient behaviour significantly reduce 
morbidity, healthcare utilisation or mortality.  
For example, a RCT of structured one-hour education sessions on the use of a written 
self-management plan and patient-initiated short courses of antibiotics and oral 
corticosteroids failed to show any added health benefit, in terms of health utilisation, or 
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self-reported outcomes, compared to usual care.491 A retrospective cohort study 
assessing the effect of prescription of antibiotics and oral corticosteroids at the time of 
issuing a self-management plan also reported disappointing findings. Whilst all patients 
received a self-management plan and education, approximately half also received a 
prescription for self-administered antibiotics and oral corticosteroids. The increased use 
of antibiotics and/or oral corticosteroids in this subgroup were not mirrored by a 
reduction in unplanned medical attendances and clearly raised concerns that patient 
initiation without consultation may not be appropriate.492 Similarly, a recent systematic 
review of five RCTs (574 patients) found evidence that action plans with limited COPD 
education aid recognition of, and response to, an exacerbation with initiation of 
antibiotics and corticosteroids. However, there was no evidence of reduced utilisation of 
healthcare resources or improved health-related quality of life.493 
There is some evidence, however, that early treatment of COPD exacerbations may 
improve outcomes. An uncontrolled study of 128 patients with COPD who recorded 
respiratory symptoms daily and were encouraged to report exacerbations to the study 
team or their GP, found that earlier treatment was associated with a faster recovery 
(regression coefficient 0.42 days/days delay; P < 0.001).494 However, the prescription 
(oral corticosteroids and/or antibiotics) of treatment for all exacerbations was at the 
discretion of the attending physician, rather than through guided self-management. 
The COPD-X Plan states that perhaps the reason for the disappointing findings 
regarding self-management of COPD is that “pharmacological treatment of COPD is 
generally less effective [as compared to pharmacological treatment of asthma] as the 
condition is, by definition, non-reversible.”443 The findings of these trials suggest that 
more intensive education and support may be required to significantly impact COPD 
outcomes. 
4.7 Pulmonary rehabilitation 
The non-pharmacological therapy of COPD, such as smoking cessation, education on 
adherence to medical therapy and collaborative self-management strategies can be given 
together in the form of a comprehensive outpatient pulmonary rehabilitation program.  
Pulmonary rehabilitation is defined as: 
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“...An evidence-based, multidisciplinary and comprehensive 
intervention for patients with chronic respiratory diseases who 
are symptomatic and often have decreased daily life activities. 
Integrated into the individualised treatment of the patient, 
pulmonary rehabilitation is designed to reduce symptoms, 
optimise functional status, increase participation and reduce 
healthcare costs through stabilising or reversing systemic 
manifestations of the disease.”495  
Pulmonary rehabilitation programs involve patient assessment, exercise training 
education, nutritional intervention and psychosocial support.496 The components of 
pulmonary rehabilitation are shown in Table 55. 
Table 55. Components of comprehensive pulmonary rehabilitation programs496 
1. Education, including self-management strategies 
2. Upper and lower extremity exercise training, resistance training 
3. Psychosocial support, when indicated 
4. Encouragement of activity and exercise in the home setting 
5. Outcome assessment 
6. Promotion of long-term adherence 
 
Although pulmonary rehabilitation has not been shown to have a substantial effect on 
the specific respiratory impairment in COPD,497 a large body of scientific evidence 
demonstrates its beneficial effects over multiple outcome areas. A RCT in the United 
Kingdom assessed the effect of outpatient pulmonary rehabilitation on the use of 
healthcare services and patients’ wellbeing over one year.498 There was no difference 
between the rehabilitation (n = 99) and control (n = 101) groups in the number of 
patients admitted to hospital (40 versus 41) but the number of days patients spent in 
hospital differed significantly (10.4 ± 9.7 versus 21.0 ± 20.7, P < 0.05). Compared with 
the control, the rehabilitation group also showed greater improvements in walking 
ability and in general and disease-specific health status. 
A systematic review of 31 RCTs examining the effects of pulmonary rehabilitation for 
COPD on health-related QOL and exercise capacity reported that in four important 
domains of QOL (Chronic Respiratory Questionnaire499 scores for dyspnoea, fatigue, 
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emotional function and mastery), the effect was larger than the minimal clinically 
important difference of 0.5 units (e.g. dyspnoea score: weighted mean difference = 1.0 
units, 95% CI 0.8-1.3 units, n = 12 trials).500 For functional and maximal exercise 
capacity, the effect was small and slightly below the threshold of clinical significance 
for the six-minute walking distance (weighted mean difference = 48 metres, 95% CI 32-
65, n = 16 trials). The authors concluded that the improvements for all outcomes were 
moderately large and clinically significant, and that the results strongly support 
pulmonary rehabilitation as part of the spectrum of the management of patients with 
COPD. The Australian Lung Foundation maintains a comprehensive national database 
of programs and can supply contact details for programs Australia-wide. Patients can 
enter a program either by asking for a referral from their GP and/or respiratory 
specialist. Many programs will also accept patients who contact them directly.  
4.8 Pharmacological therapy 
4.8.1 Inhaled bronchodilators 
The COPD-X Guidelines state “inhaled bronchodilators provide symptom relief in 
patients with COPD and may increase exercise capacity.”443 Inhaled bronchodilators 
include short- and long-acting beta-2 agonists, and short- and long-acting 
anticholinergics.  
A systematic review of four RCTs comparing the short-acing anticholinergic 
ipratropium with SABAs for acute exacerbations of COPD found no evidence that the 
degree of bronchodilation achieved with ipratropium was greater than that using a 
SABA.501 However, a systematic review of eleven RCTs (3,912 patients) comparing 
regular long-term use of ipratropium alone, or in combination with SABAs in stable 
COPD found small benefits for regimens containing ipratropium.502 There was a small 
difference in favour of ipratropium (of borderline statistical significance) between 
treatments in the baseline/pre-bronchodilator FEV1 measured at the end of the studies 
(mean difference 30 mL, 95% CI 0-60). Ipratropium was associated with a small but 
significant improvement in the baseline FVC measured at the end of the studies 
compared with SABAs (mean difference 70 mL, 95% CI 10-140). Combination therapy 
with ipratropium plus a SABA conferred benefits over a SABA alone in terms of post-
bronchodilator lung function. There was no significant benefit of combination therapy 
in subjective improvements in QOL, but there was a reduction in the requirement for 
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oral steroids. The authors noted that where there were benefits in favour of ipratropium, 
they were small and would not support a general recommendation for the use of 
ipratropium over a SABA in COPD, and patients should use the short-acting 
bronchodilator that gives them the most improvement in their symptoms. 
LABAs and long-acting anticholinergics cause prolonged bronchodilation, for 12 and 
24 hours respectively, and are thus often preferred to shorter acting agents. A systematic 
review of seven RCTs (2,652 patients) comparing the efficacy of LABAs with 
ipratropium found a greater increase in FEV1 (mean difference 60 mL, 95% CI 0-110) 
and morning PEF (mean difference 10.96 L per minute, 95% CI 5.83-16.09).503 There 
were no significant differences between ipratropium and salmeterol for QOL, functional 
capacity, symptoms, acute exacerbations or adverse effects. 
A systematic review of nine RCTs (6,584 patients) comparing the long-acting 
anticholinergic tiotropium to other bronchodilators used for stable COPD found that 
tiotropium reduced the odds of a COPD exacerbation (OR 0.74, 95% CI 0.66-0.83) and 
related hospitalisations (OR 0.64, 95% CI 0.51-0.82) compared to placebo or 
ipratropium.504 Reductions in these endpoints compared to LABAs were not statistically 
different. However, increases in lung function tests from baseline were significantly 
larger with tiotropium than with placebo, ipratropium and LABAs over 6-12 months.  
A retrospective analysis of one-year placebo-controlled trials indicated that tiotropium 
had the potential to slow the rate of decline in FEV1.505 In 921 patients, the mean 
decline in FEV1 in the first six months was 58 mL per year in the placebo group and 
12 mL per year in the tiotropium group (P < 0.01), and in the second six months was 
59 mL per year in the placebo group and 19 mL per year in the tiotropium group 
(P < 0.05) These findings led to the design of a trial to prospectively extend these 
observations to four years.506 The long-term benefits of tiotropium compared to placebo 
were recently demonstrated in the UPLIFT trial.507 A total of 5,993 patients were 
randomly assigned to receive tiotropium or placebo, plus any other respiratory 
medication, with the exception of inhaled anticholinergics, as indicated. Mean absolute 
improvements in FEV1 in the tiotropium group were maintained throughout the trial, as 
compared with the placebo group (P < 0.001). However, after day 30, the differences 
between the two groups in the rate of decline in FEV1 were not significant.507 
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The advantage of tiotropium is that it maintains bronchodilation for at least 24 hours, 
allowing once-daily administration. In Australia, tiotropium is currently the only long-
acting bronchodilator monotherapy subsidised on the Pharmaceutical Benefits Scheme 
for COPD.508 
Over the past decade, the cardiovascular adverse effects associated with inhaled 
anticholinergic medications have been debated. A media release from the US Food and 
Drug Administration (FDA) and the manufacturer of tiotropium (Boehringer Ingelheim) 
to healthcare practitioners in 2008 raised alarms about a possible increased risk of 
stroke in patients using tiotropium. Pooled analysis from 29 RCTs estimated that the 
risk of stroke was 8 per 1,000 patients treated for one year with tiotropium, and 6 per 
1,000 patients treated for one year with placebo.509 The FDA warned that these 
preliminary results should be interpreted with caution, as while the analysis provided 
early information about potential safety issues, it had inherent limitations and further 
investigation using other data sources was required.  
Following this warning, three publications highlighted concerns related to the use of 
inhaled anticholinergic medications and cardiovascular safety.510-512 The most important 
of these was a systematic review and meta-analysis by Singh et al. which seemed to 
indicate a significantly increased risk in the primary outcome (the combined incidence 
of cardiovascular death, myocardial infarction or stroke amongst people with COPD 
using inhaled anticholinergic medications; 1.8% versus 1.2% [P < 0.001] for people 
using inhaled anticholinergic medication and control medication, respectively).512 The 
data for this meta-analysis came from over 13,000 participants enrolled in 17 trials. 
Among the individual components of this outcome, only the increased risk of stroke 
failed to reach statistical significance. All-cause mortality remained unaffected. This 
study included selected RCTs of any inhaled anticholinergic medication for the 
treatment of COPD where participants received at least 30 days of treatment and were 
assessed for cardiovascular events. This meta-analysis was criticised on a number of 
grounds.513-516 None of the included trials were designed to specifically target 
cardiovascular risks, and these events were not defined or assessed consistently across 
the included trials. The majority of trials were small and of short duration, which 
resulted in few events occurring. The meta-analysis was also criticised for combining 
the results of placebo-controlled and active-controlled trials and not taking into account 
varying treatment discontinuation rates within trials. Interestingly, when data from only 
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trials involving tiotropium were considered, there was no statistically significant 
difference in adverse cardiovascular outcomes compared to control, while there was a 
statistically significant increase in the incidence of adverse cardiovascular outcomes 
when ipratropium was compared to control.  
Fortunately, additional data is now available to address this area of uncertainty. Firstly, 
the UPLIFT study, which compared long-term tiotropium to placebo in almost 6,000 
patients with COPD who were not already taking inhaled anticholinergic 
medications.507 Patients were at least 40 years of age and had a FEV1 of 70% of less 
after bronchodilation. The occurrences of serious adverse events (including 
cardiovascular events) were included as secondary endpoints of the study. There was no 
increase in the risk of adverse cardiovascular events in this study; in fact, the rate of 
serious adverse cardiac events was statistically significantly lower in patients receiving 
tiotropium. Secondly, the cardiovascular safety of tiotropium was recently evaluated in 
an analysis of data from 30 RCTs of greater than four weeks duration comparing 
tiotropium to placebo.517 Patients from these trials were included if they had spirometry-
confirmed COPD, ! 10 pack-year smoking history and age ! 40 years. Importantly, 
standardised assessment of adverse events was conducted (this was an important 
criticism of the previous meta-analysis). More than 19,000 patients from these trials 
were included. In this meta-analysis, tiotropium was associated with a reduction in the 
risk of all-cause mortality, cardiovascular mortality and cardiovascular events. In light 
of these recent results, the FDA issued a follow-up to their previous early 
communication regarding tiotropium, making the following statement: 
“The available data do not support an association between the 
use of Spiriva® (tiotropium) and an increased risk for these 
serious adverse events (stroke, myocardial infarction or death 
from a cardiovascular cause).”518 
Recent data concerning the cardiovascular outcomes associated with the use of short-
acting inhaled anticholinergics is not so positive. Given the investment required, it is 
unlikely that prospective trials to define the cardiovascular safety of inhaled ipratropium 
will ever be conducted. Therefore, healthcare professionals must consider the results of 
the Singh et al. meta-analysis, conducted in 2008,512 and additional data from recent 
cohort studies519 which raise concerns that its use might be associated with a small 
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increase in the risk of adverse cardiovascular events. The reasons for this apparent 
discrepancy are unknown. Pharmacologically, it is not clear why short-acting inhaled 
anticholinergic medications would affect the cardiovascular system differently than 
longer-acting agents. Regardless of the most recent trial data, the following statement 
seems to be a useful clinical viewpoint from a US medical specialist: 
“Patients with COPD who are taking long-term anticholinergics 
should be closely monitored for the development of the signs 
and symptoms of cardiovascular disease. However, this is best 
practice for almost all patients with COPD, since they are 
already at elevated risk for cardiovascular morbidity and 
mortality.”520 
4.8.2 Inhaled corticosteroids 
The progression of COPD is associated with inflammation.363 The COPD-X guidelines 
recommend that anti-inflammatory drugs such as ICS should be considered in patients 
with a documented response or those who have severe COPD with frequent 
exacerbations.443  
A systematic review of 47 RCTs (13,139 patients) found that long-term use of ICS 
(more than six months) did not significantly reduce the rate of decline in FEV1 
(weighted mean difference 5.80 mL/year with ICS over placebo, 95% CI 0.28-11.88), or 
mortality in COPD patients (OR 0.98, 95% CI 0.83-1.16). However, long-term use of 
ICS reduced the mean rate of exacerbations (weighted mean difference -0.26 
exacerbations per patient per year, 95% CI -1.83 to -10.60), and slowed the rate of 
decline in QOL, as measured by the St George’s Respiratory Questionnaire (weighted 
mean difference -1.22 units/year 95% CI -1.83 to -0.60). The authors concluded that 
patients and health professionals should balance the potential benefits of ICS (reduced 
rate of exacerbations, reduced decline in QOL) against the adverse effects (oral thrush, 
hoarseness and unknown long-term adverse effects).521 
4.8.3 Combination therapy 
Most studies that have explored the value of combination therapy have shown 
significant improvements over single agents alone.522,523 In a six-month RCT of 1,704 
patients with moderate to very severe COPD, the combination of budesonide and 
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eformoterol demonstrated significant improvements in lung function, dyspnoea and 
QOL scores compared to either agent alone.524 Budesonide/eformoterol 320/9 #g 
demonstrated significantly greater improvements in pre-dose FEV1 versus budesonide 
(P = 0.026) and one-hour post-dose FEV1 versus budesonide (P < 0.001) The 
combination therapy had a safety profile comparable with that of the single components 
and placebo. 
The TORCH (TOward a Revolution in COPD Health) study compared salmeterol 50 #g 
plus fluticasone 500 #g with placebo, salmeterol alone or fluticasone alone in 6,112 
patients.525 Compared with placebo, salmeterol and fluticasone in combination reduced 
the risk of death at any time during the three-year study period by 17.5% (P = 0.05). 
The risk of death in the salmeterol group and the fluticasone group did not differ 
significantly from placebo. The salmeterol/fluticasone combination was significantly 
better than each of its components alone in preventing exacerbations, and this benefit 
was accompanied by sustained improvements in health status and FEV1. 
Although to date none of the currently available pharmacological interventions have 
been shown to alter the rate of decline in lung function in COPD patients, in a post hoc 
analysis of the TORCH study, the spirometry results in 5,343 patients over three years 
suggested that the combination of salmeterol/fluticasone 50/500 #g may have a 
beneficial effect on lung function in the medium term.526 Salmeterol plus fluticasone 
reduced the rate of FEV1 decline by 16 mL per year compared with placebo (95% CI 7-
25, P < 0.001). Although the difference was smaller for both fluticasone and salmeterol 
alone compared with placebo (13 mL per year, 95% CI 5-22, P < 0.05), the rates of 
decline were similar among the active treatment arms. 
The INSPIRE (Investigating New Standards for Prophylaxis in Reducing 
Exacerbations) study compared the relative efficacy of salmeterol/fluticasone 50/500 #g 
combination twice daily and tiotropium 18 #g once daily in preventing exacerbations 
and related outcomes in 1,323 patients with severe and very severe COPD.527 
Interestingly, the study showed no difference in reduction of exacerbations between the 
groups, although patients receiving the salmeterol/fluticasone combination had better 
health status as measured by the St. George’s Respiratory Questionnaire (total score 
difference 2.1 units, 95% CI 0.1-4.0; P < 0.05) and had better survival (all-cause 
mortality rate 3% versus 6% with tiotropium, P < 0.05). This was the first study to 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 192 
directly compare an ICS/LABA combination and a long-acting anticholinergic, and has 
important implications for the choice of therapy in the management of severe COPD. 
There is evidence that the addition of fluticasone to tiotropium and salmeterol improves 
COPD outcomes. A study of 449 patients with COPD demonstrated tiotropium plus 
fluticasone/salmeterol improved lung function (P < 0.05) and disease-specific QOL 
(P < 0.05) and reduced the number of hospitalisations for COPD exacerbation (RR 0.53, 
95% CI 0.33-0.86) compared with tiotropium plus placebo.528 In contrast, tiotropium 
plus salmeterol did not statistically improve lung function or hospitalisation rates 
compared with tiotropium plus placebo. 
4.8.4 Methylxanthines 
In practice, methylxanthines are rarely used because of their narrow therapeutic index 
and potential for significant adverse effects. Systematic reviews have provided evidence 
that theophylline improves FEV1529,530 and arterial blood gas tensions530 compared to 
placebo in patients with COPD. All studies that have demonstrated efficacy of 
theophylline in COPD were done with slow release preparations. Low dose (100 mg 
twice daily) slow release theophylline has been shown to reduce exacerbations in 
patients with COPD but does not increase post-bronchodilator lung function.531 
Theophylline may be useful as adjunctive therapy in combination with a LABA in 
carefully selected patients. A 12-week study comparing salmeterol, theophylline, and a 
combination of both in 943 patients with moderate-to-severe COPD showed that the 
combination was more effective than either drug alone.532 Patients taking the 
combination therapy had greater improvements in pulmonary function, greater 
decreases in symptoms, dyspnoea and SABA use and fewer COPD exacerbations 
(P < 0.05 versus theophylline). Salmeterol treatment was associated with fewer drug-
related adverse events than either treatment that included theophylline (P < 0.05). A 
seven-year study of 36,492 patients with COPD found that patients treated with 
theophylline (either alone or in addition to ICS) were less likely to have moderate-to-
severe COPD exacerbations than patient treated with LABA (either alone [OR 0.89, 
95% CI 0.84-0.95] or in addition to ICS [OR 0.89, 95% CI 0.87-0.92]).533 However, 
patients treated with theophylline were more likely to have moderate-to-severe COPD 
exacerbations than patients treated with ICS (RR 1.07, 99% CI 1.04-1.10), and this 
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association was even stronger than patients who had a least three exacerbations in the 
year prior to cohort entry (RR 1.28, 95% CI 1.19-1.38).  
There is currently no evidence supporting the use of methylxanthines for COPD 
exacerbations. A systematic review of four RCTs (169 patients) comparing the efficacy 
of methylxanthines to placebo for COPD exacerbations found no clear indication of 
whether there was benefit in terms of reduced symptoms or hospital admissions, but 
adverse effects were found to be more common with methylxanthines.534 The odds of 
nausea or vomiting were significantly higher for patients receiving a methylxanthine 
(OR 4.6, 95% CI 1.7-12.6) than for patients receiving placebo. Trends toward more 
frequent tremor (OR 1.8, 95% CI 0.7-4.6), palpitations and arrhythmias (OR 4.1, 
95% CI 0.9-19.6) were also observed. 
According to best practice guidelines, theophylline should be considered only for 
patients in whom other treatment has failed to control symptoms adequately (e.g. after a 
trial of short-acting bronchodilators and long-acting bronchodilators), or in patients who 
are unable to use inhaled therapy.443 With close monitoring of individual patients and 
their serum drug levels, it appears that beneficial effects may be obtained in those 
symptomatic from COPD despite first-line bronchodilator therapy. 
4.8.5 Systemic corticosteroids 
Short courses of systemic corticosteroids are recommended for severe exacerbations of 
COPD.443 A systematic review of ten RCTs (921 patients) found significantly fewer 
treatment failures (defined as a return to the ED or doctor’s office, a deterioration of 
COPD leading to change in treatment, or death) within 30 days in patients given 
systemic corticosteroid treatment (OR 0.48, 95% CI 0.34-0.68).535 There were also 
significant improvements in breathlessness and blood gases 6-72 hours after treatment. 
There is also evidence that high doses (! 30 mg) of oral prednisolone improves FEV1 
over a short period (weighted mean difference 53.30 mL, 95% CI 22.21-84.39 after two 
weeks treatment).536 The most appropriate corticosteroid dosage regimen for 
exacerbations of COPD remains controversial, as the regimens used in RCTs differ 
greatly, and clinical and systematic reviews do not provide adequate guidance on these 
regimens.537 Clinical guidelines, in accordance with safety and efficacy data, 
recommend 30 to 50 mg of oral prednisolone daily for up to two weeks.369,443 
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The long-term use of oral corticosteroids for COPD is not recommended.443 A 
systematic review of 24 RCTs found that long-term use did not slow the decline in lung 
function, and increased the risk of adverse effects such as diabetes and osteoporosis.536 
Switching from the use of oral to inhaled corticosteroids is not associated with adverse 
outcomes. In one RCT involving 38 patients who were dependent on oral 
corticosteroids, there were no differences in disease exacerbation, quality of life or lung 
function when patients switched from oral to inhaled therapy.538 
4.8.6 Antibiotics 
Current evidence does not support long-term antibiotic use to prevent exacerbations in 
patients with COPD. A systematic review of nine RCTs (1,055 patients) found that 
prophylactic antibiotics in chronic bronchitis/COPD had a small but statistically 
significant effect in reducing the days of illness due to exacerbations.539 However, they 
do not have a place in routine treatment because of concerns about the development of 
antibiotic resistance and the possibility of adverse effects.  
A systematic review of eleven RCTs (917 patients) found that the use of antibiotics in 
acute COPD exacerbations, regardless of choice, reduced the risk of short-term 
mortality by 77%, decreased the risk of treatment failure by 53% and the risk of sputum 
purulence by 44%; with a small increase in the risk of diarrhoea.540 Antibiotics are 
therefore recommended for exacerbations with an increase in cough, dyspnoea, sputum 
volume or purulence. 
4.8.7 Oxygen therapy 
Continuous supplemental oxygen should be used to improve exercise capacity and 
survival in patients with moderate-to-severe COPD who have severe hypoxaemia 
(PaO2 < 55 mm Hg or SaO2 < 88%).443 A systematic review of six RCTs (567 patients) 
found that long-term home oxygen therapy improves survival in a selected group of 
patients with severe hypoxaemia (PaO2 < 55 mm Hg).541 Furthermore, there is evidence 
that short-term ambulatory oxygen improves exercise capacity.542 However, further 
research is required to determine which COPD patients benefit from ambulatory 
oxygen, how much oxygen should be provided and the long-term effects of ambulatory 
oxygen. 
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4.8.8 Mucolytics 
Mucolytics should be considered in patients with COPD who have a chronic cough 
productive of sputum.443 A systematic review of 26 RCTs (7,335 patients) reported a 
20% reduction in the number of exacerbations per patient with oral mucolytics 
compared to placebo.543 However, no differences in lung function between the 
treatments were reported. Bearing in mind there are significant QOL and healthcare 
costs that result from having exacerbations, health professionals and patients will need 
to judge whether the reduction in exacerbation rate is large enough to warrant daily 
treatment with these medicines. Benefit may be greater in patients who have frequent or 
prolonged exacerbations, or those who are repeatedly admitted to hospital with COPD 
exacerbations, although data from RCTs do not permit a test of this hypothesis.543 
4.9 Medication adherence and persistence in COPD 
4.9.1 Definitions of adherence and persistence 
Optimal disease management requires good adherence and persistence. The World 
Health Organisation states “poor adherence to long-term therapies severely 
compromises the effectiveness of treatment making this a critical issue in population 
health both from the perspective of quality of life and of health economics.”544 
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
defines medication adherence or compliance as “the extent to which a patient acts in 
accordance with the prescribed interval and dose of a dosing regimen.”545 Medication 
adherence therefore refers to the act of conforming to the recommendations made by the 
provider with respect to timing, dosage and frequency of medication taking. Although 
the terms adherence and compliance are often used interchangeably, adherence is 
preferred by many healthcare providers as it implies a co-operative, two-way 
relationship versus the one-way interaction inferred from the term compliance.546 The 
term adherence is intended to be a statement of fact rather than a judgemental term 
implying blame of the prescriber, patient or treatment.547 
Non-adherence can be broadly classified as intentional or unintentional. Intentional non-
adherence is an active process in which the patient chooses to deviate from the 
treatment regimen, whereas unintentional non-adherence is a passive process in which 
the patient may be careless or forgetful about properly adhering to the treatment 
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regimen.548 These two types of non-adherence have been associated with different 
patient characteristics and should therefore be recognised as two different phenomena. 
For example, while intentional non-adherence seems to reflect the patient’s balance of 
reasons for and against taking medication, unintentional non-adherence is less strongly 
associated with decision balance, and more so with demographics.549  
Medication persistence, as defined by ISPOR, refers to “the duration of time from 
initiation to discontinuation of therapy.”545 While medication adherence refers to 
medication-taking behaviour within a specific time interval, medication persistence 
attempts to capture the amount of time that a patient remains on chronic drug therapy.550 
While no overarching term combines medication adherence and persistence,545 by 
definition, adherence necessitates persistence. For example, a patient must be persistent 
in order to display adherent behaviour. Furthermore, to be classed as persistent, a patient 
must display mostly adherent behaviour, as persistence analyses must include a pre-
specified limit on the number of days allowed between prescription refills. This 
‘permissible gap’ should be the maximum allowable period patients could go without a 
dose and not anticipate reduced or suboptimal outcomes.545 Figure 33 displays how 
medication adherence and persistence can be quantitatively defined. Adherence is 
usually measured over a period of time and reported as a percentage, whereas 
persistence is usually reported in terms of number of days for which therapy was 
available. Both terms may also be reported as dichotomous variables (adherent/non-
adherent or persistent/non-persistent) according to pre-defined criteria at the end of a 
pre-specified time period. 
Figure 33. Quantitative definitions of compliance and persistence545 !
% of doses taken as prescribed 
ADHERENCE 
Days taking medication 
(without exceeding permissible gap) 
PERSISTENCE 
Stop medication 
or                     
end observation 
Start medication  
or  
observation 
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Medication adherence and persistence can be estimated using a variety of methods 
(Table 56). Traditional assessment measures such as patient self-report are known to 
significantly over-estimate medication adherence.260,551 Likewise, prescription records 
may be inaccurate, as they do not verify drug administration.552,553 It is recognised that a 
gold standard measure to assess medication taking behaviour does not exist.552 
Table 56. Methods of measuring adherence546,554 
Method Advantages Disadvantages 
Directly observed therapy Most accurate 
Patients can hide pills in the mouth and then 
discard them;  
Impractical for routine use 
Biological assay Objective 
Expensive;555  
Results may be altered by the patient 
improving their medication adherence in the 
days before the assay556-558 
Patient self-report 
Simple;  
Inexpensive 
Results are easily distorted by the patient, 
adherence often over-estimated260,551 
Pill counts 
Objective; 
Quantifiable;  
Easy to perform 
Results easily altered by the patient (e.g. pill 
dumping)559 
Rates of prescription refills 
Simple 
Easy to obtain data 
Does not verify drug administration;560 
Ideally requires a centralised pharmacy 
system561 
Assessment of the patient’s 
clinical response Simple 
Factors other than medication adherence can 
affect clinical response 
 
4.9.2 Rates of adherence and persistence in COPD 
COPD is a chronic disease requiring daily use of medication for most patients for the 
rest of their lives. An important contributing factor to both morbidity and mortality of 
patients with COPD is their non-adherence and non-persistence with drug therapy.562 
However, adherence to long-term preventative COPD medication regimens has been 
estimated to be as low as 28%.563 Furthermore, patients with poor adherence to COPD 
medication have been shown to have significantly better adherence rates to co-
morbidities treated with oral medications.564  
A Canadian study that assessed patterns of persistence with inhaled medications for 
COPD found low rates of persistence with long-term treatment.565 It was found that 15-
63% of patients continued on the prescribed drug for more than six months, which 
decreased to 7-53% at 12 months and 55-47% at 18 months. Patients who had no prior 
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experience with inhaled medication in the previous year had significantly shorter 
treatment persistence for all inhaled medications (P < 0.0001). The authors concluded 
that further research is needed to pursue reasons why patients do not continue on 
treatment.565 
A large analysis of medication record in the Netherlands, found that about 37% of new 
users of tiotropium continued treatment for one year, compared with 14% for 
ipratropium, 13% for LABAs and 17% for LABAs in combinations with ICS.566 
Multivariate analyses showed that patients using tiotropium were 2-3 times more 
persistent with their therapy than patients using ipratropium (RR 2.0, 95% CI 1.8-2.3), 
LABAs (RR 2.9, 95% CI 2.4-2.6), or LABAs in combination with ICS (RR 2.4, 95% CI 
2.1-2.8). 
A recent Australian study also found low rates of long-term persistence with inhaled 
respiratory medication. The study was a retrospective assessment of de-identified 
prescription claims data in a 10% random sample of Australian Medicare beneficiaries, 
between June 2003 and March 2005.567 Patients initiated on inhaled beclomethasone, 
budesonide, fluticasone, eformoterol, salmeterol, budesonide plus eformoterol, 
fluticasone plus salmeterol, ipratropium and tiotropium were included. Medications 
were further divided into major drug classes, namely ICS, LABAs, combination ICS 
plus LABAs, and short- and long-acting anticholinergics. Patients were treated as being 
initiated to therapy if the medication had not been supplied in the previous 12 months. 
Discontinuation was defined as the absence of a claim for the initiated drug for three 
consecutive months or more. Patients were subdivided as ‘naïve’ (no inhaled medication 
in the previous year) or ‘experienced’ (previous or current treatment).  
The database included 110,470 patients (66,825 naïve and 43,645 experienced) who 
were initiated on at least one of the study medications. Eight to 47% of patients 
persisted with therapy for six months, which decreased to 3-36% at 12 months and 
2-30% at 18 months. Persistence with tiotropium was increased compared with other 
medications (Figure 34).  
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Figure 34. Treatment persistence over 18 months for all study drug classes 
 
Fewer naïve patients persisted with all medications than experienced patients, which 
was evident after only three months of therapy (Figure 35). 
Figure 35. Treatment persistence after three months for naïve and experienced patients 
 
The findings of this study are consistent with reports that COPD is poorly managed in 
Australia,4 despite the availability of safe and effective respiratory medication. In 
keeping with international reports,565,566 persistence with tiotropium was higher 
compared with other respiratory medications, although long-term persistence was still 
suboptimal. 
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Poor adherence and persistence with medication is likely to be associated with an 
increased morbidity and mortality of COPD. This hypothesis was tested in a 
retrospective analysis of adherence of the TORCH study database.562 The TORCH study 
was a RCT comparing inhaled salmeterol and fluticasone with placebo in moderate-to-
severe COPD over three years. Good adherence was defined as an average adherence to 
study medications of more than 80% over the whole period of the study, and poor 
adherence was defined as an average adherence of 80% or less. Of the 4,880 patients 
(79.8%) with good adherence, 11.3% died in contrast to 26.4% among the 1232 patients 
(20.2%) with poor adherence. The annual rates of hospitalisations for exacerbations 
were 0.15 and 0.27, respectively. The association between adherence and mortality 
remained unchanged and statistically significant after adjusting for other factors related 
to prognosis with a hazard ratio of 0.40 (95% CI 0.35-0.46, P < 0.001). Similarly, the 
association between adherence and hospitalisation remained unchanged and significant 
in multivariate analysis, with a rate ratio of 0.58 (95% CI 0.44-0.73, P < 0.001). The 
authors concluded that further research is need to understand these strong 
associations.562 
4.9.3 Barriers to adherence and persistence in COPD 
Only a limited number of studies have specifically examined patient adherence with 
COPD therapy and, in general, less is known about adherence in COPD than in 
asthma.568 Medication adherence and persistence in COPD are complex concepts, and 
may be influenced by multiple factors including social/environmental, patient-related 
and treatment-related factors (Figure 36). 
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Figure 36. Factors likely to influence patient adherence and persistence in COPD569 
  
Patients with COPD have many potential risk factors for poor adherence and 
persistence.570 COPD being a condition characterised by multiple co-morbidities,571-574 
and patients are likely to be on complex medication regimens consisting of time-
contingent and symptomatic oral and inhaled respiratory medications, as well as other 
medications.575 
One of the earliest studies of adherence in COPD, conducted by Dolce et al, examined 
self-reported adherence in 78 outpatients being treated at a medical centre in the US.575 
Patients reported that they were prescribed an average of six medications, requiring 
different dosage regiments and modes of administration. More than 50% of patients 
reported regularly under-using prescribed medications. Furthermore, 31% of patients 
reported deliberately deciding not to dose. This decision was most frequently associated 
with feeling good but was also related to concerns about side effects, beliefs that the 
medication would not be effective, concerns that they would become immune to the 
medication and confusion about actual dosing schedules (Figure 37). Patients also 
reported that they were more likely to overuse rescue medications when they were 
experiencing respiratory distress.  
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Figure 37. Common causes of poor adherence in COPD patients575 
 
An Australian study aimed to identify the predictors of medication adherence in patients 
with COPD, using self-administered questionnaires, contrasting the health beliefs, 
experiences and behaviours of COPD patients self-reporting good adherence with those 
patients reporting suboptimal adherence to their medication.572 Differences in 
knowledge about the illness and treatment, faith in and satisfaction with the treatment 
and doctors, and intentional and unintentional deviations from the recommended 
treatment were detected between the adherent and less adherent groups. The 
questionnaire items “I vary my recommended management based on how I am feeling” 
and “I get confused about my medications” were found to be significant independent 
predictors of non-adherence.572 This study demonstrated that both intentional and 
unintentional forms of non-adherence are important in COPD patients. An earlier US 
study reported that nearly one-third of patients with COPD reported missing prescribed 
doses of medication because they deliberately decided not to dose, a decision that was 
most commonly associated with ‘feeling good.’575  
The route of administration can influence treatment persistence. Although the pattern of 
early discontinuation has been demonstrated with other medication classes, oral 
medications usually have a larger proportion of patients persisting for a year, compared 
with inhaled medications.576 COPD patients using tiotropium have been shown to be 
more persistent with their therapy than patients using other inhaled medication.565,566 
Once daily-dosing of tiotropium compared with LABA and ICS, which are mostly 
twice-daily, and ipratropium, which is mostly four times daily, may account for the 
enhanced persistence with tiotropium. Indeed, simplification of dosing regimens by 
reducing dose frequencies has been shown to increase medication adherence in several 
chronic diseases.577 
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The World Health Organisation states “interventions aimed at improving adherence 
would provide a significant positive return on investment through primary prevention 
(of risk factors) and secondary prevention of adverse health outcomes.”544 While a 
number of studies have reported suboptimal rates of medication persistence in 
COPD,565,566,578,579 relatively little is known about the reasons why patients with COPD 
do not continue on their prescribed medication. Before targeted interventions can be 
performed, it is essential that the factors affecting adherence and persistence be 
identified and understood.  
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CHAPTER FIVE: 
UNDERSTANDING MEDICATION PERSISTENCE IN PATIENTS WITH COPD 
5.1 Aim and objectives 
This study aimed to understand the reasons why patients with COPD do and do not 
persist with prescribed medication. Specifically, the objectives were to: 
• Identify the drivers and barriers of persistence with tiotropium in patients with 
COPD; 
• Identify the significant independent predictors of persistence with tiotropium; 
• Determine whether prior experience with respiratory medication determines the 
likelihood of persisting with tiotropium; and 
• Understand patients’ rational and emotional thoughts and feelings towards their 
condition and medication. 
5.2 Methods 
5.2.1 Study design and setting 
This study was designed to be a descriptive analysis of medication persistence in 
patients with COPD. The study utilised community pharmacists and their computerised 
prescription data to help identify patients who had ceased to persist with tiotropium 
therapy. Both quantitative and qualitative measures relating to persistence were 
explored. Participants were identified from community pharmacy dispensing records, in 
Tasmania, Australia. 
5.2.2 The data mining software 
The information technology development under this study involved modifying the 
existing MedeMine software application, used in previously described studies, to 
identify patients with COPD, as evidenced by the recent use (or at least, dispensing) of 
tiotropium. By definition, understanding the drivers and barriers of persistence with 
tiotropium required researching both persistent and non-persistent patients. Therefore, a 
specific identification algorithm was written into the software application to enable 
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detection of patients who were likely to be either persistent or non-persistent with 
tiotropium. 
Once the program was installed on a dispensing computer, the dispensing history was 
interrogated and a list of patients identified as having received tiotropium in the 
previous 12 months was generated. Patients were automatically identified as ‘persistent’ 
if they had received at least nine supplies of tiotropium in the preceding 12 months, 
including at least two units in the past 90 days. Patients were identified as ‘non-
persistent’ if they had received one to four supplies of tiotropium in the preceding 12 
months, with nil supplies in the subsequent 65 days. Non-persistent patients were 
further classified as ‘recent non-persistent’ if they had received their past supply of 
tiotropium in the last six months, or ‘late non-persistent’ if they had received their last 
supply in the past 7-12 months. This further classification was a useful tool to determine 
the likelihood of patients’ ability to accurately recall their reason(s) for non-persistence. 
For research purposes, an additional classification dimension was used, namely whether 
patients had received inhaled respiratory medication (excluding SABAs) in the year 
preceding their first tiotropium supply. The reasoning behind this additional 
classification was that previous research has demonstrated that patients who had not 
used regular inhaled respiratory medication in the year before their first tiotropium 
prescription tended to have significantly shorter treatment persistence.565 Patients were 
classed ‘respiratory medication (RM)-naïve’ if they had not received any inhaled 
respiratory medication (excluding SABAs and nebulised medication) in the 12-month 
period prior to their first supply of tiotropium, or ‘RM-experienced’ if they had received 
any inhaled respiratory medication (excluding SABAs and nebulised medication) in the 
12-month period prior to their first supply of tiotropium. 
Figure 38 displays a screen shot of an example list of patients identified using 
‘MedeMine-for-COPD.’ Functions of the software application allowed for viewing all 
identified patients (as shown), or persistent, recent non-persistent or late non-persistent 
patients separately. Personalised letters and address labels could also be printed from 
this screen. 
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Figure 38. List of identified patients in MedeMine-for-COPD 
 
A patient’s dispensing information could be viewed in detail by highlighting the 
patient’s name and clicking on ‘select patient.’ Dispensing information on the 
MedeMine-for-COPD screen, as shown in Figure 39, was engineered to look the same 
as that seen in the Fred dispensing system so that pharmacists would have an instant 
familiarity with the layout and presentation of the information. The patient screen used 
four tabs (‘Spiriva dispensings,’ ‘collated history,’ ‘all dispensing history’ and 
‘feedback’). The first three tabs displayed the patient’s history in different ways; the 
‘Spiriva dispensings’ tab showed details of all Spiriva® (tiotropium) supplies, the 
‘collated history’ counted the number of supplies of each medication dispensed and ‘all 
dispensing history’ displayed a sequential history for the patient. How much 
information was displayed was determined by selecting ‘months history to display’ (1, 
3, 6, 9, 12 or all). The ‘feedback’ tab gave the pharmacist the facility to enter free text 
relating to the patient. Patients could be excluded from the study by selecting a reason 
from the drop-down ‘reason not included’ menu on the top right hand side of the screen. 
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Figure 39. Viewing patient dispensing history in MedeMine-for-COPD 
 
In-house testing of the MedeMine-for-COPD program’s identification criteria found 
that more persistent patients would be identified than would be required. To minimise 
the cost of over-recruiting (due to the cost associated with patient incentives), 
MedeMine-for-COPD was programmed to include a maximum of ten persistent patients 
per pharmacy. Upon running the MedeMine-for-COPD program, persistent patients 
were ranked by the date of first tiotropium dispensing, and after the ten most recent 
dates, the rest of the patients were automatically excluded. This specific algorithm 
ensured that the ten persistent patients included received their first supply of tiotropium 
most recently, as they were more likely to remember details about their original 
diagnosis and prescription. 
5.2.3 Sample size 
The aim was to recruit at least 20 pharmacies from the South, North and North-West 
regions of Tasmania. Sample data from two pharmacies of small-average size suggested 
that at least four persistent patients and four non-persistent patients would be identified 
from each pharmacy. This would give a potential sample size of approximately 160 
patients across all sites. It was envisaged that an approximate 50% response rate to the 
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invitation to participate, giving a sample size of 80 patients across the sites (40 
persistent patients and 40 non-persistent patients). 
The proposed sample size reflects the mix of quantitative and qualitative research 
objectives. A larger sample size was required for quantitative purposes. The generally 
accepted rule of thumb is that a minimum of 20 usable responses per cell is required for 
the type of multivariate statistical analysis planned for this research. Clearly larger 
sample sizes are required to conduct quantitative analysis with rigour and to be able to 
cut the data on multiple dimensions (age, gender, smoking status, depression etc). Given 
that a smaller sample size would be required to provide sufficient qualitative insights, 
face-to-face interviews were conducted with only half the sample (i.e. n = 40), whereas 
the full sample will be used to collect quantitative data (i.e. n = 80). It was envisaged 
that a sufficient number of patients would be recruited for interviews until definite 
themes relating to persistence emerged. 
5.2.4 Pharmacy recruitment 
Community pharmacists throughout the Tasmania were informed about the study via 
telephone, and sent a letter (Appendix 28) and project synopsis (Appendix 29) 
informing them about the study and inviting them to participate if they were a current 
user of the Fred dispensing system. Pharmacists were required to fax an expression of 
interest form to the researchers, indicating whether they felt the study would be 
worthwhile and they had time to commit to participate (Appendix 30).  
In order to thank pharmacists for their assistance with the study, they were offered a 
$500 honorarium to compensate for their time and professional input. 
5.2.5 Installation and running the MedeMine COPD program 
The data mining application was installed in the participating pharmacies and the 
pharmacists were instructed on its use and the study’s procedures. Each pharmacy ran 
the software application and generated a list of patients identified as persistent or non-
persistent with tiotropium. 
The participating pharmacist examined the information for the patients and, using their 
professional judgement based on their knowledge of each patient, confirmed that it 
would be appropriate to send them an invitation letter. The pharmacists were 
encouraged to include all patients unless they met the pre-defined exclusion criteria. 
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• Patients who were nursing home residents were excluded because, in order to 
study the drivers and barriers of persistence, identified patients needed to be 
managing their own drug therapy;  
• Pharmacists used their knowledge and experience with patients to assess whether 
receiving an invitation letter might have overly alarmed any patients. Such 
exclusions were deemed necessary to avoid causing undue distress to some 
patients; 
• Because the study involved the completion of questionnaires and interviews, 
patients with impaired cognition or who would be too confused were excluded; 
• Deceased patients were excluded; and 
• Patients who were aged less than 40 years of age were excluded so that the 
identified patients were more likely to have a diagnosis of COPD rather than 
asthma.  
The exclusion criteria were listed in a drop down menu, as shown in Figure 40. 
Figure 40. Excluding patients in MedeMine-for-COPD 
 
In addition, if the pharmacist did not believe the patient was eligible to participate for 
any other reason, they could select ‘other...’ and type the reason. Due to the possibility 
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of patients receiving tiotropium from other pharmacies, pharmacists were also 
encouraged to exclude patients who were not regular clients of their pharmacy. 
Once a patient was deemed eligible to be included in the study, a personalised invitation 
letter (Appendix 31) and consent form (Appendix 32) were printed directly from the 
MedeMine-for-COPD program. These, in addition to a generic patient information sheet 
(Appendix 33) and postage paid envelope, were mailed to all eligible patients. 
When the process was complete and the MedeMine-for-COPD program was closed, the 
de-identified and encrypted dispensing information was automatically sent via the 
Internet to a secure server at the University of Tasmania.  
5.2.6 Patient questionnaires 
Patients who sent a signed consent to the University of Tasmania were subsequently 
sent a letter (Appendix 34) and patient questionnaire (Appendix 35). The patient 
questionnaire was composed of 20 questions, and included general non-validated 
questions relating to exposure to risk factors and a combination of validated 
questionnaires: 
• The St. George’s Respiratory Questionnaire;580  
• The Brief Illness Perception Questionnaire;581  
• The Beliefs about Medicines Questionnaire;582  
• The Hospital Anxiety and Depression Scale;583 and 
• The Tool for Adherence Behaviour Screening.348 
Patients who returned a completed questionnaire were sent a $50 gift voucher.  
5.2.6.1 St. George’s Respiratory Questionnaire 
The St. George’s Respiratory Questionnaire (SGRQ) is a disease-specific measure of 
health status for use in COPD. It is a standardised self-administered questionnaire 
divided into three subscales: Symptoms (8 items), Activity (16 items) and Impacts (26 
items).580,584 The Symptoms component is designed to assess patients’ perception of 
their recent respiratory problems. The Activity component measures disturbances to 
patients’ daily physical activity. The Impacts component covers a wide range of 
disturbances of psychosocial function. For each subscale and for the overall 
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questionnaire, scores range from zero (no impairment) to 100 (maximum impairment). 
Questions 4 through to 17 of the patient questionnaire, as displayed in Appendix 35, 
assessed all the items of the SGRQ. Questions 4 to 8 assessed symptoms, questions 11 
and 15 assessed activity limitation and questions 9 to 10, 12 to 14, and 16 to 17 assessed 
psychosocial impacts. 
There is now a wide body of published data on the SGRQ in COPD patients, including 
numerous large clinical trials of pharmacological585-590 and non-pharmacological498,591 
interventions. There is extensive literature that points to the validity of the SGRQ, both 
from cross-sectional studies between patients, and longitudinally within patients.592 The 
threshold for a clinically significant difference between groups of patients and for 
changes within groups of patients is four units.593 
5.2.6.2 Brief Illness Perception Questionnaire 
The Brief Illness perception questionnaire (IPQ) is a validated method for assessing 
cognitive representations of illness.581,594 The Brief IPQ, covered in question 18 of the 
patient questionnaire in Appendix 35, contains eight items, which are rated using a zero-
to-ten response scale. Five of the items assessed cognitive illness representations 
(consequences [18a], timeline [18b], personal control [18c], treatment control [18d and 
identity [18e]), two of the items assessed emotional representations (concern [18f] and 
emotions [18h] and one item assessed illness comprehensibility (18g). Because the brief 
IPQ is not disease-specific, the authors recommend replacing the word ‘illness’ with the 
name of the particular illness that is being examined.581 In this case, ‘respiratory 
condition’ was used. 
5.2.6.3 Beliefs about Medicines Questionnaire 
The Beliefs about Medicines Questionnaire (BMQ) is a validated method for assessing 
cognitive representations of medication.582 The BMQ comprises two sections, which 
can be used in combination or separately. The BMQ-Specific assesses representations of 
medication prescribed for personal use and the BMQ-General assesses beliefs about 
medicines in general. Because not all patients recruited to this study would be taking the 
same medication, the BMQ-general was chosen, and is covered in question 19 of the 
patient questionnaire in Appendix 35. The BMQ-General comprises a General Harm 
scale (questions 19b, 19c, 19e and 19f of the patient questionnaire) and a General 
Overuse scale (19a 19d, 19g and 19h of the patient questionnaire). The General Harm 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 212 
scale assesses beliefs about the intrinsic nature of medicines and the degree to which 
they are perceived as harmful and addictive poisons that should not be taken 
continuously. The General Overuse scale assesses beliefs about the use of medicines 
and whether doctors overprescribe them. Scores for each scale were summed, resulting 
in a range from 4 to 20. Higher scores indicate a more negative orientation towards 
medicines in general. 
5.2.6.4 Tool for Adherence Screening Behaviour 
The Tool for Adherence Behaviour Screening (TABS) is a validated scale that screens 
both intentional and unintentional non-adherence to pharmacological and non-
pharmacological disease management.348 The TABS, covered in question 20 of the 
patient questionnaire in Appendix 35, measures adherent and non-adherent behaviour 
on five-point Likert-type scales. Questions 20b, 20c, 20d and 20e assess adherent 
behaviour, and questions 20a, 20f, 20g and 20h assess non-adherent behaviour, with 
higher scores indicating higher degrees of adherent and non-adherent behaviour. The 
items used in the TABS were developed based on common adherence issues 
experienced by a sample of chronically ill patients and cover domains, judged by 
experts, to be important in adherence screening.348 
5.2.6.5 Hospital Anxiety and Depression Scale 
The Hospital Anxiety and Depression Scale (HADS) was designed to provide a simple 
yet reliable tool for use in medical practice.583 The term ‘hospital’ in its title suggests 
that is only valid in such a setting but many studies conducted throughout the world 
have confirmed that it is valid when used in community settings.595 The HADS, covered 
in question 21 of the patient questionnaire in Appendix 35, contains 14 statements 
describing symptoms of depression and anxiety. Responses options for each question 
range from zero to three and ask patients about their agreement with the statements or 
how often they apply. There are seven statements for each depression (questions 21b, 
21d, 21f, 21h, 21j, 21l and 21n of the patient questionnaire) and anxiety (questions 21a, 
21c, 21e, 21g, 21i, 21k, 21m). Domain scores range from zero to 21 and following the 
standard convention scores ! 11 indicate a probable clinical diagnosis of depression or 
anxiety.583 
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5.2.7 Patient interviews 
Approximately half of the consenting patients were invited to participate in qualitative 
face-to-face interviews. The interviews were conducted in patients’ homes, which was 
not only more comfortable for patients, but also allowed the interviewers to observe the 
environment that the patients live in and to either test or more fully explore patient 
routines in taking their medication. With the patients’ permission, each interview was 
digitally voice recorded. All interviewees received a cash gratuity of $70. 
The interviews addressed patient characteristics, diagnosis, treatment choice, day-to-day 
management and persistence with therapy. The face-to-face discussion guide, as 
displayed in Appendix 36, incorporated all of the qualitative objectives under each of 
the following discussion points:  
• Understand rational and emotional thoughts and feelings towards patients’ 
condition and health; 
• Determine what part symptoms play in the decision to go to a doctor; 
• Understand why diagnosed patients may not be filling prescriptions and 
determine the barriers to filling prescriptions; 
• If patients have stopped taking their medication, determine what encouraged 
them to stop; 
• Determine if patients use the medication on a symptomatic or regular basis; and 
• Determine what would encourage patients to take their medication as prescribed 
and whether there are any other medications they are compliant with. 
Whilst utilising a semi-structured interview outline, the emphasis and technical 
complexity of each interview naturally varied according to the expertise and perspective 
of the interviewee concerned. Best practice indicated that the interviewer was unknown 
to the participants and care was taken to ensure that the interview procedure was 
consistent during the study period. 
In addition, to account for the possibility of patients receiving tiotropium from other 
pharmacies but being identified by the MedeMine-for-COPD program as non-persistent, 
self-reported persistence was determined in the qualitative interviews. The remainder of 
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non-persistent patients who had not been interviewed were screened via telephone 
interviews to determine self-reported persistence. 
5.2.8 Handling of data and statistical analysis 
All quantitative variables were collated and entered into a statistical software package, 
Statview 5.01 for Windows (Abacus Concepts Inc, Berkeley, California, USA). 
Categorical demographic variables of the persistent patients were compared to the non-
persistent patients using the Chi Square test or Fisher’s Exact test. The Fisher’s Exact 
test was used when at least one of the variables had less than five patients or events. The 
Mann-Whitney U test was used to compare responses to individual questionnaire items 
and the questionnaires scores between persistent and non-persistent patients. 
Multivariate logistic regression models were then performed on items with significant 
univariate differences between the groups to identify the independent predictors of 
persistence. Spearman’s correlation coefficients were calculated to determine the 
relationship between the significant independent predictors. A significance level of P < 
0.05 was used for all statistical procedures. 
Each interview was digitally voice recorded and transcribed verbatim. The qualitative 
analysis encompassed the three general phases of familiarisation, data reduction, and 
interpretation. The familiarisation process involved the researchers reading and listening 
to the data, to familiarise themselves with the data and to identify the various themes 
that emerged. Each topic in the interview schedule was analysed, identifying similarities 
or differences in participant responses and summarising key points (data reduction). The 
methodology utilised to analyse the transcripts was content analysis, which followed the 
principles of ‘grounded theory’, whereby concepts, categories and themes were 
identified and developed as they emerged from the interviews and any observational 
data.596 
Interviewed and non-interviewed patients were analysed for differences in 
demographics, dispensing data, SGRQ scores and Anxiety and Depression scores.  
5.2.9 Ethical approval and trial registration 
Ethical approval was received from the Tasmanian Health and Medical Human 
Research Ethics Committee (ethics reference number H9842). The study was registered 
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with the Australian New Zealand Clinical Trial Registry (registration number 
ACTRN12608000120370). 
5.3 Results 
5.3.1 Recruitment of participants 
5.3.1.1 Pharmacist participation 
A total of 44 Tasmanian pharmacies were invited to participate in the study by 
telephone and mail. Table 57 displays the responses of pharmacists by the expression of 
interest form and follow-up telephone calls. 
Table 57. Pharmacists' willingness to participate  
Response Number of pharmacies (n = 44) 
Use the Fred dispensing system and willing to participate 37 (84.1%) 
Do not use the Fred dispensing system 2 (4.5%) 
Use the Fred dispensing system, but not able to participate 5 (11.4%) 
 
Of the 37 pharmacies that agreed to participate in the study, one (2.7%) pharmacy was 
excluded due to failure of the MedeMine-for-COPD installation. Of the 36 pharmacies 
that participated in the study, 26 (72.2%) were classed as metropolitan and 10 (27.8%) 
were classed as rural. 
5.3.1.2 Identification of patients 
The MedeMine-for-COPD program identified a total of 1,291 patients from 36 
pharmacies. Of these patients, 728 (56.4%) were identified as ‘persistent’ and 563 
(43.6%) were identified as ‘non-persistent.’ Of the non-persistent patients, 266 (47.2%) 
received their last supply of tiotropium in the past six months, and 297 (52.8%) received 
their last supply of tiotropium in the past 7-12 months.  
Table 58 displays the number of patients identified by each pharmacy. An average of 36 
patients were identified in each pharmacy. Of these patients, an average of 20 (55.6%) 
patients were identified as persistent, and an average of 16 (44.4%) were identified as 
non-persistent. 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 216 
There was a significant difference in the proportion of persistent and non-persistent 
patients identified in rural and metropolitan pharmacies. Of the 968 patients identified 
in metropolitan pharmacies, 516 (53.3%) were persistent and 452 (46.7%) were non-
persistent, whereas of the 323 patients identified in rural pharmacies, 212 (65.6%) were 
persistent and 111 (34.4%) were non-persistent (&2 = 15.0, df = 1, P = 0.001). 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 217 
Table 58. Patients identified by each pharmacy 
Non-persistent† (n = 1,126) Pharmacy 
ID 
Region Patients 
identified* 
(n = 1,291) 
Persistent†    
(n = 728) Total    
(n = 563) 
Recent    
(n = 266) 
Late    
(n = 279) 
1 Metro 35 (2.7%) 15 (42.9%) 20 (57.1%) 13 (37.1%) 7 (20.0%) 
2 Metro 15 (1.2%) 12 (80.0%) 3 (20.0%) 1 (6.7%) 2 (13.3%) 
3 Rural 48 (3.7%) 33 (68.8%) 15 (31.3%) 11 (22.9%) 4 (8.3%) 
4 Rural 23 (1.8%) 15 (65.2%) 8 (34.8%) 3 (13.0%) 5 (21.7%) 
5 Metro 25 (1.9%) 14 (56.0%) 11 (44.0%) 5 (20.0%) 6 (24.0%) 
6 Metro 27 (2.1%) 8 (29.6%) 19 (70.4%) 6 (22.2%) 13 (48.1%) 
7 Rural 22 (1.7%) 14 (63.6%) 8 (36.4%) 7 (31.8%) 1 (4.5%) 
8 Rural 39 (3.0%) 26 (66.7%) 13 (33.3%) 10 (25.6%) 3 (7.7%) 
9 Metro 52 (4.0%) 17 (32.7%) 35 (67.3%) 20 (38.5%) 15 (28.8%) 
10 Rural 23 (1.8%) 13 (56.5%) 10 (43.5%) 6 (26.1%) 4 (17.4%) 
11 Metro 24 (1.9%) 10 (41.7%) 14 (58.3%) 8 (33.3%) 6 (25.0%) 
12 Metro 33 (2.6%) 26 (78.8%) 7 (21.2%) 4 (12.1%) 3 (9.1%) 
13 Metro 41 (3.2%) 31 (75.6%) 10 (24.4%) 7 (17.1%) 3 (7.3%) 
14 Metro 65 (5.0%) 37 (56.9%) 28 (43.1%) 14 (21.5%) 14 (21.5%) 
15 Metro 9 (0.7%) 1 (11.1%) 8 (88.9%) 3 (33.3%) 5 (55.6%) 
16 Metro 28 (2.2%) 17 (60.7%) 11 (39.3%) 5 (17.9%) 6 (21.4%) 
17 Metro 102 (7.9%) 50 (49.0%) 52 (51.0%) 23 (22.5%) 29 (28.4%) 
18 Metro 50 (3.9%) 29 (58.0%) 21 (42.0%) 12 (24.0%) 9 (18.0%) 
19 Metro 17 (1.3%) 15 (88.2%) 2 (11.8%) 0 (0.0%) 2 (11.8%) 
20 Metro 26 (2.0%) 20 (76.9%) 6 (23.1%) 4 (15.4%) 2 (7.7%) 
21 Metro 39 (3.0%) 29 (74.4%) 10 (25.6%) 5 (12.8%) 5 (12.8%) 
22 Rural 18 (1.4%) 16 (88.9%) 2 (11.1%) 1 (5.6%) 1 (5.6%) 
23 Metro 21 (1.5%) 16 (76.2%) 5 (23.8%) 2 (9.5%) 3 (14.3%) 
24 Metro 33 (2.6%) 21 (63.6%) 12 (36.4%) 7 (21.2%) 5 (15.2%) 
25 Metro 72 (5.6%) 27 (37.5%) 45 (62.5%) 18 (25.0%) 27 (37.5%) 
26 Metro 83 (6.4%) 36 (43.4%) 47 (56.6%) 17 (20.5%) 30 (36.1%) 
27 Metro 29 (2.3%) 18 (62.1%) 11 (37.9%) 4 (13.8%) 7 (24.1%) 
28 Rural 35 (2.7%) 20 (57.1%) 15 (42.9%) 5 (14.3%) 10 (28.6%) 
29 Rural 33 (2.6%) 21 (63.6%) 12 (36.4%) 6 (18.2%) 6 (18.2%) 
30 Metro 24 (1.9%) 13 (54.2%) 11 (45.8%) 7 (29.2%) 4 (16.7%) 
31 Metro 64 (5.0%) 29 (45.3%) 35 (54.7%) 11 (17.2%) 24 (37.5%) 
32 Rural 74 (5.7%) 46 (62.2%) 28 (37.8%) 11 (14.9%) 17 (23.0%) 
33 Rural 8 (0.6%) 8 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
34 Metro 7 (0.5%) 1 (14.3%) 6 (85.7%) 2 (28.6%) 4 (57.1%) 
35 Metro 19 (1.5%) 14 (73.7%) 5 (26.3%) 2 (10.5%) 3 (15.8%) 
36 Metro 28 (2.2%) 10 (35.7%) 18 (64.3%) 6 (21.4%) 12 (42.9%) 
*Figures represent number (%) of total patients identified. †Figures represent number (%) of total patients 
identified in each pharmacy. 
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5.3.1.3 Patient exclusions 
Of the 1,291 patients identified, 862 (66.8%) were excluded from the study, leaving 429 
(33.2%) patients eligible to be invited to participate. Of the excluded patients, 489 
(56.7%) were excluded automatically by the MedeMine-for-COPD program as being in 
excess of recruitment requirements, and 373 (43.3%) were excluded by pharmacists. 
There was a significant difference in the excluded proportion of persistent and non-
persistent patients for the reasons ‘not a regular patient’ (0/53 [0.0%] versus 280/320 
[87.5%], respectively; &2 = 702.4, df = 1, P < 0.0001), ‘patient is deceased’ (0/53 
[0.0%] versus 10/320 [3.1%], respectively; &2 = 17.1, df = 1, P < 0.0001) and ‘patient is 
younger than 40 years of age’ (0/542 [0.0%] versus 4/320 [1.3%], &2 = 6.8, df = 1, 
P < 0.05). Table 59 displays the reasons for patient exclusion by pharmacists, with the 
assistance of a researcher.  
Table 59. Reasons for patient exclusion by pharmacists* 
Reason for exclusion  Patients excluded     
(n = 373) 
Persistent    
(n = 53) 
Non-persistent    
(n = 320) 
P 
Not a regular patient 280 (75.1%) 0 (0.0%) 280 (87.5%) < 0.0001 
Nursing home resident 47 (12.6%) 33 (62.3%) 14 (4.4%) 0.28 
May cause undue distress to patient 12 (3.2%) 7 (13.2%) 5 (1.6%) 0.74 
Patient is too confused 12 (3.2%) 8 (15.1%) 4 (1.3%) > 0.99 
Patient is deceased 10 (2.7%) 0 (0.0%) 10 (3.1%) < 0.0001 
Patient has a language barrier 5 (1.3%) 2 (3.8%) 3 (0.9%) 0.37 
Patient is younger than 40 years old 4 (1.1%) 0 (0.0%) 4 (1.3%) 0.02 
Patient is disabled 2 (0.5%) 2 (3.8%) 0 (0.0%) 0.53 
Patient is illiterate 1 (0.3%) 1 (1.9%) 0 (0.0%) > 0.99 
*Figures represent number (%) of excluded patients.  
Table 60 displays the number of patients excluded per pharmacy. All the identified 
patients were excluded in four of the pharmacies. Of the 36 pharmacies that ran the 
MedeMine-for-COPD program, 32 (88.9%) were left with patients who were eligible to 
be invited to participate. 
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Table 60. Patients excluded per pharmacy* 
Persistent Non-persistent Pharmacy 
ID Identified   
(n = 728) 
Included     
(n = 186) 
Excluded      
(n = 542) 
Identified     
(n = 563) 
Included    
(n = 243) 
Excluded    
(n = 320) 
1 15 5 (33.3%) 10 (66.7%) 20 16 (80.0%) 14 (20.0%) 
2 12 9 (75.0%) 3 (25.0%) 3 3 (100.0%) 0 (0.0%) 
3 33 9 (27.3%) 24 (72.7%) 15 7 (46.7%) 8 (53.3%) 
4 15 9 (60.0%) 6 (40.0%) 8 7 (87.5%) 1 (12.5%) 
5 14 8 (57.1%) 6 (42.9%) 11 8 (72.7%) 3 (27.3%) 
6 8 8 (100.0%) 0 (0.0%) 19 0 (0.0%) 19 (100.0%) 
7 14 9 (64.3%) 5 (35.7%) 8  6 (75.0%) 2 (25.0%) 
8 26 10 (38.5%) 16 (61.5%) 13 9 (69.2%) 4 (30.8%) 
9 17 8 (47.1%) 9 (52.9%) 35 27 (77.1%) 8 (22.9%) 
10 13 10 (76.9%) 3 (23.1%) 10 7 (70.0%) 3 (30.0%) 
11 10 8 (80.0%) 2 (20.0%) 14 3 (21.4%) 11 (78.6%) 
12 26 8 (30.8%) 18 (69.2%) 7 3 (42.9%) 4 (57.1%) 
13 31 9 (29.0%) 22 (71.0%) 10 5 (50.0%) 5 (50.0%) 
14 37 8 (21.6%) 29 (78.4%) 28 10 (35.7%) 18 (64.3%) 
15 1 0 (0.0%) 1 (100.0%) 8 5 (62.5%) 3 (37.5%) 
16 17 4 (23.5%) 13 (76.5%) 11 5 (45.5%) 6 (54.5%) 
17 50 8 (16.0%) 42 (84.0%) 52 22 (42.3%) 30 (57.7%) 
18 29 8 (27.6%) 21 (72.4%) 21 12 (57.1%) 9 (42.9%) 
19 15 10 (66.7%) 5 (33.3%) 2 2 (100.0%) 0 (0.0%) 
20 20 8 (40.0%) 12 (60.0%) 6 6 (100.0%) 0 (0.0%) 
21 29 8 (27.6%) 21 (72.4%) 10 6 (60.0%) 4 (40.0%) 
22 16 8 (50.0%) 8 (50.0%) 2 2 (100.0%) 0 (0.0%) 
23 16 3 (18.8%) 13 (81.3%) 5 3 (60.0%) 2 (40.0%) 
24 21 6 (28.6%) 15 (71.4%) 12 3 (25.0%) 9 (75.0%) 
25 27 5 (18.5%) 22 (81.5%) 45 41 (91.1%) 4 (8.9%) 
26† 36 0 (0.0%) 36 (100.0%) 47 4 (8.5%) 43 (91.5%) 
27† 18 0 (0.0%) 18 (100.0%) 11 2 (18.2%) 9 (81.8%) 
28† 20 0 (0.0%) 20 (100.0%) 15 3 (20.0%) 12 (80.0%) 
29† 21 0 (0.0%) 21 (100.0%) 12 4 (33.3%) 8 (66.7%) 
30† 13 0 (0.0%) 13 (100.0%) 11 4 (36.4%) 7 (63.6%) 
31† 29 0 (0.0%) 29 (100.0%) 35 7 (20.0%) 28 (80.0%) 
32† 46 0 (0.0%) 46 (100.0%) 28 11 (39.3%) 17 (60.7%) 
33† 8 0 (0.0%) 8 (100.0%) 0  0 (0.0%) 0 (0.0%) 
34† 1 0 (0.0%) 1 (100.0%) 6 0 (0.0%) 6 (100.0%) 
35† 14 0 (0.0%) 14 (100.0%) 5 0 (0.0%) 5 (100.0%) 
36† 10 0 (0.0%) 10 (100.0%) 18 0 (0.0%) 18 (100.0%) 
*Figures represent number (%) of patients persistent or non-persistent identified in each pharmacy. 
†Pharmacies recruited at a later date to increase numbers of non-persistent patients; all persistent patients 
were excluded from these pharmacies. 
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5.3.1.4 Patient participation 
Of the 429 patients who were sent invitations to participate in the study, 136 (31.7%) 
agreed to participate and sent signed consent forms to the researchers. A significantly 
higher proportion of persistent patients agreed to participate than non-persistent patients 
(74/186, [39.8%] versus 62/243 [25.5%], respectively; &2 = 9.9, df = 1, P < 0.01). Of the 
consenting patients, 129 (94.9%) returned the patient questionnaires. Table 61 
summarises the patient response rates. 
Table 61. Patient response rates* 
Mail-out description All patients Persistent Non-persistent P 
Sent invitation to participate by pharmacist 429  186 243  
1 
Returned consent form to researchers 136 (31.7%) 74 (39.8%) 62 (25.5%) 0.002 
Sent patient questionnaire by researchers 136 74 62  
2 
Returned patient questionnaire to researchers 129 (94.9%) 71 (95.9%) 58 (93.5%) 0.53 
*Figures represent number sent and number (%) returned. 
5.3.2 Quantitative analyses  
5.3.2.1 Consenting patients’ demographics and dispensing data 
Table 62 displays the demographic parameters and dispensing data for all consenting 
patients. No significant differences between the persistent and non-persistent patients 
were observed in terms of age, gender or region of pharmacy. 
RM-experienced patients were significantly more likely to be persistent with tiotropium 
(35/50 [70.0%] were persistent, compared with only 39/86 [45.3%] of the RM-naïve 
patients; &2 = 7.7, df = 1, P < 0.01). 
Patients who were dispensed medication for co-morbidities in the past 12 months were 
also significantly more likely to be persistent with tiotropium (69/117 [59.0%] were 
persistent, compared with only 5/19 [26.3%] of the patients who were not dispensed 
medications for co-morbidities; &2 = 7.0, df = 1, P < 0.01). 
There was no significant difference in the proportion of persistent and non-persistent 
patients who had received antidepressant medications or who had received prescriptions 
at the concession rate in the past 12 months.  
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Table 62. Patient demographics and dispensing data 
Parameter All patients*      
(n = 136) 
Persistent†     
(n = 74) 
Non-persistent†       
(n = 62) 
P 
Age in years (mean ± SD) 68.7 ± 11.2 69.8 ± 9.4 67.3 ± 13.0 0.20 
Gender 
Male 69 (50.7%) 40 (58.0%) 29 (42.0%) 
Female 67 (49.3%) 34 (50.7%) 33 (49.3%) 
0.40 
Region of pharmacy 
Metro 94 (69.1%) 49 (52.1%) 45 (47.9%) 
Rural 42 (30.9%) 25 (59.5%) 17 (40.5%) 
0.42 
RM status 
RM-experienced 50 (36.8%) 35 (70.0%) 15 (30.0%) 
RM-naïve 86 (63.2%) 39 (45.3%) 47 (54.7%) 
0.005 
Medication dispensed for co-morbidities‡ 
Yes 117 (86.0%) 69 (59.0%) 48 (41.0%) 
No 19 (14.0%) 5 (26.3%) 14 (73.7%) 
0.007 
Antidepressant dispensed‡ 
Yes 35 (25.7%) 19 (54.3%) 16 (45.7%) 
No 101 (74.3%) 55 (54.5%) 46 (45.5%) 
0.99 
Prescriptions dispensed at concession rate‡ 
Yes 124 (91.2%) 68 (54.8%) 56 (45.2%) 
No 12 (8.8%) 6 (50.0%) 6 (50.0%) 
0.75 
*Figures represent number (%) of total patients. †Figures represent number (%) of patients in each 
parameter. ‡In the 12 months preceding identification. 
Consenting patients were representative of non-consenting patients in terms of all 
dispensing data parameters, with no significant differences demonstrated between the 
consenting and non-consenting patients in pharmacy region, RM status, whether 
medications had been dispensed for co-morbidities, whether antidepressants had been 
dispensed or whether prescriptions had been dispensed at the concessional rate in the 
past year (Table 63). 
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Table 63. Comparison of consenting and declining patients’ dispensing data 
Parameter All patients* Persistent† Non-persistent† 
 Consented    (n = 136) 
Declined‡    
(n = 293) 
Consented    
(n = 74) 
Declined    
(n = 112) 
Consented    
(n = 62) 
Declined    
(n = 181) 
Region of pharmacy 
Metro 94 (69.1%) 224 (76.5%) 49 (52.1%) 82 (36.7%) 45 (47.9%) 142 (63.4%) 
Rural 42 (30.9%) 69 (23.5%) 25 (59.5%) 30 (43.5%) 17 (40.5%) 39 (56.5%) 
P value 0.11 0.31 0.34 
RM status 
Naive 86 (63.2%) 204 (69.6%) 39 (45.3%) 61 (29.9%) 47 (54.7%) 143 (70.1%) 
Experienced 50 (36.8%) 87 (29.7%) 35 (70.0%) 51 (58.6%) 15 (30.0%) 36 (41.4%) 
P value 0.16 0.81 0.50 
Medication dispensed for co-morbidities§ 
Yes 117 (86.0%) 254 (86.7%) 69 (59.0%) 106 (41.7%) 48 (41.0%) 148 (58.3%) 
No 19 (14.0%) 37 (12.6%) 5 (26.3%) 6 (16.2%) 14 (73.7%) 31 (83.8%) 
P value 0.72 0.69 0.36 
Antidepressant dispensed§ 
Yes 35 (25.7%) 70 (23.9%) 19 (54.3%) 31 (44.3%) 16 (45.7%) 39 (55.7%) 
No 101 (74.3%) 221 (75.4%) 55 (54.5%) 81 (36.7%) 46 (45.5%) 140 (63.3%) 
P value 0.71 0.76 0.52 
Prescriptions dispensed at concession rate§ 
Yes 124 (91.2%) 261 (54.9%) 68 (54.8%) 105 (40.2%) 56 (45.2%) 156 (59.8%) 
No 12 (8.8%) 30 (10.2%) 6 (50.0%) 7 (23.3%) 6 (50.0%) 23 (76.7%) 
P value 0.63 0.63 0.51 
*Figures represent number (%) of patients. †Figures represent number (%) of patients in each parameter. 
‡Percentages may not add up to 100 due to the unavailability of two patients’ dispensing data. §In the 12 
months preceding identification.  
5.3.2.2 Exposure to COPD risk factors 
Table 64 displays the exposure of patients to COPD risk factors. No significant 
differences between the persistent and non-persistent patients were observed in terms of 
previous work exposure to dust, gas or chemical fumes, current exposure to passive 
cigarette smoke at home, current smoking status, number of cigarettes smoked per day 
or pack years. 
The majority of all patients (57.4%) had previously worked for a year or more in a job 
that regularly exposed them to dust, gas or chemical fumes. The majority of all patients 
(82.2%) had been regular smokers in the past, although only 19.4% were still smokers 
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(which skewed the current average number of cigarettes smoked per day amongst all 
patients to zero), and the majority (81.4%) currently lived in smoke-free homes.  
Table 64. Exposure to COPD risk factors* 
Risk factor All patients    
(n = 129) 
Persistent    
(n = 71) 
Non-persistent    
(n = 58) 
P 
Work exposure to dust, gas or chemical fumes† 
Yes 74 (57.4%) 39 (52.7%) 35 (47.3%) 
No 55 (42.6%) 32 (58.2%) 23 (41.8%) 
0.54 
Current home exposure 
People frequently smoke in 
the house 11 (8.5%) 7 (63.6%) 4 (36.4%) 
People occasionally smoke 
in the house 13 (10.1%) 4 (30.8%) 9 (69.2%) 
My home is smoke free 105 (81.4%) 60 (57.1%) 45 (42.9%) 
0.16 
Ever regularly smoked 
Yes 106 (82.2%) 58 (54.7%) 48 (45.3%) 
No 22 (17.2%) 13 (59.1%) 9 (40.9%) 
0.71 
Current smoker     
Yes 25 (19.4%) 11 (44.0%) 14 (56.0%) 
No 104 (80.6%) 60 (57.7%) 44 (42.3%) 
0.22 
Current number of cigarettes smoked per day  
All patients 0.0 (0.0 - 0.0) 0.0 (0.0-0.0) 0.0 (0.0 - 0.0) 0.42 
Current smokers 18.8 (11.3 - 30.0) 15.0 (10.6 - 27.5) 25.0 (13.8 - 30.0) 0.64 
Pack years 32.3 (11.3 - 49.8) 33.0 (6.0 - 49.0) 32.3 (13.9 - 51.7) 0.89 
*Figures represent number (%) of all patients or median (inter-quartile range). Percentages may not add 
up to 100 due to blank responses. †Exposure for a year or more. 
5.3.2.3 Respiratory-specific health status 
Table 65 displays the component scores and total score for the St. George’s Respiratory 
Questionnaire. No statistically significant differences between the persistent and non-
persistent patients’ scores were observed. However, dissimilarities between the Impacts 
score for persistent and non-persistent patients exceeded the threshold for a clinically 
significant difference of four units,593 with non-persistent patients displaying a higher 
degree of impairment. 
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Table 65. St. George's Respiratory Questionnaire scores* 
Component All patients        
(n = 129) 
Persistent         
(n = 71) 
Non-persistent         
(n = 58) 
P 
Symptoms 63.2 (47.8 - 79.3) 63.3 (49.0 - 78.3) 62.7 (45.2 - 83.6) > 0.99 
Activity 66.3 (49.6 - 85.9) 66.2 (52.0 - 85.9) 69.3 (47.7 - 85.9) 0.90 
Impacts 36.4 (21.9 - 51.5) 33.3 (18.9 - 49.7) 40.2 (24.1 - 52.4) 0.19 
Total 51.9 (37.1 - 64.7) 50.2 (33.7 - 62.0) 54.0 (38.7 - 66.9) 0.43 
*Figures represent median (inter-quartile range) score; higher scores indicate higher degrees of 
impairment. 
5.3.2.4 Illness perception 
Table 66 displays the component scores for the Illness Perception Questionnaire. 
Persistent patients had significantly higher scores for the item “how much do you think 
your treatment can help your respiratory condition?” (U = 1613.0, Z = 2.1, P < 0.05). 
There was a non-significant trend for persistent patients to have higher scores on the 
item “how much control do you feel you have over your respiratory condition?” 
(U = 1600.5, Z = 1.9, P = 0.06). No other significant differences in illness perception 
were observed. 
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Table 66. Illness Perception Questionnaire scores* 
Item All patients     
(n = 129) 
Persistent      
(n = 71) 
Non-persistent      
(n = 58) 
P 
How much does your respiratory 
condition affect your life?† 5.0 (3.0 - 8.0) 6.0 (3.0 - 8.0) 5.0 (3.0 - 8.0) 0.42 
How long do you think your 
respiratory condition will 
continue?‡ 
10.0 (10.0 - 10.0) 10.0 (10.0 - 10.0) 10.0 (9.0 - 10.0) 0.26 
How much control do you feel you 
have over your respiratory 
condition?§ 
6.0 (4.0 - 8.0) 7.0 (5.0 - 8.0) 5.0 (2.0 - 7.0) 0.06 
How much do you think your 
treatment can help your respiratory 
condition?¶ 
8.0 (5.0 - 10.0) 8.0 (6.0 - 10.0) 7.0 (4.0 - 10.0) 0.04 
How much do you experience 
symptoms from your respiratory 
condition?†† 
6.0 (3.8 - 8.0) 6.0 (4.0 - 8.0) 5.5 (3.0 - 8.0) 0.58 
How concerned are you about your 
respiratory condition?‡‡ 8.0 (5.0 - 10.0) 8.0 (5.0 - 10.0) 8.0 (5.0 - 10.0) 0.88 
How well do you feel you 
understand your respiratory 
condition?§§ 
10.0 (6.0 - 10.0) 10.0 (6.0 - 10.0) 10.0 (6.0 - 10.0) 0.97 
How much does your respiratory 
condition affect you emotionally? 
(e.g. does it make you angry, 
scared, upset or depressed?)¶¶ 
6.0 (2.0 - 8.0) 6.0 (2.0 - 8.0) 6.0 (1.0 - 8.0) 0.79 
*Figures represent median (inter-quartile range) score. †0 = no affect at all; 10 = severely affects my life. 
‡0 = a very short time; 10 = forever. §0 = absolutely no control; 10 = extreme amount of control. ¶0= not at 
all; 10 = extremely helpful. ††0 = no symptoms at all; 10 = many severe symptoms. ‡‡0 = not at all 
concerned; 10 = extremely concerned. §§0 = don’t understand at all; 10 = understand very clearly. 
¶¶0 = not at all affected emotionally; 10 = extremely effected emotionally. 
5.3.2.5 Beliefs about medicines  
Non-persistent patients had significantly higher scores for the item “medicines do more 
harm than good” (U = 1433.5, Z = 2.8, P < 0.01) from the Beliefs about Medicines 
Questionnaire, as displayed in Table 67. There was a non-significant trend for non-
persistent patients to have higher overall Harm score (U = 1647.5, Z = 1.8, P = 0.07). 
No other significant differences were observed. 
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Table 67. Beliefs about Medicines Questionnaires scores* 
Item All patients    
(n = 129) 
Persistent    
(n = 71) 
Non-persistent    
(n = 58) 
P 
Overuse items     
Doctors prescribe too many medicines 2.0 (2.0 - 3.0) 2.0 (2.0 - 3.0) 2.0 (2.0 - 3.0) 0.68 
Natural remedies are safer than medicines 2.0 (2.0 - 3.0) 2.0 (2.0 - 3.0) 3.0 (2.0 - 3.0) 0.14 
Doctors place too much trust on medicines 2.0 (2.0 - 3.0) 2.0 (2.0 - 3.0) 2.0 (2.0 - 4.0) 0.11 
If doctors had more time with patients they 
would prescribe fewer medicines 3.0 (2.0 - 4.0) 3.0 (2.0 - 3.0) 3.0 (2.0 - 4.0) 0.12 
Harm items     
People who take medicines should stop 
their treatment for a while every now and 
again 
2.0 (1.0 - 3.0) 2.0 (1.0 - 3.0) 2.0 (1.0 - 3.0) 0.10 
Most medicines are addictive 2.0 (2.0 -3.0) 2.0 (2.0 - 3.0) 2.0 (2.0 - 3.0) 0.54 
Medicines do more harm than good 2.0 (1.0 - 2.0) 2.0 (1.0 - 2.0) 2.0 (2.0 - 3.0) 0.005 
All medicines are poisons 2.0 (1.0 - 2.5) 2.0 (1.0 - 2.0) 2.0 (1.0 - 3.0) > 0.99 
Overuse score 10.0 (8.0 - 12.0) 10.0 (8.0 - 12.0) 11.0 (8.0 - 13.3) 0.14 
Harm score 8.0 (7.0 - 10.0) 8.0 (7.0 - 9.0) 9.0 (7.0 - 11.3) 0.07 
*Figures represent median (inter-quartile range) score; 1 = strongly disagree; 5 = strongly agree. 
5.3.2.6 Medication adherence behaviour 
As displayed in Table 68, persistent patients had significantly higher scores than non-
persistent patients on two of the adherence items (“I have strict routines for using my 
regular respiratory medications” [U = 1087.0, Z = 3.6, P < 0.001] and “I keep my 
respiratory medications close to where I need to use them” [U = 1417.5, Z = 2.2, 
P < 0.05]). Non-persistent patients had significantly higher scores than persistent 
patients on three of the non-adherence items (“I get confused about my respiratory 
medications” [U = 1439.0, Z = 2.1, P < 0.05], “I vary my recommended management 
depending on how I am feeling” [U = 1269.0, Z = 2.7, P < 0.01] and “I put up with my 
respiratory problems before taking any action” [U = 1181.0, Z = 3.4, P < 0.001]). 
Persistent patients had significantly higher total adherence scores, and significantly 
lower total non-adherence scores, than non-persistent patients (U = 1231.5, Z = 2.7, 
P < 0.01 and U = 1238.0, Z = 3.1, P < 0.01, respectively). 
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Table 68. Medication adherence items and scores* 
Item All patients     
(n = 129) 
Persistent     
(n = 71) 
Non-persistent     
(n = 58) 
P 
Adherence items     
I have strict routines for using my 
respiratory medications 5.0 (4.5 - 5.0) 5.0 (5.0 - 5.0) 5.0 (3.0 - 5.0) 0.0003 
I keep my respiratory medications close 
to where I need to use them 5.0 (5.0 - 5.0) 5.0 (5.0 - 5.0) 5.0 (5.0 - 5.0) 0.03 
I ensure I have enough respiratory 
medications so that I don’t run out 5.0 (5.0 - 5.0) 5.0 (5.0 - 5.0) 5.0 (5.0 - 5.0) 0.21 
I push myself to follow the instructions 
of my doctors 5.0 (3.0 - 5.0) 5.0 (3.3 - 5.0) 4.0 (3.0 - 5.0) 0.26 
Non-adherence items     
I get confused about my respiratory 
medications 1.0 (1.0 - 2.0) 1.0 (1.0 - 1.5) 1.0 (1.0 - 2.0) 0.04 
I make changes in the recommended 
management to suit my lifestyle 2.0 (1.0 - 3.0) 2.0 (1.0 - 3.0) 2.0 (1.0 - 3.0) 0.62 
I vary my recommended management 
depending on how I am feeling 2.0 (1.0 - 3.0) 1.0 (1.0 - 3.0) 3.0 (1.0 - 3.0) 0.005 
I put up with my respiratory problems 
before taking any action 2.0 (1.0-3.0) 1.0 (1.0 - 3.0) 3.0 (2.0 - 4.0) 0.0007 
Adherence score 19.0 (17.0 - 20.0) 20.0 (18.0 - 20.0) 17.0 (16.0  -20.0) 0.007 
Non-adherence score 8.0 (5.0 - 11.0) 7.0 (4.0 - 10.0) 10 (6.0 - 12.0) 0.002 
*Figures represent median (inter-quartile range) score; 1 = never; 5 = always. 
5.3.2.7 Anxiety and depression 
No significant differences were observed in persistent and non-persistent patents’ scores 
for the Hospital Anxiety and Depression Scale, as displayed in Table 69. 
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Table 69. Anxiety and depression items and scores* 
Item All patients    
(n = 129) 
Persistent    
(n = 71) 
Non-persistent    
(n = 58) 
P 
Anxiety items     
I feel tense or wound up 1.0 (0.0 - 2.0) 1.0 (0.0 - 2.0) 1.0 (0.0 - 2.0) 0.84 
I get a sort of frightened feeling as if 
something awful is about to happen 1.0 (0.0 - 2.0) 1.0 (0.0 - 2.0) 1.0 (0.0 - 2.0) 0.37 
Worrying thoughts go through my mind 1.0 (0.0 - 2.0) 1.0 (0.0 - 2.0) 1.0 (0.0 -2 .0) 0.39 
I can sit at ease and feel relaxed† 1.0 (0.0 - 1.0) 1.0 (0.0 - 1.0) 1.0 (1.0 - 1.0) 0.50 
I get a sort of frightened feeling like butterflies 
in the stomach 1.0 (0.0 - 1.0) 1.0 (0.0 - 1.0) 1.0 (0.0 - 1.0) 0.20 
I feel restless as if I have to be on the move 1.0 (0.5 - 2.0) 1.0 (0.0 - 2.0) 1.0 (1.0 - 2.0) 0.33 
I get sudden feelings of panic 1.0 (0.0 - 1.0) 1.0 (0.0 - 1.0) 1.0 (0.0 - 1.0) 0.90 
Depression items     
I still enjoy the things I used to enjoy† 1.0 (1.0 - 1.0) 1.0 (1.0 - 1.8) 1.0 (1.0 - 2.0) 0.81 
I can laugh and see the funny side of things† 0.0 (0.0 - 1.0) 0.0 (0.0 - 1.0) 0.0 (0.0 - 1.0) 0.56 
I feel cheerful† 0.0 (0.0 - 1.0) 0.0 (0.0 - 1.0) 0.0 (0.0 -1.0) 0.52 
I feel as if I am slowed down 2.0 (1.0 - 3.0) 2.0 (1.0 - 3.0) 2.0 (1.0 - 3.0) 0.40 
I have lost interest in my appearance 0.0 (0.0 - 1.0) 0.0 (0.0 - 1.0) 1.0 (0.0 - 1.0) 0.64 
I look forward with enjoyment to things† 1.0 (0.0 - 1.0) 1.0 (0.0 - 1.0) 1.0 (0.0 - 2.0) 0.26 
I can enjoy a good book or radio or TV 
program† 0.0 (0.0 - 1.0) 0.0 (0.0 - 0.0) 0.0 (0.0 - 1.0) 0.29 
Anxiety score 6.0 (3.3 - 10.0) 6.0 (3.0 - 10.0) 7.0 (4.0 - 10.0) 0.28 
Depression score 5.0 (3.0 - 8.0) 5.0 (3.0 - 7.0) 6.0 (4.0 - 8.0) 0.24 
*Figures represent median (inter-quartile range) score; 0 = no, not at all; 3 = yes, definitely. †Reverse-
scored. 
5.3.2.8 Multivariate analysis 
When logistic regression was performed on persistence, a model comprising all of the 
significant (P < 0.05) variables from univariate analyses explained 30.8% variance in 
persistence. Low agreement with the statement “medicines do more harm than good” 
and high agreement with the statement “I have strict routines for using my respiratory 
medications” were found to be significant independent predictors for persistence, as 
displayed in Table 70. These two variables together explained 20.3% variance in 
persistence in the study population. 
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Table 70. Multivariate predictors of persistence 
Predictor &2 P 
Dispensing data   
RM status 0.9 0.33 
Medication dispensed for co-morbidities in the past 12 months 3.0 0.08 
Questionnaire items   
How much do you think your treatment can help your respiratory condition? 1.2 0.27 
Medicines do more harm than good* 7.0 0.008 
I get confused about my respiratory medications 0.3 0.56 
I have strict routines for using my respiratory medications* 10.2 0.001 
I keep my respiratory medications close to where I need to use them 3.5 0.06 
I vary my recommended management depending on how I am feeling < 0.1 0.88 
I put up with my respiratory problems before taking any action 1.1 0.29 
*Significant independent predictor. 
A significant negative correlation was demonstrated between the two independent 
predictors of persistence; patients who agreed that medicine do more harm than good 
were less likely to have strict routines for using their respiratory medications (rs = 0.2, 
P < 0.05). 
5.3.3 Qualitative analyses 
5.3.3.1 Characteristics of interviewed patients  
A convenience sample of 48 patients (33 persistent and 15 non-persistent) participated 
in face-to-face interviews. Table 71 displays the characteristics of the patients who were 
interviewed. 
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Table 71. Characteristics of interviewed patients 
Parameter All interviewed patients*     
(n = 48) 
Persistent†‡      
(n = 33) 
Non-persistent†    
(n = 15) 
Age in years (mean ± SD) 64.3 ± 10.1 65.2 ± 9.3 62.1 ± 11.8 
Gender    
Male 21 (43.8%) 14 (66.7%) 7 (33.3%) 
Female 27 (56.3%) 19 (70.4%) 8 (29.6%) 
Region of pharmacy    
Metro 25 (52.1%) 15 (60.0%) 10 (40.0%) 
Rural 23 (47.9%) 18 (78.3%) 5 (21.7%) 
RM status    
RM-experienced 22 (45.8%) 13 (59.1%) 9 (40.1%) 
RM-naive 26 (54.2%) 20 (76.9%) 6 (23.1%) 
*Figures represent number (%) of patients. †Figures represent number (%) of patients in each parameter. 
Table 72 displays the characteristics of the interviewed patients as compared to the rest 
of the consenting patients. Interviewed patients were significantly younger than the rest 
of the consenting patients (64.3 ± 10.1 versus 71.2 ± 11.0 years; U = 1337.5, Z = 3.4, 
P < 0.001), and a significantly greater proportion of interviewed patients were identified 
from rural pharmacies compared to the rest of the consenting patients (23/48 [47.9%] 
versus 19/88 [21.6%]; &2 = 10.1, df = 1, P < 0.01). Interviewed patients were 
representative of the rest of the consenting patients in terms of gender, whether 
medications had been dispensed for co-morbidities, whether antidepressants had been 
dispensed or whether prescriptions had been dispensed at the concessional rate in the 
past year, smoking history, respiratory-specific quality of life and anxiety and 
depression scores. 
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Table 72. Characteristics of interviewed patients compared to the rest of the study population 
Parameter Interviewed*     
(n = 48) 
Not interviewed*     
(n = 88) 
P 
Age in years (mean ± SD) 64.3 ± 10.1 71.2 ± 11.0 0.0007 
Gender    
Male 21 (43.8%) 48 (54.5%) 
Female 27 (56.3%) 40 (45.5%) 
0.23 
Pharmacy region    
Metro 25 (52.1%) 69 (78.4%) 
Rural 23 (47.9%) 19 (21.6%) 
0.002 
RM status    
RM-experienced 22 (45.8%) 28 (31.8%) 
RM-naive 26 (54.2%) 60 (68.2%) 
0.11 
Medication dispensed for co-morbidities†    
Yes 42 (87.5%) 75 (85.2%) 
No 6 (12.5%) 13 (14.8%) 
0.71 
Antidepressant dispensed†    
Yes 9 (18.8%) 26 (29.5%) 
No 39 (81.3%) 62 (70.5%) 
0.17 
Prescriptions dispensed at concession rate†    
Yes 43 (89.6%) 81 (92.0%) 
No 5 (10.4%) 7 (8.0%) 
0.63 
Smoking history (pack years) 32.8 ± 27.1 34.3 ± 25.2 0.50 
SGRQ score: symptoms 62.8 ± 20.7 62.0 ± 22.9 0.92 
SGRQ score: activity limitation 61.8 ± 27.2 65.1 ± 26.8 0.39 
SGRQ score: impact  35.9 ± 21.5 37.8 ± 21.2 0.74 
SGRQ score: overall 48.1 ± 21.1 50.6 ± 20.9 0.44 
HADS score: anxiety 7.0 ± 5.0 7.1 ± 4.6 0.86 
HADS score: depression 5.9 ± 3.7 6.0 ± 3.8 0.95 
*Figures represent mean ± SD or number (%) of patients interviewed or not interviewed. †In the 12 
months preceding identification. 
When asked to describe their respiratory condition, patients used a variety of terms, 
including COPD, emphysema, asthma, chronic bronchitis, chronic cough and smoker’s 
cough. A number were told they had a combination of conditions. Figure 41 displays 
the proportion of terms used to describe the condition. 
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Figure 41. Terms used to describe respiratory condition !
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5.3.3.2 Common themes relating to persistence 
The common themes relating to persistence and non-persistence are summarised in 
Table 73. 
Table 73. Common themes relating to tiotropium persistence 
Drivers of persistence 
  
Barriers of persistence 
Fear Lack of explanation and emphasis by GPs 
Faith in GPs No perceived benefit 
Noticeable benefits Side effects 
Desire to live longer with an 
improved quality of life 
 
Confusion and fear of 
overmedicating 
 
5.3.3.3 Drivers of persistence 
Fear of what might happen if tiotropium was not taken appeared to be the strongest 
driver for persistence. This was most commonly cited as fear of not being able to 
breathe or dying:  
“I’m frightened that if I don’t take it [tiotropium], I’d wake up 
the next day not being able to breathe... I don’t want to die...” 
(Female, 67) 
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“... I am too frightened to miss [a dose of tiotropium] in case I 
get an attack and can’t breathe. I don’t want to go down that 
track again, that choking feeling in my neck is terrible...” 
(Female, 65) 
Patients were also afraid of becoming dependent on oxygen therapy, requiring systemic 
corticosteroids, and being embarrassed in public by attacks of productive coughing. 
They believed that taking their tiotropium every day would prevent or delay these 
occurrences: 
“The last thing I want to do is carry around a bottle with gas, it’s 
the last thing I want to do… I really don’t know what it would 
entail but the longer I can stay away from it the better.” 
(Male, 63) 
“Every time I tried to cut it [tiotropium] back I ended up in grief 
and I had the prednisolone for much longer than I would have 
liked so now I take the Spiriva® every day!” (Female, 44) 
Fear was always greater amongst those who had known someone who had died with 
emphysema: 
“I know of one bloke who’d still be here if he kept taking his 
medication. But he decided to give it all away. He died 
remarkably quickly.” (Female, 79) 
“The last time I was in hospital I was in a ward with three other 
gentlemen and two of them died, through emphysema and the 
other had emphysema and cancer. So that has played a big part 
emotionally on my life. I still remember those people gasping 
for air and trying to breathe and the doctors telling them there 
was no more hope and just keep them comfortable... it’s 
distressing in the sense... when you see people gasping for air 
and all of a sudden they’ve stopped and they’re gone, there’s no 
coming back, they’ve gone.” (Male, 62) 
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Persistent patients also had a basic faith and trust in GPs to persist with their tiotropium, 
even if they were not sure how beneficial it was: 
“There’s no point in seeking advice and then not taking it… He 
[the GP] said, ‘Take it! Take it!’ So I did feel once I’d taken it 
[tiotropium], that things were going better. It might have been 
pure coincidence.” (Female, 79) 
“The doctors are trained, not me. If you are not going to take the 
tablets or do what they tell you, what is the point of going there 
in the first place?” (Male, 52) 
“I would take it if he told me to take it. Why not? I can’t argue 
the point with him… they [doctors] tell you to do something, 
you do it don’t you?” (Male, 79) 
Many persistent patients had experienced noticeable benefits from tiotropium: 
“I was relieved to be put on it [tiotropium]. I can walk fast again 
and I go to the gym! I never want to be without it. I don’t want 
to get the same problems back that I had before. I like to feel 
better!” (Male, 71) 
“... I find that’s [tiotropium] helped me a lot actually so I just 
keep on with it... It helped a lot. See I was using a puffer quite 
often but a puffer now will last me probably 3 weeks where 
before it was lasting me a week.” (Female, 61) 
“You can’t cut off what helps you.” (Male, 58) 
There was also a strong desire to live for longer with an improved quality of life 
amongst persistent patients: 
“I want to see my granddaughter turn twenty-one. I want to see 
her turn ten, I want to see her turn five... We want to go to Hong 
Kong… Things like that you want to do and you want to do it 
full on.” (Male, 64) 
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“I don’t want to die! I’m having too much fun! Life is what you 
make it. I believe you gotta [sic] have plenty of friends and get 
out every day and I’m out every day and that’s the way I like 
it...” (Female, 65) 
“I can work. Not really heavy, but work good. Before I was 
more or less lying down and relaxing.” (Male, 68) 
Patients were often driven to persist with tiotropium for a variety of reasons, and the key 
drivers were often inter-related: 
“It [tiotropium] was just one of the medications he [the GP] 
prescribed. He knows about it. I don’t... He’s the expert; I take 
his word for it [TRUST IN GP]... I started them [tiotropium], 
say, hypothetically on a Monday. By the next Monday I’d sent 
him [the doctor] a thank you card. I wasn’t sitting up in bed half 
the night, cough, cough, cough. I could breathe so much better 
[NOTICEABLE BENEFITS]... It’s keeping me comfortable. 
Quality of life I think is extremely important and my quality of 
life has been well maintained by the medication I take at the 
moment… I still can’t walk up hill but I am able to do 
household duties so much better. It’s such a relief [DESIRE TO 
LIVE AN IMPROVED QUALITY OF LIFE].” (Female, 71) 
2.3.3.3 Non-persistence 
The strongest barrier to persistence appeared to be a lack of explanation and emphasis 
by GPs as to why tiotropium had been prescribed:  
“...He [the GP] said I had to take this inhaler [tiotropium] once a 
day for the rest of my life... He didn’t explain it or tell me what 
was wrong or why... If there was a problem I would’ve expected 
it [referral to specialist]. There obviously wasn’t a problem...” 
(Male, 63) 
“With taking both of them [tiotropium and fluticasone combined 
with salmeterol], [GP’s name] said we’ll just try this Spiriva®... 
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The Spiriva® was an afterthought in my mind. Because [GP’s 
name] said lets try it, it’s not quite the same importance as 
taking the Seretide®.” (Female, 71) 
“I get a bit breathless but the doctor has never said anything... 
They [his GPs] have never said anything about specific 
problems.” (Male, 63) 
This often led to a poor understanding of the diagnosed condition and unrealistic 
expectations of treatment, with patients discontinuing tiotropium if they did not perceive 
any benefit: 
“I expected that my lung capacity would increase. I thought 
that’s a good thing. It's [tiotropium] obviously going to loosen 
all the nicotine and tar up in my lungs. And I’m going to cough 
it up. So I expected to cough. I didn’t cough. So I thought it’s 
funny. I thought it’s not doing its job. It’s not worth having.” 
(Male, 63) 
“I tried it [tiotropium] and for about six weeks and I didn’t see 
any benefit. I didn’t notice anything... I’m not going to put 
anything into my body that I don’t need to...” (Male, 51) 
“Well with that Spiriva® I thought I’d feel it straight away but I 
didn’t... So I was like given a script for this and I’m going to the 
chemist and I get it filled and then he shows me how to do it all 
and oh, it’s a miracle you know. This miracle thing’s going to 
fix me. I was a bit disappointed because it didn’t.” (Female, 50) 
Unrealistic expectations of treatment also led to patients deciding to discontinue 
tiotropium on their own accord, if they who experienced side effects: 
“All it did was give me an unproductive cough so if it couldn’t 
help with me sputum there was no point in continuing.” 
(Male, 75) 
“I couldn’t get on with that Spiriva®, which I’ve got to go and 
tell him [the GP]... I was so hoarse I lost my voice and I 
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persisted with it for months and I couldn’t clear my throat... I 
gave it some time, several months. I don’t discard things quickly 
but I guess I wasn’t prepared to put up with the side effects... 
(Female, 71) 
Other patients were confused about the advice they had from GPs and were afraid of 
over-medicating, if they were already using another inhaled respiratory medication: 
“He [the GP] said he didn’t want to interfere with my other 
medication but I should give this a try. You know I didn’t want 
to double up, they did the same thing or so I thought... I didn’t 
see the point of taking both.” (Female, 71) 
“He [the GP] said I could take both, but I was a bit confused, 
they told me that the Spiriva® dilates the bronchial tubes just the 
same as the Seretide® only that the Spiriva® lasts longer and as 
it’s only once a day... I’ll switch over but I won’t take both.” 
(Female, 69) 
5.4 Discussion 
5.4.1 Recruitment of participants 
5.4.1.1 Pharmacist participation 
Approximately 50% of Tasmanian pharmacies use the Fred dispensing system. The 
responses of pharmacists to the expression of interest form showed a very high 
proportion of pharmacists (approximately 84%) used the Fred dispensing system and 
were willing to participate. However, it should be noted that the researchers targeted 
those pharmacists for recruitment who were known (or suspected) users of the Fred 
dispensing system, and who had successfully participated in data mining studies 
previously. The proportions of metropolitan and rural pharmacies (approximately 72% 
and 28% respectively) that participated in the study closely reflected the total 
proportions of metropolitan and rural pharmacies (80% and 20% respectively) in 
Tasmania.597 
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5.4.1.2 Identification of patients 
An average of 36 patients were identified by each pharmacy. In-house testing of the 
MedeMine-for-COPD program and the identification criteria ensured an approximate 
even split of persistent and non-persistent patients per pharmacy; just over half of the 
identified patients were classed as persistent, and just under half were classed as non-
persistent. The split of recent and late non-persistent patients was approximately even. 
There was a significant difference in the proportion of persistent and non-persistent 
patients identified in rural and metropolitan pharmacies, with a greater proportion of 
persistent patients being identified in rural pharmacies. Anecdotal evidence suggests 
that pharmacists in rural pharmacies tend to have more time available to spend with 
patients and may be more likely to prompt patients to refill their tiotropium 
prescriptions. However, this difference may have simply been a result of patients 
tending to be more loyal clients in rural pharmacies. Indeed, once patients who were not 
regular clients had been excluded from each pharmacy, no significant differences 
between the persistent and non-persistent patients were observed in terms of pharmacy 
region. 
5.4.1.3 Patient exclusions 
MedeMine-for-COPD was programmed to include a maximum of 10 persistent patients 
per pharmacy. Upon running the MedeMine-for-COPD program, persistent patients 
were ranked by the date of first tiotropium dispensing, and after the 10 most recent 
dates, the rest of the patients were automatically excluded. Furthermore, an additional 
11 pharmacies were recruited to the study in an attempt to increase the numbers of non-
persistent patients. All of the persistent patients were excluded in these pharmacies 
under the reason ‘not required.’ This algorithm accounted for over half of all the patient 
exclusions. 
The possibility of patients receiving tiotropium from other pharmacies was recognised 
as a potential limitation of the identification algorithm for non-persistence. It was 
possible that patients identified by the MedeMine-for-COPD program as non-persistent 
had simply received their tiotropium from a different pharmacy. Indeed, the most 
common reason for exclusion by the pharmacist was ‘not a regular patient,’ accounting 
for about three-quarters of all the exclusions made by pharmacists and nearly 90% of 
the non-persistent patient exclusions made by pharmacists. 
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In addition to the pre-defined exclusion criteria, three other reasons for exclusion 
emerged. These were ‘patient has a language barrier,’ ‘patient is disabled’ and ‘patient 
is illiterate.’ These were obvious barriers to completing a questionnaire and/or an 
interview. 
It was not surprising that no persistent patients were excluded as being deceased, as the 
identification algorithm specified that persistent patients had to have received 
tiotropium recently (at least two supplies in the last 90 days). In addition, no persistent 
patients were excluded for being younger than 40 years old. It was probably less likely 
that patients under the age of 40 were diagnosed with COPD, and were probably more 
likely to have been prescribed a short trial of tiotropium for another condition, such as 
asthma.  
5.4.1.4 Patient participation 
It was not surprising that significantly more persistent patients agreed to participate than 
non-persistent patients. It is plausible that non-persistent patients did not believe the 
study would be relevant to them and therefore did not participate. This was despite the 
fact that the patient information sheet (Appendix 47) stated that the researchers were 
interested in studying people’s experience with respiratory medication regardless of 
whether they had ceased their medication.  
It is essential that the offer of incentives be kept in mind when interpreting patient 
response rates in this study. It was interesting that signing a consent form seemed to 
have more of an effect on response rates than the offer of monetary incentives. After 
sending out invitations to participate with the offer of incentives, approximately one-
third of the patients consented to participate. This initial response rate of approximately 
30% was considered to be quite low, given that the average patient response rate to 
postal questionnaires (with monetary incentives) reported in medical journals is 
approximately 50-80%.598-600 The low response rate for patients consenting to 
participate may have led to a degree of self-selection bias, which should be borne in 
mind when interpreting the results. However, after signing the consent form, the 
responses to the questionnaire rose to over 90%.  
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5.4.2 Quantitative analyses 
5.4.2.1 Consenting patients’ demographics and dispensing data 
The finding that significantly more non-persistent patients were RM-naïve was in 
keeping with the results of a Canadian study of treatment persistence in COPD.565 
Cramer et al. reported that most RM-naïve patients had significantly shorter treatment 
persistence for tiotropium than RM-experienced patients (27% versus 55% at 12 
months, respectively, P < 0.0001). The authors explained this finding based on the 
assumption that previous use of respiratory medications may be a marker for respiratory 
disease severity and therefore an increased likelihood of medication persistence.  
It was not surprising that patients who were dispensed medications for co-morbidities in 
the past 12 months were significantly more likely to be persistent with tiotropium. The 
collection of other medications would bring the patient into more regular contact with 
their community pharmacist, who could have monitored the patient’s supply of 
tiotropium, and reminded them to collect their next supply and when they were due for a 
new prescription. 
The likelihood of persistence was not statistically different between patients who had 
and had not received antidepressant medication in the past 12 months. This was a 
reasonable finding, given the multitude of indications for antidepressant medication, 
which is not always used to treat depression, and may have been used to treat other 
conditions such as neuropathic pain, anxiety and urge incontinence. Furthermore, 
patients who were non-persistent with tiotropium may have also been non-persistent 
with antidepressant medication. Therefore, patients’ HADS scores were probably a 
more reliable test of whether mental state had any effect on persistence, as discussed 
later. 
In the Australian population, use of respiratory medications is reported to be higher 
amongst people living in metropolitan areas, who may have more accessible healthcare 
services, and people with concession cards, who are able to purchase medications at a 
much cheaper price.270 It was therefore expected that tiotropium persistence would be 
higher amongst metropolitan and concessional patients. However, the low number of 
rural patients and non-concessional patients may have prevented any statistically 
significant difference in persistence from being detected. It was reasonable that more 
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than 90% of all patients were concessional, given that the average age was over 60 
years; thus many patients would have been pensioner-concession cardholders. 
5.4.2.2 Exposure to COPD risk factors 
No significant differences between the persistent and non-persistent patients were 
observed in terms of previous work exposure to dust, gas or chemical fumes, current 
exposure to passive cigarette smoke at home, current smoking status, number of 
cigarettes smoked per day or pack years. Exposure to these risk factors can be divided 
into current exposure (current exposure to passive cigarette smoke at home, current 
smoking status and number of cigarettes smoked per day) and previous exposure 
(previous work exposure to dust, gas or chemical fumes, ever regularly smoked 
cigarettes and pack years). It is understandable that previous exposure may not affect 
current behaviours in persistence. While it is conceivable that current exposure to 
COPD risk factors (particularly self-inflicted exposure) may predict persistence to 
COPD medication, the low numbers of patients who were currently exposed to risk 
factors may have prevented any statistically significant difference in persistence from 
being detected. 
5.4.2.3 Respiratory-specific health status 
Although there were no statistically significant differences between the persistent and 
non-persistent patients’ SGRQ scores, dissimilarities between the Impacts score for 
persistent and non-persistent patients exceeded the threshold for a clinically significant 
difference of four units.593 The minimum clinically important difference is the threshold 
that detects a ‘just-noticeable-difference’ within or between patients.601 Taking the 
minimum threshold for a clinically important difference into account, non-persistent 
patients displayed a higher degree of impairment. In particular, the Impacts component 
of the SGRQ was made up of questions that assessed the impact of COPD on daily life, 
activities and work, as well as the impact of respiratory medication on daily living. A 
possible explanation is that persistent patients were benefiting from the effects of 
appropriate drug treatment, and therefore displayed fewer disturbances of psychosocial 
function due to COPD. 
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5.4.2.4 Illness perception 
Persistent patients had higher scores for how much control they felt they had over their 
respiratory condition, and for how much they thought their treatment could help their 
respiratory condition. It is likely that perception of treatment control and personal 
control are inter-connected. To speculate, a patient who believed their treatment could 
not help their condition may have felt that they did not have any control over their 
condition as a consequence. It is therefore reasonable to expect that if a patient believed 
that tiotropium did not and could not help their respiratory condition, they may have 
chosen to cease their therapy. This finding is consistent with the Health Belief 
Model,602,603 which suggests that a patient’s perception of the effectiveness of a 
recommended action (e.g. taking medication) predicts the likelihood of taking that 
action. This is also consistent with the qualitative analysis, with many non-persistent 
patients describing a lack of perceived benefit from treatment with tiotropium. 
Available data suggests that a stronger emotional representation of illness, that is, how 
much an illness affects a person emotionally, has been negatively associated with 
personal control and treatment control beliefs, and a stronger belief in treatment control 
has been associated with fewer symptoms associated with the illness.604 In addition, 
people who have not yet received a diagnosis for their symptoms report lower treatment 
control beliefs.581 This is also in keeping with the qualitative analysis of non-persistent 
patients, with many patients describing a lack of explanation and emphasis by GPs as to 
why tiotropium had been prescribed, leading to a poor understanding of the diagnosed 
condition and unrealistic expectations of treatment. 
5.4.2.5 Beliefs about medicines 
A number of studies have reported that medication beliefs explain a significant portion 
of variation in medication non-adherence.266,605-607 This study demonstrated that non-
persistent patients were significantly more likely to believe that medicines do more 
harm than good. This is consistent with reports that patients’ fear of adverse effects is an 
important barrier to medication adherence.608-611 This finding is also consistent with the 
Health Belief Model,602,603 which suggests that a patient’s perception of susceptibility 
(e.g. risk of suffering an adverse drug event), severity (e.g. seriousness of an adverse 
drug event), barriers (e.g. tangible and psychological costs of taking the prescribed 
medication) and benefits (e.g. positive consequences of taking the prescribed 
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medication) predict behavioural response to treatment. It is evident that increased 
awareness of patients’ beliefs about medicines is needed among healthcare providers, 
and patients should be encouraged to express their views about medicine in order to 
optimise and personalise their therapy. 
Low agreement with the statement “medicines do more harm than good” remained a 
significant independent predictor of persistence in the multivariate analysis. This study 
therefore identified a specific patient cognition relating to medication that can act as 
either a help or a hindrance to treatment persistence. Identification of this cognition can 
facilitate the development of interventions that modify or take account of specific 
patient perceptions.  
5.4.2.6 Medication adherence behaviour 
Non-persistence represents a form of non-adherence. It was therefore not surprising that 
persistent and non-persistent patients had significantly different scores for more than 
half of the TABS items, or that the total adherence and non-adherence scores remained 
significantly different. Non-persistent patients had significantly higher scores than 
persistent patients on three of the non-adherence items (“I get confused about my 
respiratory medications,” “I vary my recommended management depending on how I 
am feeling” and “I put up with my respiratory problems before taking any action”). 
Interestingly, two of these items (“I get confused about my respiratory medications” and 
“I vary my recommended management depending on how I am feeling”) were found to 
be significant independent predictors of non-adherence in an Australian study of 
patients with COPD.572  
Persistent patients had significantly higher scores than non-persistent patients on two of 
the adherence items (“I have strict routines for using my regular respiratory 
medications” and “I keep my respiratory medications close to where I need to use 
them”). Out of all the TABS items, the item “I have strict routines for using my regular 
respiratory medications” had the strongest significant difference between persistent and 
non-persistent patients (P < 0.001), and remained a significant independent predictor of 
persistence in the multivariate analysis. Qualitative analysis provided further insight to 
why persistent patients had strict medication routines, and persisted with the 
medication. 
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5.4.2.7 Anxiety and depression 
This study showed no significant differences in persistent and non-persistent patents’ 
scores for the Hospital Anxiety and Depression Scale. This is consistent with the 
finding that the likelihood of persistence was not statistically different between patients 
who had and had not received antidepressant medication in the past 12 months.  
Psychiatric co-morbidity is common in patients with COPD. Up to 40% are clinically 
depressed; a similar number also experience moderate to high levels of anxiety.612-616 
Both depression and anxiety result in lower health status and greater functional 
impairments, and depression has been linked with lower medication adherence.617 
Additionally, a stable family life with caregivers who provide support and 
encouragement is associated with improved medication-taking behaviour.618 
The instruction at the introduction to the HADS is to best indicate how the respondent 
has felt ‘in the past week.’ As it is a measure of current symptoms of mood disorders, 
this may have limited the likelihood of the scores relating to persistence, because the 
decision to cease therapy may have occurred up to 12 months ago according to the 
definition of non-persistence.  
5.4.2.8 Multivariate analysis 
Low agreement with the statement “medicines do more harm than good” and high 
agreement with the statement “I have strict routines for using my respiratory 
medications” were found to be significant independent predictors for persistence. 
Furthermore, a significant negative correlation was demonstrated between the two 
items; patients who agreed that medicines do more harm than good were less likely to 
have strict routines for using their respiratory medications. As the former item is a 
belief, whereas the latter item is a behaviour, it is reasonable to expect that patients’ 
perception of the risks and benefits of medication determine their routinisation of 
respiratory medication use. This relationship seems to support the possibility that 
patients’ perception of the risks and benefits of medication could be independently 
targeted for an interventional strategy to improve persistence and medication-taking 
behaviour. 
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5.4.3 Qualitative analysis 
5.4.3.1 Characteristics of interviewed patients  
The interviewed patients’ characteristics were not exactly matched to the rest of the 
consenting patients. This can be explained by the fact that the interviewed patients were 
a convenience sample rather than a random sample and the fact that representation in 
the sample was largely due to the willingness of participants or whether they had time to 
participate in an interview. Other drivers for the difference included cost and scheduling 
of interviews (scheduling being more important) in that the interviews had to be done in 
specific geographic locations.  
Interviewed patients were significantly younger than the rest of the consenting patients. 
This was not surprising, as the younger patients tended to be more desirable candidates 
for interviewing, in that they tended to have more detailed memories of the initial 
diagnosis of their respiratory condition and initial prescription of tiotropium. 
Furthermore, only one patient over the age of 80 was interviewed, as the other two 
patients over the age of 80 who had booked in for an interview were too ill to 
participate. 
A significantly greater proportion of interviewed patients were identified in rural 
pharmacies compared to the rest of the consenting patients. Of the patients who were 
not interviewed, less than a quarter were identified in rural pharmacies, whereas an 
approximately even number of metropolitan and rural patients were asked to participate 
in interviews to ensure any drivers and barriers relating to region could be identified. 
Interviewed patients were representative of the rest of the consenting patients in terms 
of gender, whether medications had been dispensed for co-morbidities, whether 
antidepressants had been dispensed or whether prescriptions had been dispensed at the 
concessional rate in the past year. 
5.4.3.2 Persistence 
Fear of what might happen if tiotropium was not taken appeared to be the strongest 
driver for persistence. The consequences of not taking tiotropium that patients were 
fearful of were both short-term (not being able to breathe, embarrassment due to 
coughing and producing phlegm in public and requiring systemic corticosteroids) and 
long-term (missing out on life and requiring supplemental oxygen therapy). Other 
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research has demonstrated that patients with COPD who are adherent with their 
medication have a higher perceived influence of management over the future course of 
COPD.619 
Persistent patients also demonstrated a basic faith and trust in their GP’s advice. This 
trust was apparent for both long-term GPs (10-15 years) and where patients had new 
doctors every two to three years. Some younger patients, while they respected their 
doctor’s training, did not endow all GPs with the same level of confidence and respect, 
as did the older patients. In most cases, patients felt that their tiotropium did make 
‘some’ difference but their trust in their GP leant itself towards ensuring that they 
trialled their medication for long enough for it to take effect. However, those with 
considerable faith in their GP accepted their explanations more fully and sometimes 
took treatment solely on the GP’s advice. Satisfaction and faith in the treating doctor are 
known from other studies to be critical for optimal adherence in both COPD and other 
patient populations.572,620 
Not surprisingly, persistent patients had experienced noticeable benefits from 
tiotropium. Persistent patients’ expectations of the benefits of tiotropium seemed to be 
more realistic than those of the non-persistent patients. For example, persistent patients 
expected tiotropium to ease their shortness of breath, whereas many non-persistent 
patients expected a reduction of phlegm production and coughing. An Australian study 
demonstrated that patients with COPD who are adherent with their medication have 
greater confidence that their management will keep their illness under control.572 
Persistent patients possessed a strong desire to live for longer with an improved quality 
of life, and believed that continuing to take their tiotropium everyday would help them 
achieve these things. These patients focussed more on the long-term benefits of taking 
tiotropium rather than day-to-day improvements, usually had a positive outlook on life 
and had a supportive family.  
5.4.3.3 Non-persistence 
The strongest barrier to persistence appeared to be a lack of explanation and emphasis 
by GPs as to why tiotropium had been prescribed, leading to a poor understanding of the 
diagnosed condition and unrealistic expectations of treatment. It is known that poorer 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 247 
patient knowledge about their disease and treatment negatively affects medication-
taking behaviour.572,620 
Interestingly, a recent qualitative study of Tasmanian GPs found that making a 
diagnosis of COPD by GPs is often delayed, and that this delay may be intentional.621 
The study also found that even after a diagnosis had been made, it was often not 
communicated to patients. Not communicating a formal diagnosis to patients was 
rationalised by misperception of patients’ unwillingness to be given a diagnosis and 
GPs’ pessimistic attitudes to prognosis.621 These results highlight the need for efforts to 
increase the awareness and understanding of COPD in the community, and education 
for GPs to reduce their nihilistic attitudes towards the condition. 
While a lack of explanation and emphasis by GPs as to why tiotropium had been 
prescribed was identified as a barrier to persistence, it was not a sole reason for 
discontinuation of therapy. Rather, it was likely to lead to unrealistic expectations of 
treatment and misconceptions about the risks and benefits of tiotropium. These patients 
were then more likely to discontinue therapy for the common reasons identified; a 
perceived lack of benefit, experiencing adverse effects, fear of potential adverse effects 
and confusion with fear of over-medicating. Beliefs about medication not working and 
concerns about long-term effects have previously been identified as reasons for non-
adherence amongst patients with COPD.619 The reasons for non-persistence with 
tiotropium are consistent with the Health Belief Model,602,603 and the results 
demonstrate that patients tend to perform their own-risk/benefit analysis on the 
prescribed medication, the outcome of such an analysis being strongly influenced by the 
emphasis given by GPs at the time of initial prescribing. 
5.4.4 Study limitations 
There are limitations to this study, which are integral to the interpretation of both the 
quantitative and qualitative findings. An important limitation was the presumption that 
patients collected their medication exclusively from the pharmacy from which they 
were identified. This may have resulted in incorrect classification of patients as non-
persistent, if they collected tiotropium from another pharmacy. To account for this, 
patients who more obviously used multiple pharmacies were excluded at the outset, 
however this may have resulted in the exclusion of some patients who may have been 
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more likely to be non-persistent or non-adherent because they did not have a consistent 
relationship with their pharmacist.  
It is also important to recognise that dispensing data does not verify administration. The 
data does, however, directly address the question of availability. Clearly, patients cannot 
persist with a drug therapy if they have not obtained the prescribed drug, so persistence 
is secondary to availability. 
While this study used quantitative and qualitative methods to analyse medication 
persistence, it did not provide any evidence as to which measure has more accuracy in 
predicting persistence. Medication persistence and adherence can be estimated using a 
variety of methods, including the use of biologic assays of drug in body fluids, pill 
counts, electronic monitoring and self-report, and it is recognised that each method has 
its limitations and that a gold standard measure does not exist.552  
Lastly, there may have been a degree of self-selection bias, as significantly more 
persistent patients agreed to participate than non-persistent patients. It is therefore 
possible that more predictors for non-persistence that were not identified in this study 
may exist. This was controlled for in some degree by the dispensing data comparison of 
consenting and non-consenting patients, which revealed no significant differences. The 
low response rate for patients consenting to participate (approximately 30%) may have 
also led to a degree of self-selection bias, which should be borne in mind when 
interpreting the results. 
5.5 Conclusions  
This was an innovative study, which utilised a largely untapped health resource - 
community pharmacists and their computerised prescription data - to help identify 
patients with COPD as evidenced by their use of tiotropium. The data mining software, 
compatible with the Fred dispensing system, identified an average of 15 non-persistent 
patients per pharmacy. Approximately 2,250 of the 4,500 pharmacies in Australia use 
Fred Dispense. Therefore, if the software was available to all compatible pharmacies in 
Australia, approximately 33,750 non-persistent patients could be identified and targeted 
for an intervention aiming to improve tiotropium persistence.  
The quantitative and qualitative analyses of patients who were identified by their 
pharmacy dispensing records as persistent or non-persistent with tiotropium identified 
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key variables relating to medication persistence. In the quantitative analysis, low 
agreement with the statement “medicines do more harm than good” and high agreement 
with the statement “I have strict routines for using my respiratory medications” were 
found to be significant independent predictors for persistence. In the qualitative 
analysis, patients’ perceptions of the risks and benefits of tiotropium, which appeared to 
be strongly influenced by personal experience and the prescriber’s attitude, were found 
to be determinants of persistence. The drivers of persistence identified in this study were 
consistent with perceptions that taking tiotropium was more likely to result in 
favourable outcomes, whereas the barriers of persistence were consistent with 
perceptions that taking tiotropium was more likely to result in ineffectual or harmful 
outcomes. Identification of these variables can facilitate the development of 
interventions that modify or take account of specific patient adherence behaviours and 
perceptions about the risks and benefits of medication. It is evident that increased 
awareness of the patients’ beliefs about medicines is needed among healthcare 
providers, and patients should be encouraged to express their views about medicine. In 
particular, patients need to be more informed about the long-term benefits of tiotropium 
therapy and that, in most cases, the potential benefits outweighs the potential risks of 
therapy. The development of a more collaborative relationship between patients and 
healthcare providers is also necessary in order to optimise and personalise their therapy 
and prompt patients to refill their tiotropium prescriptions.  
 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 250 
PART FOUR: 
GENERAL DISCUSSION AND CONCLUSIONS 
All of the work described in this thesis showed that community pharmacists and their 
dispensing records can be effectively utilised to identify management issues in patients 
with asthma and COPD. The use of electronic information technologies to manage 
health information is likely to generate many benefits for patients in terms of improved 
quality and continuity of care. However, it also greatly increases the potential for patient 
information to be collated, to be combined with information from different sources, and 
to be used and disclosed - all potentially without the knowledge of the patient, for 
purposes that they may or may not consider to be in their interests.622 
Throughout the studies performed in this thesis, there were two potential points in the 
utilisation of health information that may have raised privacy concerns amongst 
patients: 
• The use of data mining by the community pharmacist to identify and contact 
patients; and 
• The analysis of de-identified dispensing records by the researchers. 
Although protecting confidentiality in healthcare is usually paramount, the legal 
obligation is not absolute. There are some occasions when sharing information is 
encouraged. In the case of community pharmacists using dispensing records to identify 
and contact patients with asthma or COPD management issues, they are acting in the 
best interests of the patient’s health. In accordance with the National Privacy Principles, 
health information may be used or disclosed for a secondary purpose other than the 
primary purpose for which it was collected if the use by a healthcare professional is 
reasonably necessary for provision of a further health service to the patient.623 
• An Australian qualitative study found that while patients see their personal health 
information as private, they want to share this information with healthcare 
professionals in order to facilitate communication and good treatment decisions 
 In fact, in contrast to family, friendship circles and community contexts, the patient-
healthcare professional relationship was the only one where there was no reservation 
about sharing the health information.624 Another Australian study recently found that 
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older patients with multiple chronic medical conditions believe that improving the 
quality of their healthcare outweighs the risk of losing health information privacy.625 
The analysis of patients’ de-indentified dispensing data without obtaining consent in 
this study brings up a second issue relating to patient privacy. There is professional 
consensus that consent must be obtained from patients prior to their inclusion in 
research studies, but there is less agreement when such involvement is restricted to 
collecting information from patient records. Although some believe that failure to seek 
consent is always wrong,626 it has been argued that collection of data from records 
without seeking patient consent can be justified, providing certain minimal conditions 
are met.627,628 These conditions include research when the patients’ data is de-identified, 
the invasiveness and risks of the research are negligible, the requirement for informed 
consent might jeopardise methodological rigour, and a research ethics committee has 
waived the requirement to seek consent for pressing and justifiable reasons.  
There is growing concern that sharing health information data, in particular for research, 
may influence patients’ willingness to divulge clinically relevant information to 
healthcare professionals. This in turn may compromise professionals’ ability to provide 
optimum care. It is important that patients trust healthcare professionals and are not 
deterred from seeking treatment for fear that their personal information may be 
disclosed without authorisation or consent.629 
A study carried out in the United Kingdom aimed to explore the views and attitudes of 
patients regarding the sharing of health information data, with particular reference to 
data sharing for research purposes and the impact that this may have on the trust 
between patients and healthcare professionals.630 Interestingly, patients generally saw 
concepts such as audit and national disease registries positively and were happy for 
anonymous data to be shared in order to monitor and promote good standards of care. 
Furthermore, surveys from 1,719 patients with asthma and 1,710 patients with stable 
angina showed that only 9.8% refused consent to the collection of data from their 
clinical records.631 
Although privacy must be safeguarded, the safeguards need not be inconsistent with the 
goal of obtaining complete data and advancement of knowledge. Sadly, around the 
world, data repositories are now at risk of significant bias because concern about patient 
privacy has led to the requirement that consent be obtained before an individual’s data 
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can be included.632 For example, a Canadian study showed that obtaining written 
informed consent for inclusion in a stroke registry led to important selection bias.633 
Similarly, in the 2006-07 pilot asthma study, intervention patients who returned the 
baseline questionnaires were found to have a significantly higher preventer-to-reliever 
ratio and daily usage of ICS than those who did not return the questionnaires. In other 
words, patients who had better asthma management tended to return the 
questionnaires.5,304 Thus, patients who actively participate in research are often not 
representative of the entire population of interest, a phenomenon termed ‘authorisation 
bias.’634 These findings highlight the importance of developing new privacy legislation 
and policies allowing waivers of informed consent for minimal-risk research on the 
ground of impracticability. A reasonable alternative way of obtaining data from a 
representative sample of patients is to collect de-identified data from patient’s medical 
records without obtaining consent but with appropriate confidentiality safeguards in 
place.633 Indeed, this method was employed as a way of collecting and analysing 
medication data in all of the studies described in this thesis.  
Issues in asthma and COPD management in Australia are well documented.3,4 Despite 
its national health priority status, the management of asthma remains a problem in 
Australia. Research has shown that a significant proportion of people with asthma still 
do not have a written AAP, have poorly controlled asthma and over-rely on their 
reliever medication.6 Patients need to be more educated about asthma and the need for 
regular preventive therapy and monitoring, so that their perceptions of asthma control 
are more realistic. Healthcare professionals should also work together to encourage 
patients to be more forthcoming about their asthma symptoms, so that their therapy can 
be tailored and optimised to ensure adequate asthma control.  
There is irrefutable evidence that COPD is a significant public health problem in 
Australia. Unlike asthma, however, it is not a National Health Priority area, despite a 
mortality rate ten times that of asthma and annual costs that exceed $8 billion.7,8 This 
suggests a lack of awareness of the present and future burden from COPD, perceptions 
and societal stigmas around its cause, and insufficient understanding of its public health 
importance.9 In order to reduce the burden of COPD in Australia, it is imperative that 
healthcare professionals develop a collaborative management approach to ensure the 
early and accurate diagnosis of COPD, which can then drive the implementation of 
effective treatments. Patients should also be encouraged to express their views about the 
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condition and its treatment in order to optimise and personalise their therapy, ensuring 
adherence and persistence with prescribed medications. 
Pharmacists are ideally placed in the healthcare system to address asthma and COPD 
management issues and they have the necessary skills to communicate with other 
healthcare providers and patients themselves to improve these conditions. There is 
enormous scope for community pharmacists to become the feedback link between 
patients and GPs, which would answer the societal need for improved management of 
asthma and COPD. Community pharmacists are trained in counselling and educating 
patients about their condition and prescribed medications, and have access to patients’ 
dispending records, meaning they are uniquely placed to monitor medication adherence 
issues. 
Community pharmacists assisted in the implementation of all of the projects described 
in this thesis. While there clearly is the potential for community pharmacists to have an 
impact in improving the management of asthma and COPD, such approaches are most 
likely to be successful if they can be easily integrated into pharmacists’ workflow, and 
the need for further research testing strategies that are pragmatic in busy community 
pharmacies has been identified.10-14 
Time has clearly been identified in pervious studies as a major factor that significantly 
prevents community pharmacists from undertaking any additional extended role in 
healthcare.11-14,340,341 The workload in community pharmacy practice is such that 
research is perceived as having low priority because it would have to be taken on as an 
additional role.11 The projects described in this thesis required minimal time and 
additional training on the part of the pharmacist, and could be easily integrated into their 
workflow. Pharmacists assessed the projects favourably, and believed that they were a 
positive move towards recognition of their role in patient care. 
This body of work presents a number of solutions to issues surrounding the 
management of asthma and COPD in the community. With the knowledge gained from 
the results of these projects and using aspects of interventions described in this thesis, 
community pharmacists have the potential to dramatically improve the management of 
these conditions. Community pharmacists have the necessary skills to communicate 
with other healthcare providers and patients themselves to improve the management of 
asthma and COPD, and software tools such as MedeMine can aid in the efficient 
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 254 
targeting of patients. A national roll-out of the asthma intervention, and a specifically 
designed COPD intervention may result in better health outcomes for patients, and 
ultimately less burden on the health system. 
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Appendix 1. GP invitation letter 
 
 
 
 
 
 
Improving the management of asthma 
 
<Date> 
 
Dear <GP’s name> 
 
The Tasmanian School of Pharmacy is currently undertaking a follow-up research project 
aiming to determine the feasibility of a community pharmacy intervention to improve the 
management of asthma, conducted in 2006-07. 
As part of this follow-up project, general practitioners, community pharmacists and patients 
who were previously involved in the intervention project will be interviewed, to explore their 
views on the management of asthma, their perceived roles of health professionals and their 
perceived feasibility of a community pharmacist initiated intervention. This will help to 
determine what practice changes are required to successfully implement the asthma 
intervention on a national scale.  
How can you help? 
 
Once your consent form is received, a researcher will contact you to schedule a face-to-face 
interview. We estimate that the interview will take 20 to 30 minutes, and upon the completion 
of the interview, you will receive remuneration of $200 for your time. 
If you have any queries regarding the project’s procedures, please contact Bonnie Bereznicki 
at the Tasmanian School of Pharmacy on 6226 2191 or bonnie.bereznicki@utas.edu.au. 
Yours sincerely,
 
Bonnie Bereznicki B.Pharm (Hons) 
Clinical Research Pharmacist and PhD Candidate 
Unit for Medication Outcomes Research and Education 
Tasmanian School of Pharmacy 
University of Tasmania 
Private Bag 26 
Hobart Tasmania 7001 
Ph (03) 6226 2191 
Fax (03) 6226 7627 
Bonnie.Bereznicki@utas.edu.au 
 
 
 
Dr Shane Jackson B.Pharm (Hons) PhD 
Senior Research Fellow 
Unit for Medication Outcomes Research and Education 
Tasmanian School of Pharmacy 
University of Tasmania 
 
All you have to do is: 
1. Read the enclosed Project Information Sheet and Participant Consent Form 
2. Sign the Participant Consent Form and send it to the University using the 
postage paid envelope provided or fax it to 6226 7627. 
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Appendix 2. Project information sheet 
 
 
 
 
 
 
Improving the management of asthma 
 
PROJECT INFORMATION SHEET 
 
Why this research is needed 
Asthma affects over 2 million Australians and causes thousands of hospital admissions each 
year. Recent findings suggest that the management of Asthma in Australia needs to be 
improved.!
Aim of this research 
The aim of this research is to gain insight into people’s perceptions of community pharmacist 
initiated interventions to improve asthma management. 
About the project 
The project is being conducted by the Tasmanian School of Pharmacy and is a follow-up of a 
previous Tasmanian intervention project that encouraged people with poorly controlled 
asthma to review their condition with their doctor. The intervention resulted in a three-fold 
improvement in the management of asthma, measured by a significant shift towards patients 
using preventer medication and relying less on reliever medications. There were also 
significant improvements in self-reported asthma control and quality of life. 
As part of this follow-up project, people with asthma, as well as doctors and pharmacists will 
be interviewed, exploring their views regarding the management of asthma and the feasibility 
of a community pharmacist initiated intervention. The project will form part of a PhD thesis, 
which aims to improve the management and quality of life of Tasmanians with asthma. 
How can you help? 
 
 
What happens next? 
If you return a signed consent form, a researcher will contact you, and a time will be arranged 
for a face-to-face interview. An expert in qualitative research will conduct all of the 
interviews, and you will not be required to discuss any issues of a sensitive nature. With your 
permission, the interview will be digitally recorded, so that common views amongst 
interviewees can be compared. The interview will take no more than one hour, and upon the 
completion of the interview, you will receive remuneration of <amount> for your time. 
Special note on privacy 
Please be assured that your privacy will be maintained, and no one at the University will be 
able to identify the information that you provide. Your name and address will not be sent to 
the University unless you send them the signed consent form. 
All you have to do is: 
1. Read and sign the enclosed consent form 
2. Send it to the University using the postage paid envelope or fax it to 6226 7627. 
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Appendix 3. Participant consent form 
 
 
This project is funded by the Commonwealth Department of Health and Ageing and the Asthma Foundations 
Australia via an Asthma Targeted Intervention Grant. 
 
 
 
 
Improving the management of asthma 
 
PARTICIPANT CONSENT FORM 
By signing this consent form I am agreeing to participate in this research project and declare that; 
1 I have read and understood the ‘Project Information Sheet’ for this research project.  
2 I acknowledge that the nature, purpose and contemplated effects of the project so far as it affects 
me, and I understand that my consent is given voluntarily. 
3 I understand that the project involves the following procedures: 
! Upon signing the consent form and mailing it to the researchers, I will be contacted regarding 
the scheduling of a face-to-face interview. 
! The interview will be about my views on asthma, its management, and the role and feasibility 
of a community pharmacist initiated intervention to improve the management of asthma in the 
community. 
! The interview will be digitally recorded and analysed. 
4 I understand that all research data will be securely stored on the University of Tasmania premises 
for at least five years, and will then be destroyed. 
5 Any questions that I have asked have been answered to my satisfaction. 
6 I agree that research data gathered from me for the study may be published provided that I cannot 
be identified as a participant. 
7 I understand that the researchers will maintain my identity confidential and that any information I 
supply to the researchers will be used only for the purposes of the research. 
8 I agree to participate in this investigation and understand that I may withdraw at any time without 
any effect, and if I so wish, may request that any data I have supplied to date be withdrawn from 
the research. 
9 I understand that I am not giving up my legal rights by signing this consent form. 
10 I understand that the project has received ethical approval from the Tasmanian Social Sciences 
Human Research Ethics Committee. I have been provided with adequate contact details if I wish 
to express any concerns of an ethical nature or complaints about the manner in which the project is 
conducted. 
 
Name of Participant:…………………………………………………………………………………....... 
 
Address:………………………….……………………………………………......................................... 
 
………………………………………………………………………………………………...………..... 
 
Daytime telephone number:…………………….  Email address:............................................................. 
 
Preferred day and time of interview:.......................................................................................................... 
 
Signature of Participant: ………………………………………......………  Date:……………………... 
Please mail the signed consent form to the University of Tasmania 
in the postage paid envelope provided or fax it to  6226 7627. 
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Appendix 4. Pharmacist invitation letter 
 
 
 
 
 
 
 
Improving the management of asthma 
 
<Date> 
 
Dear colleague, 
 
The Tasmanian School of Pharmacy is currently undertaking a follow-up research project 
aiming to determine the feasibility of a community pharmacy intervention to improve the 
management of asthma, conducted in 2006-07. The intervention encouraged people with 
poorly controlled asthma to review their condition with their doctor. The result was a three-
fold improvement in the management of asthma, measured by a significant shift towards 
patients using preventer medication and relying less on reliever medications. 
 
As part of this follow-up project, community pharmacists, general practitioners and patients 
who were previously involved in the intervention project will be interviewed, to explore their 
views on the management of asthma, their perceived roles of health professionals and their 
perceived feasibility of a community pharmacist initiated intervention. This will help to 
determine what practice changes are required to successfully implement the asthma 
intervention on a national scale. The project will also form part of a PhD thesis, which aims to 
improve the management and quality of life of Tasmanians with asthma. 
 
We are writing to you to ask for your involvement in this important project. Should you wish 
to assist us, you will be asked to participate in a face-to-face interview and/or assist with the 
recruitment of patients for interviews. An expert in qualitative research will conduct all of the 
interviews, and you will not be required to discuss any issues of a sensitive nature. We 
estimate that the interview will take 30 to 40 minutes, and upon the completion of the 
interview, you will receive remuneration of $100 for your time. 
 
We are also inviting pharmacists to assist with the recruitment of patients for face-to-face 
interviews. If you are interested in participating in the recruitment phase, you will be asked to 
mail invitation letters and consent forms to approximately 10 patients who previously 
participated in the intervention. A researcher will provide you with the ID numbers of former 
participants from your pharmacy. These codes are linked to the Fred dispensing system and 
will re-identify the patients, allowing you to send out invitation letters and consent forms. To 
protect patients’ privacy, you will not be required to disclose any patients’ identities to the 
researchers without their consent. We anticipate that this will require approximately 
15 minutes of your time. In order to thank you for your assistance with the patient 
recruitment, we are offering $50 to compensate you for your time. In addition, the project will 
cover associated stationery and postage costs. 
 
The project has received ethical approval from the Tasmanian Social Sciences Human 
Research Ethics Committee. If you have any concerns of an ethical nature or complaints 
about the manner in which the project is conducted, you may contact the Executive Officer of 
the Tasmanian Human Research Ethics Committee (Tasmania) Network on 6226 7479 or 
human.ethics@utas.edu.au. You will need to quote ethics reference number H10378. 
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The project is being funded by the Asthma Foundations Australia, and it is intended that the 
results will be disseminated to Australian GPs and pharmacists by presentations at national 
meetings and in peer-reviewed journals. We can assure you that no identifying information 
relating to patients, doctors or pharmacists will be disseminated. All project results will be de-
identified and pooled. 
Enclosed is an “Expression of Interest” form for you to return to us. Please indicate whether 
or not you are willing and able to participate in a face-to-face interview and/or assist with the 
patient recruitment process. You can either fax the form it back to us on 6226 7627 or send it 
back to us in the reply paid envelope provided.  
 
If you have any queries about this project please contact Bonnie Bereznicki at the Tasmanian 
School of Pharmacy on telephone 6226 2191 or email bonnie.bereznicki@utas.edu.au. We 
will be contacting you shortly to discuss your willingness to participate in this project. 
 
Yours sincerely
 
Bonnie Bereznicki B.Pharm (Hons) 
Clinical Research Pharmacist and PhD Candidate 
Unit for Medication Outcomes Research and Education 
Tasmanian School of Pharmacy 
University of Tasmania  
Private Bag 26 
Hobart Tasmania 7001  
Ph (03) 6226 2191  
Fax (03) 6226 7627  
Bonnie.Bereznicki@utas.edu.au 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dr Shane Jackson B.Pharm (Hons) PhD  
Senior Research Fellow 
Unit for Medication Outcomes Research and Education 
Tasmanian School of Pharmacy 
University of Tasmania
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Appendix 5. Pharmacist expression of interest form 
 
 
 
 
 
 
 
Improving the management of asthma 
 
Expression of Interest 
 
Attention: Bonnie Bereznicki 
 
  Yes, I am interested in participating in the research project, Improving the management 
of asthma, being conducted by the Tasmanian School of Pharmacy. In particular, I am 
interested in:  
 Participating in a face-to-face interview, and/or 
 Assisting with the patient recruitment process 
 
 
  Sorry, I am not able to participate in this project. 
 
 
 
Name of Pharmacist(s) <pharmacist’s name> 
Pharmacy Name: <pharmacy name> 
Pharmacy Address: <pharmacy address line 1> 
 <pharmacy address line 2> 
 
 
 
 
 
 
Private Bag 26 Hobart 
Tasmania Australia 7001 
Telephone  6226 2191 
Facsimile  6226 7627 
!"##$%&!%'%(#$)*$+,-./&%0,&., 
 
 
Please return this form to the Tasmanian School of Pharmacy in the reply paid 
envelope provided or fax it to 6226 7627. 
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Appendix 6. Pharmacist interview letter 
 
 
 
 
 
Improving the management of asthma 
 
Pharmacist interviews 
 
<Date> 
 
Dear <Pharmacist’s name>, 
 
Thankyou for expressing an interest in participating in a qualitative interview for the research 
project Improving the management of asthma, being conducted by the Tasmanian School of 
Pharmacy. Please find enclosed a Project Information Sheet and Participant Consent Form.  
 
 
 
Once your consent form is received, a researcher will contact you to schedule a face-to-face 
interview. We estimate that the interview will take 30 to 40 minutes, and upon the completion 
of the interview, you will receive remuneration of $100 for your time. 
 
If you have any queries or concerns about this project please contact Bonnie Bereznicki at the 
School of Pharmacy on telephone 6226 2191 or email bonnie.bereznicki@utas.edu.au.  
 
Once again, thankyou for your assistance with our research. 
 
Yours sincerely,
 
Bonnie Bereznicki B.Pharm (Hons)  
Clinical Research Pharmacist and PhD Candidate 
Unit for Medication Outcomes Research and Education  
Tasmanian School of Pharmacy  
University of Tasmania  
Private Bag 26  
Hobart Tasmania 7001  
Ph (03) 6226 2191 
Fax (03) 6226 7627 
Bonnie.Bereznicki@utas.edu.au 
 
 
 
 
 
 
 
 
 
Dr Shane Jackson B.Pharm (Hons) PhD 
Senior Research Fellow 
Unit for Medication Outcomes Research and Education 
Tasmanian School of Pharmacy 
University of Tasmania 
 
All you have to do is: 
1. Read the enclosed Project Information Sheet and Participant Consent Form 
2. Sign the Participant Consent Form and send it to the University using the 
postage paid envelope provided or fax it to 6226 7627. 
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Appendix 7. Patient recruitment instructions 
 
 
 
 
 
Improving the management of asthma 
 
Patient recruitment instructions 
 
<Date> 
 
Dear <Pharmacist’s name>, 
 
Thankyou for agreeing to assist with the patient recruitment process for the research project 
Improving the management of asthma, being conducted by the Tasmanian School of 
Pharmacy. Please find enclosed <number> patient recruitment packs. Each pack contains a 
blank postage paid envelope, an Invitation Letter, a Project Information Sheet, a Participant 
Consent form and a University-addressed postage paid envelope. 
 
The ID numbers of the former participants from your pharmacy are: 
 
<ID number> 
<ID number> 
<ID number> 
<ID number> 
 
Entering these numbers, one at a time, into the patient field in Fred Dispense should identify 
the participants’ names.  
 
Once you have identified the potential participants, please write their name on the top of the 
Invitation Letter, and sign the letter. Please place the Invitation Letter, a Project Information 
Sheet, a Participant Consent Form and a University-addressed postage paid envelope inside a 
blank postage paid envelope and address the envelope to the patient, and place it in the mail. 
 
Please note that no identifying information will be released to the researchers unless the 
patient signs the consent form and returns it to the University. Once your patients’ consent 
forms are received, a researcher will contact them to schedule a face-to-face interview. We 
estimate that the interview will take no longer than one hour, and upon the completion of the 
interview, they will receive remuneration of $50 for their time. 
 
In order to thank you for your assistance with this study, we are offering $50 to compensate 
you for your time and professional input. To receive payment, please generate a tax invoice 
for $50 (inclusive of GST) with a description of professional services rendered - ATIG 
project, and mail or fax to: 
 
Kimbra Fitzmaurice 
Unit for Medication Outcomes Research and Education 
Tasmanian School of Pharmacy 
University of Tasmania 
Private Bag 26  
Hobart TAS 7001 
Facsimile: 6226 7627 
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Appendix 8. Patient invitation letter 
 
 
<proprietor name> 
<pharmacy name> 
<pharmacy address line 1> 
<pharmacy address line 2> 
Ph: <ph num> 
 
 
Improving the management of asthma 
 
<Date> 
 
Dear <patient’s name> 
 
The Tasmanian School of Pharmacy is currently undertaking a follow-up research project 
aiming to determine the feasibility of a community pharmacy intervention to improve the 
management of asthma, conducted in 2006-07. 
As part of this follow-up project, people with asthma, as well as doctors and pharmacists will 
be interviewed, to explore their views on the management of asthma, their perceived roles of 
health professionals and their perceived feasibility of a community pharmacist initiated 
intervention. This will help to determine what practice changes are required to successfully 
implement the asthma intervention on a national scale.  
How can you help? 
 
 
Once your consent form is received, a researcher will contact you to schedule a face-to-face 
interview. The interview will take no more than one hour, and upon the completion of the 
interview, you will receive remuneration of $50 for your time. 
Please be assured that you name and private information has not been released to the 
University. Your name and address will not be sent to the University unless you send them 
the signed consent form. 
If you have any questions about this project, or your asthma, please give me a call at the 
pharmacy.  
Yours sincerely, 
 
 
<pharmacist’s name> 
All you have to do is: 
1. Read the enclosed Project Information Sheet and Participant Consent Form 
2. Sign the Participant Consent Form and send it to the University using the 
postage paid envelope provided or fax it to 6226 7627. 
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Appendix 9. Discussion guide for qualitative interviews 
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Appendix 10. Pharmacist invitation letter 
 
 
 
 
 
 
 
Improving the management of asthma 
<Date> 
 
Dear <Pharmacist’s name>, 
 
As a healthcare provider in your local community you would be aware that one of the major 
contributing factors to both morbidity and mortality of patients with asthma is their over-
reliance of reliever medication, and under-use of preventive medication. A number of studies 
have shown that a high usage of relieve medication, relative to preventer medication, is 
associated with poorer clinical outcomes in asthma. With over 2 million Australians affected 
by asthma and with regular use of preventive medication estimated as low as 14%, we are 
seeking your assistance. 
 
The Tasmanian School of Pharmacy at the University of Tasmania is currently undertaking a 
research project aiming to improve the management of asthma. We are writing to you to ask 
for your involvement in our project, which requires the use of Fred Dispense. A data mining 
software tool has been developed for Fred Dispense, which enables easy identification of 
patients who may benefit from review of their asthma therapy. Fred Dispense are aware and 
supportive of this project. Your role as the community pharmacist, if you choose to 
participate, will involve assisting with the patient identification process and the provision of 
an educational intervention, either by mail or in person over a six-week period. 
 
The research project will assess the uptake and effect of face-to-face and mailed interventions, 
delivered by community pharmacists. Each participating pharmacy will be randomly assigned 
to deliver only one type of intervention. Use of the data mining software tool ensures that the 
intervention process is streamlined, and can be easily incorporated into busy community 
pharmacy practice. Please refer to the attached synopsis for details regarding the project’s 
methods and procedures.  
 
If you would like to be involved or require further information about the project, please 
complete the attached form and either fax it back to the Tasmanian School of Pharmacy on 
6226 7627 or send it back to us in the reply paid envelope provided.  
 
In order to thank you for your assistance with this study, we are offering $200 to compensate 
you for your time and professional input into this project. In addition, the project will cover 
stationery and postage costs relevant to project participation. 
 
The project has received ethical approval from the Tasmania Health and Medical Human 
Research Ethics Committee. If you have any concerns of an ethical nature or complaints about 
the manner in which the project is conducted, you may contact the Executive Officer of the 
Tasmanian Human Research Ethics Committee (Tasmania) Network on 62267479 or 
human.ethics@utas.edu.au. You will need to quote ethics reference number H9823.  
 
The project is funded by the Department of Health and Ageing under the Fourth Community 
Pharmacy Agreement Research and Development Program, administered by the Pharmacy 
Guild of Australia. We can assure you that no identifying information relating to patients, 
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doctors or pharmacists will be disseminated. All project results will be de-identified and 
pooled for statistical analysis prior to a final report and publication. 
 
If you have any queries regarding this project please contact Bonnie Bereznicki at the 
Tasmanian School of Pharmacy on 6226 2191. We will be contacting you shortly to discuss 
your willingness to participate in this project. 
 
Yours sincerely, 
 
 
Bonnie Bereznicki B.Pharm (Hons) 
Clinical Research Pharmacist and PhD Candidate  
Unit for Medication Outcomes Research and Education  
Tasmanian School of Pharmacy  
University of Tasmania  
Private Bag 83 Hobart 
Tasmania  7001  
Telephone  6226 2191  
Facsimile  6226 7627 
Bonnie.Bereznicki@utas.edu.au  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dr Shane Jackson B.Pharm (Hons) PhD  
Senior Research Fellow 
Unit for Medication Outcomes Research and Education  
Tasmanian School of Pharmacy  
University of Tasmania  
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Appendix 11. Project synopsis for pharmacists 
 
 
 
 
 
 
 
 
Pharmacy dispensing records to identify and educate patients with  
suboptimal asthma management 
 
Project Synopsis 
 
This multi-centre project will develop strategic linkages across general practice and 
community pharmacy that, along with patient empowerment, will enhance the management of 
asthma. It will utilise a largely untapped health resource - community pharmacists and their 
computerised prescription data - to help identify and educate patients with suboptimal 
management of asthma. These patients will be identified from their dispensed medication 
history - in particular, a high provision of asthma reliever medication will be used. These 
patients will be provided with educational material from their pharmacist and advised to seek 
a review of their asthma management from their general practitioner.  
 
A software application that extracts data from the market leading pharmacy dispensing 
software system in Australia (Fred Dispense) developed by the research team will be refined. 
Community pharmacies using the Fred dispensing system throughout Tasmania, Victoria and 
South Australia will be invited to participate, and with their permission, a researcher will 
install the software application on the dispensing computer. 
 
The software will interrogate the dispensing history and produce a list of patients who have 
received six or more canisters of short-acting beta-2-agonists in the preceding 12 months 
(with at least three relievers in each six-month period). This indicates that the patient may be 
using on average three or more inhalations per day of reliever medication, which is in excess 
of contemporary guidelines for optimal asthma control. The software excludes patients 
receiving inhaled anticholinergic therapy or methylxanthines, indicating the likely presence of 
chronic obstructive pulmonary disease (COPD), or leukotriene-receptor antagonists indicating 
the probable diagnosis of severe asthma under the care of a respiratory specialist. Identified 
patients will be randomised to an intervention or control group. The participating pharmacist 
will examine the dispensing information for each patient identified and will be able to exclude 
patients from being sent an invitation to participate if they believe the patient is aged under 18 
years, is residing in an aged care facility, is deceased, is significantly cognitively or would be 
alarmed excessively by participating in the project. Once a patient is deemed suitable for 
inclusion, the software will print materials required for an intervention pack. 
 
This project will test the uptake and effectiveness of two types of community pharmacist 
interventions; intervention patients will either receive a mailed personalised letter and 
intervention pack or an ‘alert flag’ will be placed in their personal details within the 
dispensing system so that the pharmacist can give them an intervention pack with appropriate 
counselling on their next visit to the pharmacy. The intervention will occur over a six-week 
period, to allow time to mail intervention packs, or time for patients to visit the pharmacy to 
receive a face-to-face intervention. The intervention pack will consist of the following 
information: 
! a computer-generated personalised letter, suggesting the patient visit their GP and seek a 
review of their asthma management. 
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This project is funded by the Pharmacy Guild of Australia Fourth Community Pharmacy Agreement  
Research and Development Program via an Investigator Initiated Grant 
 
! an educational leaflet about asthma, 
! computer-generated asthma control, quality of life, and medication adherence 
questionnaires, 
! a computer-generated letter (and medication history) to give to their GP, and 
! a computer-generated GP satisfaction/perception survey of the intervention to give to 
their GP. 
 
Control patients will receive usual care until follow-up, 12 months later. At this time they will 
receive an intervention pack and all intervention patients will receive repeat asthma-related 
questionnaires. Changes in asthma medication usage and questionnaire scores will be 
examined. Patient, pharmacist and GP satisfaction with the program will also be assessed. A 
pilot study demonstrated major improvements in the use of preventer medication at follow-up, 
and GPs, pharmacists and patients were highly satisfied with the intervention. 
 
All participating community pharmacists will be provided with the study’s key outcomes. It is 
intended that the results of the study will not only improve the management of asthma, but 
also demonstrate the most effective level of intervention required to reach that outcome. The 
project will also trial a valuable new role for community pharmacists - assisting in the 
detection of suboptimal use of medicines, including poor adherence to therapy, with the aid of 
information technology. Importantly, the solution requires minimal training and time 
commitments from pharmacists, and will be easily incorporated into busy community  
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This project is funded by the Pharmacy Guild of Australia Fourth Community Pharmacy Agreement  
Research and Development Program via an Investigator Initiated Grant 
 
 
 
 
Pharmacy dispensing records to identify and educate patients with  
suboptimal asthma management 
Pharmacies ranked by approval number, and 
then randomly allocated to perform mailed or 
personal intervention 
Report generated and patients ranked 
according to use of reliever medications 
Patients receiving six or more reliever 
medications in preceding 12 months, with at 
least three in each six month period 
Intervention group 
- Pharmacist deems eligibility 
- Patients receive (either mailed or in person) 
individualised information letter, education 
materials and letter to give to GP 
- Asthma control, QOL and medication 
adherence questionnaires supplied 
- De-identified dispensing information provided 
to researchers 
Intervention group 
- Repeat asthma control, QOL and medication 
adherence questionnaires 
- Patient satisfaction questionnaires also 
supplied 
- De-identified dispensing information provided 
researchers 
Patients receiving any drug on exclusion 
list: ipratropium, tiotropium, zafirlukast, 
montelukast, theophylline 
Patients receiving less than six relievers in 
preceding 12 months, or less than three in 
each preceding six month period 
Control group 
- Information stored for 12 months, pharmacist 
blinded to control patients 
- No education or information provided at this 
stage. 
- De-identified information provided to 
researchers 
Control group 
- Pharmacist deems eligibility. 
- Patients receive individualised information 
letter, education materials and letter to give to 
GP 
- Asthma control, QOL and medication 
adherence questionnaires supplied. 
- De-identified dispensing information provided 
to researchers 
12 months 
Excluded 
Excluded 
Key: 
Project methods 
Program algorithm 
Randomisation 
Identification of patients dispensed any 
asthma-related medication in the last 12 
months and not flagged as deceased 
Run software application 
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Appendix 12. Pharmacist expression of interest form 
 
 
 
 
 
 
 
 
 
Improving the management of asthma 
 
 
Attention: Bonnie Bereznicki 
 
 
  Yes, our pharmacy uses Fred Dispense, and we are willing to participate in the project, 
Pharmacy dispensing records to identify and educate patients with suboptimal asthma 
management, being conducted by the Tasmanian School of Pharmacy. Please contact us 
to discuss the details further. 
 
 Sorry, we do not use Fred Dispense 
 
  Sorry, we use Fred Dispense but don’t feel able to participate in this project. 
 
 
Pharmacist Name: .......................................................... 
 
Pharmacy Name: .......................................................... 
 
Pharmacy Address: .......................................................... 
 
 .......................................................... 
 
Pharmacy Phone:  .......................................................... 
 
Pharmacy Fax .......................................................... 
 
Signature of pharmacist …………………………………… Date…………………….. 
 
 
 
 
Private Bag 83 Hobart 
Tasmanian, Australia 7001 
Telephone  6227 2191 
Facsimile  6226 7627 
Bonnie.Bereznicki@utas.edu.au 
 
Please return this form to the Tasmanian School of Pharmacy in the reply paid 
envelope provided or by faxing it to us on  6226 7627. 
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Appendix 13. GP project information sheet 
 
 
 
Improving the control of asthma 
 
GENERAL PRACTITIONER PROJECT INFORMATION SHEET  
 
Why this project is needed 
One of the major contributing factors to both morbidity and mortality of patients with asthma 
is their over-reliance on reliever medication, and under-use of preventive medication. A 
number of studies have shown that a high usage of reliever medication, relative to preventer 
medication, is associated with poorer clinical outcomes in asthma. With over 2 million 
Australians affected by asthma and only 14% of patients indicating regular use of preventive 
medication, we are seeking your assistance. 
 
About this project 
The project is being conducted by the University of Tasmania’s School of Pharmacy with the 
help of selected pharmacies in Tasmania. A software program has been developed, which 
enables pharmacists to identify patients with asthma whose control may be suboptimal. 
Patients who receive six (6) or more reliever medications dispensed from the pharmacy in the 
last 12 months will be identified. Patients who are likely to have chronic obstructive 
pulmonary disease (i.e. receiving anticholinergic bronchodilators) will be excluded.  
Patients are given educational material (developed by the Asthma Foundation) from the 
pharmacy and advised to seek a review of their asthma management from their GP. In order 
to help us learn more about how asthma affects people in the community, patients will also be 
asked to compete surveys about their asthma. Patient and GP surveys will be used to evaluate 
uptake and effectiveness of the intervention program. 
The project has the support and involvement of the Tasmanian Divisions of General Practice. 
 
Special note on privacy 
Please be assured that your patient’s identity has not been released to the University. No one 
at the University can identify the information that you or your patients provide; the survey 
forms are anonymous. No identifying information relating to patients, doctors or pharmacists 
will be disseminated. All project results will be de-identified and pooled for statistical 
analysis prior to a final report and publication. 
 
Contact Information 
If you have any concerns or queries about the project, please contact your local participating 
pharmacist, or Bonnie Bereznicki at the Tasmanian School of Pharmacy on telephone 
6226 2191 or email bonnie.bereznicki@utas.edu.au. 
The project has received ethical approval from the Tasmanian Health and Medical Human 
Research Ethics Committee. If you have any concerns of an ethical nature or complaints about 
the manner in which the project is conducted, you may contact the Executive Officer of the 
Tasmanian Human Research Ethics Committee (Tasmania) Network on 6226 7479 or 
human.ethics@utas.edu.au. You will need to quote ethics reference number H9823. 
 
 
 
This program is funded by the Australian Government Department of Health and Ageing 
as part of the Fourth Community Pharmacy Agreement through the Fourth Community 
Pharmacy Agreement Grants Program managed!"#!$%&!'%()*(+#!,-./0!12!3-4$)(/.(!
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Appendix 14. MedeMine-for-Asthma instructions for researchers 
 
 
 
 1 
Pharmacy dispensing records to identify and educate 
patients with suboptimal asthma management 
Instructions for installing and running MedeMine  
 
Step 1. Obtain a portable copy of the MedeMine program 
Download the updated version of MedeMine from: 
http://www.pharmacy.utas.edu.au/UMORE/downloads/Medeminev2.1.24.exe 
This icon will appear on your desktop. It is the installation package. 
 
Copy this icon to your USB device. 
Step 1. Locate the Fred Server 
If the pharmacist is unsure which computer is the Fred Server, you can check in Fred, by 
going to Setup (one of the options at the top of the main Fred screen):  
 
 
 
 
 
 
Select System Configuration: 
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 2 
If you are using the Fred Server, the Station will be MAIN, if you are not at the Fred Server, 
the Station will be TERMINAL: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 3. Install MedeMine 
Plug your USB device into the Fred Server computer.  
Copy the installation package from your USB device to the Fred Server’s desktop. Double-
click on the installation package icon to start the installation.  
This screen will appear. Please wait. 
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After a brief pause you will see this screen. Click Enter Passwords.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enter the following password: 
bAnan4 [bAnan(four)] for pharmacies randomised to type 1 (mailed) intervention, OR 
0rag3s [(zero)rang(three)s] for pharmacies randomised to type 2 (face-to-face) intervention. 
(Note: the password only has to be entered when the program is opened for the first time) 
The list of intervention patients will now appear. 
 
 
Refer to the Pharmacist’s Instructions. Go through these instructions with the pharmacist to 
ensure that they are confident with how to use the MedeMine program. Once the pharmacist 
is confident, you can close the MedeMine program. 
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Step 5. Close the MedeMine program 
When the MedeMine program closes, this screen will appear: 
 
When this is complete, this screen will appear. 
 
Step 6. Obtain a back-up of the de-identified dispensing data 
Insert your USB stick into the Server’s USB drive. 
Go to My Computer and open the C-drive.  
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Locate and double-click on Program Files. Locate and double click on MedeMine.  
Locate and right-click on the Data folder, select Copy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copy the Data folder to your USB device 
Right-click to re-name the Data folder with the pharmacy’s approval number. This will aid in 
keeping track of which data comes from which pharmacy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eject your USB device. You are now ready to visit the next pharmacy. 
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Appendix 15. Pharmacist instructions for mailed intervention 
 
 
 
 1 
Pharmacy dispensing records to identify and educate 
patients with suboptimal asthma management 
 
Intervention type I 
 
Your simple step-by step instructions to successfully 
participate in this project 
 
1. Install the MedeMine program on the Fred server 
2. Run the program to identify eligible patients 
3. Exclude any intervention patients as necessary 
4. Mail packs to each included intervention patient 
5. Document any feedback 
6. Six-week follow-up 
7. Run the program again in 12 months  
8. Mail follow-up letter and surveys to each included 
intervention patient 
9. Exclude any control patients as necessary 
10. Mail packs to each included control patient 
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Additional Notes - Internet 
The program requires an active Internet connection to send information to the server at the 
University of Tasmania. 
Only de-identified and encrypted information is sent to the secure server. The program uses a 
1024 bit key to securely send information. 
If an Internet connection is not available the program will prompt you to connect to the 
Internet.  If you do not connect to the Internet the program will still work, and will send the 
information using the Internet at a later time. 
Every time the MedeMine program closes, this screen will appear. This shows that the de-
identified and encrypted information is being sent to the secure server at the University. 
 
When this is complete, this screen will appear. 
 
 
Step 4. Mail packs to each included intervention patient 
The first thing you need to do is to check that the printer is set up correctly. The program 
should have automatically selected the printer that you normally print notes or CMIs to.  
To check if the program has selected the correct printer; click on the picture of the printer as 
shown below (located on the bottom right-hand side of the screen showing the list of patients) 
and select the printer that you normally print A4 pages to with Fred. 
 
Once the correct printer is selected, click on the Print Letters button (located on the bottom 
right-hand side of the screen showing the list of patients). Please enter your name when 
prompted. This will print the materials for each patient that you have not excluded. 
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Collate the printed material as follows: 
! The first page is a personalised letter to the patient explaining that your pharmacy is 
participating in the research project. Please sign the bottom of this letter. This letter is to 
be placed in an A4 envelope provided by you Project Officer. This envelope will already 
contain an educational brochure about asthma (‘Asthma: the basic facts’). 
! All documents with a small ‘A’ in the bottom right hand corner are to be placed in 
‘Envelope A – Information for your doctor’. There should be a letter to the GP and an 
‘Evaluation by General Practitioners’ survey. Please sign the bottom of the GP letter. 
Envelope A will already contain a General Practitioner Project Information Sheet and a 
reply paid envelope for the GPs to return their completed anonymous survey to the 
University. 
! All documents with a small ‘B’ in the bottom right hand corner are to be placed in 
‘Envelope B – Please join our survey’.  There will be three patient surveys titled ‘Patient 
Asthma Survey (Quality of Life)’, ‘Patient Asthma Survey (Asthma Control)’, and 
‘Patient Asthma Survey (Medication Adherence)’. Envelope B will already contain a 
Survey Information Sheet for patients and a reply paid envelope for the patients to return 
their completed anonymous surveys to the University. 
! Place envelope A and envelope B inside the A4 envelope. 
Address labels for the A4 envelopes can be printed by placing Avery L7162 label sheets in 
the A4 paper tray of your notes printer. Select Print Labels. 
Alternatively, address labels for the A4 envelopes can be printed using Fred. 
Send the packs to all included intervention patients with $1.00 postage. You will be 
reimbursed for the postage costs at the time of the first payment (see Step 6). 
Step 5. Document any feedback 
In the next six weeks if a patient who was sent a pack contacts you about the project we 
would encourage you to enter information into the Extra Information tab of the patient 
details screen. This tab is used provide further feedback to the researchers about the project. 
There are two basic types of feedback; 
! feedback from the patient about how they feel, and  
! feedback the patient relays to you about how the GP feels. 
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Now is also the time you can exclude patients from further participation in the project, if 
necessary. Any secondary exclusion reasons can be chosen from the Reason for exclusion 
drop-down menu - this is located in the top right hand corner of the screen. The secondary 
exclusion reasons are those BENEATH the black line, and include 
! Letter returned to sender  
! Declines to participate 
! Prefers no further contact 
! Privacy concerns 
! If you have another reason to exclude the patient select other…. and type the reason.  
 
The first secondary exclusion reason lets the researchers know to exclude the patient from 
analysis because if the intervention pack was returned to sender, the patient would not have 
received an intervention. 
The other secondary exclusion reasons ensure the patient is excluded from follow-up contact 
at 12 months. 
 
Step 6. Six-week follow-up 
After six weeks have elapsed, your local project officer will arrange a time to visit your 
pharmacy. At this point you will given instructions on how to claim your first payment, which 
will include reimbursement for postage costs. You will also be asked to complete a short 
survey regarding your perceptions of the project. You have now finished the first part of the 
project. 
Over the next 12 months if a patient who was sent a pack contacts you about the project we 
would encourage you to enter information into the Extra Information tab of the patient 
details screen. 
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Step 7. Run the program again in 12 months 
After 12 months have elapsed, the second phase of the trial will begin. 
! Your local project officer will arrange a time to visit your pharmacy. You will be 
provided with a password.   
! Run the MedeMine program again and left-click on the Enter passwords button and enter 
the password you were given. 
After you have entered the correct password the program will reveal the names of the patients 
assigned to the control group. 
 
 
Step 8. Mail follow-up letter and surveys to each included intervention patient 
Select Show Intervention Patients 
! This will give you a list of all intervention patients who were originally sent a pack and 
not subsequently excluded from the trial. 
Select Print Letters 
! Please enter your name when prompted. The program will print four surveys and a cover 
letter for each intervention patient who was originally sent a pack and not subsequently 
excluded from the trial. 
! Please sign the cover letter, and place the letters and surveys in the envelopes provided by 
your Project Officer. This envelope will already contain a reply paid envelope for the 
patients to return their completed anonymous surveys to the University. 
! Send the letters and surveys to all included intervention patients with $1.00 postage. 
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Step 9. Exclude any control patients as necessary 
Select Show Control Patients 
! This will give you a list of patients who were originally identified as receiving 6 or more 
canisters of asthma reliever medication (salbutamol/terbutaline) the 12 months prior to the 
project start date, and who were assigned to the control group. 
! You now need to exclude any of the control patients who meet the pre-defined exclusion 
criteria. Do this using the same method that was used at the beginning of the trial for the 
Intervention Patients. (See Step 3) 
! Highlight a Control Patient’s name by a single left-click, and then left-click on Select 
Patient, which you will see in the bottom right hand corner of the screen.   
! OR 
! Double left-click on the control patient’s name. 
! To EXCLUDE a control patient, select a reason from the Reason for exclusion drop-
down menu - this is located in the top right hand corner of the screen. 
! For each patient identified by the software, you will need to exclude any who meet the 
pre-defined exclusion criteria, listed in the drop-down menu, ABOVE the black line (too 
confused, deceased, patient has COPD, nursing home resident, may cause undue distress, 
under 18 years old, or other). 
All included control patients will now be sent an intervention pack. Therefore, you will need 
to exclude any control patients who no longer qualify for an intervention pack, that is, if they 
have received less than 6 canisters of asthma reliever medication in the past 12 months). 
! Select a patient, click on Collated History and select 12 months. Exclude any control 
patients who have received less than 6 relievers in the last 12 months. To exclude such 
patients from receiving an intervention pack, select Other.… and type “<6 relievers”. 
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Once you have reviewed each control patient on the list to determine their eligibility, you are 
ready to print the letters and surveys  
Step 10. Mail packs to each included control patient 
On the screen showing the list of patients, select Show Control Patients and click on the 
Print Letters button. Please enter your name when prompted. This will print the materials for 
each control patient that you have not excluded.  
Collate the printed material as follows: 
! The first page is a personalised letter to the patient explaining that the pharmacy is 
participating in the research project. Please sign the bottom of this letter. This letter is to 
be placed in an A4 envelope. This envelope will already contain an educational brochure 
about asthma (‘Asthma: the basic facts’). 
! All documents with a small ‘A’ in the bottom right hand corner are to be placed in 
‘Envelope A – Information for your doctor’. There should be a letter to the GP and an 
‘Evaluation by General Practitioners’ survey. This envelope will already contain a 
General Practitioner Project Information Sheet and a reply paid envelope for the GPs to 
return their completed survey in. 
! All documents with a small ‘B’ in the bottom right hand corner are to be placed in 
‘Envelope B – Please join our survey’.  There will be three patient surveys titled ‘Patient 
Asthma Survey (Quality of Life)’, ‘Patient Asthma Survey (Asthma Control)’, and 
‘Patient Asthma Survey (Medication Adherence)’. Envelope B will already contain a 
Survey Information Sheet and a reply paid envelope for the patients to return their 
completed surveys in. 
! Place envelope A and envelope B inside the A4 envelope. 
Address labels for the A4 envelopes can be printed by placing Avery L7162 label sheets in 
the A4 paper tray of your notes printer. Select Print Labels. 
Alternatively, address labels for the A4 envelopes can be printed using Fred. 
Send the packs to all included intervention patients with $1.00 postage. 
At this point you will given instructions on how to claim your final payment, which will 
include reimbursement for postage costs.  
You have now finished the project. 
 
Thankyou for your participation! 
 
 
 
 
 
 
This program is funded by the Australian Government Department of Health and Ageing as 
part of the Fourth Community Pharmacy Agreement through the Fourth Community 
Pharmacy Agreement Grants Program managed by the Pharmacy Guild of Australia 
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Appendix 16. Pharmacist instructions for face-to-face intervention 
 
 
 
 1 
Pharmacy dispensing records to identify and educate 
patients with suboptimal asthma management 
 
Intervention type II  
 
Your simple step-by step instructions to successfully 
participate in this project 
 
1. Install the MedeMine program on the Fred server 
2. Run the program to identify eligible patients 
3. Exclude any intervention patients as necessary 
4. Hand-out packs to each included intervention patient 
5. Document any feedback 
6. Six-week follow-up 
7. Run the program again in 12 months  
8. Mail follow-up letter and surveys to each included 
intervention patient 
9. Exclude any control patients as necessary 
10. Mail packs to each included control patient 
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Step 1. Install the MedeMine program on the Fred server 
Your Project Officer will install the MedeMine program on your Fred Server. This is usually 
the main Fred Computer and will be the computer you run monthly updates on. 
Once the program is installed, the Project Officer will place it in a folder on your desktop: 
 
Step 2. Run the program to identify eligible patients 
Run the MedeMine program by double-clicking on the MedeMine icon, located in the 
MedeMine folder on the desktop of your Fred Server. 
 
You will see the first screen: 
 
After a brief pause you will see the main window: 
 
This is the list of patients identified by the software as eligible for inclusion into the study. 
That is, patients who have received 6 or more canisters of asthma reliever medication 
(salbutamol/terbutaline) in the past 12 months, with at least 3 canisters supplied in each six-
month period. 
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Step 3. Exclude any intervention patients as necessary 
For each patient identified by the software, you will need to exclude any who meet the pre-
defined exclusion criteria. 
Highlight a patient’s name by a single left-click, and then left-click on Select Patient, which 
you will see in the bottom right hand corner of the screen  OR 
Double left-click on a patient’s name. 
This will open up an individual patient’s file as seen below: 
 
This screen uses tabs to show more information on a single screen.   
For more information on these tabs, please refer to the additional notes on the next page. 
A patient can be excluded at two distinct time points: before the pack is sent to the patient, or 
after the pack is sent. To EXCLUDE a patient, select a reason from the Reason for Exclusion 
drop-down menu - this is located in the top right-hand corner of the screen. 
For each patient identified by the software, you will need to exclude any who meet the pre-
defined exclusion criteria, listed in the drop-down menu, ABOVE the black line: 
! Too confused 
! Deceased 
! Patient has COPD 
! Nursing home resident 
! May cause undue distress 
! Under 18 years old 
! If you have another reason to exclude the patient select other  …. and type the reason. 
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Once you have selected a reason for exclusion for a patient, you will be directed to the Extra 
Information screen. If you have any information to add as to why the patient should be 
excluded, you can free-type in the boxes within this screen. Otherwise, just click Close. This 
will take you back to the list of patients. 
Once you have reviewed each patient on the list to determine their eligibility, you are ready to 
print the letters and surveys  
 
Additional notes - Tabs 
The first three tabs (Asthma-related Dispensings, Collated History and All Dispensing 
History) are ways of looking at the patient's history. For the first three tabs you can vary the 
amount of history you can see by selecting a time frame from the Months History to display 
option group (1,3,6,9,12 or all) – this is located immediately above the tabs.  
Asthma-related dispensings 
This is a list of the patient’s history that only shows you asthma-related medicines.  You can 
show more or less history by clicking on the Months History to display option group. 
Collated History 
This tab will show each generic drug/ form/ strength the patient had dispensed, in order of the 
number of supplies in the time period specified.  For example if the patient had one supply of 
Ventolin® MDI 100mcg and one supply of Asmol® MDI 100mcg there would be two supplies 
of Salbutamol MDI 100mcg.  The directions shown are of the last dispensing, and the date 
shown is the last dispensing date. You can show more or less history by clicking on the month 
in the Months History to display option group. 
All Dispensing History 
All dispensing history is similar to the history you see in Fred dispense except patient notes 
are not shown and cancelled scripts are shown (in grey type). You can show more or less 
history by clicking on the month in Months History to display option group. 
Extra Information 
Please refer to Step 5 for information about this Tab. 
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Additional Notes - Internet 
The program requires an active Internet connection to send information to the server at the 
University of Tasmania. 
Only de-identified and encrypted information is sent to the secure server. The program uses a 
1024 bit key to securely send information. 
If an Internet connection is not available the program will prompt you to connect to the 
Internet.  If you do not connect to the Internet the program will still work, and will send the 
information using the Internet at a later time. 
Every time the MedeMine program closes, this screen will appear. This shows that the de-
identified and encrypted information is being sent to the secure server at the University. 
 
When this is complete, this screen will appear. 
 
Step 4. Hand-out packs to each included intervention patient 
The next time you use Fred to dispense a medication for an included intervention patient, an 
alert flag will pop up, reminding you to access the MedeMine program to print materials for 
the patient and provide them with an intervention pack. 
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Open the MedeMine program by double-clicking on the MedeMine icon, located in the 
MedeMine folder on the desktop of your Fred Server. 
 
 
 
After a brief pause you will see the main window: 
 
The first thing you need to do is to check that the printer is set up correctly. The program 
should have automatically selected the printer that you normally print notes or CMIs to.  
To check if the program has selected the correct printer; click on the picture of the printer as 
shown below (located on the bottom right-hand side of the screen showing the list of patients) 
and select the printer that you normally print A4 pages to with Fred. 
 
Once the correct printer is selected, highlight a patient’s name by a single left-click, and then 
left-click on ‘Select Patient’, which you will see in the bottom right hand corner of the screen. 
OR 
Double left-click on a patient’s name.  
This will open up an individual patient’s file as seen below: 
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Click on the Print Letters button, located on the bottom right-hand side of the screen. Please 
enter your name when prompted. This will print the materials for the patient. 
Collate the printed material as follows: 
! The first page is a personalised letter to the patient explaining that your pharmacy is 
participating in the research project. Please sign the bottom of this letter. This letter is to 
be placed in an A4 envelope provided by you Project Officer. This envelope will already 
contain an educational brochure about asthma (‘Asthma: the basic facts’). 
! All documents with a small ‘A’ in the bottom right hand corner are to be placed in 
‘Envelope A – Information for your doctor’. There should be a letter to the GP and an 
‘Evaluation by General Practitioners’ survey. Please sign the bottom of the GP letter. 
Envelope A will already contain a General Practitioner Project Information Sheet and a 
reply paid envelope for the GPs to return their completed anonymous survey to the 
University. 
! All documents with a small ‘B’ in the bottom right hand corner are to be placed in 
‘Envelope B – Please join our survey’.  There will be three patient surveys titled ‘Patient 
Asthma Survey (Quality of Life)’, ‘Patient Asthma Survey (Asthma Control)’, and 
‘Patient Asthma Survey (Medication Adherence)’. Envelope B will already contain a 
Survey Information Sheet for patients and a reply paid envelope for the patients to return 
their completed anonymous surveys to the University. 
! Place envelope A and envelope B inside the A4 envelope. 
Hand the A4 envelope to the patient. 
Step 5. Document any feedback 
In the next six weeks, continue to print and hand out the intervention packs to patients as they 
present to the pharmacy for prescriptions. If a patient who is given a pack talks you about the 
project we would encourage you to enter information into the Extra Information tab of the 
patient details screen. This tab is used provide further feedback to the researchers about the 
project. 
There are two basic types of feedback; 
! feedback from the patient about how they feel, and  
! feedback the patient relays to you about how the GP feels. 
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Now is also the time you can exclude patients from further participation in the project, if 
necessary. Any secondary exclusion reasons can be chosen from the Reason for exclusion 
drop-down menu - this is located in the top right hand corner of the screen. The secondary 
exclusion reasons are those BENEATH the black line, and include 
! Letter returned to sender (not relevant to this type of intervention) 
! Declines to participate 
! Prefers no further contact 
! Privacy concerns 
! If you have another reason to exclude the patient select other…. and type the reason.  
 
The secondary exclusion reasons ensure the patient is excluded from follow-up contact at 12 
months. 
 
Step 6. Six-week follow-up 
After six weeks have elapsed, your local project officer will arrange a time to visit your 
pharmacy. At this point you will given instructions on how to claim your first payment, which 
will include reimbursement for postage costs. You will also be asked to complete a short 
survey regarding your perceptions of the project. You have now finished the first part of the 
project. 
Over the next 12 months if a patient who was given a pack talks to you about the project we 
would encourage you to enter information into the ‘Extra Information’ tab of the patient 
details screen. 
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Step 7. Run the program again in 12 months 
After 12 months have elapsed, the second phase of the trial will begin. 
! Your local project officer will arrange a time to visit your pharmacy. You will be 
provided with a password.   
! Run the MedeMine program again and left-click on the Enter passwords button and enter 
the password you were given. 
After you have entered the correct password the program will reveal the names of the patients 
assigned to the control group. 
 
Step 8. Mail follow-up letter and surveys to each included intervention patient 
Select Show Intervention Patients 
! This will give you a list of all intervention patients who were originally sent a pack and 
not subsequently excluded from the trial. 
Select Print Letters 
! Please enter your name when prompted. The program will print four surveys and a cover 
letter for each intervention patient who was originally sent a pack and not subsequently 
excluded from the trial. 
! Please sign the cover letter, and place the letters and surveys in the envelopes provided by 
your Project Officer. This envelope will already contain a reply paid envelope for the 
patients to return their completed anonymous surveys to the University. 
! Send the letters and surveys to all included intervention patients with $1.00 postage. 
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Step 9. Exclude any control patients as necessary 
Select Show Control Patients 
! This will give you a list of patients who were originally identified as receiving 6 or more 
canisters of asthma reliever medication (salbutamol/terbutaline) the 12 months prior to the 
project start date, and who were assigned to the control group. 
! You now need to exclude any of the control patients who meet the pre-defined exclusion 
criteria. Do this using the same method that was used at the beginning of the trial for the 
Intervention Patients. (See Step 3) 
! Highlight a Control Patient’s name by a single left-click, and then left-click on Select 
Patient, which you will see in the bottom right hand corner of the screen.   
! OR 
! Double left-click on the control patient’s name. 
! To EXCLUDE a control patient, select a reason from the Reason for exclusion drop-
down menu - this is located in the top right hand corner of the screen. 
! For each patient identified by the software, you will need to exclude any who meet the 
pre-defined exclusion criteria, listed in the drop-down menu, ABOVE the black line (too 
confused, deceased, patient has COPD, nursing home resident, may cause undue distress, 
under 18 years old, or other). 
All included control patients will now be sent an intervention pack. Therefore, you will need 
to exclude any control patients who no longer qualify for an intervention pack, that is, if they 
have received less than 6 canisters of asthma reliever medication in the past 12 months). 
! Select a patient, click on Collated History and select 12 months. Exclude any control 
patients who have received less than 6 relievers in the last 12 months. To exclude such 
patients from receiving an intervention pack, select Other…. and type “<6 relievers”. 
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Once you have reviewed each control patient on the list to determine their eligibility, you are 
ready to print the letters and surveys. 
Step 10. Mail pack to each included control patient 
On the screen showing the list of patients, select Show Control Patients and click on the 
Print Letters button. Please enter your name when prompted. This will print the materials for 
each control patient that you have not excluded.  
Collate the printed material as follows: 
! The first page is a personalised letter to the patient explaining that the pharmacy is 
participating in the research project. Please sign the bottom of this letter. This letter is to 
be placed in an A4 envelope. This envelope will already contain an educational brochure 
about asthma (‘Asthma: the basic facts’). 
! All documents with a small ‘A’ in the bottom right hand corner are to be placed in 
‘Envelope A – Information for your doctor’. There should be a letter to the GP and an 
‘Evaluation by General Practitioners’ survey. This envelope will already contain a 
General Practitioner Project Information Sheet and a reply paid envelope for the GPs to 
return their completed survey in. 
! All documents with a small ‘B’ in the bottom right hand corner are to be placed in 
‘Envelope B – Please join our survey’.  There will be three patient surveys titled ‘Patient 
Asthma Survey (Quality of Life)’, ‘Patient Asthma Survey (Asthma Control)’, and 
‘Patient Asthma Survey (Medication Adherence)’. Envelope B will already contain a 
Survey Information Sheet and a reply paid envelope for the patients to return their 
completed surveys in. 
! Place envelope A and envelope B inside the A4 envelope. 
Address labels for the A4 envelopes can be printed by placing Avery L7162 label sheets in 
the A4 paper tray of your notes printer. Select Print Labels. 
Alternatively, address labels for the A4 envelopes can be printed using Fred. 
Send the packs to all included intervention patients with $1.00 postage. 
At this point you will given instructions on how to claim your final payment, which will 
include reimbursement for postage costs.  
You have now finished the project. 
 
Thankyou for your participation! 
 
 
 
 
 
 
This program is funded by the Australian Government Department of Health and Ageing as 
part of the Fourth Community Pharmacy Agreement through the Fourth Community 
Pharmacy Agreement Grants Program managed by the Pharmacy Guild of Australia 
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Appendix 17. Patient intervention letter 
 
 
 
<patient name> 
<patient address> 
<patient suburb> 
<patient state>   <postcode> 
 
 
 
 
<proprietor name> 
<pharmacy name> 
<pharmacy address> 
<pharmacy suburb> 
<pharmacy state>   < postcode> 
Ph: <ph num>  fax: <fax num> 
 
Improving the control of asthma 
 
<date> 
 
Dear <patient name> 
 
Our pharmacy is taking part in a research project with the University of Tasmania’s School of 
Pharmacy to try and improve the control of asthma in the community. 
 
I have enclosed some information about asthma, because I noticed that you have had 6 or 
more asthma reliever medications dispensed from the pharmacy in the last year. This may be 
a sign that your asthma control could be improved. 
 
Just to make sure that your asthma is under control and that you are getting the best possible 
treatment, I suggest that you please do both of the following: 
 
 
Please be assured that your identity has not been released to the University, and the survey 
forms are all anonymous. 
 
If you have any questions about this project, or your asthma, please give me a call at the 
pharmacy.  
 
Yours Sincerely 
 
 
 
<pharmacist name> 
1. Help us help you - make an appointment with your GP  
Please take Envelope A- INFORMATION FOR YOUR DOCTOR along to this 
appointment. This includes a letter for the doctor and your prescription dispensing 
record which will help the doctor assess your asthma control. 
AND 
2. Help us help others - join our survey 
Please read the information inside Envelope B - PLEASE JOIN OUR SURVEY. 
Complete the surveys and return them to the University in the supplied reply paid 
envelope. This will help us develop a better understanding of asthma and how it affects 
people in the community. 
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Appendix 18. Patient asthma control survey 
 
This program is funded by the Australian Government Department of Health and Ageing as part of the Fourth Community Pharmacy 
Agreement through the Fourth Community Pharmacy Agreement Grants Program managed by the Pharmacy Guild of Australia 
 
           <Patient ID> B 
Patient Asthma Survey (Asthma Control) 
 
Please complete all questions by ticking the box that best describes how you have been during the last 
two weeks as a result of your asthma. 
 
 All of the 
time 
Most of the 
time 
Some of the 
time 
A little of 
the time 
None of the 
time 
1 During the last 2 weeks, how much of the time 
did your asthma keep you from getting as much 
done at work, school or home? 
     
 More than 
once a day 
Once  
a day 
3 to 6 times 
a week 
Once or 
twice a 
week 
Not  
at all 
2 During the last 2 weeks, how often have you had 
shortness of breath? 
     
 4 or more 
nights a 
week 
2 or 3 nights 
a week 
Once a  
week 
Once or 
twice 
Not  
at all 
3 During the last 2 weeks, how often did your 
asthma symptoms (wheezing, coughing, 
shortness of breath, chest tightness) wake you up 
at night or earlier than usual in the morning? 
     
 3 or more 
times per 
day 
1 or 2 times 
per day 
2 or 3 times 
per week 
Once a week 
or less 
Not  
at all 
4 During the last 2 weeks, how often have you 
used your rescue inhaler or nebuliser 
medication? 
     
 Not at all 
controlled 
Poorly 
controlled 
Somewhat 
controlled 
Well 
controlled 
Completely 
controlled 
5 How would you rate your asthma control during 
the last 2 weeks? 
     
 < 18 18-29 30-39 40-49 50-59 60+ 
6 What is your age? 
      
   Male Female   
7 What is your gender   
  
  
  Yes No   
8 Do you have a written Asthma Action Plan, that 
is, written instructions of what to do if your 
asthma is worse or out of control? 
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Appendix 19. Patient quality of life survey 
 
This program is funded by the Australian Government Department of Health and Ageing as part of the Fourth Community Pharmacy 
Agreement through the Fourth Community Pharmacy Agreement Grants Program managed by the Pharmacy Guild of Australia 
 
           <Patient ID> B 
Patient Asthma Survey (Quality of Life) 
 
Please complete all questions by ticking the box that best describes how you have been during the last 
2 weeks as a result of your asthma. 
 
In general, how much of the time 
during the last 2 weeks did you: 
All of the 
time 
Most of 
the time 
A good bit 
of the time 
Some of 
the time 
A little of 
the time 
Hardly any 
of the time 
None of 
the time 
1 Feel short of breath as a result of 
your asthma? 
       
2 Feel bothered by or have to avoid 
dust in the environment? 
       
3 Feel frustrated as a result of your 
asthma? 
       
4 Feel bothered by coughing? 
   
 
   
5 Feel afraid of not having your 
asthma medication available? 
       
6 Experience a feeling of chest 
tightness or chest heaviness? 
       
7 Feel bothered by or have to avoid 
cigarette smoke in the 
environment? 
       
8 Have difficulty getting a good 
night’s sleep as a result of your 
asthma? 
       
9 Feel concerned about having 
asthma? 
       
10 Experience a wheeze in your 
chest? 
       
11 Feel bothered by or have to avoid 
going outside because of weather 
or air pollution? 
       
How limited have you been during 
the last 2 weeks doing these activity 
as a result of your asthma? 
Totally 
limited 
Extremely 
limited 
Very 
limited 
Moderate 
limitation 
Some 
limitation 
A little 
limitation 
Not at all 
limited 
12 Strenuous activities (such as 
hurrying, exercising, running up 
stairs, sports) 
       
13 Moderate activities (such as 
walking, housework, gardening, 
shopping, climbing stairs) 
       
14 Social activities (such as talking, 
playing with pets/children, 
visiting friends/relatives) 
       
15 Work related at activities* (tasks 
you have to do at work) 
       
*If you are not employed or self-employed, these should be tasks you have to do most days 
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Appendix 20. Patient medication adherence survey 
 
This program is funded by the Australian Government Department of Health and Ageing as part of the Fourth Community Pharmacy 
Agreement through the Fourth Community Pharmacy Agreement Grants Program managed by the Pharmacy Guild of Australia 
 
           <Patient ID> B 
Patient Asthma Survey (Medication Adherence) 
 
Many people find a way of using their medicines that suits them. This may differ from the instructions 
on the label or from what their doctor had said. Here are some ways in which people have said they 
use their asthma medications. For each statement, please tick the box that best applies to you. 
 
 Never Rarely Sometimes Often Always 
1 I get confused about my asthma 
medications  
     
2 I have strict routines for using my regular 
asthma medications  
     
3 I keep my asthma medications close to 
where I need to use them  
     
4 I ensure I have enough asthma 
medications so that I don’t run out  
     
5 I push myself to follow the instructions of 
my doctors 
     
6 I make changes in the recommended 
asthma management to suit my lifestyle 
     
7 I vary my recommended asthma 
management based on how I am feeling  
     
8 I put up with my asthma symptoms 
before taking any action 
     

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Appendix 21. Patient survey information sheet 
 
 
Improving the control of asthma 
 
SURVEY INFORMATION SHEET 
 
Why this research is needed 
Asthma affects over 2 million Australians and causes thousands of hospital admissions each 
year. Recent findings suggest that the control of Asthma in Australia needs to be improved.   
 
Aim of this research 
The aim of this research is to improve the control of asthma and develop a better understanding 
of asthma and how it affects people in the community.  
 
About the survey 
The survey is being conducted by the University of Tasmania’s School of Pharmacy with the 
help of selected pharmacies in Tasmania. 
 
Special note on privacy 
Please be assured that your identity has not been released to the University. No one at the 
University can identify the information that you provide; your survey forms are anonymous. 
 
How can you help? 
 
 
What next? 
In about 12 months, your pharmacist will send you another survey, to see how helpful the 
information was. 
 
Any problems? 
If you have any concerns or queries about the survey or your participation in the project, please 
contact your regular pharmacist, or Bonnie Bereznicki at the Tasmanian School of Pharmacy on 
telephone 6226 2191 or email bonnie.bereznicki@utas.edu.au. 
 
The project has received ethical approval from the Tasmanian Health and Medical Human 
Research Ethics Committee. If you have any concerns of an ethical nature or complaints about 
the manner in which the project is conducted, you may contact the Executive Officer of the 
Tasmanian Human Research Ethics Committee (Tasmania) Network on 62267479 or 
human.ethics@utas.edu.au. You will need to quote ethics reference number H9823. 
 
 
 
 
 

All you have to do is: 
1. Complete the three surveys the best you can;  
2. Use the enclosed reply paid envelope to post them to the University. 
This program is funded by the Australian Government Department of Health and Ageing 
as part of the Fourth Community Pharmacy Agreement through the Fourth Community 
Pharmacy Agreement Grants Program managed!"#!$%&!'%()*(+#!,-./0!12!3-4$)(/.(!
Improving the management of asthma and COPD 
  
 
Bonnie Bereznicki 358 
Appendix 22. GP letter 
 
<proprietor name> 
<pharmacy name> 
<pharmacy address> 
<pharmacy suburb> 
<pharmacy state>   < postcode> 
Ph: <ph num>  fax: <fax num> 
 
Improving the control of asthma 
 
Dear Doctor  
 
<Pharmacy Name> is participating in a research project with the University of Tasmania’s 
School of Pharmacy which aims to identify patients whose asthma may not be optimally 
controlled and refer these patients to their GP for a review of their asthma therapy. 
 
One of your patients, <Patient Name>, has been identified by <Pharmacy Name> as possibly 
requiring a review of <his/her> asthma therapy. That is, as evidenced by the accompanying 
prescription dispensing information, your patient has received six (6) or more reliever 
medications in the last 12 months. This usage, if reflecting dispensing, would exceed 3 puffs of 
reliever medication per day, which is clearly higher than that recommended by the National 
Asthma Council and the Asthma Foundation as indicating good control. 
 
The prescription dispensing record from the pharmacy indicates that <Patient Name> has had 
<collated relievers and preventers> in the last 12 months. A full dispensing history appears 
below. 
 
No. Dispensings  Last Dispensed  Drug Name 
<number>   <date>    <drug name and dose> 
 
<Patient Name> has been provided with educational material regarding asthma and has been 
asked to contact <his/her> GP for a review of <his/her> asthma. This may be an opportunity for 
you to develop or review the patient’s written Asthma Action Plan. 
 
I kindly ask that you complete the attached GP survey regarding your perceptions of this 
program. 
 
Please see the enclosed Project Information Sheet for more information regarding the project. If 
you would like further information about any aspect of the project, please contact me at the 
pharmacy, or Bonnie Bereznicki at the Tasmanian School of Pharmacy on telephone: 
6226 2191 or email: bonnie.bereznicki@utas.edu.au. 
 
Thankyou for your assistance. 
 
Yours Sincerely 
 
 
<Pharmacist name> 
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Appendix 23. GP survey 
 
This program is funded by the Australian Government Department of Health and Ageing as part of the Fourth Community Pharmacy 
Agreement through the Fourth Community Pharmacy Agreement Grants Program managed by the Pharmacy Guild of Australia 
 
           <Patient ID> A 
Improving the control of asthma 
 
EVALUATION BY GENERAL PRACTITIONERS  
 
Please complete this survey at the end of the consultation and post using the reply paid envelope provided. 
 
Date of Consultation:       /       / 
 
 
1. I modified (or intend to modify) my patient’s therapy as a result of the pharmacist’s referral 
Yes  
No  
Please elaborate… 
 
 
2. I feel that the pharmacist appropriately identified my patient as needing a review of their asthma therapy 
Yes  
No  If No, what is the reason? 
 
3. I believe that my patient will benefit from this intervention 
     
Strongly agree Agree Neutral Disagree Strongly disagree 
4. I believe that pharmacists, utilising dispensing records, are well placed to identify patients who may need 
review of their asthma by their doctor 
     
Strongly agree Agree Neutral Disagree Strongly disagree 
5. I believe that there is an evident need for improved asthma control in the community 
     
Strongly agree Agree Neutral Disagree Strongly disagree 
6. I believe that this type of program delivered by community pharmacists would be likely to improve 
asthma control in the community, if implemented on a larger scale 
     
Strongly agree Agree Neutral Disagree Strongly disagree 
7. Do you have any general or specific comments regarding this intervention program? 
 
 
 
 
 
........................................................................................................................................................................
........................................................................................................................................................................ 
............................................................................................
............................................................................................ 
............................................................................................
............................................................................................ 
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Appendix 24. Pharmacist satisfaction survey 
 
 
 
 1 of 3 
Improving the control of asthma 
 
PHARMACIST SATISFACTION SURVEY 
 
Thank you for participating in this project. Please complete this survey at the end of the six-week 
intervention period. Your input is valued and greatly appreciated. 
 
1. I believe that there is an evident need for improved asthma control in the community 
      
Strongly agree Agree Neutral Disagree Strongly disagree  
 
2. I believe that this project appropriately identified patients with poorly controlled asthma 
      
Strongly agree Agree Neutral Disagree Strongly disagree  
 
3.  I believe that the patients identified to be in the intervention group will generally benefit from 
this project 
      
Strongly agree Agree Neutral Disagree Strongly disagree  
 
4. I believe that mailing information and surveys to patients only is an appropriate way to help 
them improve their asthma management and control 
      
Strongly agree Agree Neutral Disagree Strongly disagree  
  
5.  I believe that handing out information and surveys to patients (face-to-face) only is an 
appropriate way to help them improve their asthma management and control 
      
Strongly agree Agree Neutral Disagree Strongly disagree  
 
6. Which type of intervention would you prefer to perform in usual practice? 
      
Mailed Face-to-face     
 Please elaborate 
  
 
 
 
 
 
 
 
……………………………………………................................................................................ 
……………………………………………......……………………………………….............. 
……………………………………………......……………………………………….............. 
……………………………………………......……………………………………….............. 
……………………………………………......……………………………………….............. 
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 3 of 3 
15.  I believe that this type of program delivered by community pharmacists will improve asthma 
control in the community if implemented on a larger scale 
      
Strongly agree Agree Neutral Disagree Strongly disagree  
 
16.  Did you receive any feedback (positive or negative) from patients or GPs regarding this 
project? 
      
Yes No     
 If yes, please elaborate 
  
 
 
 
 
 
 
 
 
17.  Do you have any general or specific comments or concerns regarding this project? 
 
 
 
 
 
 
 
 
 
18.  Would you be willing to participate in other similar projects utilising dispensing records to 
improve the management of chronic diseases? 
      
Yes No Unsure    
 
 
----------------------------------------------- END OF SURVEY ----------------------------------------------- 
 
 
Thank you for completing this survey 
 
 
Please either hand back to your Project Officer 
or post to the University using the reply paid envelope provided 
 
 
……………………………………………................................................................................ 
……………………………………………......……………………………………….............. 
……………………………………………......……………………………………….............. 
……………………………………………......………………………………………..............
………………………………………………......………………………………………..........
……………………………………………................................................................................ 
……………………………………………......……………………………………….............. 
……………………………………………......……………………………………….............. 
……………………………………………......……………………………………….............. 
…………………………………………......……………………………………….................. 
This program is funded by the Australian Government Department of Health and Ageing as 
part of the Fourth Community Pharmacy Agreement through the Fourth Community 
Pharmacy Agreement Grants Program managed!"#!$%&!'%()*(+#!,-./0!12!3-4$)(/.(!
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Appendix 25. Patient satisfaction survey 
 
This program is funded by the Australian Government Department of Health and Ageing as part of the Fourth Community Pharmacy 
Agreement through the Fourth Community Pharmacy Agreement Grants Program managed by the Pharmacy Guild of Australia 
 
           <Patient ID> B 
Patient Satisfaction Survey 
 
Please complete all questions by filling in the box with a mark that best describes your opinions 
about this project. 
 
 Strongly 
agree 
Agree Unsure Disagree Strongly 
disagree 
1 I feel that I was appropriately identified by my 
pharmacist as needing a review of my asthma by my 
doctor 
     
2 Use of my asthma reliever medication (Ventolin, 
Airomir, Asmol, Bricanyl) has reduced over the last 
year 
     
3 I found the information on asthma management that 
was sent out with the surveys 12 months ago useful      
4 I believe that my asthma control has improved as a 
result of this project      
5 I believe that pharmacists are well placed to identify 
patients who may need a review of their asthma by 
their doctors 
     
6 I believe that this type of program delivered by 
community pharmacists will improve asthma care in 
the community if implemented in a larger program 
     
7 I am satisfied with the level of asthma care that I 
usually receive from my doctor      
8 I am satisfied with the level of asthma care that I 
usually receive from my pharmacist      
9 I regularly discuss my asthma control and/or 
management with my pharmacist      
10 Do you have any general or specific comments or concerns regarding this project? 
............................................................................................................................................................................. 
............................................................................................................................................................................. 
............................................................................................................................................................................. 
............................................................................................................................................................................. 
............................................................................................................................................................................. 
............................................................................................................................................................................. 
............................................................................................................................................................................. 
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Appendix 26. Intervention follow-up instructions for researchers  
 
 
 
 1 
Pharmacy dispensing records to identify and educate 
patients with suboptimal asthma management 
 
Intervention follow-up instructions for researchers 
 
Step 1. Locate Fred Server 
The MedeMine program should be located on the Fred Server computer. 
If the pharmacist is not sure which computer is the Fred Server, you can check in Fred, by 
going to Setup (one of the options at the top of the main Fred screen):  
 
 
 
 
 
 
 
Select System Configuration: 
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 7 
The first page is a personalised letter to the patient. Please ask the pharmacist to sign the 
bottom of this letter.  
There will be four patient surveys titled ‘Patient Asthma Survey (Quality of Life)’, ‘Patient 
Asthma Survey (Asthma Control)’, ‘Patient Asthma Survey (Medication Adherence)’ and 
‘Patient Satisfaction Survey’.  
Place each letter with its surveys in the blank C5 envelope. This envelope should already 
contain a reply paid envelope for the patients to return their completed anonymous surveys to 
the University, and a Survey Information Sheet. 
PLEASE DO NOT SEPARATE THE COVER LETTER FROM ITS MATCHING 
SURVEYS. THE SURVEYS ARE UNIQUELY CODED TO MATCH THE PATIENT. 
Address labels for the C5 envelopes can be printed by placing Avery L7162 label sheets face-
down in the A4 paper tray of the notes printer the A4 paper tray of the notes printer. Select 
Print Labels. 
Alternatively, address labels for the C5 envelopes can be printed using Fred. 
Double check that postcodes have been included on the address labels. Add if necessary. 
Mail the letters and surveys to all included intervention patients with $1.10 postage. 
Step 9. Exclude any control who no longer qualify for an intervention 
On the main screen, select Show Control Patients: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This will give you a list of patients who were originally identified as receiving 6 or more 
canisters of asthma reliever medication (salbutamol/terbutaline) the 12 months prior to the 
project start date, and who were assigned to the control group. 
You now need to exclude any of the control patients who meet the pre-defined exclusion 
criteria.  
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 8 
Double left-click on the control patient’s name. 
This will open up an individual patient’s file as seen: 
All included control patients will be sent an intervention pack. Therefore, you will need to 
exclude any control patients who no longer qualify for an intervention pack, that is, if they 
have received less than 6 canisters of asthma reliever medication in the past 12 months. 
Select a patient, click on Collated History and select 12 months:  
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 10 
Once you have selected a reason for exclusion for a patient, you will be directed to the Extra 
Information screen. If you have any information to add as to why the patient should be 
excluded, you can free-type in the boxes within this screen. Otherwise, just click Close. This 
will take you back to the list of patients. 
Once you have reviewed each control patient on the list to determine their eligibility, you are 
ready to print the control patients’ letters and surveys. 
Step 11. Print letters and surveys for included control patients 
On the screen showing the list of patients, select Show Control Patients and click on the 
Print Letters button. Please enter the pharmacist’s name when prompted. This will print the 
materials for each control patient that you have not excluded.  
PLEASE DO NOT SEPARATE THE COVER LETTER FROM ITS MATCHING 
SURVEYS. THE SURVEYS ARE UNIQUELY CODED TO MATCH THE PATIENT. 
Collate the printed material as follows: 
• The first page is a personalised letter to the patient explaining that the pharmacy is 
participating in the research project. Please ask the pharmacist to sign the bottom of this 
letter. This letter is to be placed in the blank A4 envelope. This envelope should already 
contain an educational brochure about asthma (‘Asthma: the basic facts’). 
• All documents with a small A in the bottom right hand corner are to be placed in 
Envelope A – Information for your doctor. There should be a letter to the GP (one or 
two pages) and an ‘Evaluation by General Practitioners’ survey. This envelope should 
already contain a reply paid envelope for the GPs to return their completed anonymous 
surveys to the University, and a General Practitioner Project Information Sheet. Please ask 
the pharmacist to sign the end of the GP letter. 
• All documents with a small B in the bottom right hand corner are to be placed in 
Envelope B – Please join our survey. There will be three patient surveys titled ‘Patient 
Asthma Survey (Quality of Life)’, ‘Patient Asthma Survey (Asthma Control)’, and 
‘Patient Asthma Survey (Medication Adherence)’. Envelope B should already contain a 
reply paid envelope for the patients to return their completed anonymous surveys to the 
University, and a Survey Information Sheet. 
• Leave Envelopes A and B unsealed, and place them inside the A4 envelope. 
Address labels for the A4 envelopes can be printed by placing Avery L7162 label sheets face-
down in the A4 paper tray of the notes printer. Select Print Labels. 
Alternatively, address labels for the A4 envelopes can be printed using Fred. 
Double check that postcodes have been included on the address labels. Add if necessary. 
Send the packs to all included control patients with $1.10 postage. 
Step 12. Print payment instructions 
The pharmacist is now eligible to claim for their final payment.  
Please ascertain whether or not the pharmacists will be posting the envelope themselves (and 
therefore will need to be reimbursed for postage costs). 
In the MedeMine program, you need to type ONE of the following passwords: 
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payme$ [payme(shift four)] if THE PHARMACIST is mailing the packs  
or 
cH33p5k8 [cH(three)(three)p(five)k(eight)] if YOU are mailing the packs 
This will print instructions for the pharmacist on how to claim their payment.  
NB: The amount should be $100.00 ± $1.10 per pack mailed. The date the invoice is due will 
also be worked out automatically, as six weeks from the date the instructions are printed. 
Step 13. Close the MedeMine program 
You can now close the MedeMine program. 
When the MedeMine program closes, this screen will appear: 
 
When this is complete, this screen will appear. 
 
Step 14. Obtain a back-up of the de-identified dispensing data 
Create a new folder on your USB device, and name it with the pharmacy’s approval number. 
Go to My Computer and open the C-drive.  
Locate and double-click on Program Files. Locate and double click on the MedeMine 
folder.  
In the MedeMine folder, locate the Data folder and the Backups folder. 
Copy both the Data AND Backups folder to the folder you created on your USB device. 
Eject your USB device.  
Step 15. Update the MedeMine shortcut on the desktop 
Most pharmacies will have a MedeMine shortcut located in a MedeMine folder on the 
desktop. This shortcut will no longer work once you have updated the program. 
To update this shortcut, right-click on the MedeMine icon inside the MedeMine folder 
located in Program Files and select “Create Shortcut". Copy this shortcut to the MedeMine 
Folder on the desktop and delete the old MedeMine icon inside this folder. 
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Appendix 1. If MedeMine program has been wiped from the Fred Server 
NB: You need to be 100% sure that the program has been wiped before doing this (do a 
search for “MedeMine”). 
If you’re not sure, please call Bonnie on 03 6226 2191 or 0407 550 115. 
2. Locate the backup data belonging to the pharmacy on your USB device. It will be a folder 
named according to the pharmacy’s name and/or approval number. 
3. Copy this folder onto the C-drive [My Computer - Local Disk (C:)] on the Fred Server. 
Double check that you have copied the correct data over. 
4. Rename the data folder hat you have just pasted, as Data. 
5. Locate the installation package on your USB device. It is called MedeMinev2.1.26.exe. 
Copy it to the Server’s desktop. 
6. Double-click on the installation package, and follow the prompts by clicking “next” etc. 
until the installation is complete. 
7. If the installer package created a MedeMine shortcut on the desktop, you can delete it – it 
is the old version and needs to be updated. 
8. Locate the updated MedeMine program on your USB device. It is called Medemine.exe. 
Copy the program and paste it in the MedeMine folder inside Program Files. [My 
Computer - Local Disk (C:) - Program Files - MedeMine]. 
9. Go to Step 4: Run the MedeMine program. 
 
Appendix 2. MedeMine passwords 
 
 
Password Description 
A57MaD3m Asthma denominators. Historical use of denominators if program 
was run in all the years the dispensing package recorded info. 
3nd1t Used to 'end the trial' – sets the finished flag to true, and enters the 
stop date of the trial. 
payme$ Displays the contact details and the amount the pharmacist can send 
an invoice (postage included). 
cH33p5k8 Displays the contact details and the amount the pharmacist can send 
an invoice, where only the base price and not postage is calculated. 
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Appendix 27. Follow-up patient letter 
 
 
 
<patient name> 
<patient address> 
<patient suburb> 
<patient state>   <postcode> 
 
 
 
 
<proprietor name> 
<pharmacy name> 
<pharmacy address> 
<pharmacy suburb> 
<pharmacy state>   < postcode> 
Ph: <ph num>  fax: <fax num> 
 
Improving the control of asthma 
 
<date> 
 
Dear <patient name> 
 
<Pharmacy name> is taking part in a research project with the University of Tasmania’s 
School of Pharmacy to try and improve the control of asthma in the community. You may 
recall that approximately 12 months ago we gave you some information about asthma and 
suggested that you visit your GP to discuss your asthma control. 
 
We hope that the information was useful and that you have had success with the control of 
your asthma.  
 
You may also recall that there were three surveys included in the information supplied to you. 
Although you may have already completed the surveys 12 months ago, we are hoping that 
you will fill out the short surveys again, to help my colleagues and I with our ongoing efforts 
to learn more about asthma, and see how people’s asthma has changed over the last year. 
 
 
 
Please be assured that your identity has not been released to the University, and the survey 
forms are all anonymous.  
 
If you have any questions about this project, or your asthma, please give me a call at the 
pharmacy. 
 
 
Yours Sincerely 
 
 
 
<pharmacist name> 
All you have to do is: 
1. Please complete the four surveys as best you can; 
2. Used the enclosed reply paid envelope to post them to the University 
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Appendix 28. Pharmacist invitation letter 
 
 
 
 
 
 
 
 
 
Understanding patient experiences with respiratory medication 
 
<Date> 
 
Dear <Pharmacist Name> 
 
As a healthcare provider in your local community you would be aware that one of the major 
contributing factors to both morbidity and mortality of patients with COPD is their non-
adherence to drug therapy. With 20,000 cases of COPD diagnosed in Australia each year and 
with adherence to long-term preventive medication regimens being estimated to be as low as 
28%, we are seeking your assistance. 
The Tasmanian School of Pharmacy, in collaboration with P Group Research, is currently 
undertaking a research project aiming to identify and understand why patients are persistent or 
not with COPD therapy. The project will also form part of Bonnie Bereznicki’s PhD thesis 
which aims to identify management issues relating to chronic respiratory conditions, and 
establish a potential new role for community pharmacists in this area. 
In order to conduct this study, your involvement is vital for the patient recruitment process. A 
data mining software tool has been developed for the Fred dispensing system which enables 
easy identification of patients who may and may not be persisting with Spiriva® therapy. 
Should you wish to assist us with this important study, you will be asked to view the 
dispensing information for each identified respiratory patient and exclude any who meet the 
pre-specified exclusion criteria. The attached project synopsis highlights these criteria and is 
sensitive to individual patient situations. Demands on your time are minimal from this point 
as the software application will then automatically print invitation letters and consent forms 
for patients. Please note that no identifying information will be released to us unless the 
patient signs the consent form and returns it to the University. 
The Tasmanian School of Pharmacy will then send the consenting patients a questionnaire 
assessing their health and illness beliefs and experiences with respiratory medication, and 
invite some patients to participate in qualitative face-to-face interviews with P Group 
researchers. Please refer to the attached project synopsis for further details on the proposed 
methodology. 
We anticipate that participation in the study will require approximately 20 minutes of your 
time. Involvement in this project requires the use of the Fred dispensing system. If you would 
like to be involved or require further information about the project, please complete the 
attached form and fax back to the Tasmanian School of Pharmacy.  
In order to thank you for your assistance with this study, we are offering $500 to compensate 
you for your time and professional input. 
The project has received ethical approval from the Tasmania Health and Medical Human 
Research Ethics Committee. If you have any concerns of an ethical nature or complaints about 
the manner in which the project is conducted, you may contact the Executive Officer of the 
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Tasmanian Human Research Ethics Committee (Tasmania) Network on 6226 7479 or 
human.ethics@utas.edu.au. You will need to quote ethics reference number H9842. 
The project is being sponsored by Boehringer Ingelheim, and it is intended that the results 
will be disseminated to Australian GPs and pharmacists by presentations at national meetings 
and in peer-reviewed journals. We can assure you that no identifying information relating to 
patients, doctors or pharmacists will be disseminated. All project results will be de-identified 
and pooled. 
Attached is a form for you to return to us if you are willing to participate in this project. 
Please either fax it back to us on 6226 7627 or send it back to us in the reply paid envelope 
provided.  
If you have any queries regarding this project please contact Bonnie Bereznicki at the 
Tasmanian School of Pharmacy on 6226 2191. We will be contacting you shortly to discuss 
your willingness to participate in this project. 
 
 
Yours sincerely, 
 
Bonnie Bereznicki B.Pharm (Hons) 
Clinical Research Pharmacist and PhD Candidate  
Unit for Medication Outcomes Research and Education  
Tasmanian School of Pharmacy  
University of Tasmania  
Private Bag 83 Hobart 
Tasmania  7001  
Telephone  6226 2191  
Facsimile  6226 7627  
Bonnie.Bereznicki@utas.edu.au  
 
 
 
 
 
Dr Shane Jackson B.Pharm (Hons) PhD MPS 
Senior Research Fellow 
Unit for Medication Outcomes Research and Education  
Tasmanian School of Pharmacy  
University of Tasmania  
 
 
 
 
 
 
 
 
 
 
 
 
 
The research unit at the Tasmanian School of Pharmacy (UMORE; Unit for Medication 
Outcomes Research and Education) is a premier source of information, education and 
collaborative research in the assessment and improvement of medication outcomes. 
 
 
 
 
 
P Group Research Pty Ltd specialised in delivering the highest quality in qualitative research 
and has available highly experienced consultants, all of which are AMSRS members and thus 
adhere stringently to the AMSRS Professional Code of Conduct and the Market and Social 
Research Privacy Principles. Their specialist interviewers have conducted hundreds of 
interviews with patients and are highly sensitive and empathetic to patient issues.  
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Appendix 29. Project synopsis for pharmacists 
 
This project is funded by Boehringer Ingelheim 
 
 
 
 
Understanding patient experiences with respiratory medication 
 
Project Synopsis 
The project objective is to understand the drivers and barriers of persistence with respiratory 
medication. The most effective and reliable method to accomplish this is to employ a key 
healthcare provider and resource - community pharmacists and their computerised 
prescription data. This will help identify patients with COPD as evidenced by their use of 
Spiriva® (tiotropium). 
The research team has developed a software application that extracts data from the market 
leading pharmacy dispensing software system in Australia (Fred Dispense; PCA/NU 
Systems). The software application not only ensures correct identification of suitable 
participants, it also minimises the time required of the pharmacist. Community pharmacies 
throughout Tasmania will be invited to participate, and with their permission, a researcher 
will install the software application on the pharmacy dispensing computer. 
The software will interrogate the dispensing history and produce a list of patients that meet 
the following criteria: 
! “Persistent” patients: those to whom Spiriva® was dispensed at least nine times in the 
preceding 12-month period, including at least two units in the past 90 days.  
! “Non-persistent” patients: those to whom Spiriva® was dispensed between one and 
four times (inclusive) in the preceding six-month period, with nil dispensings in the 
subsequent 65 days. Such patients would also have had nil Spiriva® dispensed in the 
12-months prior to the first dispensing of Spiriva®.  
The participating pharmacist will examine the dispensing information for each patient 
identified and will be able to exclude patients from being sent an invitation to participate if 
they believe the patient is aged under 40 years, is residing in an aged care facility, is deceased, 
is significantly cognitively impaired or would not understand the letter, or would be alarmed 
excessively by receiving the letter and participating in the project. Patients deemed suitable 
for inclusion will be sent a letter by the community pharmacist, to invite them to participate, 
along with patient information sheets and consent forms.  
All consenting patients will subsequently be sent questionnaires by the researchers, assessing 
health and illness beliefs, experience with respiratory medication and general health-related 
demographic variables. Approximately half of the patients will also participate in qualitative 
face-to-face interviews addressing patient characteristics, diagnosis, treatment choice, day-to-
day management, fulfilment, and persistence with therapy. Project deliverables will include 
utilising key dispensing information to identify key barriers and predictors of poor persistence 
to respiratory medication, and the development of belief/behaviour maps for identified 
patients, leading to a clear set of recommendations regarding persistence triggers amongst 
patient types. 
All participating community pharmacists will be provided with the study’s key outcomes. It is 
intended that the outcomes of the study will improve awareness of the drivers and barriers of 
persistence with respiratory medication. Awareness of these drivers and barriers amongst 
patient types will make it easier for community pharmacists to offer targeted encouragement 
to patients to take their medication in the manner in which it was prescribed. 
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Appendix 30. Pharmacist expression of interest form 
 
 
 
 
 
 
 
 
Understanding patient experiences with respiratory medication 
 
 
Attention: Bonnie Bereznicki 
 
 
!  Yes, our pharmacy has the Fred dispensing system, and we are willing to participate in 
the project, Understanding patient experiences with respiratory medication, being 
conducted by the Tasmanian School of Pharmacy and P Group Research. Please contact 
us to discuss the details further. 
 
 
!  Sorry, we do not have the Fred dispensing system 
 
 
!  Sorry, we have the Fred dispensing system but don’t feel able to participate in this 
project. 
 
 
 
Pharmacist Name: <Pharmacist Name> 
Pharmacy Name: <Pharmacy Name> 
Pharmacy Address: <Pharmacy Address line 1> 
 <Pharmacy Address line 2> 
 
 
 
 
 
 
Private Bag 83 Hobart 
Tasmania Australia 7001 
Telephone  6226 2191 
Facsimile  6226 7627 
Bonnie.Bereznicki@utas.edu.au 
 
Please return this form to the Tasmanian School of Pharmacy in the reply paid 
envelope provided or by faxing it to us on  6226 7627. 
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Appendix 31. Patient invitation letter 
 
 
This study has received financial support from Boehringer Ingelheim 
<patient name> 
<patient address> 
<patient suburb> 
 
 
 
<proprietor name> 
<pharmacy name> 
<pharmacy address> 
<pharmacy suburb> 
Ph: <ph number> 
Understanding patient experiences with respiratory medication 
 
<date> 
 
Dear <patient name> 
 
Our pharmacy is taking part in a research project with the University of Tasmania to try to 
learn more about people’s experiences with respiratory medication. The project is part of a 
pharmacy student’s PhD thesis which aims to improve the management of chronic respiratory 
conditions. 
 
What prompted me to write to you is that our records show that that you have received at least 
one supply of respiratory medication from the pharmacy over the past 12 months. The 
University is interested in learning about people’s views and experiences, regardless of 
whether they are still taking respiratory medication or not.  
 
Participation will involve filling out a questionnaire about your health, medical condition and 
respiratory medication use. You may also be asked if you would like to participate in a face-
to-face interview.  
 
The University is offering reasonable reimbursement to you for your participation in the 
project. 
 
To participate in this project: 
 
 
 
Your name and address will not be sent to the University unless you send them the 
signed consent form. 
 
If you have any questions about this project, please give me a call at the pharmacy.  
 
Thank you for your assistance. 
 
Yours sincerely, 
 
 
 
<pharmacist name> 
1. Read the information sheet and sign the consent form 
2. Send the signed consent form to the University using the postage paid envelope 
provided, or fax it to  6226 7627 by Friday 18th April. 
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Appendix 32. Patient consent form 
 
 
 
 
 
Understanding patient experiences with respiratory medication 
 
PATIENT CONSENT FORM 
By signing this consent form I am agreeing to participate in this research project and declare that; 
1 I have read and understood the ‘Patient Information Sheet’ for this research project. I 
acknowledge that the nature, purpose and contemplated effects of the project so far as it affects 
me, and I understand that my consent is given voluntarily. 
2 I understand that the project involves the following procedures: 
! Upon signing the consent form and mailing it to the researchers, I will be sent a questionnaire 
regarding my health and medication use. 
! My pharmacy medication records and questionnaire results will be analysed by the researchers. 
! I may be asked to take part in a face-to-face interview about my experiences with respiratory 
medication. 
3 Any questions that I have asked have been answered to my satisfaction. 
4 I am informed that no information regarding any medical history will be divulged and the results 
of any questionnaires or interviews involving me will not be published so as to reveal my identity. 
5 I understand that my involvement in the project will not affect my relationship with my 
pharmacist or doctor in their management of my health. I also understand that I am free to 
withdraw from the project at any stage and any of my data that has been collected. My withdrawal 
will not affect my legal rights, my medical care or my relationship with my pharmacist. 
6 I understand that the trial will be conducted in accordance with the latest versions of the National 
Statement on Ethical Conduct in Human Research 2007 and applicable privacy laws. 
7 I understand that I am not giving up my legal rights by signing this consent form. 
8 I understand that the project has received ethical approval from the Tasmanian Health and Medical 
Human Research Ethics Committee. I have been provided with adequate contact details if I wish 
to express any concerns of an ethical nature or complaints about the manner in which the project is 
conducted. 
 
Name of Participant:…………………………………………………………………………………....... 
 
Address:………………………….……………………………………………......................................... 
 
………………………………………………………………………………………………...…………. 
 
Daytime telephone number: (03)…………………………………. What is your age?.....................years 
 
What is your gender? (circle)    Male      Female           Are you a current smoker? (circle)    Yes      No 
 
 
Signature of Participant: …………………………………………………....Date:……………………... 
Please mail the signed consent form to the University of Tasmania by Friday 18th April 
in the postage paid envelope provided or fax it to  6226 7627.       Consent form number: <patient ID> 
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Appendix 33. Patient information sheet 
 
 
 
 
 
 
Understanding patient experiences with respiratory medication 
 
PATIENT INFORMATION SHEET 
 
We would like to invite you to participate in the following research project, conducted by the 
Tasmanian School of Pharmacy. You have been asked to participate because your community 
pharmacist noticed that you have received at least one supply of respiratory medication from 
the pharmacy over the past 12 months. We are interested in your participation regardless of 
whether you are still taking respiratory medication or not. We would like to assure you that 
your community pharmacist will not release any of your information to the Tasmanian School 
of Pharmacy without your consent. 
 
We are interested in to trying to learn more people’s experiences with respiratory medication 
and to identify why people do or do not continue to take particular medications. 
 
To help with this research, we will ask you some questions about your health and illness 
beliefs, and experiences with respiratory medication. We will also ask you a few questions 
regarding your age, gender and smoking status. These questions will be mailed to you in the 
form of a questionnaire. Your personal details will not be included in the questionnaire; 
therefore your responses will not be identifiable by the researchers. You may also be asked if 
you would like to take part in a face-to-face interview about your experiences with respiratory 
medication. To do the face-to-face interviews, we have teamed up with P Group Research, 
who are experts in this area, to ask you about how you use your medicines.  
 
After completing and returning the questionnaire, you will receive a $50 gift voucher, and if 
you are selected to also participate in a face-to-face interview, you will receive remuneration 
of $70. 
 
If you have any concerns or questions about the questionnaire or your participation in the 
study, please contact the University (contact details are on the following page). The results of 
this study may be published in the future, but your name will not be mentioned, and all of the 
information that you provide us with will be treated confidentially. You are free to not 
participate in the project if you wish. If this is the case, do not sign the consent form. If you 
agree to take part, please sign the attached consent form and return it to the University by 
Friday 18th April. Once you have signed the consent form, the Tasmanian School of 
Pharmacy will mail you the questionnaire and a reply paid envelope in which to return them. 
Then you may be contacted by P Group Research and asked if you would like to take part in a 
face-to-face interview. You are free to withdraw from participating in the study at any time if 
you wish. 
 
The project has received ethical approval from the Tasmanian Health and Medical Human 
Research Ethics Committee. If you have any concerns of an ethical nature or complaints 
about the manner in which the project is conducted, you may contact the Executive Officer of 
the Tasmanian Human Research Ethics Committee (Tasmania) Network on 62267479 or 
human.ethics@utas.edu.au. You will need to quote ethics reference number H9842. 
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This study has received financial support from Boehringer Ingelheim 
Results of this work may be published in pharmacy and medical journals and shown at 
pharmacy conferences. We can assure you that your personal details, the medications you 
take and other information we collect will not be given to anyone else. We will ensure all 
information about you will be kept private and confidential. All of the results are pooled 
together and then analysed. 
 
Please do not hesitate to contact us if you have any questions or concerns regarding the 
project. 
 
Yours sincerely 
 
 
 
 
Bonnie Bereznicki B.Pharm (Hons) 
Clinical Research Pharmacist and PhD Candidate  
Unit for Medication Outcomes Research and Education  
Tasmanian School of Pharmacy  
University of Tasmania  
Private Bag 83 Hobart 
Tasmania  7001  
Telephone  6226 2191  
Facsimile  6226 7627  
Bonnie.Bereznicki@utas.edu.au  
 
 
 
 
 
Dr Shane Jackson B.Pharm (Hons) PhD MPS 
Senior Research Fellow 
Unit for Medication Outcomes Research and Education  
Tasmanian School of Pharmacy  
University of Tasmania  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The research unit at the Tasmanian School of Pharmacy (UMORE; Unit for Medication 
Outcomes Research and Education) is a premier source of information, education and 
collaborative research in the assessment and improvement of medication outcomes. 
 
 
 
 
 
 
 
P Group Research Pty Ltd specialised in delivering the highest quality in qualitative research 
and has available highly experienced consultants, all of which are AMSRS members and thus 
adhere stringently to the AMSRS Professional Code of Conduct and the Market and Social 
Research Privacy Principles. Their specialist interviewers have conducted hundreds of 
interviews with patients and are highly sensitive and empathetic to patient issues.  
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Appendix 34. Patient letter regarding questionnaire 
 
This study has received financial support from Boehringer Ingelheim 
 
 
 
Understanding patient experiences with respiratory medication 
 
 
Dear <patient name> 
 
 
Thank you for agreeing to participate in the project Understanding patient experiences with 
respiratory medication, being conducted by the Tasmanian School of Pharmacy and P Group 
Research. Your participation and support is vital to improve the management and quality of 
life of people for people with respiratory conditions and is thus greatly appreciated. 
 
Please find enclosed a Patient Questionnaire for you to complete. Please be assured that all of 
your responses to the questionnaires will be anonymous. If have any queries or concerns 
about any part of the questionnaire, please don’t hesitate to contact Bonnie Bereznicki at the 
Tasmanian School of Pharmacy, on the details below. 
 
Once you have completed the questionnaire, please return it to the Tasmanian School of 
Pharmacy in the postage paid envelope provided. 
 
We estimate that completion of the questionnaire will take 20-30 minutes of your time. Upon 
receipt of the completed questionnaire, the Tasmanian School of Pharmacy will send you a 
$50 Coles Group and Myer Gift Card, which will be redeemable at Coles, Myer, Target, 
Kmart and Officeworks stores. All questionnaires are uniquely identified by a number, which 
will allow the researchers to mail you a Gift Card upon receipt of the completed 
questionnaire. The identification number will be removed from the questionnaire prior to data 
entry to ensure your responses are not identifiable. 
 
Please also find enclosed a copy of your signed consent form for your own records. 
 
Once again, we thank you for your assistance in our research. 
 
Yours Sincerely,
 
 
Bonnie Bereznicki B.Pharm (Hons) 
Clinical Research Pharmacist and PhD Candidate  
Unit for Medication Outcomes Research and Education  
Tasmanian School of Pharmacy  
University of Tasmania  
Private Bag 83 Hobart 
Tasmania  7001  
Telephone  6226 2191  
Facsimile  6226 7627  
Bonnie.Bereznicki@utas.edu.au  
 
 
 
 
Dr Shane Jackson B.Pharm (Hons) PhD MPS 
Senior Research Fellow 
Unit for Medication Outcomes Research and Education  
Tasmanian School of Pharmacy  
University of Tasmania  
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Appendix 35. Patient questionnaire 
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Appendix 36. Discussion guide for qualitative interviews 
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COPD patient research: discussion guide 
1. Introduction  
Briefly explain the following points: 
! Research objectives: to understand what it is like to live with a respiratory 
condition such as COPD/emphysema/chronic bronchitis, particularly how 
patients manage their condition on a day-to-day basis.  
! Confidentiality and anonymity, privacy.  
! Timing: interview will take about 60 minutes. 
! Commissioning client: can be revealed at the end of the interview. 
! Pre-interview survey: collect and confirm that questionnaire completed as 
per instructions.  
2. Patient profile             ~5 minutes 
Briefly review demographics contained in pre-interview survey (family situation, 
employment status, income source, smoking history, does anyone else in the house 
smoke etc) 
Using the Data Sheet provided, collect the following patient information: 
! Self-reported diagnosis (note that if the patient believes they have asthma or 
something other than COPD, refer to whichever ‘respiratory condition’ the 
patient believes they have throughout the remainder of the interview); 
! Co-morbid conditions;  
! Therapeutic regimen for co-morbid conditions – brand and indication; 
! Approximate monthly spend on managing [INSERT respiratory condition].  
3. Patient experience   
Fully explore, using the therapeutic buying process as an organising framework [i.e. 
origination ! diagnosis ! treatment choice/practice! fulfilment ! persistence]  
Explain we are interested to hear the patient’s story right from the beginning. 
Encourage them to cast their minds back and walk the interviewer through their total 
experience in as much detail as they can recall.  
3.2 Origination: Explore how the patient came to be diagnosed with [INSERT 
respiratory condition] in the first place.           ~5 minutes 
Prompt as required:  
o What led to you being prescribed medicine for a respiratory condition 
(e.g. did they just go the doctor/spontaneously? Prompted by 
family/friends? Prompted by healthcare professional?) Why/why not?  
o What were their symptoms? Severity? Did they have a cough that 
wouldn’t go away (and what time of year was it)? 
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